{"PMC6977179": [["OBSERVATIONSince its first appearance in 2012, Middle East respiratory syndrome (MERS) has affected more than 25 countries in 4 continents, with more than 2,400 cases and an extremely high fatality rate of more than 30%.", [["Middle East respiratory syndrome", "DISEASE", 47, 79], ["MERS", "DISEASE", 81, 85], ["Middle East respiratory syndrome", "PROBLEM", 47, 79], ["Middle", "ANATOMY_MODIFIER", 47, 53], ["respiratory syndrome", "OBSERVATION", 59, 79]]], ["The total number of mortalities due to MERS is already greater than that due to severe acute respiratory syndrome.", [["MERS", "DISEASE", 39, 43], ["acute respiratory syndrome", "DISEASE", 87, 113], ["MERS", "PROBLEM", 39, 43], ["severe acute respiratory syndrome", "PROBLEM", 80, 113], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["mortalities", "OBSERVATION", 20, 31], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["respiratory syndrome", "OBSERVATION", 93, 113]]], ["MERS coronavirus (MERS-CoV), a betacoronavirus from subgenus Merbecovirus, has been confirmed to be the etiological agent (1).", [["Merbecovirus", "CHEMICAL", 61, 73], ["MERS coronavirus", "ORGANISM", 0, 16], ["MERS-CoV", "ORGANISM", 18, 26], ["MERS coronavirus", "SPECIES", 0, 16], ["MERS coronavirus", "SPECIES", 0, 16], ["MERS-CoV", "SPECIES", 18, 26], ["MERS coronavirus", "PROBLEM", 0, 16], ["a betacoronavirus from subgenus Merbecovirus", "PROBLEM", 29, 73]]], ["Human dipeptidyl peptidase 4 was found to be the cellular receptor for MERS-CoV (2).", [["cellular", "ANATOMY", 49, 57], ["Human", "ORGANISM", 0, 5], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 6, 28], ["cellular", "CELL", 49, 57], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["Human dipeptidyl peptidase 4", "PROTEIN", 0, 28], ["cellular receptor", "PROTEIN", 49, 66], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["MERS-CoV", "SPECIES", 71, 79], ["Human dipeptidyl peptidase", "TREATMENT", 0, 26]]], ["Subsequent detection of MERS-CoV and its antibodies in dromedary, or one-humped, camels (Camelus dromedarius) in various countries in the Middle East and North Africa have suggested that these animals are probably the reservoir for MERS-CoV (3\u20135).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 24, 32], ["camels", "ORGANISM", 81, 87], ["Camelus dromedarius", "ORGANISM", 89, 108], ["MERS-CoV", "ORGANISM", 232, 240], ["MERS-CoV", "PROTEIN", 24, 32], ["antibodies", "PROTEIN", 41, 51], ["Camelus dromedarius", "SPECIES", 89, 108], ["MERS-CoV", "SPECIES", 24, 32], ["Camelus dromedarius", "SPECIES", 89, 108], ["MERS-CoV", "SPECIES", 232, 240], ["MERS", "PROBLEM", 24, 28], ["CoV", "PROBLEM", 29, 32], ["Middle", "ANATOMY_MODIFIER", 138, 144]]], ["Other betacoronaviruses in bats from the subgenus Merbecovirus (e.g., Tylonycteris bat CoV HKU4, Pipistrellus bat CoV HKU5, Hypsugo bat CoV HKU25), and hedgehogs were found to be closely related to MERS-CoV (6\u20139).OBSERVATIONIn addition to the dromedaries, there are two additional surviving Old World camels, the Bactrian, or two-humped, camels (Camelus bactrianus) and the wild Bactrian camels (Camelus ferus), both inhabitants of Central Asia.", [["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 6, 23], ["Tylonycteris bat CoV HKU4", "ORGANISM", 70, 95], ["Pipistrellus bat CoV HKU5", "ORGANISM", 97, 122], ["Hypsugo bat CoV HKU25", "ORGANISM", 124, 145], ["MERS-CoV", "ORGANISM", 198, 206], ["camels", "ORGANISM", 338, 344], ["Camelus bactrianus", "ORGANISM", 346, 364], ["Bactrian camels", "ORGANISM", 379, 394], ["Camelus ferus", "ORGANISM", 396, 409], ["Tylonycteris", "SPECIES", 70, 82], ["bat CoV", "SPECIES", 83, 90], ["Pipistrellus", "SPECIES", 97, 109], ["bat CoV", "SPECIES", 110, 117], ["Hypsugo", "SPECIES", 124, 131], ["bat CoV", "SPECIES", 132, 139], ["Camelus bactrianus", "SPECIES", 346, 364], ["camels", "SPECIES", 388, 394], ["Camelus ferus", "SPECIES", 396, 409], ["Tylonycteris bat CoV", "SPECIES", 70, 90], ["Pipistrellus bat CoV", "SPECIES", 97, 117], ["Hypsugo bat CoV", "SPECIES", 124, 139], ["MERS-CoV", "SPECIES", 198, 206], ["Camelus bactrianus", "SPECIES", 346, 364], ["Bactrian camels", "SPECIES", 379, 394], ["Camelus ferus", "SPECIES", 396, 409], ["Other betacoronaviruses", "PROBLEM", 0, 23], ["the subgenus Merbecovirus", "TEST", 37, 62], ["Tylonycteris", "TEST", 70, 82], ["HKU4", "TEST", 91, 95], ["Pipistrellus", "TEST", 97, 109], ["HKU5", "TEST", 118, 122], ["Hypsugo bat CoV HKU25", "TEST", 124, 145], ["Central", "ANATOMY_MODIFIER", 432, 439]]], ["Moreover, a dromedary and a Bactrian camel can mate and result in a hybrid camel offspring.", [["camel", "ORGANISM", 37, 42], ["camel", "ORGANISM", 75, 80], ["camel", "SPECIES", 37, 42], ["camel", "SPECIES", 75, 80], ["camel", "SPECIES", 75, 80], ["a Bactrian camel", "TREATMENT", 26, 42]]], ["Previous published serological studies showed that sera of Bactrian camels were all negative for MERS-CoV antibodies, suggesting that Bactrian camels may not be a reservoir of MERS-CoV (Fig. 1) (10\u201314).", [["sera", "ANATOMY", 51, 55], ["sera", "ORGANISM_SUBSTANCE", 51, 55], ["Bactrian camels", "ORGANISM", 59, 74], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["Bactrian camels", "ORGANISM", 134, 149], ["MERS-CoV", "ORGANISM", 176, 184], ["MERS-CoV antibodies", "PROTEIN", 97, 116], ["Bactrian camels", "SPECIES", 59, 74], ["MERS-CoV", "SPECIES", 97, 105], ["MERS-CoV", "SPECIES", 176, 184], ["Previous published serological studies", "TEST", 0, 38], ["sera of Bactrian camels", "TEST", 51, 74], ["MERS", "PROBLEM", 97, 101], ["CoV antibodies", "TEST", 102, 116], ["Bactrian camels", "PROBLEM", 134, 149]]], ["However, a recent study revealed that direct inoculation of Bactrian camels intranasally with MERS-CoV can lead to infection with abundant virus shedding and seroconversion (15).", [["intranasally", "ANATOMY", 76, 88], ["infection", "DISEASE", 115, 124], ["Bactrian camels", "ORGANISM", 60, 75], ["MERS-CoV", "ORGANISM", 94, 102], ["Bactrian camels intranasally", "SPECIES", 60, 88], ["MERS-CoV", "SPECIES", 94, 102], ["a recent study", "TEST", 9, 23], ["direct inoculation of Bactrian camels", "TREATMENT", 38, 75], ["MERS", "PROBLEM", 94, 98], ["CoV", "PROBLEM", 99, 102], ["infection", "PROBLEM", 115, 124], ["abundant virus shedding", "PROBLEM", 130, 153], ["seroconversion", "TEST", 158, 172], ["infection", "OBSERVATION", 115, 124], ["abundant", "OBSERVATION_MODIFIER", 130, 138], ["virus", "OBSERVATION", 139, 144]]], ["Therefore, we hypothesize that those Bactrian camels, and even the hybrid camels, that reside in countries where there are dromedaries can be infected with MERS-CoV.", [["MERS-CoV", "ORGANISM", 156, 164], ["MERS-CoV", "SPECIES", 156, 164], ["infected", "OBSERVATION", 142, 150]]], ["To test this hypothesis, we examined the presence of MERS-CoV antibodies in Bactrian and hybrid camels in Dubai, the United Arab Emirates (where dromedaries are also present), and Bactrian camels in Xinjiang, China (where dromedaries are absent), using a MERS-CoV spike (S) protein-based enzyme-linked immunosorbent assay (ELISA) and neutralization antibody test.OBSERVATIONA total of 29 and 11 serum samples, respectively, were collected from 29 Bactrian camels and 11 hybrid camels from a private collection in Dubai (April to May 2019) (Table 1), and 92 serum samples were collected from Bactrian camels on a camel farm in Xinjiang (November 2012) (16).", [["serum samples", "ANATOMY", 395, 408], ["serum samples", "ANATOMY", 557, 570], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["serum samples", "ORGANISM_SUBSTANCE", 395, 408], ["camels", "ORGANISM", 477, 483], ["serum samples", "ORGANISM_SUBSTANCE", 557, 570], ["MERS-CoV antibodies", "PROTEIN", 53, 72], ["MERS-CoV spike (S) protein", "PROTEIN", 255, 281], ["MERS-CoV", "SPECIES", 53, 61], ["MERS", "PROBLEM", 53, 57], ["CoV antibodies in Bactrian", "PROBLEM", 58, 84], ["a MERS", "TEST", 253, 259], ["CoV spike", "TEST", 260, 269], ["protein", "TEST", 274, 281], ["based enzyme", "TEST", 282, 294], ["immunosorbent assay", "TEST", 302, 321], ["ELISA", "TEST", 323, 328], ["neutralization antibody test", "TEST", 334, 362], ["serum samples", "TEST", 395, 408], ["serum samples", "TEST", 557, 570]]], ["Antibodies against the S protein of MERS-CoV were tested using microplates precoated with purified (His)6-tagged recombinant receptor-binding domain of S (RBD-S) of MERS-CoV and detected with 1:8,000 diluted horseradish peroxidase-conjugated goat anti-llama IgG (Life Technologies, Carlsbad, CA, USA) conjugate (S-ELISA) (17).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 165, 173], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 208, 230], ["S protein", "PROTEIN", 23, 32], ["MERS-CoV", "PROTEIN", 36, 44], ["purified (His)6-tagged recombinant receptor-binding domain", "PROTEIN", 90, 148], ["RBD", "PROTEIN", 155, 158], ["S", "PROTEIN", 159, 160], ["MERS", "PROTEIN", 165, 169], ["1:8,000 diluted horseradish peroxidase", "PROTEIN", 192, 230], ["conjugated goat anti-llama IgG", "PROTEIN", 231, 261], ["horseradish", "SPECIES", 208, 219], ["goat", "SPECIES", 242, 246], ["MERS-CoV", "SPECIES", 36, 44], ["MERS-CoV", "SPECIES", 165, 173], ["goat", "SPECIES", 242, 246], ["Antibodies", "TEST", 0, 10], ["CoV", "PROBLEM", 41, 44], ["S (RBD", "TEST", 152, 158], ["MERS", "PROBLEM", 165, 169], ["CoV", "TEST", 170, 173], ["diluted horseradish peroxidase", "TREATMENT", 200, 230], ["conjugated goat anti-llama IgG", "TREATMENT", 231, 261]]], ["The cutoff of the ELISA was defined as three standard deviations above the mean absorbance value of 10 dromedary serum samples that tested negative with the neutralization antibody test.", [["serum samples", "ANATOMY", 113, 126], ["serum samples", "ORGANISM_SUBSTANCE", 113, 126], ["the ELISA", "TEST", 14, 23], ["the mean absorbance value", "TEST", 71, 96], ["dromedary serum samples", "TEST", 103, 126], ["the neutralization antibody test", "TEST", 153, 185]]], ["The neutralization antibody test was performed by incubating serially diluted camel sera with 100 50% tissue culture infective dose (TCID50) MERS-CoV for 2 hours before infecting the Vero cells for 1 hour.", [["sera", "ANATOMY", 84, 88], ["tissue", "ANATOMY", 102, 108], ["Vero cells", "ANATOMY", 183, 193], ["camel", "ORGANISM", 78, 83], ["sera", "ORGANISM_SUBSTANCE", 84, 88], ["tissue", "TISSUE", 102, 108], ["Vero cells", "CELL", 183, 193], ["Vero cells", "CELL_LINE", 183, 193], ["camel", "SPECIES", 78, 83], ["MERS-CoV", "SPECIES", 141, 149], ["The neutralization antibody test", "TEST", 0, 32], ["Vero cells", "OBSERVATION", 183, 193]]], ["The cytopathic effect (CPE) was observed for 5 days, and the sera were regarded as positive for neutralizing antibody if no CPE was observed in the infected cells (18).", [["sera", "ANATOMY", 61, 65], ["cells", "ANATOMY", 157, 162], ["sera", "ORGANISM_SUBSTANCE", 61, 65], ["cells", "CELL", 157, 162], ["neutralizing antibody", "PROTEIN", 96, 117], ["infected cells", "CELL_TYPE", 148, 162], ["The cytopathic effect (CPE", "PROBLEM", 0, 26], ["the sera", "TEST", 57, 65], ["neutralizing antibody", "PROBLEM", 96, 117], ["CPE", "PROBLEM", 124, 127], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21], ["infected cells", "OBSERVATION", 148, 162]]], ["All tests were performed in triplicate.OBSERVATIONFor the 29 serum samples from Bactrian camels in Dubai tested with the S-ELISA and neutralization antibody test, 14 (48%) and 12 (41%), respectively, were positive for MERS-CoV antibodies (Fig. 2A and Table 1).", [["serum samples", "ANATOMY", 61, 74], ["serum samples", "ORGANISM_SUBSTANCE", 61, 74], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 218, 226], ["MERS-CoV antibodies", "PROTEIN", 218, 237], ["Fig. 2A and Table 1", "PROTEIN", 239, 258], ["MERS-CoV", "SPECIES", 218, 226], ["All tests", "TEST", 0, 9], ["serum samples", "TEST", 61, 74], ["Bactrian camels", "TEST", 80, 95], ["the S-ELISA", "TEST", 117, 128], ["neutralization antibody test", "TEST", 133, 161], ["MERS", "TEST", 218, 222], ["CoV antibodies", "TEST", 223, 237]]], ["All the 12 serum samples that were positive with the neutralization antibody test were also positive for the S-ELISA.", [["serum samples", "ANATOMY", 11, 24], ["serum samples", "ORGANISM_SUBSTANCE", 11, 24], ["S-ELISA", "PROTEIN", 109, 116], ["All the 12 serum samples", "TEST", 0, 24], ["the neutralization antibody test", "TEST", 49, 81]]], ["For the 11 serum samples from hybrid camels in Dubai tested with the S-ELISA and neutralization antibody test, 6 (55%) and 9 (82%), respectively, were positive for MERS-CoV antibodies (Fig. 2A and Table 1).", [["serum samples", "ANATOMY", 11, 24], ["serum samples", "ORGANISM_SUBSTANCE", 11, 24], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 164, 172], ["MERS-CoV antibodies", "PROTEIN", 164, 183], ["Fig. 2A and Table 1", "PROTEIN", 185, 204], ["MERS-CoV", "SPECIES", 164, 172], ["the 11 serum samples", "TEST", 4, 24], ["hybrid camels", "TEST", 30, 43], ["the S-ELISA", "TEST", 65, 76], ["neutralization antibody test", "TEST", 81, 109], ["MERS", "TEST", 164, 168], ["CoV antibodies", "TEST", 169, 183]]], ["All the 6 serum samples that were positive for the S-ELISA were also positive with the neutralization antibody test.", [["serum samples", "ANATOMY", 10, 23], ["serum samples", "ORGANISM_SUBSTANCE", 10, 23], ["S-ELISA", "GENE_OR_GENE_PRODUCT", 51, 58], ["S-ELISA", "PROTEIN", 51, 58], ["All the 6 serum samples", "TEST", 0, 23], ["the S-ELISA", "TEST", 47, 58], ["the neutralization antibody test", "TEST", 83, 115]]], ["There was a strong correlation between the antibody levels detected by S-ELISA and neutralizing antibody titers, with a Spearman coefficient of 0.6262 (P < 0.0001; 95% confidence interval, 0.5062 to 0.7225) (Fig. 2B).", [["S-ELISA", "PROTEIN", 71, 78], ["the antibody levels", "TEST", 39, 58], ["S-ELISA", "TEST", 71, 78], ["neutralizing antibody titers", "TEST", 83, 111], ["a Spearman coefficient", "TEST", 118, 140]]], ["All 92 Bactrian camel serum samples from Xinjiang were negative for MERS-CoV antibodies tested with both S-ELISA and the neutralization antibody test (Fig. 2A and Table 1).OBSERVATIONWe showed that MERS-CoV antibodies were present in Bactrian and hybrid camels from Dubai.", [["serum samples", "ANATOMY", 22, 35], ["camel", "ORGANISM", 16, 21], ["serum samples", "ORGANISM_SUBSTANCE", 22, 35], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 68, 76], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 198, 206], ["MERS-CoV antibodies", "PROTEIN", 68, 87], ["S-ELISA", "PROTEIN", 105, 112], ["MERS-CoV antibodies", "PROTEIN", 198, 217], ["camel", "SPECIES", 16, 21], ["MERS-CoV", "SPECIES", 68, 76], ["MERS-CoV", "SPECIES", 198, 206], ["All 92 Bactrian camel serum samples", "TEST", 0, 35], ["Xinjiang", "TEST", 41, 49], ["MERS", "TEST", 68, 72], ["CoV antibodies", "TEST", 73, 87], ["the neutralization antibody test", "TEST", 117, 149], ["CoV antibodies", "TEST", 203, 217], ["hybrid camels", "OBSERVATION", 247, 260]]], ["When the reservoir of MERS-CoV was first discovered in dromedaries (3), it was wondered whether Bactrian camels are also another possible source of the virus.", [["MERS-CoV", "ORGANISM", 22, 30], ["Bactrian camels", "ORGANISM", 96, 111], ["MERS-CoV", "SPECIES", 22, 30], ["Bactrian camels", "PROBLEM", 96, 111], ["the virus", "PROBLEM", 148, 157], ["virus", "OBSERVATION", 152, 157]]], ["However, in all the studies that looked for MERS-CoV in both wild (China, n = 190; Kazakhstan, n = 95; Mongolia, n = 200) and captive (the Netherlands, n = 2; Chile, n = 2; Japan, n = 5; Germany, n = 16) Bactrian camels, it was found that none of the Bactrian camels, as tested with neutralization antibody test, ELISA, immunofluorescence assay, plaque reduction neutralization test, and/or protein microarray, had MERS-CoV antibodies (10\u201314).", [["plaque", "ANATOMY", 346, 352], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["camels", "ORGANISM", 213, 219], ["camels", "ORGANISM", 260, 266], ["MERS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 415, 434], ["MERS-CoV antibodies", "PROTEIN", 415, 434], ["MERS-CoV", "SPECIES", 44, 52], ["all the studies", "TEST", 12, 27], ["MERS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["neutralization antibody test", "TEST", 283, 311], ["ELISA", "TEST", 313, 318], ["immunofluorescence assay", "TEST", 320, 344], ["plaque reduction neutralization test", "TEST", 346, 382], ["protein microarray", "TEST", 391, 409], ["MERS", "TEST", 415, 419], ["CoV antibodies", "TEST", 420, 434]]], ["However, the sera from all these studies were obtained from Bactrian camels in geographical regions where there were no dromedaries that were positive for MERS-CoV or its antibodies.", [["sera", "ANATOMY", 13, 17], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 155, 163], ["MERS", "PROTEIN", 155, 159], ["antibodies", "PROTEIN", 171, 181], ["MERS-CoV", "SPECIES", 155, 163], ["the sera", "TEST", 9, 17], ["all these studies", "TEST", 23, 40], ["dromedaries", "PROBLEM", 120, 131], ["MERS", "PROBLEM", 155, 159], ["no", "UNCERTAINTY", 117, 119]]], ["Interestingly, in a recent study that investigated the susceptibility of Bactrian camels to MERS-CoV, upon intranasal inoculation with 107 TCID50 of MERS-CoV, the Bactrian camels developed clinical signs of transient upper respiratory tract infections, such as nasal discharge and coughing, with shedding of up to 106.5 to 106.8 plaque forming units/ml of MERS-CoV from the upper respiratory tract and development of neutralizing antibodies against MERS-CoV (15).", [["upper respiratory tract", "ANATOMY", 217, 240], ["nasal", "ANATOMY", 261, 266], ["plaque", "ANATOMY", 329, 335], ["upper respiratory tract", "ANATOMY", 374, 397], ["upper respiratory tract infections", "DISEASE", 217, 251], ["coughing", "DISEASE", 281, 289], ["MERS-CoV", "ORGANISM", 92, 100], ["MERS-CoV", "ORGANISM", 149, 157], ["Bactrian camels", "ORGANISM", 163, 178], ["upper", "ORGANISM_SUBDIVISION", 217, 222], ["respiratory tract", "ORGANISM_SUBDIVISION", 223, 240], ["nasal", "ORGANISM_SUBDIVISION", 261, 266], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 356, 364], ["upper respiratory", "ORGANISM_SUBDIVISION", 374, 391], ["tract", "ORGANISM_SUBDIVISION", 392, 397], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 449, 457], ["neutralizing antibodies", "PROTEIN", 417, 440], ["Bactrian camels", "SPECIES", 73, 88], ["MERS-CoV", "SPECIES", 92, 100], ["MERS-CoV", "SPECIES", 149, 157], ["MERS-CoV", "SPECIES", 356, 364], ["MERS-CoV", "SPECIES", 449, 457], ["a recent study", "TEST", 18, 32], ["intranasal inoculation", "TREATMENT", 107, 129], ["transient upper respiratory tract infections", "PROBLEM", 207, 251], ["nasal discharge", "PROBLEM", 261, 276], ["coughing", "PROBLEM", 281, 289], ["shedding", "PROBLEM", 296, 304], ["MERS", "PROBLEM", 356, 360], ["CoV", "PROBLEM", 361, 364], ["the upper respiratory tract", "PROBLEM", 370, 397], ["neutralizing antibodies", "PROBLEM", 417, 440], ["transient", "OBSERVATION_MODIFIER", 207, 216], ["upper", "ANATOMY_MODIFIER", 217, 222], ["respiratory tract", "ANATOMY", 223, 240], ["infections", "OBSERVATION", 241, 251], ["nasal", "ANATOMY", 261, 266], ["discharge", "OBSERVATION", 267, 276], ["coughing", "OBSERVATION", 281, 289], ["upper", "ANATOMY_MODIFIER", 374, 379], ["respiratory tract", "ANATOMY", 380, 397], ["neutralizing antibodies", "OBSERVATION", 417, 440]]], ["This suggested that Bactrian camels can be susceptible to MERS-CoV infection and may actually be another possible reservoir for MERS-CoV.", [["infection", "DISEASE", 67, 76], ["Bactrian camels", "ORGANISM", 20, 35], ["MERS-CoV", "ORGANISM", 58, 66], ["MERS-CoV", "ORGANISM", 128, 136], ["MERS-CoV", "SPECIES", 58, 66], ["MERS-CoV", "SPECIES", 128, 136], ["Bactrian camels", "PROBLEM", 20, 35], ["MERS", "PROBLEM", 58, 62], ["CoV infection", "PROBLEM", 63, 76], ["infection", "OBSERVATION", 67, 76]]], ["In the present study, we showed that MERS-CoV antibodies were present in 41% of the Bactrian camels and 55% of the hybrid camels from a private collection in Dubai using two independent assays.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 37, 45], ["camels", "ORGANISM", 122, 128], ["MERS-CoV antibodies", "PROTEIN", 37, 56], ["MERS-CoV", "SPECIES", 37, 45], ["the present study", "TEST", 3, 20], ["CoV antibodies", "TEST", 42, 56], ["the hybrid camels", "PROBLEM", 111, 128]]], ["These camels were kept as hobby animals.", [["camels", "ORGANISM", 6, 12]]], ["MERS-CoV has been consistently detected in these camel farms in the last few years, and the MERS-CoV seropositive rate increased as the age of the dromedaries increased (17).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "ORGANISM", 92, 100], ["MERS-CoV", "DNA", 0, 8], ["MERS-CoV", "SPECIES", 0, 8], ["camel", "SPECIES", 49, 54], ["MERS-CoV", "SPECIES", 92, 100], ["the MERS", "TEST", 88, 96], ["CoV seropositive rate", "TEST", 97, 118]]], ["The Bactrian camels were imported from Kazakhstan more than 10 years ago, whereas the hybrid camels were the offspring of mating between dromedaries and the Bactrian camels.", [["camels", "ORGANISM", 13, 19], ["camels", "ORGANISM", 93, 99]]], ["Some of the hybrid camels were sometimes used for camel racing and therefore had more frequent contacts with dromedaries.", [["dromedaries", "DISEASE", 109, 120], ["camels", "ORGANISM", 19, 25], ["camel", "ORGANISM", 50, 55], ["camel", "SPECIES", 50, 55]]], ["It is likely that some of the Bactrian and hybrid camels might have acquired the MERS-CoV during their contacts with dromedaries that were shedding the virus, and the virus subsequently infected other Bactrian and hybrid camels in the collection.OBSERVATIONTo prevent MERS in humans, it might be worthwhile to immunize Bactrian and hybrid camels in addition to the dromedaries.", [["hybrid camels", "ORGANISM", 43, 56], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 81, 89], ["humans", "ORGANISM", 276, 282], ["camels", "ORGANISM", 339, 345], ["humans", "SPECIES", 276, 282], ["MERS-CoV", "SPECIES", 81, 89], ["humans", "SPECIES", 276, 282], ["the Bactrian and hybrid camels", "PROBLEM", 26, 56], ["shedding the virus", "PROBLEM", 139, 157], ["the virus", "PROBLEM", 163, 172], ["hybrid camels in the collection", "PROBLEM", 214, 245], ["hybrid camels", "PROBLEM", 332, 345], ["is likely", "UNCERTAINTY", 3, 12], ["infected", "OBSERVATION", 186, 194], ["hybrid camels", "OBSERVATION", 214, 227], ["MERS", "OBSERVATION", 268, 272]]], ["So far, as determined from the results of phylogenomic analyses, several clades of MERS-CoV are circulating in dromedaries.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["MERS-CoV", "DNA", 83, 91], ["MERS-CoV", "SPECIES", 83, 91], ["phylogenomic analyses", "TEST", 42, 63], ["CoV", "PROBLEM", 88, 91]]], ["Although it seems that the ultimate origin of MERS-CoV was from bats (6), there are still significant differences between the genome sequences of these betacoronaviruses in bats from the subgenus Merbecovirus and MERS-CoV, suggesting that interspecies jumping from bats to camels may not be a very recent event, and hence the dromedaries are probably the reservoir of MERS-CoV where the virus was transmitted to humans.", [["MERS-CoV", "ORGANISM", 46, 54], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 152, 169], ["MERS-CoV", "ORGANISM", 213, 221], ["bats", "ORGANISM", 265, 269], ["camels", "ORGANISM", 273, 279], ["MERS-CoV", "ORGANISM", 368, 376], ["humans", "ORGANISM", 412, 418], ["humans", "SPECIES", 412, 418], ["MERS-CoV", "SPECIES", 46, 54], ["MERS-CoV", "SPECIES", 213, 221], ["MERS-CoV", "SPECIES", 368, 376], ["humans", "SPECIES", 412, 418], ["CoV", "PROBLEM", 51, 54], ["these betacoronaviruses", "PROBLEM", 146, 169], ["the dromedaries", "PROBLEM", 322, 337], ["the virus", "PROBLEM", 383, 392], ["MERS", "OBSERVATION", 46, 50], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["subgenus Merbecovirus", "OBSERVATION", 187, 208]]], ["In the last few years, a number of MERS-CoV vaccines have been developed for their potential use in dromedaries (19\u201323).", [["MERS-CoV", "ORGANISM", 35, 43], ["MERS-CoV", "SPECIES", 35, 43], ["MERS-CoV vaccines", "TREATMENT", 35, 52]]], ["In this study, our results indicated that Bactrian and hybrid camels are also potential sources of MERS-CoV infection.", [["infection", "DISEASE", 108, 117], ["hybrid camels", "ORGANISM", 55, 68], ["MERS-CoV", "ORGANISM", 99, 107], ["MERS-CoV", "SPECIES", 99, 107], ["this study", "TEST", 3, 13], ["Bactrian and hybrid camels", "PROBLEM", 42, 68], ["MERS", "PROBLEM", 99, 103], ["CoV infection", "PROBLEM", 104, 117], ["CoV", "OBSERVATION_MODIFIER", 104, 107], ["infection", "OBSERVATION", 108, 117]]], ["Therefore, Bactrian and hybrid camels, in addition to the dromedaries, should be immunized in order to reduce the chance of transmitting the virus to humans.", [["hybrid camels", "ORGANISM", 24, 37], ["humans", "ORGANISM", 150, 156], ["humans", "SPECIES", 150, 156], ["humans", "SPECIES", 150, 156], ["Bactrian", "TREATMENT", 11, 19], ["hybrid camels", "TREATMENT", 24, 37], ["the dromedaries", "TREATMENT", 54, 69]]]], "PMC7086538": [["BackgroundThe PLCG2 gene encodes phospholipase C\u03b32 (PLC\u03b32), a transmembrane signaling enzyme that catalyzes the production of second messenger molecules, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), that utilizes calcium as a cofactor and propagates downstream signals in a variety of hematopoietic cells.", [["transmembrane", "ANATOMY", 62, 75], ["hematopoietic cells", "ANATOMY", 301, 320], ["diacylglycerol", "CHEMICAL", 154, 168], ["DAG", "CHEMICAL", 170, 173], ["inositol 1,4,5-trisphosphate", "CHEMICAL", 179, 207], ["IP3", "CHEMICAL", 209, 212], ["calcium", "CHEMICAL", 229, 236], ["diacylglycerol", "CHEMICAL", 154, 168], ["DAG", "CHEMICAL", 170, 173], ["inositol 1,4,5-trisphosphate", "CHEMICAL", 179, 207], ["calcium", "CHEMICAL", 229, 236], ["PLCG2", "GENE_OR_GENE_PRODUCT", 14, 19], ["phospholipase C\u03b32", "GENE_OR_GENE_PRODUCT", 33, 50], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 52, 57], ["diacylglycerol", "SIMPLE_CHEMICAL", 154, 168], ["DAG", "SIMPLE_CHEMICAL", 170, 173], ["inositol 1,4,5-trisphosphate", "SIMPLE_CHEMICAL", 179, 207], ["IP3", "SIMPLE_CHEMICAL", 209, 212], ["calcium", "SIMPLE_CHEMICAL", 229, 236], ["hematopoietic cells", "CELL", 301, 320], ["PLCG2 gene", "DNA", 14, 24], ["phospholipase C\u03b32", "PROTEIN", 33, 50], ["PLC\u03b32", "PROTEIN", 52, 57], ["transmembrane signaling enzyme", "PROTEIN", 62, 92], ["second messenger molecules", "PROTEIN", 126, 152], ["hematopoietic cells", "CELL_TYPE", 301, 320], ["The PLCG2 gene encodes phospholipase C\u03b32", "TEST", 10, 50], ["PLC", "TEST", 52, 55], ["a transmembrane signaling enzyme", "TEST", 60, 92], ["diacylglycerol (DAG)", "TREATMENT", 154, 174], ["inositol 1,4,5-trisphosphate (IP3", "TREATMENT", 179, 212], ["calcium", "TREATMENT", 229, 236], ["a cofactor", "PROBLEM", 240, 250], ["hematopoietic cells", "OBSERVATION", 301, 320]]], ["IP3 increases intracellular calcium levels by inducing the release of endoplasmic reticulum (ER) calcium stores.", [["intracellular", "ANATOMY", 14, 27], ["endoplasmic reticulum", "ANATOMY", 70, 91], ["ER", "ANATOMY", 93, 95], ["IP3", "CHEMICAL", 0, 3], ["calcium", "CHEMICAL", 28, 35], ["calcium", "CHEMICAL", 97, 104], ["calcium", "CHEMICAL", 28, 35], ["calcium", "CHEMICAL", 97, 104], ["IP3", "SIMPLE_CHEMICAL", 0, 3], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["calcium", "SIMPLE_CHEMICAL", 28, 35], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 70, 91], ["ER", "GENE_OR_GENE_PRODUCT", 93, 95], ["calcium", "SIMPLE_CHEMICAL", 97, 104], ["ER", "PROTEIN", 93, 95], ["IP3", "TEST", 0, 3], ["intracellular calcium levels", "TEST", 14, 42], ["calcium stores", "TEST", 97, 111], ["endoplasmic reticulum", "OBSERVATION", 70, 91]]], ["The released intracellular Ca2+ leads to the translocation of additional PLC\u03b32 to the plasma membrane, where its activation leads to the sustained influx of extracellular Ca2+ across the plasma membrane [1].BackgroundRecently, heterozygous germline mutations in human PLCG2 were linked to two clinical phenotypes with some overlapping features\u2014PLC\u03b32-associated antibody deficiency and immune dysregulation syndrome (PLAID) and autoinflammation, antibody deficiency, and immune dysregulation syndrome (APLAID) [2\u20134].", [["intracellular", "ANATOMY", 13, 26], ["plasma membrane", "ANATOMY", 86, 101], ["extracellular", "ANATOMY", 157, 170], ["plasma membrane", "ANATOMY", 187, 202], ["Ca2", "CHEMICAL", 27, 30], ["Ca2", "CHEMICAL", 171, 174], ["immune dysregulation syndrome", "DISEASE", 385, 414], ["PLAID", "DISEASE", 416, 421], ["autoinflammation", "DISEASE", 427, 443], ["antibody deficiency", "DISEASE", 445, 464], ["immune dysregulation syndrome", "DISEASE", 470, 499], ["Ca2+", "CHEMICAL", 27, 31], ["Ca2+", "CHEMICAL", 171, 175], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["Ca2+", "SIMPLE_CHEMICAL", 27, 31], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 73, 78], ["plasma membrane", "CELLULAR_COMPONENT", 86, 101], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 170], ["Ca2+", "SIMPLE_CHEMICAL", 171, 175], ["plasma membrane", "CELLULAR_COMPONENT", 187, 202], ["human", "ORGANISM", 262, 267], ["PLCG2", "GENE_OR_GENE_PRODUCT", 268, 273], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 344, 349], ["Ca2", "PROTEIN", 27, 30], ["PLC\u03b32", "PROTEIN", 73, 78], ["Ca2", "PROTEIN", 171, 174], ["human PLCG2", "DNA", 262, 273], ["PLC\u03b32", "PROTEIN", 344, 349], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 262, 267], ["The released intracellular Ca2", "TREATMENT", 0, 30], ["extracellular Ca2", "TEST", 157, 174], ["heterozygous germline mutations in human PLCG2", "PROBLEM", 227, 273], ["some overlapping features", "PROBLEM", 318, 343], ["PLC", "TEST", 344, 347], ["antibody deficiency", "PROBLEM", 361, 380], ["immune dysregulation syndrome", "PROBLEM", 385, 414], ["PLAID)", "PROBLEM", 416, 422], ["autoinflammation", "PROBLEM", 427, 443], ["antibody deficiency", "PROBLEM", 445, 464], ["immune dysregulation syndrome", "PROBLEM", 470, 499], ["intracellular Ca2", "OBSERVATION", 13, 30], ["plasma membrane", "ANATOMY", 86, 101], ["germline mutations", "OBSERVATION", 240, 258], ["antibody deficiency", "OBSERVATION", 361, 380], ["immune dysregulation syndrome", "OBSERVATION", 385, 414], ["antibody deficiency", "OBSERVATION", 445, 464], ["immune dysregulation syndrome", "OBSERVATION", 470, 499]]], ["The majority of these mutations occur in the autoinhibitory C-terminal SH2 domain, conferring gain-of-function activity (Fig. 2a).", [["C", "CHEMICAL", 60, 61], ["autoinhibitory C-terminal SH2 domain", "PROTEIN", 45, 81], ["these mutations", "PROBLEM", 16, 31], ["mutations", "OBSERVATION", 22, 31]]], ["These PLCG2 variants have also been described as somatic mutations causing clonal expansion in Ibrutinib-resistant chronic lymphocytic leukemia (CLL) [5].", [["chronic lymphocytic leukemia", "ANATOMY", 115, 143], ["CLL", "ANATOMY", 145, 148], ["Ibrutinib", "CHEMICAL", 95, 104], ["chronic lymphocytic leukemia", "DISEASE", 115, 143], ["CLL", "DISEASE", 145, 148], ["Ibrutinib", "CHEMICAL", 95, 104], ["PLCG2", "GENE_OR_GENE_PRODUCT", 6, 11], ["Ibrutinib-resistant chronic lymphocytic leukemia", "CANCER", 95, 143], ["CLL", "CANCER", 145, 148], ["PLCG2", "PROTEIN", 6, 11], ["somatic mutations", "PROBLEM", 49, 66], ["clonal expansion", "PROBLEM", 75, 91], ["Ibrutinib-resistant chronic lymphocytic leukemia (CLL)", "PROBLEM", 95, 149], ["clonal", "OBSERVATION_MODIFIER", 75, 81], ["expansion", "OBSERVATION_MODIFIER", 82, 91], ["Ibrutinib", "OBSERVATION_MODIFIER", 95, 104], ["resistant", "OBSERVATION_MODIFIER", 105, 114], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["lymphocytic leukemia", "OBSERVATION", 123, 143]]], ["Another hotspot region in the PLC\u03b32 protein associated with Ibrutinib resistance mutations is amino acids 1139 to 1141 within the C2 domain which is involved in calcium binding and membrane anchoring of PLC\u03b32 [6].BackgroundTo our knowledge, there has never been a report of a germline mutation affecting the C2 domain of PLC\u03b32.", [["membrane", "ANATOMY", 181, 189], ["Ibrutinib", "CHEMICAL", 60, 69], ["amino acids", "CHEMICAL", 94, 105], ["calcium", "CHEMICAL", 161, 168], ["Ibrutinib", "CHEMICAL", 60, 69], ["amino acids", "CHEMICAL", 94, 105], ["calcium", "CHEMICAL", 161, 168], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 30, 35], ["Ibrutinib", "GENE_OR_GENE_PRODUCT", 60, 69], ["amino acids", "AMINO_ACID", 94, 105], ["1141", "AMINO_ACID", 114, 118], ["calcium", "SIMPLE_CHEMICAL", 161, 168], ["membrane", "CELLULAR_COMPONENT", 181, 189], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 321, 326], ["PLC\u03b32 protein", "PROTEIN", 30, 43], ["amino acids 1139 to 1141", "PROTEIN", 94, 118], ["C2 domain", "PROTEIN", 130, 139], ["PLC\u03b32", "PROTEIN", 203, 208], ["germline", "DNA", 276, 284], ["C2 domain", "PROTEIN", 308, 317], ["PLC\u03b32", "PROTEIN", 321, 326], ["Another hotspot region", "PROBLEM", 0, 22], ["Ibrutinib resistance mutations", "PROBLEM", 60, 90], ["amino acids", "TEST", 94, 105], ["calcium binding", "PROBLEM", 161, 176], ["a germline mutation", "PROBLEM", 274, 293], ["associated with", "UNCERTAINTY", 44, 59], ["Ibrutinib resistance", "OBSERVATION", 60, 80], ["C2", "ANATOMY", 130, 132], ["calcium binding", "OBSERVATION", 161, 176], ["germline mutation", "OBSERVATION", 276, 293], ["C2", "ANATOMY", 308, 310], ["PLC", "ANATOMY", 321, 324]]], ["Here we report 3 patients from 2 families with a novel gain-of-function heterozygous missense mutation in the C2 domain of PLCG2 (c.", [["patients", "ORGANISM", 17, 25], ["PLCG2", "GENE_OR_GENE_PRODUCT", 123, 128], ["C2 domain", "PROTEIN", 110, 119], ["PLCG2", "PROTEIN", 123, 128], ["patients", "SPECIES", 17, 25], ["a novel gain", "PROBLEM", 47, 59], ["heterozygous missense mutation", "PROBLEM", 72, 102], ["C2", "ANATOMY", 110, 112]]], ["3422 T>A) [p.Met1141Lys], which are associated with clinical symptoms that expand the phenotype of PLCG2 mutations.Patient Samples ::: Materials and MethodsWritten informed consent for genetic testing and participation for all three patients was provided by the parent and/or for their children in accordance with the Declaration of Helsinki.", [["3422 T>A", "GENE_OR_GENE_PRODUCT", 0, 8], ["Met1141Lys", "GENE_OR_GENE_PRODUCT", 13, 23], ["PLCG2", "GENE_OR_GENE_PRODUCT", 99, 104], ["patients", "ORGANISM", 233, 241], ["children", "ORGANISM", 286, 294], ["Patient", "SPECIES", 115, 122], ["patients", "SPECIES", 233, 241], ["children", "SPECIES", 286, 294], ["clinical symptoms", "PROBLEM", 52, 69], ["PLCG2 mutations", "PROBLEM", 99, 114], ["genetic testing", "TEST", 185, 200]]], ["Blood was collected from healthy pediatric sex-matched donors after consent at BC Children\u2019s Hospital or through the BC Children\u2019s Hospital BioBank.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["donors", "ORGANISM", 55, 61], ["Children", "SPECIES", 82, 90], ["Children", "SPECIES", 120, 128], ["Blood", "TEST", 0, 5]]], ["This research study was approved by the University of British Columbia institutional review board.Whole-Exome Sequencing of Patient ::: Materials and MethodsWhole-exome sequencing (WES) was performed at Canada\u2019s Michael Smith Genome Sciences Centre.", [["Patient", "SPECIES", 124, 131], ["This research study", "TEST", 0, 19]]], ["Exome library was constructed using the Agilent All Exon V4+UTR capture kit and sequenced on Illumina Hiseq2000.", [["Agilent All Exon V4", "DNA", 40, 59], ["Illumina Hiseq2000", "DNA", 93, 111], ["Exome library", "TEST", 0, 13], ["the Agilent All Exon V4+UTR capture kit", "TREATMENT", 36, 75], ["Illumina Hiseq2000", "TREATMENT", 93, 111]]], ["Reads were aligned to the human genome (GRCh37-lite) using Burrows\u2013Wheeler Aligner and duplicate marked with Picard [7, 8].", [["human", "ORGANISM", 26, 31], ["human genome", "DNA", 26, 38], ["GRCh37", "DNA", 40, 46], ["lite", "DNA", 47, 51], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["marked", "OBSERVATION_MODIFIER", 97, 103]]], ["Variants were called using mpileup (SAMtools), subsequently filtered with varFilter, and annotated using an in-house pipeline that combines SnpEff [9], Ensembl variant database (including pathogenicity prediction), dbSNP [10], NHLBI exome sequencing database (https://esp.gs.washington.edu/drupal/), COSMIC [11], and an in-house human variation database [12].", [["human", "ORGANISM", 329, 334], ["mpileup", "DNA", 27, 34], ["SAMtools", "DNA", 36, 44], ["varFilter", "DNA", 74, 83], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 329, 334], ["varFilter", "TREATMENT", 74, 83], ["NHLBI exome sequencing database", "TEST", 227, 258]]], ["Annotated variants were then filtered: (1) according to the inheritance mode, (2) ExAC Browser (exac.broadinstitute.org) and (3) previous reported pathogenicity with a phenotype of B cell defects in the Online Mendelian Inheritance in Man (OMIM) and ClinVar databases.", [["B cell", "ANATOMY", 181, 187], ["Mendelian Inheritance", "DISEASE", 210, 231], ["B cell", "CELL", 181, 187], ["ExAC Browser", "DNA", 82, 94], ["Annotated variants", "PROBLEM", 0, 18], ["B cell defects", "PROBLEM", 181, 195], ["B cell defects", "OBSERVATION", 181, 195]]], ["There were 193 unique variants identified of which PLCG2 was considered to be the most suitable for further evaluation based on in silico modeling and its known role in B cell development.", [["B cell", "ANATOMY", 169, 175], ["PLCG2", "GENE_OR_GENE_PRODUCT", 51, 56], ["B cell", "CELL", 169, 175], ["PLCG2", "PROTEIN", 51, 56], ["further evaluation", "TEST", 100, 118], ["silico modeling", "TEST", 131, 146], ["B cell", "OBSERVATION", 169, 175]]], ["The heterozygous variant was identified in 50 of 96 reads.Cell Lines and Reagents ::: Materials and MethodsHuman CD19+ B cells were incubated in RPMI medium (Gibco\u00ae, Waltham, USA), 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin/streptomycin.", [["Cell", "ANATOMY", 58, 62], ["MethodsHuman CD19+ B cells", "ANATOMY", 100, 126], ["fetal bovine serum", "ANATOMY", 185, 203], ["L-glutamine", "CHEMICAL", 208, 219], ["penicillin", "CHEMICAL", 228, 238], ["streptomycin", "CHEMICAL", 239, 251], ["L-glutamine", "CHEMICAL", 208, 219], ["penicillin", "CHEMICAL", 228, 238], ["streptomycin", "CHEMICAL", 239, 251], ["Cell", "CELL", 58, 62], ["CD19", "GENE_OR_GENE_PRODUCT", 113, 117], ["bovine", "ORGANISM", 191, 197], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["L-glutamine", "SIMPLE_CHEMICAL", 208, 219], ["penicillin", "SIMPLE_CHEMICAL", 228, 238], ["streptomycin", "SIMPLE_CHEMICAL", 239, 251], ["MethodsHuman CD19+ B cells", "CELL_LINE", 100, 126], ["bovine", "SPECIES", 191, 197], ["bovine", "SPECIES", 191, 197], ["The heterozygous variant", "PROBLEM", 0, 24], ["Materials", "TEST", 86, 95], ["MethodsHuman CD19+ B cells", "TREATMENT", 100, 126], ["Gibco\u00ae", "TEST", 158, 164], ["fetal bovine serum", "TEST", 185, 203], ["1% L-glutamine", "TREATMENT", 205, 219], ["1% penicillin", "TREATMENT", 225, 238], ["streptomycin", "TREATMENT", 239, 251], ["heterozygous variant", "OBSERVATION", 4, 24]]], ["The wild-type and PLC\u03b32 knockout DT40 chicken B cell lines were a kind gift from Dr. Michael Gold (University of British Columbia) and grown in RPMI medium (Gibco\u00ae), 10% fetal bovine serum, 1% chicken serum, 1% L-glutamine, and 1% penicillin/streptomycin.Isolation of Peripheral Blood Mononuclear Cells ::: Materials and MethodsPeripheral blood was collected via a peripheral blood draw into blood collection tubes containing ACD (trisodium citrate, citric acid, and dextrose) (BD Vacutainer\u00ae).", [["B cell lines", "ANATOMY", 46, 58], ["fetal bovine serum", "ANATOMY", 170, 188], ["serum", "ANATOMY", 201, 206], ["Peripheral Blood Mononuclear Cells", "ANATOMY", 268, 302], ["MethodsPeripheral blood", "ANATOMY", 321, 344], ["peripheral blood", "ANATOMY", 365, 381], ["blood", "ANATOMY", 392, 397], ["L-glutamine", "CHEMICAL", 211, 222], ["penicillin", "CHEMICAL", 231, 241], ["streptomycin", "CHEMICAL", 242, 254], ["trisodium citrate", "CHEMICAL", 431, 448], ["citric acid", "CHEMICAL", 450, 461], ["dextrose", "CHEMICAL", 467, 475], ["L-glutamine", "CHEMICAL", 211, 222], ["penicillin", "CHEMICAL", 231, 241], ["streptomycin", "CHEMICAL", 242, 254], ["trisodium citrate", "CHEMICAL", 431, 448], ["citric acid", "CHEMICAL", 450, 461], ["dextrose", "CHEMICAL", 467, 475], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 18, 23], ["B cell lines", "CELL", 46, 58], ["Gibco\u00ae", "SIMPLE_CHEMICAL", 157, 163], ["bovine", "ORGANISM", 176, 182], ["serum", "ORGANISM_SUBSTANCE", 183, 188], ["chicken", "ORGANISM", 193, 200], ["serum", "ORGANISM_SUBSTANCE", 201, 206], ["L-glutamine", "SIMPLE_CHEMICAL", 211, 222], ["penicillin", "SIMPLE_CHEMICAL", 231, 241], ["streptomycin", "SIMPLE_CHEMICAL", 242, 254], ["Peripheral Blood Mononuclear Cells", "CELL", 268, 302], ["MethodsPeripheral blood", "ORGANISM_SUBSTANCE", 321, 344], ["peripheral blood", "ORGANISM_SUBSTANCE", 365, 381], ["blood", "ORGANISM_SUBSTANCE", 392, 397], ["ACD", "SIMPLE_CHEMICAL", 426, 429], ["trisodium citrate", "SIMPLE_CHEMICAL", 431, 448], ["citric acid", "SIMPLE_CHEMICAL", 450, 461], ["dextrose", "SIMPLE_CHEMICAL", 467, 475], ["wild-type and PLC\u03b32 knockout DT40 chicken B cell lines", "CELL_LINE", 4, 58], ["Peripheral Blood Mononuclear Cells", "CELL_TYPE", 268, 302], ["chicken", "SPECIES", 38, 45], ["bovine", "SPECIES", 176, 182], ["chicken", "SPECIES", 193, 200], ["chicken", "SPECIES", 38, 45], ["bovine", "SPECIES", 176, 182], ["chicken", "SPECIES", 193, 200], ["The wild-type and PLC\u03b32 knockout DT40 chicken B cell lines", "TREATMENT", 0, 58], ["Gibco\u00ae", "TEST", 157, 163], ["fetal bovine serum", "TEST", 170, 188], ["serum", "TEST", 201, 206], ["L-glutamine", "TEST", 211, 222], ["1% penicillin", "TREATMENT", 228, 241], ["streptomycin", "TREATMENT", 242, 254], ["MethodsPeripheral blood", "TREATMENT", 321, 344], ["a peripheral blood draw into blood collection tubes", "TREATMENT", 363, 414], ["ACD (trisodium citrate", "TREATMENT", 426, 448], ["citric acid", "TREATMENT", 450, 461], ["dextrose", "TREATMENT", 467, 475], ["BD Vacutainer\u00ae)", "TREATMENT", 478, 493], ["cell lines", "OBSERVATION", 48, 58], ["Peripheral", "ANATOMY_MODIFIER", 268, 278], ["Blood", "ANATOMY", 279, 284], ["Mononuclear Cells", "OBSERVATION", 285, 302]]], ["Human peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood samples of patient #3 and healthy controls by Ficoll-Paque (GE Healthcare Life Sciences) density centrifugation method.Isolation of Human CD19+ B Cells ::: Materials and MethodsHuman B cells were purified after isolation of PBMCs as described above by negative selection using the StemSep\u00ae Human B Cell Enrichment kit according to the manufacturer\u2019s instructions (StemCell Technologies, Vancouver, Canada).", [["peripheral blood mononuclear cells", "ANATOMY", 6, 40], ["PBMCs", "ANATOMY", 42, 47], ["blood samples", "ANATOMY", 74, 87], ["CD19+ B Cells", "ANATOMY", 218, 231], ["MethodsHuman B cells", "ANATOMY", 250, 270], ["PBMCs", "ANATOMY", 304, 309], ["Cell", "ANATOMY", 378, 382], ["Human", "ORGANISM", 0, 5], ["peripheral blood mononuclear cells", "CELL", 6, 40], ["PBMCs", "CELL", 42, 47], ["blood samples", "ORGANISM_SUBSTANCE", 74, 87], ["patient", "ORGANISM", 91, 98], ["Human", "ORGANISM", 212, 217], ["CD19", "GENE_OR_GENE_PRODUCT", 218, 222], ["MethodsHuman B cells", "CELL", 250, 270], ["PBMCs", "CELL", 304, 309], ["Human", "ORGANISM", 370, 375], ["B Cell", "CELL", 376, 382], ["Human peripheral blood mononuclear cells", "CELL_TYPE", 0, 40], ["PBMCs", "CELL_TYPE", 42, 47], ["CD19", "PROTEIN", 218, 222], ["MethodsHuman B cells", "CELL_LINE", 250, 270], ["PBMCs", "CELL_TYPE", 304, 309], ["Human", "SPECIES", 0, 5], ["patient", "SPECIES", 91, 98], ["Human", "SPECIES", 212, 217], ["Human", "SPECIES", 370, 375], ["Human", "SPECIES", 0, 5], ["Human peripheral blood mononuclear cells", "TEST", 0, 40], ["PBMCs", "TEST", 42, 47], ["fresh blood samples", "TEST", 68, 87], ["Ficoll-Paque (GE Healthcare Life Sciences", "TREATMENT", 126, 167], ["MethodsHuman B cells", "TREATMENT", 250, 270], ["isolation of PBMCs", "TREATMENT", 291, 309], ["the StemSep\u00ae Human B Cell Enrichment kit", "TREATMENT", 357, 397], ["peripheral", "ANATOMY_MODIFIER", 6, 16], ["blood", "ANATOMY", 17, 22], ["mononuclear cells", "OBSERVATION", 23, 40]]], ["The purity of the CD19+ fraction was > 95% as determined by CD19 expression by FACS on an LSRII flow cytometer (BD Biosciences).Cell Lysis, Immunoprecipitation, SDS-PAGE, and Western Blotting ::: Materials and MethodsCell lysates of isolated primary CD19+ B cells from patient #3 and healthy controls were prepared using cell lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 \u03bcg/ml leupeptin; Cell Signaling) in the presence of protease inhibitor cocktails (Roche, Germany).", [["Cell", "ANATOMY", 128, 132], ["Cell lysates", "ANATOMY", 217, 229], ["primary CD19+ B cells", "ANATOMY", 242, 263], ["cell", "ANATOMY", 321, 325], ["Cell", "ANATOMY", 503, 507], ["Tris-HCl", "CHEMICAL", 346, 354], ["NaCl", "CHEMICAL", 372, 376], ["Na2EDTA", "CHEMICAL", 383, 390], ["EGTA", "CHEMICAL", 397, 401], ["sodium pyrophosphate", "CHEMICAL", 421, 441], ["beta-glycerophosphate", "CHEMICAL", 448, 469], ["Na3VO4", "CHEMICAL", 476, 482], ["Tris-HCl", "CHEMICAL", 346, 354], ["NaCl", "CHEMICAL", 372, 376], ["Na2EDTA", "CHEMICAL", 383, 390], ["EGTA", "CHEMICAL", 397, 401], ["sodium pyrophosphate", "CHEMICAL", 421, 441], ["beta-glycerophosphate", "CHEMICAL", 448, 469], ["Na3VO4", "CHEMICAL", 476, 482], ["leupeptin", "CHEMICAL", 492, 501], ["CD19", "GENE_OR_GENE_PRODUCT", 18, 22], ["CD19", "GENE_OR_GENE_PRODUCT", 60, 64], ["Cell", "CELL", 128, 132], ["Cell lysates", "CELL", 217, 229], ["CD19", "GENE_OR_GENE_PRODUCT", 250, 254], ["patient", "ORGANISM", 269, 276], ["cell", "CELL", 321, 325], ["Tris-HCl", "SIMPLE_CHEMICAL", 346, 354], ["Na2EDTA", "SIMPLE_CHEMICAL", 383, 390], ["EGTA", "SIMPLE_CHEMICAL", 397, 401], ["Triton", "SIMPLE_CHEMICAL", 406, 412], ["sodium pyrophosphate", "SIMPLE_CHEMICAL", 421, 441], ["beta-glycerophosphate", "SIMPLE_CHEMICAL", 448, 469], ["Na3VO4", "SIMPLE_CHEMICAL", 476, 482], ["leupeptin", "SIMPLE_CHEMICAL", 492, 501], ["Cell", "CELL", 503, 507], ["CD19", "PROTEIN", 18, 22], ["CD19", "PROTEIN", 60, 64], ["primary CD19+ B cells", "CELL_TYPE", 242, 263], ["patient", "SPECIES", 269, 276], ["the CD19+ fraction", "TEST", 14, 32], ["an LSRII flow cytometer", "TREATMENT", 87, 110], ["Cell Lysis", "TREATMENT", 128, 138], ["MethodsCell lysates", "TEST", 210, 229], ["cell lysis buffer", "TREATMENT", 321, 338], ["pH", "TEST", 356, 358], ["NaCl", "TEST", 372, 376], ["1 mM EGTA", "TREATMENT", 392, 401], ["1% Triton", "TREATMENT", 403, 412], ["2.5 mM sodium pyrophosphate", "TREATMENT", 414, 441], ["1 mM beta-glycerophosphate", "TREATMENT", 443, 469], ["1 mM Na3VO4", "TREATMENT", 471, 482], ["leupeptin", "TREATMENT", 492, 501], ["protease inhibitor cocktails", "TREATMENT", 538, 566], ["primary CD19", "OBSERVATION", 242, 254]]], ["Equal amounts of protein were separated by 10% SDS-PAGE gel, transferred to PVDF membrane, and blocked with 2% BSA.", [["PVDF membrane", "ANATOMY", 76, 89], ["PVDF", "CHEMICAL", 76, 80], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["BSA", "SIMPLE_CHEMICAL", 111, 114], ["2% BSA", "TREATMENT", 108, 114], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["PLC\u03b32 protein was detected by rabbit anti-PLC\u03b32 (Q-20) polyclonal antibody (Santa Cruz Biotechnology, Dallas, USA).", [["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 0, 5], ["rabbit", "ORGANISM", 30, 36], ["PLC\u03b32 protein", "PROTEIN", 0, 13], ["rabbit anti-PLC\u03b32 (Q-20) polyclonal antibody", "PROTEIN", 30, 74], ["Santa Cruz Biotechnology", "PROTEIN", 76, 100], ["rabbit", "SPECIES", 30, 36], ["rabbit", "SPECIES", 30, 36], ["PLC\u03b32 protein", "TEST", 0, 13], ["rabbit anti-PLC\u03b32", "TEST", 30, 47], ["polyclonal antibody", "TEST", 55, 74]]], ["After washing, bound antibody was detected with HRP-conjugated anti-rabbit secondary antibody and Novex ECL chemiluminescent substrate (Invitrogen/ThermoFisher Scientific, MA, USA) or with anti-rabbit 680RD secondary antibody on the LiCor Phosphorimager Odyssey (LiCor, USA).B Cell Immunophenotyping ::: Materials and MethodsImmunophenotyping on isolated PBMCs from patient #3 and healthy controls was performed using combinations of Brilliant Violet 605\u2122-CD19 (SJ25C1; BioLegend), PE-Cy7-CD19 (HIB19; BioLegend), Pacific Blue\u2122-CD19 (HIB19; BioLegend), PerCP-CD24 (ML5; BioLegend), Brilliant Violet 421\u2122-CD38 (HIT2; BioLegend), V450-CD38 (HIT2; BD Biosciences), PE-CD38 (HIT2, BioLegend), PE-CD27 (M-T271; BioLegend), FITC-IgD (IA6-2; BioLegend), FITC-CD21 (Bu32; BioLegend), PE-Cy5-CD21 (B-ly4; BD Pharmingen), Alexa Fluor\u00ae 700-CD10 (CB-CALLA; eBioscience), APC-CD10 (HI10a; BioLegend), and APC-IgM (MHM-88; BioLegend).", [["Cell", "ANATOMY", 277, 281], ["PBMCs", "ANATOMY", 355, 360], ["FITC", "CHEMICAL", 718, 722], ["FITC", "CHEMICAL", 747, 751], ["HRP", "SIMPLE_CHEMICAL", 48, 51], ["B Cell", "CELL", 275, 281], ["PBMCs", "CELL", 355, 360], ["patient", "ORGANISM", 366, 373], ["CD19", "GENE_OR_GENE_PRODUCT", 456, 460], ["BioLegend", "GENE_OR_GENE_PRODUCT", 470, 479], ["CD19", "GENE_OR_GENE_PRODUCT", 489, 493], ["BioLegend", "GENE_OR_GENE_PRODUCT", 502, 511], ["CD19", "GENE_OR_GENE_PRODUCT", 528, 532], ["BioLegend", "GENE_OR_GENE_PRODUCT", 541, 550], ["PerCP-CD24", "GENE_OR_GENE_PRODUCT", 553, 563], ["CD38", "GENE_OR_GENE_PRODUCT", 604, 608], ["BioLegend", "GENE_OR_GENE_PRODUCT", 616, 625], ["V450-CD38", "GENE_OR_GENE_PRODUCT", 628, 637], ["PE-CD38", "GENE_OR_GENE_PRODUCT", 662, 669], ["BioLegend", "GENE_OR_GENE_PRODUCT", 677, 686], ["CD27", "GENE_OR_GENE_PRODUCT", 692, 696], ["BioLegend", "GENE_OR_GENE_PRODUCT", 706, 715], ["FITC-IgD", "GENE_OR_GENE_PRODUCT", 718, 726], ["BioLegend", "GENE_OR_GENE_PRODUCT", 735, 744], ["FITC-CD21", "GENE_OR_GENE_PRODUCT", 747, 756], ["BioLegend", "GENE_OR_GENE_PRODUCT", 764, 773], ["CD21", "GENE_OR_GENE_PRODUCT", 783, 787], ["B-ly4", "GENE_OR_GENE_PRODUCT", 789, 794], ["CD10", "GENE_OR_GENE_PRODUCT", 829, 833], ["APC-CD10", "GENE_OR_GENE_PRODUCT", 859, 867], ["BioLegend", "GENE_OR_GENE_PRODUCT", 876, 885], ["APC", "GENE_OR_GENE_PRODUCT", 892, 895], ["BioLegend", "GENE_OR_GENE_PRODUCT", 909, 918], ["HRP-conjugated anti-rabbit secondary antibody", "PROTEIN", 48, 93], ["anti-rabbit 680RD secondary antibody", "PROTEIN", 189, 225], ["PBMCs", "CELL_TYPE", 355, 360], ["CD19", "PROTEIN", 456, 460], ["SJ25C1", "PROTEIN", 462, 468], ["BioLegend", "PROTEIN", 470, 479], ["PE", "PROTEIN", 482, 484], ["Cy7", "PROTEIN", 485, 488], ["CD19", "PROTEIN", 489, 493], ["HIB19", "PROTEIN", 495, 500], ["BioLegend", "PROTEIN", 502, 511], ["Pacific Blue\u2122", "PROTEIN", 514, 527], ["CD19", "PROTEIN", 528, 532], ["HIB19", "PROTEIN", 534, 539], ["BioLegend", "PROTEIN", 541, 550], ["PerCP", "PROTEIN", 553, 558], ["CD24", "PROTEIN", 559, 563], ["ML5", "PROTEIN", 565, 568], ["BioLegend", "PROTEIN", 570, 579], ["Brilliant Violet 421\u2122", "PROTEIN", 582, 603], ["CD38", "PROTEIN", 604, 608], ["HIT2", "PROTEIN", 610, 614], ["BioLegend", "PROTEIN", 616, 625], ["V450", "PROTEIN", 628, 632], ["CD38", "PROTEIN", 633, 637], ["HIT2", "PROTEIN", 639, 643], ["BD Biosciences", "PROTEIN", 645, 659], ["PE", "PROTEIN", 662, 664], ["CD38", "PROTEIN", 665, 669], ["HIT2", "PROTEIN", 671, 675], ["BioLegend", "PROTEIN", 677, 686], ["PE", "PROTEIN", 689, 691], ["CD27", "PROTEIN", 692, 696], ["T271", "PROTEIN", 700, 704], ["BioLegend", "PROTEIN", 706, 715], ["FITC", "PROTEIN", 718, 722], ["IgD", "PROTEIN", 723, 726], ["IA6", "PROTEIN", 728, 731], ["BioLegend", "PROTEIN", 735, 744], ["FITC", "PROTEIN", 747, 751], ["CD21", "PROTEIN", 752, 756], ["Bu32", "PROTEIN", 758, 762], ["BioLegend", "PROTEIN", 764, 773], ["PE", "PROTEIN", 776, 778], ["CD21", "PROTEIN", 783, 787], ["B", "PROTEIN", 789, 790], ["ly4", "PROTEIN", 791, 794], ["BD Pharmingen", "PROTEIN", 796, 809], ["Alexa Fluor\u00ae 700", "DNA", 812, 828], ["CD10", "PROTEIN", 829, 833], ["CB", "PROTEIN", 835, 837], ["CALLA", "PROTEIN", 838, 843], ["eBioscience", "PROTEIN", 845, 856], ["APC", "DNA", 859, 862], ["CD10", "PROTEIN", 863, 867], ["HI10a", "DNA", 869, 874], ["BioLegend", "PROTEIN", 876, 885], ["APC", "DNA", 892, 895], ["IgM", "PROTEIN", 896, 899], ["MHM", "DNA", 901, 904], ["BioLegend", "DNA", 909, 918], ["anti-rabbit", "SPECIES", 63, 74], ["anti-rabbit", "SPECIES", 189, 200], ["patient", "SPECIES", 366, 373], ["anti-rabbit", "SPECIES", 189, 200], ["bound antibody", "TEST", 15, 29], ["HRP", "TEST", 48, 51], ["conjugated anti-rabbit", "TREATMENT", 52, 74], ["antibody", "TEST", 85, 93], ["Novex ECL chemiluminescent substrate", "TREATMENT", 98, 134], ["anti-rabbit", "TREATMENT", 189, 200], ["MethodsImmunophenotyping", "TREATMENT", 318, 342], ["isolated PBMCs", "TREATMENT", 346, 360], ["Brilliant Violet", "TREATMENT", 434, 450], ["PE", "TEST", 482, 484], ["HIT2", "TEST", 610, 614], ["BioLegend", "TEST", 616, 625], ["HIT2", "TEST", 639, 643], ["BD Biosciences", "TEST", 645, 659], ["PE", "TEST", 662, 664], ["CD38", "TEST", 665, 669], ["HIT2", "TEST", 671, 675], ["BioLegend", "TEST", 677, 686], ["PE", "TEST", 689, 691], ["CD27", "TEST", 692, 696], ["M", "TEST", 698, 699], ["BioLegend", "TEST", 706, 715], ["FITC", "TEST", 718, 722], ["IgD", "TEST", 723, 726], ["IA6", "TEST", 728, 731], ["BioLegend", "TEST", 735, 744], ["FITC", "TEST", 747, 751], ["CD21", "TEST", 752, 756], ["Bu32", "TEST", 758, 762], ["BioLegend", "TEST", 764, 773], ["PE", "TEST", 776, 778], ["Cy5", "TEST", 779, 782], ["CD21", "TEST", 783, 787], ["B", "TEST", 789, 790], ["BD Pharmingen", "TEST", 796, 809], ["Alexa Fluor\u00ae", "TEST", 812, 824], ["CB", "TEST", 835, 837], ["CALLA", "TEST", 838, 843], ["eBioscience", "TEST", 845, 856], ["APC", "TEST", 859, 862], ["CD10", "TEST", 863, 867], ["HI10a", "TEST", 869, 874], ["BioLegend", "TEST", 876, 885], ["APC", "TEST", 892, 895], ["IgM", "TEST", 896, 899], ["MHM", "TEST", 901, 904], ["Cell Immunophenotyping", "OBSERVATION", 277, 299], ["PE", "OBSERVATION", 482, 484], ["PE", "OBSERVATION", 662, 664], ["PE", "OBSERVATION", 689, 691], ["PE", "OBSERVATION", 776, 778]]], ["Intracellular staining was done with a combination of BD Cytofix\u2122 incubation on ice for 15 min and BD FACS Permeabilizing Solution 2 incubation at room temperature for 10 min.", [["Intracellular", "ANATOMY", 0, 13], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Intracellular staining", "TEST", 0, 22], ["BD Cytofix", "TREATMENT", 54, 64], ["ice", "TREATMENT", 80, 83], ["BD FACS Permeabilizing Solution", "TREATMENT", 99, 130], ["staining", "OBSERVATION", 14, 22]]], ["Cells were analyzed using a LSR II flow cytometer (BD Biosciences) and data was analyzed using FlowJo (Tree Star, Ashland, OR, USA).Calcium Flux Assay ::: Materials and MethodsPBMCs from patient #3 and healthy controls were washed once in HBSS (no Ca2+, no Mg2+, Life Technologies) + 1% FBS (Gibco\u00ae) and resuspended in dye-loading buffer consisting of 4 \u03bcM FLUO-4AM (Molecular Probes) and Probenecid (Life Technologies) in HBSS+1% FBS for 45 min at 37 \u00b0C at a concentration of 1 \u00d7 106 PBMCs/mL.", [["Cells", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 287, 290], ["FBS", "ANATOMY", 431, 434], ["PBMCs", "ANATOMY", 485, 490], ["Calcium", "CHEMICAL", 132, 139], ["Ca2", "CHEMICAL", 248, 251], ["Gibco\u00ae", "CHEMICAL", 292, 298], ["FLUO-4AM", "CHEMICAL", 357, 365], ["Probenecid", "CHEMICAL", 389, 399], ["Calcium", "CHEMICAL", 132, 139], ["Ca2+", "CHEMICAL", 248, 252], ["Mg2+", "CHEMICAL", 257, 261], ["FLUO-4AM", "CHEMICAL", 357, 365], ["Probenecid", "CHEMICAL", 389, 399], ["Cells", "CELL", 0, 5], ["Calcium", "SIMPLE_CHEMICAL", 132, 139], ["MethodsPBMCs", "CELL", 169, 181], ["patient", "ORGANISM", 187, 194], ["Ca2+", "SIMPLE_CHEMICAL", 248, 252], ["Mg2+", "SIMPLE_CHEMICAL", 257, 261], ["FBS", "ORGANISM_SUBSTANCE", 287, 290], ["Gibco\u00ae", "SIMPLE_CHEMICAL", 292, 298], ["FLUO-4AM", "SIMPLE_CHEMICAL", 357, 365], ["Probenecid", "SIMPLE_CHEMICAL", 389, 399], ["FBS", "ORGANISM_SUBSTANCE", 431, 434], ["LSR II", "PROTEIN", 28, 34], ["MethodsPBMCs", "CELL_TYPE", 169, 181], ["patient", "SPECIES", 187, 194], ["a LSR II flow cytometer", "TREATMENT", 26, 49], ["BD Biosciences", "TEST", 51, 65], ["Calcium Flux Assay", "TEST", 132, 150], ["MethodsPBMCs", "TEST", 169, 181], ["HBSS", "TEST", 239, 243], ["Ca2", "TEST", 248, 251], ["Mg2", "TEST", 257, 260], ["Life Technologies", "TEST", 263, 280], ["dye-loading buffer", "TREATMENT", 319, 337], ["4 \u03bcM FLUO", "TREATMENT", 352, 361], ["Molecular Probes", "TREATMENT", 367, 383], ["Probenecid (Life Technologies", "TREATMENT", 389, 418], ["HBSS", "TEST", 423, 427], ["FBS", "TEST", 431, 434]]], ["Cells were washed again with HBSS+1%FBS and then incubated on ice for 20 min with 5 \u03bcL of Pacific Blue\u2122-CD19 (HIB19; BioLegend) followed by addition of 1 mL HBSS+1%FBS.", [["Cells", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 36, 39], ["FBS", "ANATOMY", 164, 167], ["Cells", "CELL", 0, 5], ["FBS", "ORGANISM_SUBSTANCE", 36, 39], ["CD19", "GENE_OR_GENE_PRODUCT", 104, 108], ["FBS", "ORGANISM_SUBSTANCE", 164, 167], ["CD19", "PROTEIN", 104, 108], ["HIB19", "PROTEIN", 110, 115], ["BioLegend", "PROTEIN", 117, 126], ["HBSS", "TEST", 29, 33], ["ice", "TREATMENT", 62, 65], ["Pacific Blue\u2122", "TREATMENT", 90, 103], ["1 mL HBSS", "TREATMENT", 152, 161]]], ["Samples were warmed again to 37 \u00b0C and within 10 min baseline fluorescence was detected with FITC filter on LSR II flow cytometer in the CD19+ positive fraction.", [["Samples", "ANATOMY", 0, 7], ["FITC", "CHEMICAL", 93, 97], ["FITC", "SIMPLE_CHEMICAL", 93, 97], ["CD19", "GENE_OR_GENE_PRODUCT", 137, 141], ["LSR II", "PROTEIN", 108, 114], ["CD19", "PROTEIN", 137, 141], ["Samples", "TEST", 0, 7], ["FITC filter", "TREATMENT", 93, 104], ["LSR II flow cytometer", "TEST", 108, 129], ["the CD19", "TEST", 133, 141], ["FITC filter", "OBSERVATION", 93, 104], ["CD19", "ANATOMY", 137, 141], ["positive fraction", "OBSERVATION", 143, 160]]], ["Intracellular calcium flux was induced by BCR stimulation with 10 \u03bcg/mL anti-IgM antibody (Jackson Immunoresearch) followed by the addition of extracellular Ca2+ to measure external flux.Intracellular ERK Phosphorylation ::: Materials and MethodsFreshly isolated PBMCs from patient #3 and healthy controls were stimulated with 10 \u03bcg/mL soluble anti-IgM antibody (Jackson Immunoresearch Labs, West Grove, USA) at 37 \u00b0C. At indicated time-points, cells were fixed with BD Phosflow\u2122 Fix Buffer I for 10 min at 37 \u00b0C followed by permeabilization with BD FACS Permeabilizing Solution 2 for 10 min at room temperature.", [["Intracellular", "ANATOMY", 0, 13], ["extracellular", "ANATOMY", 143, 156], ["Intracellular", "ANATOMY", 187, 200], ["PBMCs", "ANATOMY", 263, 268], ["cells", "ANATOMY", 445, 450], ["calcium", "CHEMICAL", 14, 21], ["Ca2", "CHEMICAL", 157, 160], ["calcium", "CHEMICAL", 14, 21], ["Ca2+", "CHEMICAL", 157, 161], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["calcium", "SIMPLE_CHEMICAL", 14, 21], ["BCR", "GENE_OR_GENE_PRODUCT", 42, 45], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 143, 156], ["Ca2+", "SIMPLE_CHEMICAL", 157, 161], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 200], ["ERK", "GENE_OR_GENE_PRODUCT", 201, 204], ["PBMCs", "CELL", 263, 268], ["patient", "ORGANISM", 274, 281], ["controls", "ORGANISM", 297, 305], ["cells", "CELL", 445, 450], ["BCR", "PROTEIN", 42, 45], ["IgM antibody", "PROTEIN", 77, 89], ["Jackson Immunoresearch", "PROTEIN", 91, 113], ["Ca2", "PROTEIN", 157, 160], ["ERK", "PROTEIN", 201, 204], ["PBMCs", "CELL_TYPE", 263, 268], ["IgM antibody", "PROTEIN", 349, 361], ["patient", "SPECIES", 274, 281], ["Immunoresearch", "SPECIES", 371, 385], ["Intracellular calcium flux", "TEST", 0, 26], ["BCR stimulation", "TEST", 42, 57], ["extracellular Ca2", "TREATMENT", 143, 160], ["Intracellular ERK Phosphorylation", "TEST", 187, 220], ["Methods", "TEST", 239, 246], ["BD Phosflow\u2122 Fix Buffer I", "TREATMENT", 467, 492], ["BD FACS Permeabilizing Solution", "TREATMENT", 547, 578], ["calcium flux", "OBSERVATION", 14, 26], ["ERK Phosphorylation", "OBSERVATION", 201, 220]]], ["Cells were then stained with V450-CD20 (L27, BD Bioscience), Alexa Fluor 488 \u2013 phospho-PLC\u03b32 (pY759) (K86-689.37; BD Biosciences) and PerCP-eFluor\u00ae 710 phospho-ERK1/2 (T202/Y204) (MILAN8R, eBioscience) for 20 min at RT and analyzed on a BD LSR II flow cytometer.Collagen Stimulation of Platelets ::: Materials and MethodsWhole blood was collected in a BD Vacutainer\u00ae Plus plastic citrate tube (0.109 Molar/3.2% sodium citrate) from patient #3 and healthy controls after a 3 mL discard.", [["Cells", "ANATOMY", 0, 5], ["Platelets", "ANATOMY", 286, 295], ["blood", "ANATOMY", 327, 332], ["plastic citrate", "CHEMICAL", 372, 387], ["sodium citrate", "CHEMICAL", 411, 425], ["Alexa Fluor 488", "CHEMICAL", 61, 76], ["phospho", "CHEMICAL", 79, 86], ["phospho", "CHEMICAL", 152, 159], ["citrate", "CHEMICAL", 380, 387], ["sodium citrate", "CHEMICAL", 411, 425], ["Cells", "CELL", 0, 5], ["CD20", "GENE_OR_GENE_PRODUCT", 34, 38], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 61, 76], ["phospho-PLC\u03b32", "SIMPLE_CHEMICAL", 79, 92], ["phospho-ERK1/2", "GENE_OR_GENE_PRODUCT", 152, 166], ["Collagen", "GENE_OR_GENE_PRODUCT", 262, 270], ["Platelets", "CELL", 286, 295], ["blood", "ORGANISM_SUBSTANCE", 327, 332], ["sodium citrate", "SIMPLE_CHEMICAL", 411, 425], ["patient", "ORGANISM", 432, 439], ["V450", "PROTEIN", 29, 33], ["CD20", "PROTEIN", 34, 38], ["L27", "PROTEIN", 40, 43], ["BD", "PROTEIN", 45, 47], ["Alexa Fluor 488", "PROTEIN", 61, 76], ["phospho", "PROTEIN", 79, 86], ["PLC\u03b32", "PROTEIN", 87, 92], ["pY759", "PROTEIN", 94, 99], ["BD Biosciences", "PROTEIN", 114, 128], ["PerCP", "PROTEIN", 134, 139], ["phospho", "PROTEIN", 152, 159], ["ERK1/2", "PROTEIN", 160, 166], ["T202", "PROTEIN", 168, 172], ["Y204", "PROTEIN", 173, 177], ["MILAN8R", "PROTEIN", 180, 187], ["eBioscience", "PROTEIN", 189, 200], ["BD LSR II", "PROTEIN", 237, 246], ["Platelets", "CELL_TYPE", 286, 295], ["patient", "SPECIES", 432, 439], ["Cells", "TEST", 0, 5], ["CD20", "TEST", 34, 38], ["Alexa Fluor", "TEST", 61, 72], ["phospho", "TEST", 79, 86], ["BD Biosciences", "TEST", 114, 128], ["PerCP", "TEST", 134, 139], ["eFluor\u00ae", "TEST", 140, 147], ["phospho", "TEST", 152, 159], ["ERK1/2", "TEST", 160, 166], ["T202", "TEST", 168, 172], ["Collagen Stimulation of Platelets", "TREATMENT", 262, 295], ["a BD Vacutainer", "TREATMENT", 350, 365], ["plastic citrate tube", "TREATMENT", 372, 392], ["Molar/3.2% sodium citrate", "TREATMENT", 400, 425], ["citrate tube", "OBSERVATION", 380, 392]]], ["A total of 90 \u03bcL of whole blood was then immediately mixed with 10 \u03bcL of PBS containing soluble native collagen fibrils (type I) (Chrono-log Corporation) at indicated concentration for 15 min.", [["\u03bcL", "ANATOMY", 14, 16], ["whole blood", "ANATOMY", 20, 31], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["collagen", "GENE_OR_GENE_PRODUCT", 103, 111], ["collagen fibrils", "PROTEIN", 103, 119], ["whole blood", "TREATMENT", 20, 31], ["PBS", "TREATMENT", 73, 76], ["soluble native collagen fibrils", "TREATMENT", 88, 119]]], ["Subsequently, 5 \u03bcL of this mixture was incubated with a flow cytometry antibody mix of 3 \u03bcL of FITC-CD61 (VI-PL2; BioLegend) and APC-CD62P (P-Selectin) (AK4; BioLegend) each for 15 min on ice in the dark.", [["FITC", "CHEMICAL", 95, 99], ["FITC-CD61", "SIMPLE_CHEMICAL", 95, 104], ["BioLegend", "GENE_OR_GENE_PRODUCT", 114, 123], ["APC-CD62P", "GENE_OR_GENE_PRODUCT", 129, 138], ["P-Selectin", "SIMPLE_CHEMICAL", 140, 150], ["FITC", "PROTEIN", 95, 99], ["CD61", "PROTEIN", 100, 104], ["VI", "PROTEIN", 106, 108], ["PL2", "PROTEIN", 109, 112], ["BioLegend", "PROTEIN", 114, 123], ["APC", "PROTEIN", 129, 132], ["CD62P", "PROTEIN", 133, 138], ["P", "PROTEIN", 140, 141], ["Selectin", "PROTEIN", 142, 150], ["AK4", "PROTEIN", 153, 156], ["BioLegend", "PROTEIN", 158, 167], ["this mixture", "TREATMENT", 22, 34], ["a flow cytometry antibody mix", "TEST", 54, 83], ["FITC", "TEST", 95, 99], ["CD61", "TEST", 100, 104], ["VI", "TEST", 106, 108], ["PL2", "TEST", 109, 112], ["BioLegend", "TEST", 114, 123], ["APC", "TEST", 129, 132], ["CD62P", "TEST", 133, 138]]], ["At the end of the incubation, 1 mL of 1% paraformaldehyde solution was added and the final mixture was acquired on a LSRII cytometer (BD Biosciences).Cloning and Transfection Studies ::: Materials and MethodsPlasmids used for transfection studies contained full-length wild-type PLCG2 cloned into pCMV6-Entry with a C-terminal Myc-DDK (FLAG) tag (Origene, Rockville, MD, USA) or an empty vector.", [["paraformaldehyde", "CHEMICAL", 41, 57], ["C", "CHEMICAL", 316, 317], ["paraformaldehyde", "SIMPLE_CHEMICAL", 41, 57], ["PLCG2", "GENE_OR_GENE_PRODUCT", 279, 284], ["pCMV6", "GENE_OR_GENE_PRODUCT", 297, 302], ["PLCG2", "DNA", 279, 284], ["pCMV6", "DNA", 297, 302], ["C-terminal Myc-DDK (FLAG) tag", "DNA", 316, 345], ["1% paraformaldehyde solution", "TREATMENT", 38, 66], ["a LSRII cytometer", "TREATMENT", 115, 132], ["Materials", "TREATMENT", 187, 196], ["MethodsPlasmids", "TREATMENT", 201, 216], ["transfection studies", "TEST", 226, 246], ["a C", "TEST", 314, 317], ["empty vector", "OBSERVATION", 382, 394]]], ["A mutant PLCG2 plasmid corresponding to our patient\u2019s genetic variant was constructed by site-directed mutagenesis (Q5 Site-Directed Mutagenesis Kit, New England BioLabs Inc., MA, USA) as per manufacturer\u2019s instructions.", [["PLCG2", "GENE_OR_GENE_PRODUCT", 9, 14], ["patient", "ORGANISM", 44, 51], ["mutant PLCG2 plasmid", "DNA", 2, 22], ["patient", "SPECIES", 44, 51], ["A mutant PLCG2 plasmid", "TREATMENT", 0, 22]]], ["For transfection studies, 1 \u00d7 106 PLC\u03b32\u2212/\u2212 DT40 cells were transfected with 0.5 \u03bcg of plasmid DNA in Opti-MEM (Gibco\u00ae) by using the B-023 program in an Amaxa Nucleofector II device (Lonza, Allendale, NJ, USA).", [["\u03b32\u2212/\u2212 DT40 cells", "ANATOMY", 37, 53], ["plasmid", "ANATOMY", 86, 93], ["B-023", "CHEMICAL", 132, 137], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["PLC\u03b32\u2212/\u2212 DT40 cells", "CELL_LINE", 34, 53], ["plasmid DNA", "DNA", 86, 97], ["transfection studies", "TEST", 4, 24], ["PLC", "TEST", 34, 37], ["DT40 cells", "TEST", 43, 53], ["plasmid DNA", "TREATMENT", 86, 97], ["an Amaxa Nucleofector II device", "TREATMENT", 149, 180]]], ["After overnight incubation, cells were stimulated with 10 \u03bcg/mL of anti-chicken IgM (#8300-01, Southern Biotech) in HBSS (no Ca2+, no Mg2+, Life Technologies) + 1% FBS (Gibco\u00ae) and calcium flux analyzed as described.Statistical Analysis ::: Materials and MethodsDescriptive statistics were generated on all data using Prism version 6 for Mac (GraphPad Software, San Diego, CA, USA).", [["cells", "ANATOMY", 28, 33], ["FBS", "ANATOMY", 164, 167], ["Ca2", "CHEMICAL", 125, 128], ["calcium", "CHEMICAL", 181, 188], ["Ca2+", "CHEMICAL", 125, 129], ["Mg2+", "CHEMICAL", 134, 138], ["calcium", "CHEMICAL", 181, 188], ["cells", "CELL", 28, 33], ["HBSS", "SIMPLE_CHEMICAL", 116, 120], ["Ca2+", "SIMPLE_CHEMICAL", 125, 129], ["Mg2+", "SIMPLE_CHEMICAL", 134, 138], ["FBS", "ORGANISM_SUBSTANCE", 164, 167], ["Gibco\u00ae", "SIMPLE_CHEMICAL", 169, 175], ["calcium", "SIMPLE_CHEMICAL", 181, 188], ["anti-chicken IgM", "PROTEIN", 67, 83], ["anti-chicken IgM", "TEST", 67, 83], ["HBSS", "TEST", 116, 120], ["Ca2", "TEST", 125, 128], ["Mg2", "TEST", 134, 137], ["Life Technologies", "TEST", 140, 157], ["FBS", "TEST", 164, 167], ["Gibco\u00ae", "TEST", 169, 175], ["calcium flux", "TEST", 181, 193], ["Prism version", "TREATMENT", 318, 331]]], ["Significance of observed changes was determined using paired and unpaired Student t tests and two-tailed Mann-Whitney test.Cases #1 and #2 ::: ResultsA 21-month-old female presented with a history of recurrent rashes since birth and scattered atrophic scarring on physical examination.", [["rashes", "DISEASE", 210, 216], ["female", "ORGANISM", 165, 171], ["observed changes", "PROBLEM", 16, 32], ["Student t tests", "TEST", 74, 89], ["recurrent rashes", "PROBLEM", 200, 216], ["scattered atrophic scarring", "PROBLEM", 233, 260], ["physical examination", "TEST", 264, 284], ["recurrent", "OBSERVATION_MODIFIER", 200, 209], ["rashes", "OBSERVATION", 210, 216], ["scattered", "OBSERVATION_MODIFIER", 233, 242], ["atrophic", "OBSERVATION_MODIFIER", 243, 251], ["scarring", "OBSERVATION", 252, 260]]], ["At 2 days of life, she developed vesiculobullous eruptions positive for Serratia marcescens.", [["eruptions", "DISEASE", 49, 58], ["Serratia marcescens", "ORGANISM", 72, 91], ["Serratia marcescens", "SPECIES", 72, 91], ["Serratia marcescens", "SPECIES", 72, 91], ["vesiculobullous eruptions", "PROBLEM", 33, 58], ["Serratia marcescens", "PROBLEM", 72, 91], ["vesiculobullous", "OBSERVATION_MODIFIER", 33, 48], ["Serratia marcescens", "OBSERVATION", 72, 91]]], ["She continued to develop recurrent episodes of 1\u20132 mm erythematous, non-folliculocentric papules that evolved into urticarial lesions or flaccid vesicles on an erythematous base.", [["papules", "ANATOMY", 89, 96], ["urticarial lesions", "ANATOMY", 115, 133], ["flaccid vesicles", "ANATOMY", 137, 153], ["erythematous base", "ANATOMY", 160, 177], ["papules", "DISEASE", 89, 96], ["papules", "PATHOLOGICAL_FORMATION", 89, 96], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 115, 133], ["1\u20132 mm erythematous, non-folliculocentric papules", "PROBLEM", 47, 96], ["urticarial lesions", "PROBLEM", 115, 133], ["flaccid vesicles", "PROBLEM", 137, 153], ["an erythematous base", "PROBLEM", 157, 177], ["recurrent", "OBSERVATION_MODIFIER", 25, 34], ["1\u20132 mm", "OBSERVATION_MODIFIER", 47, 53], ["erythematous", "OBSERVATION_MODIFIER", 54, 66], ["non-folliculocentric", "OBSERVATION_MODIFIER", 68, 88], ["papules", "OBSERVATION", 89, 96], ["urticarial", "OBSERVATION_MODIFIER", 115, 125], ["lesions", "OBSERVATION", 126, 133], ["flaccid vesicles", "OBSERVATION", 137, 153], ["erythematous", "OBSERVATION_MODIFIER", 160, 172], ["base", "ANATOMY_MODIFIER", 173, 177]]], ["Lesions appeared in migrating crops and resolved spontaneously over 1\u20132 weeks with rare atrophic scarring (Fig. 1).", [["Lesions", "PROBLEM", 0, 7], ["rare atrophic scarring", "PROBLEM", 83, 105], ["migrating", "OBSERVATION_MODIFIER", 20, 29], ["crops", "OBSERVATION_MODIFIER", 30, 35], ["rare", "OBSERVATION_MODIFIER", 83, 87], ["atrophic", "OBSERVATION_MODIFIER", 88, 96], ["scarring", "OBSERVATION", 97, 105], ["Fig", "OBSERVATION_MODIFIER", 107, 110]]], ["The eruptions were exacerbated by heat and moisture.", [["eruptions", "DISEASE", 4, 13], ["The eruptions", "PROBLEM", 0, 13], ["eruptions", "OBSERVATION", 4, 13]]], ["In addition to cutaneous findings, she also had recurrent episodes of bloody stools and was treated for multiple respiratory infections, including RSV, adenovirus, and coronavirus.", [["cutaneous", "ANATOMY", 15, 24], ["respiratory", "ANATOMY", 113, 124], ["bloody stools", "DISEASE", 70, 83], ["respiratory infections", "DISEASE", 113, 135], ["RSV, adenovirus, and coronavirus", "DISEASE", 147, 179], ["RSV", "ORGANISM", 147, 150], ["adenovirus", "ORGANISM", 152, 162], ["coronavirus", "SPECIES", 168, 179], ["RSV", "SPECIES", 147, 150], ["adenovirus", "SPECIES", 152, 162], ["bloody stools", "PROBLEM", 70, 83], ["multiple respiratory infections", "PROBLEM", 104, 135], ["RSV", "PROBLEM", 147, 150], ["adenovirus", "PROBLEM", 152, 162], ["coronavirus", "PROBLEM", 168, 179], ["cutaneous", "ANATOMY", 15, 24], ["bloody stools", "OBSERVATION", 70, 83], ["respiratory", "ANATOMY", 113, 124], ["infections", "OBSERVATION", 125, 135]]], ["There were no ocular symptoms.", [["ocular", "ANATOMY", 14, 20], ["ocular symptoms", "PROBLEM", 14, 29], ["no", "UNCERTAINTY", 11, 13], ["ocular", "ANATOMY", 14, 20], ["symptoms", "OBSERVATION", 21, 29]]], ["Immune cell subset abnormalities included a reduced percentage of CD19+CD27+IgM+IgD\u2212 B cells of total CD19+ B cells (0.1%; normal range 0.2\u20130.3%), a reduced IgM level (0.23 g/L; normal range 0.4\u20131.9 g/L), and elevated soluble B cell\u2013activating factor (BAFF) level (2382 pg/mL).", [["Immune cell", "ANATOMY", 0, 11], ["CD19+CD27+IgM+IgD\u2212 B cells", "ANATOMY", 66, 92], ["CD19+ B cells", "ANATOMY", 102, 115], ["Immune cell", "CELL", 0, 11], ["CD19", "GENE_OR_GENE_PRODUCT", 66, 70], ["CD27", "GENE_OR_GENE_PRODUCT", 71, 75], ["IgM", "GENE_OR_GENE_PRODUCT", 76, 79], ["CD19", "GENE_OR_GENE_PRODUCT", 102, 106], ["IgM", "GENE_OR_GENE_PRODUCT", 157, 160], ["B cell\u2013activating factor", "GENE_OR_GENE_PRODUCT", 226, 250], ["BAFF", "GENE_OR_GENE_PRODUCT", 252, 256], ["CD19", "PROTEIN", 66, 70], ["CD27", "PROTEIN", 71, 75], ["IgM", "PROTEIN", 76, 79], ["IgD", "PROTEIN", 80, 83], ["CD19", "PROTEIN", 102, 106], ["B cells", "CELL_TYPE", 108, 115], ["IgM", "PROTEIN", 157, 160], ["soluble B cell\u2013activating factor", "PROTEIN", 218, 250], ["BAFF", "PROTEIN", 252, 256], ["Immune cell subset abnormalities", "PROBLEM", 0, 32], ["CD19", "TEST", 66, 70], ["CD27", "TEST", 71, 75], ["IgM", "TEST", 76, 79], ["total CD19", "TEST", 96, 106], ["B cells", "TEST", 108, 115], ["a reduced IgM level", "PROBLEM", 147, 166], ["elevated soluble B cell\u2013activating factor", "PROBLEM", 209, 250], ["reduced", "OBSERVATION_MODIFIER", 44, 51], ["percentage", "OBSERVATION_MODIFIER", 52, 62], ["B cells", "OBSERVATION", 108, 115]]], ["There were no documented autoantibodies.", [["autoantibodies", "PROTEIN", 25, 39], ["documented autoantibodies", "PROBLEM", 14, 39], ["no documented", "UNCERTAINTY", 11, 24], ["autoantibodies", "OBSERVATION", 25, 39]]], ["Her antibody responses to tetanus, diphtheria, and pneumococcal vaccinations were normal.Cases #1 and #2 ::: ResultsFamily history was significant for a similar history of relapsing-and-remitting polymorphic eruptions in her mother occurring since infancy resulting in extensive atrophic scarring (Fig. 1).", [["tetanus", "DISEASE", 26, 33], ["diphtheria", "DISEASE", 35, 45], ["eruptions", "DISEASE", 208, 217], ["pneumococcal", "ORGANISM", 51, 63], ["pneumococcal", "SPECIES", 51, 63], ["Her antibody responses", "TEST", 0, 22], ["tetanus", "TEST", 26, 33], ["diphtheria", "PROBLEM", 35, 45], ["pneumococcal vaccinations", "TEST", 51, 76], ["remitting polymorphic eruptions", "PROBLEM", 186, 217], ["extensive atrophic scarring", "PROBLEM", 269, 296], ["relapsing", "OBSERVATION_MODIFIER", 172, 181], ["remitting", "OBSERVATION_MODIFIER", 186, 195], ["polymorphic", "OBSERVATION_MODIFIER", 196, 207], ["eruptions", "OBSERVATION", 208, 217], ["extensive", "OBSERVATION_MODIFIER", 269, 278], ["atrophic", "OBSERVATION_MODIFIER", 279, 287], ["scarring", "OBSERVATION", 288, 296], ["Fig", "OBSERVATION_MODIFIER", 298, 301]]], ["Her mother also had a history of significant respiratory infections and chronic obstructive pulmonary disease.", [["respiratory", "ANATOMY", 45, 56], ["pulmonary", "ANATOMY", 92, 101], ["respiratory infections", "DISEASE", 45, 67], ["chronic obstructive pulmonary disease", "DISEASE", 72, 109], ["pulmonary", "ORGAN", 92, 101], ["significant respiratory infections", "PROBLEM", 33, 67], ["chronic obstructive pulmonary disease", "PROBLEM", 72, 109], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["respiratory", "ANATOMY", 45, 56], ["infections", "OBSERVATION", 57, 67], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["obstructive", "OBSERVATION_MODIFIER", 80, 91], ["pulmonary", "ANATOMY", 92, 101], ["disease", "OBSERVATION", 102, 109]]], ["Additionally, she reported episodes of episcleritis, arthritis, and recurrent urinary tract infections.", [["urinary tract", "ANATOMY", 78, 91], ["episcleritis", "DISEASE", 39, 51], ["arthritis", "DISEASE", 53, 62], ["urinary tract infections", "DISEASE", 78, 102], ["urinary tract", "ORGANISM_SUBDIVISION", 78, 91], ["episcleritis", "PROBLEM", 39, 51], ["arthritis", "PROBLEM", 53, 62], ["recurrent urinary tract infections", "PROBLEM", 68, 102], ["episcleritis", "OBSERVATION", 39, 51], ["arthritis", "OBSERVATION", 53, 62], ["urinary tract", "ANATOMY", 78, 91], ["infections", "OBSERVATION", 92, 102]]], ["B cell immunophenotyping showed an increased percentage of na\u00efve B cell populations in the total CD19+ B cell population: CD19+CD27\u2212 (89%, normal range 40\u201380%), CD19+CD27\u2212CD21+ (86%, normal range 35\u201376%), and CD19+CD27\u2212IgM+IgD+ (87%, normal range 33\u201376%).", [["B cell", "ANATOMY", 0, 6], ["B cell", "ANATOMY", 65, 71], ["CD19+ B cell", "ANATOMY", 97, 109], ["CD19+CD27\u2212", "ANATOMY", 122, 132], ["CD19+CD27\u2212CD21", "ANATOMY", 161, 175], ["B cell", "CELL", 0, 6], ["B cell populations", "CELL", 65, 83], ["CD19", "GENE_OR_GENE_PRODUCT", 97, 101], ["CD19", "GENE_OR_GENE_PRODUCT", 122, 126], ["CD27", "GENE_OR_GENE_PRODUCT", 127, 131], ["CD19", "GENE_OR_GENE_PRODUCT", 161, 165], ["CD27", "GENE_OR_GENE_PRODUCT", 166, 170], ["CD21", "GENE_OR_GENE_PRODUCT", 171, 175], ["CD19", "GENE_OR_GENE_PRODUCT", 209, 213], ["CD27", "GENE_OR_GENE_PRODUCT", 214, 218], ["IgM", "GENE_OR_GENE_PRODUCT", 219, 222], ["IgD", "GENE_OR_GENE_PRODUCT", 223, 226], ["na\u00efve B cell populations", "CELL_TYPE", 59, 83], ["CD19", "PROTEIN", 97, 101], ["CD19", "PROTEIN", 122, 126], ["CD27", "PROTEIN", 127, 131], ["CD19", "PROTEIN", 161, 165], ["CD27", "PROTEIN", 166, 170], ["CD21", "PROTEIN", 171, 175], ["CD19", "PROTEIN", 209, 213], ["CD27", "PROTEIN", 214, 218], ["IgM", "PROTEIN", 219, 222], ["IgD", "PROTEIN", 223, 226], ["B cell immunophenotyping", "TEST", 0, 24], ["an increased percentage of na\u00efve B cell populations", "PROBLEM", 32, 83], ["the total CD19", "TEST", 87, 101], ["CD19", "TEST", 122, 126], ["CD27", "TEST", 127, 131], ["CD19", "TEST", 161, 165], ["CD27", "TEST", 166, 170], ["CD21", "TEST", 171, 175], ["CD19", "TEST", 209, 213], ["CD27", "TEST", 214, 218], ["IgM", "TEST", 219, 222], ["IgD", "TEST", 223, 226], ["cell immunophenotyping", "OBSERVATION", 2, 24], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["percentage", "OBSERVATION_MODIFIER", 45, 55], ["na\u00efve B cell populations", "OBSERVATION", 59, 83]]], ["There was a decreased percentage of CD19+CD27+IgM+IgD-cells of total CD19+ B cells (0.7%; normal range 1.5\u20136.2%) similar to her daughter.", [["CD19+CD27+IgM+IgD-cells", "ANATOMY", 36, 59], ["CD19+ B cells", "ANATOMY", 69, 82], ["CD19", "GENE_OR_GENE_PRODUCT", 36, 40], ["CD27", "GENE_OR_GENE_PRODUCT", 41, 45], ["CD19", "GENE_OR_GENE_PRODUCT", 69, 73], ["CD19", "PROTEIN", 36, 40], ["CD27", "PROTEIN", 41, 45], ["IgM", "PROTEIN", 46, 49], ["IgD", "PROTEIN", 50, 53], ["CD19", "PROTEIN", 69, 73], ["B cells", "CELL_TYPE", 75, 82], ["CD19", "TEST", 36, 40], ["CD27", "TEST", 41, 45], ["IgM", "TEST", 46, 49], ["total CD19", "TEST", 63, 73], ["B cells", "TEST", 75, 82], ["decreased", "OBSERVATION_MODIFIER", 12, 21], ["percentage", "OBSERVATION_MODIFIER", 22, 32], ["IgD-cells", "OBSERVATION", 50, 59], ["B cells", "OBSERVATION", 75, 82]]], ["She also had a reduced IgM level (0.32 g/L; normal range 0.5\u20133.7 g/L).", [["She", "ORGANISM", 0, 3], ["IgM", "GENE_OR_GENE_PRODUCT", 23, 26], ["IgM", "PROTEIN", 23, 26], ["a reduced IgM level", "PROBLEM", 13, 32], ["reduced", "OBSERVATION_MODIFIER", 15, 22], ["IgM", "OBSERVATION", 23, 26]]], ["She has been treated with regular intravenous immunoglobulin (IVIG) infusions, high-dose steroids, omalizumab, and, most recently, anakinra resulting in improved skin manifestations.", [["intravenous", "ANATOMY", 34, 45], ["skin", "ANATOMY", 162, 166], ["steroids", "CHEMICAL", 89, 97], ["omalizumab", "CHEMICAL", 99, 109], ["anakinra", "CHEMICAL", 131, 139], ["steroids", "CHEMICAL", 89, 97], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 45], ["immunoglobulin", "SIMPLE_CHEMICAL", 46, 60], ["IVIG", "SIMPLE_CHEMICAL", 62, 66], ["omalizumab", "SIMPLE_CHEMICAL", 99, 109], ["anakinra", "SIMPLE_CHEMICAL", 131, 139], ["skin", "ORGAN", 162, 166], ["regular intravenous immunoglobulin (IVIG) infusions", "TREATMENT", 26, 77], ["high-dose steroids", "TREATMENT", 79, 97], ["omalizumab", "TREATMENT", 99, 109], ["anakinra", "TREATMENT", 131, 139], ["improved skin manifestations", "PROBLEM", 153, 181], ["improved", "OBSERVATION_MODIFIER", 153, 161], ["skin", "ANATOMY", 162, 166], ["manifestations", "OBSERVATION", 167, 181]]], ["A fever/autoinflammatory disorders next-generation sequencing panel (Fulgent Genetics, CA, USA) performed on the mother only reported two potential variations of significance in PLCG2 and CARD14.", [["fever", "DISEASE", 2, 7], ["autoinflammatory disorders", "DISEASE", 8, 34], ["PLCG2", "GENE_OR_GENE_PRODUCT", 178, 183], ["CARD14", "GENE_OR_GENE_PRODUCT", 188, 194], ["PLCG2", "PROTEIN", 178, 183], ["CARD14", "PROTEIN", 188, 194], ["A fever/autoinflammatory disorders", "PROBLEM", 0, 34], ["sequencing panel", "TEST", 51, 67], ["CARD14", "TREATMENT", 188, 194], ["fever", "OBSERVATION", 2, 7], ["autoinflammatory", "OBSERVATION", 8, 24]]], ["Targeted sequencing for those two genes was performed in the daughter, identifying the missense mutation in PLCG2, c.3422 T>A [p.Met1141Lys] that was common to both affected individuals (Fig. 2a).Case #3 ::: ResultsA 6-year-old girl presented with a history of recurrent viral (parainfluenza virus type 2, respiratory syncytial virus (RSV) and bacterial (Haemophilus influenzae) respiratory infections resulting in restrictive lung disease.", [["respiratory", "ANATOMY", 379, 390], ["lung", "ANATOMY", 427, 431], ["parainfluenza virus type 2", "DISEASE", 278, 304], ["respiratory syncytial virus", "DISEASE", 306, 333], ["RSV", "DISEASE", 335, 338], ["Haemophilus influenzae", "DISEASE", 355, 377], ["respiratory infections", "DISEASE", 379, 401], ["restrictive lung disease", "DISEASE", 415, 439], ["PLCG2", "GENE_OR_GENE_PRODUCT", 108, 113], ["c.3422 T>A", "GENE_OR_GENE_PRODUCT", 115, 125], ["girl", "ORGANISM", 228, 232], ["parainfluenza virus type 2", "ORGANISM", 278, 304], ["respiratory syncytial virus", "ORGANISM", 306, 333], ["RSV", "ORGANISM", 335, 338], ["Haemophilus influenzae", "ORGANISM", 355, 377], ["lung", "ORGAN", 427, 431], ["girl", "SPECIES", 228, 232], ["parainfluenza virus", "SPECIES", 278, 297], ["respiratory syncytial virus", "SPECIES", 306, 333], ["RSV", "SPECIES", 335, 338], ["Haemophilus influenzae", "SPECIES", 355, 377], ["respiratory syncytial virus", "SPECIES", 306, 333], ["RSV", "SPECIES", 335, 338], ["Haemophilus influenzae", "SPECIES", 355, 377], ["the missense mutation", "PROBLEM", 83, 104], ["PLCG2", "TEST", 108, 113], ["recurrent viral (parainfluenza virus type 2", "PROBLEM", 261, 304], ["respiratory syncytial virus (RSV)", "PROBLEM", 306, 339], ["bacterial (Haemophilus influenzae)", "PROBLEM", 344, 378], ["respiratory infections", "PROBLEM", 379, 401], ["restrictive lung disease", "PROBLEM", 415, 439], ["parainfluenza virus", "OBSERVATION", 278, 297], ["respiratory", "ANATOMY", 306, 317], ["syncytial virus", "OBSERVATION", 318, 333], ["bacterial", "OBSERVATION_MODIFIER", 344, 353], ["respiratory infections", "OBSERVATION", 379, 401], ["restrictive", "OBSERVATION_MODIFIER", 415, 426], ["lung", "ANATOMY", 427, 431], ["disease", "OBSERVATION", 432, 439]]], ["There was no history of ocular, dermatologic, or inflammatory symptoms.", [["ocular", "ANATOMY", 24, 30], ["ocular, dermatologic", "PROBLEM", 24, 44], ["inflammatory symptoms", "PROBLEM", 49, 70], ["no history of", "UNCERTAINTY", 10, 23], ["ocular", "ANATOMY", 24, 30], ["inflammatory", "OBSERVATION_MODIFIER", 49, 61]]], ["Her father died at the age of 51 years due to emphysema.Case #3 ::: ResultsShe met laboratory criteria for CVID with undetectable IgA (< 0.04 g/L), IgM (< 0.03 g/L), and IgG (< 0.27 g/L) levels, and normal total T (CD3+, CD3+CD4+, CD3+CD8+), CD19+ B, and CD3\u2212CD56+ NK absolute cell counts.", [["CD3+, CD3+CD4+, CD3+CD8+), CD19+ B", "ANATOMY", 215, 249], ["CD3\u2212CD56+ NK", "ANATOMY", 255, 267], ["cell", "ANATOMY", 277, 281], ["emphysema", "DISEASE", 46, 55], ["CVID", "DISEASE", 107, 111], ["emphysema", "PATHOLOGICAL_FORMATION", 46, 55], ["She", "ORGANISM", 75, 78], ["IgA", "GENE_OR_GENE_PRODUCT", 130, 133], ["IgG", "GENE_OR_GENE_PRODUCT", 170, 173], ["T", "GENE_OR_GENE_PRODUCT", 212, 213], ["CD3", "GENE_OR_GENE_PRODUCT", 215, 218], ["CD3", "GENE_OR_GENE_PRODUCT", 221, 224], ["CD4", "GENE_OR_GENE_PRODUCT", 225, 228], ["CD3", "GENE_OR_GENE_PRODUCT", 231, 234], ["CD8", "GENE_OR_GENE_PRODUCT", 235, 238], ["CD19", "GENE_OR_GENE_PRODUCT", 242, 246], ["B", "GENE_OR_GENE_PRODUCT", 248, 249], ["CD3", "GENE_OR_GENE_PRODUCT", 255, 258], ["CD56", "GENE_OR_GENE_PRODUCT", 259, 263], ["IgA", "PROTEIN", 130, 133], ["IgM", "PROTEIN", 148, 151], ["IgG", "PROTEIN", 170, 173], ["CD3", "PROTEIN", 215, 218], ["CD3", "PROTEIN", 221, 224], ["CD4", "PROTEIN", 225, 228], ["CD3", "PROTEIN", 231, 234], ["CD8", "PROTEIN", 235, 238], ["CD19", "PROTEIN", 242, 246], ["CD3", "PROTEIN", 255, 258], ["CD56", "PROTEIN", 259, 263], ["emphysema", "PROBLEM", 46, 55], ["CVID", "PROBLEM", 107, 111], ["IgA", "TEST", 130, 133], ["IgM", "TEST", 148, 151], ["IgG", "TEST", 170, 173], ["levels", "TEST", 187, 193], ["CD3", "TEST", 215, 218], ["CD3", "TEST", 221, 224], ["CD4", "TEST", 225, 228], ["CD3", "TEST", 231, 234], ["CD8", "TEST", 235, 238], ["CD19", "TEST", 242, 246], ["CD3", "TEST", 255, 258], ["CD56", "TEST", 259, 263], ["absolute cell counts", "TEST", 268, 288], ["emphysema", "OBSERVATION", 46, 55], ["NK absolute cell counts", "OBSERVATION", 265, 288]]], ["Lymphocyte proliferation in response to phytohemagglutinin (PHA), pokeweed (PWM), and Staphylococcus aureus Cowan I (SAC) was normal.", [["Lymphocyte", "ANATOMY", 0, 10], ["PHA", "CHEMICAL", 60, 63], ["Lymphocyte", "CELL", 0, 10], ["phytohemagglutinin", "SIMPLE_CHEMICAL", 40, 58], ["PHA", "SIMPLE_CHEMICAL", 60, 63], ["Staphylococcus aureus Cowan I", "ORGANISM", 86, 115], ["SAC", "CANCER", 117, 120], ["phytohemagglutinin", "PROTEIN", 40, 58], ["PHA", "PROTEIN", 60, 63], ["pokeweed", "PROTEIN", 66, 74], ["PWM", "PROTEIN", 76, 79], ["Staphylococcus aureus", "SPECIES", 86, 107], ["Staphylococcus aureus Cowan I", "SPECIES", 86, 115], ["Lymphocyte proliferation", "PROBLEM", 0, 24], ["phytohemagglutinin (PHA)", "TEST", 40, 64], ["pokeweed (PWM)", "TEST", 66, 80], ["Staphylococcus aureus", "PROBLEM", 86, 107], ["proliferation", "OBSERVATION", 11, 24], ["response to phytohemagglutinin", "OBSERVATION", 28, 58], ["Staphylococcus aureus", "OBSERVATION", 86, 107], ["normal", "OBSERVATION", 126, 132]]], ["Even though her blood type is Group O, anti-A and anti-B isohemagglutinins were not detectable.", [["blood", "ANATOMY", 16, 21], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["anti-A", "SIMPLE_CHEMICAL", 39, 45], ["anti-B isohemagglutinins", "SIMPLE_CHEMICAL", 50, 74], ["anti-B isohemagglutinins", "PROTEIN", 50, 74], ["her blood type", "TEST", 12, 26], ["anti-B isohemagglutinins", "TREATMENT", 50, 74]]], ["Furthermore, despite documented hepatitis B, vaccination the anti-HBs titer was non-reactive.", [["hepatitis B", "DISEASE", 32, 43], ["hepatitis B", "ORGANISM", 32, 43], ["anti-HBs", "GENE_OR_GENE_PRODUCT", 61, 69], ["hepatitis B", "TREATMENT", 32, 43], ["vaccination the anti-HBs titer", "TEST", 45, 75], ["hepatitis", "OBSERVATION", 32, 41]]], ["This was not tested upon boost vaccination.", [["boost vaccination", "TREATMENT", 25, 42]]], ["B cell immunophenotyping showed (i) increased fraction of transitional B cells (Fig. 3a, b, e), (ii) lack of memory B cells (Fig. 3c, d, e), and (iii) lack of marginal zone B cells (Fig. 3c).", [["B cell", "ANATOMY", 0, 6], ["transitional B cells", "ANATOMY", 58, 78], ["memory B cells", "ANATOMY", 109, 123], ["marginal zone B cells", "ANATOMY", 159, 180], ["B cell", "CELL", 0, 6], ["transitional B cells", "CELL", 58, 78], ["memory B cells", "CELL", 109, 123], ["marginal zone B cells", "CELL", 159, 180], ["transitional B cells", "CELL_TYPE", 58, 78], ["memory B cells", "CELL_TYPE", 109, 123], ["marginal zone B cells", "CELL_TYPE", 159, 180], ["B cell immunophenotyping", "TEST", 0, 24], ["increased fraction", "PROBLEM", 36, 54], ["transitional B cells", "PROBLEM", 58, 78], ["memory B cells", "PROBLEM", 109, 123], ["marginal zone B cells", "PROBLEM", 159, 180], ["cell immunophenotyping", "OBSERVATION", 2, 24], ["transitional B cells", "OBSERVATION", 58, 78], ["marginal zone B cells", "OBSERVATION", 159, 180]]], ["She is currently treated with monthly IVIG infusions.Case #3 ::: ResultsWhole-exome sequencing identified a heterozygous single nucleotide variant in PLCG2, c.3422 T>A, resulting in a missense protein variant [p.Met1141Lys] (Fig. 2a).", [["IVIG", "SIMPLE_CHEMICAL", 38, 42], ["PLCG2", "GENE_OR_GENE_PRODUCT", 150, 155], ["c.3422 T>A", "GENE_OR_GENE_PRODUCT", 157, 167], ["monthly IVIG infusions", "TREATMENT", 30, 52], ["a heterozygous single nucleotide variant", "PROBLEM", 106, 146], ["PLCG2", "TEST", 150, 155], ["a missense protein variant", "PROBLEM", 182, 208]]], ["All rare variants identified, unique to the patient, are available in a supplementary file.Characterization of the PLCG2, c.3422 T>A [p.Met1141Lys] Variant ::: ResultsA missense variant in PLCG2, c.3422 T>A [p.Met1141Lys] in all three affected individuals.", [["patient", "ORGANISM", 44, 51], ["PLCG2", "GENE_OR_GENE_PRODUCT", 115, 120], ["c.3422 T>A", "GENE_OR_GENE_PRODUCT", 122, 132], ["PLCG2", "GENE_OR_GENE_PRODUCT", 189, 194], ["c.3422 T>A", "GENE_OR_GENE_PRODUCT", 196, 206], ["PLCG2", "DNA", 115, 120], ["patient", "SPECIES", 44, 51], ["All rare variants", "PROBLEM", 0, 17], ["Characterization", "TEST", 91, 107], ["the PLCG2", "TEST", 111, 120], ["ResultsA missense variant", "PROBLEM", 160, 185], ["PLCG2", "TEST", 189, 194], ["T", "TEST", 203, 204], ["rare", "OBSERVATION_MODIFIER", 4, 8], ["variants", "OBSERVATION", 9, 17]]], ["This variant was not found in any population databases that aggregate next-generation sequencing data, including Exome Aggregation Consortium (ExAC) [13], Genome Aggregation Database (gnomAD) (10.1101/531210), 1000 Genomes Project [14], ClinVar [15], dbSNP [10], and Exome Variant Server (https://evs.gs.washington.edu/EVS; accessed May 24, 2019) (Supplementary Table 1).", [["ExAC", "TEST", 143, 147], ["Genome Aggregation Database (gnomAD)", "TREATMENT", 155, 191]]], ["However, it was found in the Catalogue of Somatic Mutations in Cancer [11], associated with chronic lymphocytic leukemia originally [6], which suggests potential gain-of-function activity.", [["Cancer", "ANATOMY", 63, 69], ["chronic lymphocytic leukemia", "ANATOMY", 92, 120], ["Somatic Mutations", "DISEASE", 42, 59], ["Cancer", "DISEASE", 63, 69], ["chronic lymphocytic leukemia", "DISEASE", 92, 120], ["Cancer", "CANCER", 63, 69], ["chronic lymphocytic leukemia", "CANCER", 92, 120], ["Somatic Mutations in Cancer", "PROBLEM", 42, 69], ["chronic lymphocytic leukemia", "PROBLEM", 92, 120], ["Somatic Mutations", "OBSERVATION", 42, 59], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["lymphocytic leukemia", "OBSERVATION", 100, 120]]], ["The region surrounding the p.Met1141Lys substitution was also found to be highly conserved in evolution as evidenced by sequence alignment (Fig. 2b) and in silico conservation metrics (PhyloP = 2.192, fitCons = 0.745) (Supplementary Table 2).", [["p.Met", "GENE_OR_GENE_PRODUCT", 27, 32], ["p.Met1141Lys", "DNA", 27, 39], ["PhyloP", "TEST", 185, 191], ["fitCons", "TEST", 201, 208]]], ["Of note, a variety of in silico pathogenicity prediction tools predicted this PLCG2 variant to be pathogenic (Supplementary Table 3), including Combined Annotation Dependent Depletion (CADD = 29) [16], Deleterious Annotation of genetic variants using Neural Networks (DANN = 0.989) [17], Rare Exome Variant Ensemble Learner (REVEL = 0.711) [18], Variant Effect Scoring Tool (VEST4 = 0.838), MetaLR = 0.334 and MetaSVM = \u2212 0.378 [19], Mendelian Clinically Applicable Pathogenicity score (M-CAP = 0.04) [20], GenoCanyon (damaging) [21], Polyphen-2 (damaging) [22], MutationTaster2 (disease causing) [23], SIFT [24], Functional Analysis through Hidden Markov Models (FATHMM = \u2212 0.28) [25], and Protein Variation Effect Analyzer (PROVEAN = \u2212 5.09) [26].Hematological Cells Manifest Evidence of Altered Function of PLCG2 ::: ResultsTo investigate the relevance of the PLC\u03b32 variant, we performed functional assays on hematopoietic cells from patient #3 assessing calcium flux, downstream signaling, and platelet activation related to PLC\u03b32 function.Hematological Cells Manifest Evidence of Altered Function of PLCG2 ::: ResultsWe measured intracellular and plasma Ca2+ flux after B cell receptor (BCR) stimulation in the patient\u2019s primary B cells by flow cytometry.", [["Cells", "ANATOMY", 763, 768], ["hematopoietic cells", "ANATOMY", 912, 931], ["platelet", "ANATOMY", 998, 1006], ["Cells", "ANATOMY", 1058, 1063], ["intracellular", "ANATOMY", 1134, 1147], ["plasma", "ANATOMY", 1152, 1158], ["B cell", "ANATOMY", 1175, 1181], ["primary B cells", "ANATOMY", 1226, 1241], ["calcium", "CHEMICAL", 958, 965], ["Ca2", "CHEMICAL", 1159, 1162], ["calcium", "CHEMICAL", 958, 965], ["Ca2+", "CHEMICAL", 1159, 1163], ["PLCG2", "GENE_OR_GENE_PRODUCT", 78, 83], ["Hematological Cells", "CELL", 749, 768], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 863, 868], ["hematopoietic cells", "CELL", 912, 931], ["patient", "ORGANISM", 937, 944], ["calcium", "SIMPLE_CHEMICAL", 958, 965], ["platelet", "CELL", 998, 1006], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 1029, 1034], ["Hematological Cells", "CELL", 1044, 1063], ["PLCG2", "GENE_OR_GENE_PRODUCT", 1105, 1110], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 1134, 1147], ["plasma", "ORGANISM_SUBSTANCE", 1152, 1158], ["Ca2+", "SIMPLE_CHEMICAL", 1159, 1163], ["B cell receptor", "GENE_OR_GENE_PRODUCT", 1175, 1190], ["BCR", "GENE_OR_GENE_PRODUCT", 1192, 1195], ["patient", "ORGANISM", 1216, 1223], ["B cells", "CELL", 1234, 1241], ["PLCG2 variant", "DNA", 78, 91], ["PLCG2", "PROTEIN", 810, 815], ["PLC\u03b32 variant", "PROTEIN", 863, 876], ["hematopoietic cells", "CELL_TYPE", 912, 931], ["PLC\u03b32", "PROTEIN", 1029, 1034], ["PLCG2", "PROTEIN", 1105, 1110], ["Ca2", "PROTEIN", 1159, 1162], ["B cell receptor", "PROTEIN", 1175, 1190], ["BCR", "PROTEIN", 1192, 1195], ["primary B cells", "CELL_TYPE", 1226, 1241], ["patient", "SPECIES", 937, 944], ["patient", "SPECIES", 1216, 1223], ["pathogenic", "PROBLEM", 98, 108], ["Combined Annotation Dependent Depletion", "TREATMENT", 144, 183], ["CADD", "TEST", 185, 189], ["VEST4", "TEST", 375, 380], ["MetaLR", "TEST", 391, 397], ["MetaSVM", "TEST", 410, 417], ["Pathogenicity score", "TEST", 466, 485], ["CAP", "TEST", 489, 492], ["GenoCanyon (damaging)", "TREATMENT", 507, 528], ["Polyphen", "TEST", 535, 543], ["MutationTaster2 (disease", "PROBLEM", 563, 587], ["Functional Analysis", "TEST", 614, 633], ["Hidden Markov Models", "TEST", 642, 662], ["FATHMM", "TEST", 664, 670], ["Protein Variation Effect Analyzer", "TEST", 691, 724], ["PROVEAN", "TEST", 726, 733], ["Hematological Cells", "TEST", 749, 768], ["calcium flux", "TEST", 958, 970], ["downstream signaling", "PROBLEM", 972, 992], ["platelet activation", "TEST", 998, 1017], ["PLC", "TEST", 1029, 1032], ["Hematological Cells", "TEST", 1044, 1063], ["Altered Function of PLCG2", "PROBLEM", 1085, 1110], ["intracellular", "TEST", 1134, 1147], ["plasma Ca2", "TEST", 1152, 1162], ["B cell receptor (BCR) stimulation", "TREATMENT", 1175, 1208], ["flow cytometry", "TEST", 1245, 1259], ["Dependent Depletion", "OBSERVATION", 164, 183], ["platelet activation", "OBSERVATION", 998, 1017], ["flow cytometry", "OBSERVATION", 1245, 1259]]], ["We found that BCR stimulation induced increased external calcium entry in the patient\u2019s primary B cells relative to controls (Fig. 4a).", [["primary B cells", "ANATOMY", 88, 103], ["calcium", "CHEMICAL", 57, 64], ["calcium", "CHEMICAL", 57, 64], ["BCR", "GENE_OR_GENE_PRODUCT", 14, 17], ["calcium", "SIMPLE_CHEMICAL", 57, 64], ["patient", "ORGANISM", 78, 85], ["B cells", "CELL", 96, 103], ["BCR", "PROTEIN", 14, 17], ["primary B cells", "CELL_TYPE", 88, 103], ["patient", "SPECIES", 78, 85], ["BCR stimulation", "PROBLEM", 14, 29], ["increased external calcium entry", "PROBLEM", 38, 70], ["primary B cells", "PROBLEM", 88, 103], ["BCR stimulation", "OBSERVATION", 14, 29], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["external", "OBSERVATION_MODIFIER", 48, 56], ["calcium entry", "OBSERVATION", 57, 70]]], ["Adding to the significance of this observation, the patient\u2019s B cell population was enriched in transitional B cells, B cells that typically exhibit a reduced calcium response compared with na\u00efve and IgM+CD27+ B cells normally [27].", [["B cell", "ANATOMY", 62, 68], ["transitional B cells", "ANATOMY", 96, 116], ["B cells", "ANATOMY", 118, 125], ["IgM+CD27+ B cells", "ANATOMY", 200, 217], ["calcium", "CHEMICAL", 159, 166], ["calcium", "CHEMICAL", 159, 166], ["patient", "ORGANISM", 52, 59], ["B cell", "CELL", 62, 68], ["transitional B cells", "CELL", 96, 116], ["B cells", "CELL", 118, 125], ["calcium", "SIMPLE_CHEMICAL", 159, 166], ["IgM", "GENE_OR_GENE_PRODUCT", 200, 203], ["CD27", "GENE_OR_GENE_PRODUCT", 204, 208], ["B cell population", "CELL_TYPE", 62, 79], ["transitional B cells", "CELL_TYPE", 96, 116], ["B cells", "CELL_TYPE", 118, 125], ["IgM", "PROTEIN", 200, 203], ["CD27", "PROTEIN", 204, 208], ["B cells", "CELL_TYPE", 210, 217], ["patient", "SPECIES", 52, 59], ["this observation", "TEST", 30, 46], ["the patient\u2019s B cell population", "PROBLEM", 48, 79], ["transitional B cells", "PROBLEM", 96, 116], ["a reduced calcium response", "PROBLEM", 149, 175], ["na\u00efve", "TEST", 190, 195], ["IgM", "TEST", 200, 203], ["CD27", "TEST", 204, 208]]], ["Altogether, these findings suggest that the patient\u2019s mutation leads to PLC\u03b32 gain-of-function.Hematological Cells Manifest Evidence of Altered Function of PLCG2 ::: ResultsThe increased production of DAG could activate downstream effectors such as extracellular signal-regulated kinase (ERK).", [["Cells", "ANATOMY", 109, 114], ["DAG", "CHEMICAL", 201, 204], ["DAG", "CHEMICAL", 201, 204], ["patient", "ORGANISM", 44, 51], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 72, 77], ["Hematological Cells", "CELL", 95, 114], ["DAG", "SIMPLE_CHEMICAL", 201, 204], ["extracellular signal-regulated kinase", "GENE_OR_GENE_PRODUCT", 249, 286], ["ERK", "GENE_OR_GENE_PRODUCT", 288, 291], ["PLC", "PROTEIN", 72, 75], ["PLCG2", "PROTEIN", 156, 161], ["downstream effectors", "PROTEIN", 220, 240], ["extracellular signal-regulated kinase", "PROTEIN", 249, 286], ["ERK", "PROTEIN", 288, 291], ["patient", "SPECIES", 44, 51], ["the patient\u2019s mutation", "PROBLEM", 40, 62], ["PLC", "TEST", 72, 75], ["Hematological Cells", "TEST", 95, 114], ["The increased production of DAG", "PROBLEM", 173, 204], ["downstream effectors", "PROBLEM", 220, 240], ["extracellular signal", "TEST", 249, 269], ["increased", "OBSERVATION_MODIFIER", 177, 186], ["production", "OBSERVATION_MODIFIER", 187, 197]]], ["We evaluated ERK phosphorylation after BCR stimulation by flow cytometry analysis.", [["ERK", "GENE_OR_GENE_PRODUCT", 13, 16], ["BCR", "GENE_OR_GENE_PRODUCT", 39, 42], ["ERK", "PROTEIN", 13, 16], ["BCR", "PROTEIN", 39, 42], ["ERK phosphorylation", "TEST", 13, 32], ["BCR stimulation", "TEST", 39, 54], ["flow cytometry analysis", "TEST", 58, 81]]], ["We found that despite equivalent levels of PLC\u03b32 phosphorylation between samples, there was more prolonged ERK phosphorylation in the affected patient B cells relative to controls (Fig. 4b, d).", [["samples", "ANATOMY", 73, 80], ["B cells", "ANATOMY", 151, 158], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 43, 48], ["ERK", "GENE_OR_GENE_PRODUCT", 107, 110], ["patient", "ORGANISM", 143, 150], ["B cells", "CELL", 151, 158], ["PLC\u03b32", "PROTEIN", 43, 48], ["ERK", "PROTEIN", 107, 110], ["B cells", "CELL_TYPE", 151, 158], ["patient", "SPECIES", 143, 150], ["PLC\u03b32 phosphorylation", "TREATMENT", 43, 64], ["prolonged ERK phosphorylation", "PROBLEM", 97, 126], ["ERK phosphorylation", "OBSERVATION", 107, 126]]], ["This gain-of-function activity was not the result of increased PLC\u03b32 protein expression as total PLC\u03b32 expression in primary CD19+ B cell lysates from a patient and healthy control was comparable as detected by immunoblot (Fig. 4e).Hematological Cells Manifest Evidence of Altered Function of PLCG2 ::: ResultsIn murine models of PLC\u03b32 gain-of-function mutations, platelets showed enhanced \u03b1-granule secretion upon stimulation with collagen [28].", [["primary CD19+", "ANATOMY", 117, 130], ["B cell lysates", "ANATOMY", 131, 145], ["Cells", "ANATOMY", 246, 251], ["platelets", "ANATOMY", 364, 373], ["\u03b1-granule", "ANATOMY", 390, 399], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 63, 68], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 97, 102], ["CD19", "GENE_OR_GENE_PRODUCT", 125, 129], ["B cell lysates", "CELL", 131, 145], ["patient", "ORGANISM", 153, 160], ["Hematological Cells", "CELL", 232, 251], ["PLCG2", "GENE_OR_GENE_PRODUCT", 293, 298], ["murine", "ORGANISM", 313, 319], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 330, 335], ["platelets", "CELL", 364, 373], ["\u03b1-granule", "SIMPLE_CHEMICAL", 390, 399], ["collagen", "GENE_OR_GENE_PRODUCT", 432, 440], ["PLC\u03b32", "PROTEIN", 63, 68], ["PLC\u03b32", "PROTEIN", 97, 102], ["CD19", "PROTEIN", 125, 129], ["PLCG2", "PROTEIN", 293, 298], ["PLC", "PROTEIN", 330, 333], ["platelets", "CELL_TYPE", 364, 373], ["collagen", "PROTEIN", 432, 440], ["patient", "SPECIES", 153, 160], ["murine", "SPECIES", 313, 319], ["This gain", "TEST", 0, 9], ["increased PLC\u03b32 protein expression", "PROBLEM", 53, 87], ["total PLC", "TEST", 91, 100], ["B cell lysates", "TEST", 131, 145], ["Hematological Cells", "TEST", 232, 251], ["Altered Function of PLCG2", "PROBLEM", 273, 298], ["PLC", "TEST", 330, 333], ["platelets", "TEST", 364, 373], ["enhanced \u03b1-granule secretion", "PROBLEM", 381, 409], ["cell lysates", "OBSERVATION", 133, 145]]], ["We evaluated secretion of \u03b1-granules using surface expression of CD62P (P-selectin) on freshly isolated human platelets after collagen stimulation.", [["surface", "ANATOMY", 43, 50], ["platelets", "ANATOMY", 110, 119], ["\u03b1-granules", "SIMPLE_CHEMICAL", 26, 36], ["CD62P", "GENE_OR_GENE_PRODUCT", 65, 70], ["P-selectin", "GENE_OR_GENE_PRODUCT", 72, 82], ["human", "ORGANISM", 104, 109], ["platelets", "CELL", 110, 119], ["collagen", "GENE_OR_GENE_PRODUCT", 126, 134], ["CD62P", "PROTEIN", 65, 70], ["P", "PROTEIN", 72, 73], ["selectin", "PROTEIN", 74, 82], ["freshly isolated human platelets", "CELL_TYPE", 87, 119], ["collagen", "PROTEIN", 126, 134], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["secretion of \u03b1-granules", "PROBLEM", 13, 36], ["CD62P", "TEST", 65, 70], ["freshly isolated human platelets", "TREATMENT", 87, 119], ["collagen stimulation", "TREATMENT", 126, 146]]], ["Platelet activation results in the flipping of CD62P on the inner membrane to the outside of the cell as granules release their contents.", [["Platelet", "ANATOMY", 0, 8], ["inner membrane", "ANATOMY", 60, 74], ["cell", "ANATOMY", 97, 101], ["granules", "ANATOMY", 105, 113], ["Platelet", "CELL", 0, 8], ["CD62P", "GENE_OR_GENE_PRODUCT", 47, 52], ["inner membrane", "CELLULAR_COMPONENT", 60, 74], ["cell", "CELL", 97, 101], ["granules", "ORGANISM_SUBSTANCE", 105, 113], ["CD62P", "PROTEIN", 47, 52], ["Platelet activation", "TEST", 0, 19], ["the inner membrane", "TREATMENT", 56, 74], ["inner membrane", "ANATOMY_MODIFIER", 60, 74]]], ["We found that the patient\u2019s platelets have enhanced \u03b1-granule release after stimulation with collagen in vitro (Fig. 4c).", [["platelets", "ANATOMY", 28, 37], ["\u03b1-granule", "ANATOMY", 52, 61], ["patient", "ORGANISM", 18, 25], ["platelets", "CELL", 28, 37], ["\u03b1-granule", "SIMPLE_CHEMICAL", 52, 61], ["collagen", "GENE_OR_GENE_PRODUCT", 93, 101], ["platelets", "CELL_TYPE", 28, 37], ["collagen", "PROTEIN", 93, 101], ["patient", "SPECIES", 18, 25], ["the patient\u2019s platelets", "TEST", 14, 37], ["collagen in vitro (Fig. 4c", "TREATMENT", 93, 119]]], ["These data provide support for a gain-of-function phenotype.PLCG2 (p.(Met1141Lys)) Mutation is Characterized by the Ability to Amplify BCR-Triggered External Calcium Flux ::: ResultsTo experimentally confirm the gain-of-function activity of the PLCG2M1141K genetic variant, we transiently transfected a PLC\u03b32 knockout (KO) DT40 cell line with a wild-type and mutant PLCG2 construct and assessed calcium flux after BCR stimulation.", [["PLC\u03b32 knockout (KO) DT40 cell line", "ANATOMY", 303, 337], ["Calcium", "CHEMICAL", 158, 165], ["calcium", "CHEMICAL", 395, 402], ["Calcium", "CHEMICAL", 158, 165], ["calcium", "CHEMICAL", 395, 402], ["PLCG2", "GENE_OR_GENE_PRODUCT", 60, 65], ["BCR", "GENE_OR_GENE_PRODUCT", 135, 138], ["PLCG2M1141K", "GENE_OR_GENE_PRODUCT", 245, 256], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 303, 308], ["PLCG2", "GENE_OR_GENE_PRODUCT", 366, 371], ["calcium", "SIMPLE_CHEMICAL", 395, 402], ["BCR", "GENE_OR_GENE_PRODUCT", 414, 417], ["BCR", "PROTEIN", 135, 138], ["PLCG2M1141K genetic variant", "DNA", 245, 272], ["PLC\u03b32 knockout (KO) DT40 cell line", "CELL_LINE", 303, 337], ["mutant PLCG2 construct", "DNA", 359, 381], ["BCR", "PROTEIN", 414, 417], ["DT40 cell line", "TREATMENT", 323, 337], ["mutant PLCG2 construct", "TREATMENT", 359, 381], ["calcium flux", "TEST", 395, 407], ["BCR stimulation", "TREATMENT", 414, 429], ["cell line", "OBSERVATION", 328, 337]]], ["BCR stimulation of PLC\u03b32 KO DT40 cells transfected with the mutant PLCG2 (p.(Met1141Lys)) construct resulted in increased external calcium flux compared with a wild-type PLCG2 construct (Fig. 5a).", [["PLC\u03b32 KO DT40 cells", "ANATOMY", 19, 38], ["calcium", "CHEMICAL", 131, 138], ["calcium", "CHEMICAL", 131, 138], ["BCR", "GENE_OR_GENE_PRODUCT", 0, 3], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 19, 24], ["PLCG2", "GENE_OR_GENE_PRODUCT", 67, 72], ["p.(Met1141Lys)", "GENE_OR_GENE_PRODUCT", 74, 88], ["calcium", "SIMPLE_CHEMICAL", 131, 138], ["PLCG2", "GENE_OR_GENE_PRODUCT", 170, 175], ["BCR", "PROTEIN", 0, 3], ["PLC\u03b32 KO DT40 cells", "CELL_LINE", 19, 38], ["mutant PLCG2 (p.(Met1141Lys)) construct", "DNA", 60, 99], ["wild-type PLCG2 construct", "DNA", 160, 185], ["BCR stimulation", "TEST", 0, 15], ["PLC", "TEST", 19, 22], ["the mutant PLCG2", "TEST", 56, 72], ["increased external calcium flux", "PROBLEM", 112, 143], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["external", "OBSERVATION_MODIFIER", 122, 130], ["calcium flux", "OBSERVATION", 131, 143]]], ["The difference in area under the curve for calcium flux starting at 60 s between wild-type and mutant PLCG2 was significant (463 \u00b1 25, 414\u2013512 versus 937 \u00b1 40, 858\u20131017, p = 0.02; (mean \u00b1 SEM, 95% CI)).", [["calcium", "CHEMICAL", 43, 50], ["calcium", "CHEMICAL", 43, 50], ["calcium", "SIMPLE_CHEMICAL", 43, 50], ["PLCG2", "GENE_OR_GENE_PRODUCT", 102, 107], ["mutant PLCG2", "PROTEIN", 95, 107], ["the curve", "TEST", 29, 38], ["calcium flux", "TEST", 43, 55], ["mutant PLCG2", "TEST", 95, 107], ["p", "TEST", 170, 171], ["mean", "TEST", 181, 185], ["SEM", "TEST", 188, 191], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["There was no significant difference in transfection efficiency between wild-type and mutant plasmid (27.13 \u00b1 1.04% versus 28.23 \u00b1 0.20%, p = NS) and equal expression was confirmed by Western blotting.DiscussionWe have identified a germline heterozygous gain-of-function mutation in the C2 domain of PLC\u03b32, which was previously identified as a somatic mutation in CLL, thus further expanding the phenotype of PLCG2-related inherited immunodeficiencies.", [["plasmid", "ANATOMY", 92, 99], ["CLL", "ANATOMY", 363, 366], ["CLL", "DISEASE", 363, 366], ["PLCG2", "CHEMICAL", 408, 413], ["inherited immunodeficiencies", "DISEASE", 422, 450], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 299, 304], ["CLL", "CANCER", 363, 366], ["PLCG2", "GENE_OR_GENE_PRODUCT", 408, 413], ["mutant plasmid", "DNA", 85, 99], ["germline", "DNA", 231, 239], ["C2 domain", "PROTEIN", 286, 295], ["PLC\u03b32", "PROTEIN", 299, 304], ["PLCG2", "PROTEIN", 408, 413], ["significant difference in transfection efficiency", "PROBLEM", 13, 62], ["mutant plasmid", "TEST", 85, 99], ["p", "TEST", 137, 138], ["NS", "TEST", 141, 143], ["a germline heterozygous gain", "PROBLEM", 229, 257], ["function mutation", "PROBLEM", 261, 278], ["a somatic mutation in CLL", "PROBLEM", 341, 366], ["PLCG2", "TEST", 408, 413], ["inherited immunodeficiencies", "PROBLEM", 422, 450], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["transfection efficiency", "OBSERVATION", 39, 62], ["C2", "ANATOMY", 286, 288], ["PLC", "ANATOMY", 299, 302], ["CLL", "OBSERVATION", 363, 366], ["immunodeficiencies", "OBSERVATION", 432, 450]]], ["Our experimental studies confirm that the genetic variant was associated with increased BCR-triggered external calcium flux in primary B cells, increased and prolonged BCR-triggered ERK phosphorylation in primary B cells and platelet hyper-reactivity.", [["primary B cells", "ANATOMY", 127, 142], ["primary B cells", "ANATOMY", 205, 220], ["platelet", "ANATOMY", 225, 233], ["calcium", "CHEMICAL", 111, 118], ["calcium", "CHEMICAL", 111, 118], ["BCR", "GENE_OR_GENE_PRODUCT", 88, 91], ["calcium", "SIMPLE_CHEMICAL", 111, 118], ["B cells", "CELL", 135, 142], ["BCR", "GENE_OR_GENE_PRODUCT", 168, 171], ["ERK", "GENE_OR_GENE_PRODUCT", 182, 185], ["B cells", "CELL", 213, 220], ["platelet", "CELL", 225, 233], ["BCR", "PROTEIN", 88, 91], ["primary B cells", "CELL_TYPE", 127, 142], ["BCR", "PROTEIN", 168, 171], ["ERK", "PROTEIN", 182, 185], ["primary B cells", "CELL_TYPE", 205, 220], ["Our experimental studies", "TEST", 0, 24], ["increased BCR", "PROBLEM", 78, 91], ["external calcium flux", "PROBLEM", 102, 123], ["primary B cells", "PROBLEM", 127, 142], ["prolonged BCR", "PROBLEM", 158, 171], ["ERK phosphorylation", "PROBLEM", 182, 201], ["primary B cells", "PROBLEM", 205, 220], ["platelet hyper-reactivity", "PROBLEM", 225, 250], ["BCR", "OBSERVATION", 88, 91], ["calcium flux", "OBSERVATION", 111, 123], ["primary B cells", "OBSERVATION", 127, 142], ["increased", "OBSERVATION_MODIFIER", 144, 153], ["prolonged BCR", "OBSERVATION", 158, 171], ["platelet hyper-reactivity", "OBSERVATION", 225, 250]]], ["A potentially causative relationship between the candidate genotype and the clinical phenotype was suggested by transfecting a PLC\u03b32 knockout DT40 B cell line with mutant PLCG2 (c.3422 T>A [p.Met1141Lys]) which resulted in increased external calcium flux after BCR stimulation similar to the patient\u2019s primary B cells.DiscussionIn antigen-stimulated B cells, the first transient Ca2+ flux is caused by inositol 1,4,5-trisphosphate (IP3) binding to IP3 receptors (IP3R), which triggers rapid Ca2+ release from finite internal Ca2+ stores in the endoplasmic reticulum (ER).", [["DT40 B cell line", "ANATOMY", 142, 158], ["primary B cells", "ANATOMY", 302, 317], ["B cells", "ANATOMY", 350, 357], ["endoplasmic reticulum", "ANATOMY", 544, 565], ["ER", "ANATOMY", 567, 569], ["calcium", "CHEMICAL", 242, 249], ["Ca2", "CHEMICAL", 379, 382], ["inositol 1,4,5-trisphosphate", "CHEMICAL", 402, 430], ["IP3", "CHEMICAL", 432, 435], ["IP3", "CHEMICAL", 448, 451], ["Ca2", "CHEMICAL", 491, 494], ["Ca2", "CHEMICAL", 525, 528], ["calcium", "CHEMICAL", 242, 249], ["Ca2+", "CHEMICAL", 379, 383], ["inositol 1,4,5-trisphosphate", "CHEMICAL", 402, 430], ["IP3", "CHEMICAL", 432, 435], ["Ca2+", "CHEMICAL", 491, 495], ["Ca2+", "CHEMICAL", 525, 529], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 127, 132], ["DT40 B cell line", "CELL", 142, 158], ["PLCG2", "GENE_OR_GENE_PRODUCT", 171, 176], ["c.3422 T>A", "GENE_OR_GENE_PRODUCT", 178, 188], ["calcium", "SIMPLE_CHEMICAL", 242, 249], ["BCR", "GENE_OR_GENE_PRODUCT", 261, 264], ["patient", "ORGANISM", 292, 299], ["B cells", "CELL", 310, 317], ["antigen", "GENE_OR_GENE_PRODUCT", 331, 338], ["B cells", "CELL", 350, 357], ["Ca2+", "SIMPLE_CHEMICAL", 379, 383], ["inositol 1,4,5-trisphosphate", "SIMPLE_CHEMICAL", 402, 430], ["IP3", "SIMPLE_CHEMICAL", 432, 435], ["IP3 receptors", "GENE_OR_GENE_PRODUCT", 448, 461], ["IP3R", "GENE_OR_GENE_PRODUCT", 463, 467], ["Ca2+", "SIMPLE_CHEMICAL", 491, 495], ["Ca2+", "SIMPLE_CHEMICAL", 525, 529], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 544, 565], ["ER", "GENE_OR_GENE_PRODUCT", 567, 569], ["PLC\u03b32 knockout DT40 B cell line", "CELL_LINE", 127, 158], ["mutant PLCG2", "PROTEIN", 164, 176], ["BCR", "PROTEIN", 261, 264], ["primary B cells", "CELL_TYPE", 302, 317], ["DiscussionIn antigen-stimulated B cells", "CELL_LINE", 318, 357], ["Ca2", "PROTEIN", 379, 382], ["IP3 receptors", "PROTEIN", 448, 461], ["IP3R", "PROTEIN", 463, 467], ["Ca2", "PROTEIN", 491, 494], ["Ca2", "PROTEIN", 525, 528], ["ER", "PROTEIN", 567, 569], ["patient", "SPECIES", 292, 299], ["mutant PLCG2", "TEST", 164, 176], ["increased external calcium flux", "PROBLEM", 223, 254], ["BCR stimulation", "TREATMENT", 261, 276], ["inositol", "TEST", 402, 410], ["trisphosphate (IP3)", "TREATMENT", 417, 436], ["IP3 receptors", "TEST", 448, 461], ["rapid Ca2+ release", "PROBLEM", 485, 503], ["cell line", "OBSERVATION", 149, 158], ["increased", "OBSERVATION_MODIFIER", 223, 232], ["external", "OBSERVATION_MODIFIER", 233, 241], ["calcium flux", "OBSERVATION", 242, 254], ["endoplasmic reticulum", "ANATOMY", 544, 565]]], ["This initial phase of receptor-activated Ca2+ signaling is followed by a sustained influx of extracellular Ca2+ across the plasma membrane [1, 29].", [["extracellular", "ANATOMY", 93, 106], ["plasma membrane", "ANATOMY", 123, 138], ["Ca2", "CHEMICAL", 41, 44], ["Ca2", "CHEMICAL", 107, 110], ["Ca2+", "CHEMICAL", 41, 45], ["Ca2+", "CHEMICAL", 107, 111], ["Ca2+", "SIMPLE_CHEMICAL", 41, 45], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 93, 106], ["Ca2+", "SIMPLE_CHEMICAL", 107, 111], ["plasma membrane", "CELLULAR_COMPONENT", 123, 138], ["Ca2", "PROTEIN", 41, 44], ["Ca2", "PROTEIN", 107, 110], ["extracellular Ca2", "TEST", 93, 110], ["the plasma membrane", "TEST", 119, 138], ["plasma membrane", "ANATOMY", 123, 138]]], ["The C2 domain of PLC\u03b32, in which this mutation resides, has previously been shown to play two roles in this second phase.", [["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 17, 22], ["C2 domain", "PROTEIN", 4, 13], ["PLC\u03b32", "PROTEIN", 17, 22], ["C2", "ANATOMY", 4, 6], ["PLC", "ANATOMY", 17, 20]]], ["Firstly, the initial Ca2+ flux via IP3R promotes lipase-independent translocation of additional PLC\u03b32 from the cytosol to the plasma membrane leading to more production of IP3 and DAG after binding to the adapter protein BLNK [1].", [["cytosol", "ANATOMY", 111, 118], ["plasma membrane", "ANATOMY", 126, 141], ["Ca2", "CHEMICAL", 21, 24], ["IP3", "CHEMICAL", 172, 175], ["DAG", "CHEMICAL", 180, 183], ["Ca2+", "CHEMICAL", 21, 25], ["DAG", "CHEMICAL", 180, 183], ["Ca2+", "SIMPLE_CHEMICAL", 21, 25], ["IP3R", "SIMPLE_CHEMICAL", 35, 39], ["lipase", "GENE_OR_GENE_PRODUCT", 49, 55], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 96, 101], ["cytosol", "CELLULAR_COMPONENT", 111, 118], ["plasma membrane", "CELLULAR_COMPONENT", 126, 141], ["IP3", "SIMPLE_CHEMICAL", 172, 175], ["DAG", "SIMPLE_CHEMICAL", 180, 183], ["BLNK [1]", "GENE_OR_GENE_PRODUCT", 221, 229], ["Ca2", "PROTEIN", 21, 24], ["IP3R", "PROTEIN", 35, 39], ["lipase", "PROTEIN", 49, 55], ["PLC\u03b32", "PROTEIN", 96, 101], ["IP3", "PROTEIN", 172, 175], ["adapter protein", "PROTEIN", 205, 220], ["BLNK", "PROTEIN", 221, 225], ["the initial Ca2", "TEST", 9, 24], ["lipase", "TEST", 49, 55], ["additional PLC\u03b32", "TREATMENT", 85, 101], ["IP3", "PROBLEM", 172, 175]]], ["DAG in turn activates more influx of Ca2+ by directly activating transient receptor potential cation (TRPC) Ca2+ channels in the plasma membrane [30].", [["plasma membrane", "ANATOMY", 129, 144], ["DAG", "CHEMICAL", 0, 3], ["Ca2", "CHEMICAL", 37, 40], ["Ca2", "CHEMICAL", 108, 111], ["DAG", "CHEMICAL", 0, 3], ["Ca2+", "CHEMICAL", 37, 41], ["Ca2+", "CHEMICAL", 108, 112], ["DAG", "SIMPLE_CHEMICAL", 0, 3], ["Ca2+", "SIMPLE_CHEMICAL", 37, 41], ["transient receptor potential cation", "GENE_OR_GENE_PRODUCT", 65, 100], ["TRPC", "GENE_OR_GENE_PRODUCT", 102, 106], ["Ca2+", "SIMPLE_CHEMICAL", 108, 112], ["plasma membrane", "CELLULAR_COMPONENT", 129, 144], ["Ca2", "PROTEIN", 37, 40], ["transient receptor potential cation (TRPC) Ca2+ channels", "PROTEIN", 65, 121], ["the plasma membrane", "TEST", 125, 144], ["plasma membrane", "ANATOMY", 129, 144]]], ["The C2 domain is critical for this Ca2+ entry\u2013dependent translocation of PLC\u03b32 as deletion of one of the expected Ca2+ binding sites in the C2 domain of PLC\u03b32 (\u03941138E-1140D) results in the absence of this second sustained phase [1].", [["Ca2", "CHEMICAL", 35, 38], ["Ca2", "CHEMICAL", 114, 117], ["Ca2+", "CHEMICAL", 35, 39], ["Ca2+", "CHEMICAL", 114, 118], ["Ca2+", "SIMPLE_CHEMICAL", 35, 39], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 73, 78], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 153, 158], ["\u03941138E-1140D", "GENE_OR_GENE_PRODUCT", 160, 172], ["C2 domain", "PROTEIN", 4, 13], ["Ca2", "PROTEIN", 35, 38], ["PLC\u03b32", "PROTEIN", 73, 78], ["Ca2", "PROTEIN", 114, 117], ["C2 domain", "PROTEIN", 140, 149], ["PLC\u03b32", "PROTEIN", 153, 158], ["\u03941138E", "PROTEIN", 160, 166], ["this Ca2", "PROBLEM", 30, 38], ["entry\u2013dependent translocation of PLC\u03b32", "PROBLEM", 40, 78], ["C2", "ANATOMY", 4, 6], ["binding sites", "OBSERVATION", 119, 132], ["C2", "ANATOMY", 140, 142]]], ["The proximity of the amino acid substitution in the patient\u2019s PLC\u03b32 (M1141K) to this putative calcium-binding site may result in the formation of a higher affinity Ca2+ binding site, leading to increased IP3 and DAG production.", [["amino acid", "CHEMICAL", 21, 31], ["calcium", "CHEMICAL", 94, 101], ["Ca2", "CHEMICAL", 164, 167], ["IP3", "CHEMICAL", 204, 207], ["DAG", "CHEMICAL", 212, 215], ["amino acid", "CHEMICAL", 21, 31], ["calcium", "CHEMICAL", 94, 101], ["Ca2+", "CHEMICAL", 164, 168], ["DAG", "CHEMICAL", 212, 215], ["amino acid", "AMINO_ACID", 21, 31], ["patient", "ORGANISM", 52, 59], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 62, 67], ["calcium", "SIMPLE_CHEMICAL", 94, 101], ["Ca2+", "SIMPLE_CHEMICAL", 164, 168], ["IP3", "SIMPLE_CHEMICAL", 204, 207], ["DAG", "SIMPLE_CHEMICAL", 212, 215], ["PLC\u03b32 (M1141K)", "PROTEIN", 62, 76], ["putative calcium-binding site", "DNA", 85, 114], ["Ca2", "PROTEIN", 164, 167], ["patient", "SPECIES", 52, 59], ["the amino acid substitution", "TREATMENT", 17, 44], ["this putative calcium-binding site", "PROBLEM", 80, 114], ["a higher affinity Ca2+ binding site", "PROBLEM", 146, 181], ["increased IP3 and DAG production", "PROBLEM", 194, 226], ["amino", "OBSERVATION", 21, 26], ["acid substitution", "OBSERVATION", 27, 44], ["increased", "OBSERVATION_MODIFIER", 194, 203], ["IP3", "OBSERVATION", 204, 207], ["DAG production", "OBSERVATION", 212, 226]]], ["Secondly, binding of the PLC\u03b32 SH2 domain to BLNK is stabilized by the PLC\u03b32 C2 domain in a Ca2+-regulated manner [31].", [["Ca2", "CHEMICAL", 92, 95], ["Ca2+", "CHEMICAL", 92, 96], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 25, 30], ["BLNK", "GENE_OR_GENE_PRODUCT", 45, 49], ["Ca2+", "SIMPLE_CHEMICAL", 92, 96], ["PLC\u03b32 SH2 domain", "PROTEIN", 25, 41], ["BLNK", "PROTEIN", 45, 49], ["PLC\u03b32 C2 domain", "PROTEIN", 71, 86], ["Ca2", "PROTEIN", 92, 95]]], ["Interestingly, total deletion of the C2 domain in PLC\u03b32 ablated both intracellular and extracellular BCR-triggered Ca2+ responses [1].", [["intracellular", "ANATOMY", 69, 82], ["extracellular", "ANATOMY", 87, 100], ["Ca2", "CHEMICAL", 115, 118], ["Ca2+", "CHEMICAL", 115, 119], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 50, 55], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 100], ["BCR", "GENE_OR_GENE_PRODUCT", 101, 104], ["Ca2+", "SIMPLE_CHEMICAL", 115, 119], ["C2 domain", "PROTEIN", 37, 46], ["PLC\u03b32", "PROTEIN", 50, 55], ["BCR", "PROTEIN", 101, 104], ["Ca2", "PROTEIN", 115, 118], ["total deletion of the C2 domain", "PROBLEM", 15, 46], ["extracellular BCR", "TEST", 87, 104], ["total", "OBSERVATION_MODIFIER", 15, 20], ["C2", "ANATOMY", 37, 39], ["extracellular BCR", "OBSERVATION", 87, 104]]], ["The additional requirement of the C2 domain for the initial BCR-mediated Ca2+ flux could be explained by the universal role of C2 domains in promoting binding to phospholipid bilayers.", [["Ca2", "CHEMICAL", 73, 76], ["Ca2+", "CHEMICAL", 73, 77], ["BCR", "GENE_OR_GENE_PRODUCT", 60, 63], ["Ca2+", "SIMPLE_CHEMICAL", 73, 77], ["phospholipid bilayers", "SIMPLE_CHEMICAL", 162, 183], ["C2 domain", "PROTEIN", 34, 43], ["BCR", "PROTEIN", 60, 63], ["Ca2", "PROTEIN", 73, 76], ["C2 domains", "PROTEIN", 127, 137], ["the C2 domain", "TREATMENT", 30, 43], ["the initial BCR", "TEST", 48, 63], ["C2", "ANATOMY", 127, 129]]], ["A mutation within the C2 domain has the potential to affect the association of PLC\u03b32 with the plasma membrane.", [["plasma membrane", "ANATOMY", 94, 109], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 79, 84], ["plasma membrane", "CELLULAR_COMPONENT", 94, 109], ["C2 domain", "PROTEIN", 22, 31], ["PLC\u03b32", "PROTEIN", 79, 84], ["A mutation within the C2 domain", "PROBLEM", 0, 31], ["mutation", "OBSERVATION", 2, 10], ["C2", "ANATOMY", 22, 24], ["plasma membrane", "OBSERVATION", 94, 109]]], ["For example, mutants that increase the positive surface charge of the C2 domain in p110\u03b1, a catalytic subunit of PI3K involved in tonic BCR signaling, lead to a gain-of-function [32].", [["surface", "ANATOMY", 48, 55], ["p110\u03b1", "GENE_OR_GENE_PRODUCT", 83, 88], ["PI3K", "GENE_OR_GENE_PRODUCT", 113, 117], ["BCR", "GENE_OR_GENE_PRODUCT", 136, 139], ["C2 domain", "PROTEIN", 70, 79], ["p110\u03b1", "PROTEIN", 83, 88], ["catalytic subunit", "PROTEIN", 92, 109], ["PI3K", "PROTEIN", 113, 117], ["BCR", "PROTEIN", 136, 139], ["mutants", "PROBLEM", 13, 20], ["a catalytic subunit of PI3K", "TREATMENT", 90, 117], ["tonic BCR signaling", "PROBLEM", 130, 149], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["positive", "OBSERVATION_MODIFIER", 39, 47], ["surface", "OBSERVATION_MODIFIER", 48, 55], ["C2", "ANATOMY", 70, 72]]], ["This is analogous to our variant as methionine is substituted with positively charged lysine at position 1141.DiscussionThe clinical findings in the first two cases share some of the clinical features previously reported in patients with APLAID, including polymorphous rashes, lack of cold-induced urticaria, colitis, arthritis, episcleritis, and immunodeficiency.", [["methionine", "CHEMICAL", 36, 46], ["lysine", "CHEMICAL", 86, 92], ["APLAID", "DISEASE", 238, 244], ["rashes", "DISEASE", 269, 275], ["urticaria", "DISEASE", 298, 307], ["colitis", "DISEASE", 309, 316], ["arthritis", "DISEASE", 318, 327], ["episcleritis", "DISEASE", 329, 341], ["immunodeficiency", "DISEASE", 347, 363], ["methionine", "CHEMICAL", 36, 46], ["lysine", "CHEMICAL", 86, 92], ["methionine", "SIMPLE_CHEMICAL", 36, 46], ["lysine", "AMINO_ACID", 86, 92], ["position 1141", "AMINO_ACID", 96, 109], ["patients", "ORGANISM", 224, 232], ["colitis", "PATHOLOGICAL_FORMATION", 309, 316], ["patients", "SPECIES", 224, 232], ["methionine", "TREATMENT", 36, 46], ["APLAID", "TREATMENT", 238, 244], ["polymorphous rashes", "PROBLEM", 256, 275], ["cold-induced urticaria", "PROBLEM", 285, 307], ["colitis", "PROBLEM", 309, 316], ["arthritis", "PROBLEM", 318, 327], ["episcleritis", "PROBLEM", 329, 341], ["immunodeficiency", "PROBLEM", 347, 363], ["urticaria", "OBSERVATION", 298, 307], ["colitis", "OBSERVATION", 309, 316], ["arthritis", "OBSERVATION", 318, 327], ["episcleritis", "OBSERVATION", 329, 341], ["immunodeficiency", "OBSERVATION", 347, 363]]], ["There are notable differences in the dermatological presentation as patients #1 and #2 appear to have a broader spectrum of cutaneous manifestations including urticarial, granulomatous, and vesiculobullous rashes, while patient #3 has no significant cutaneous findings to date.", [["cutaneous", "ANATOMY", 124, 133], ["granulomatous", "ANATOMY", 171, 184], ["rashes", "DISEASE", 206, 212], ["patients", "ORGANISM", 68, 76], ["rashes", "PATHOLOGICAL_FORMATION", 206, 212], ["patient", "ORGANISM", 220, 227], ["patients", "SPECIES", 68, 76], ["patient", "SPECIES", 220, 227], ["cutaneous manifestations", "PROBLEM", 124, 148], ["urticarial", "PROBLEM", 159, 169], ["granulomatous", "PROBLEM", 171, 184], ["vesiculobullous rashes", "PROBLEM", 190, 212], ["significant cutaneous findings", "PROBLEM", 238, 268], ["notable", "OBSERVATION_MODIFIER", 10, 17], ["differences", "OBSERVATION_MODIFIER", 18, 29], ["cutaneous", "ANATOMY", 124, 133], ["urticarial", "OBSERVATION_MODIFIER", 159, 169], ["granulomatous", "OBSERVATION", 171, 184], ["vesiculobullous", "OBSERVATION_MODIFIER", 190, 205], ["rashes", "OBSERVATION", 206, 212], ["no", "UNCERTAINTY", 235, 237], ["significant", "OBSERVATION_MODIFIER", 238, 249], ["cutaneous", "ANATOMY", 250, 259], ["findings", "OBSERVATION", 260, 268]]], ["One of the limitations of our study is that we were unable to obtain a more detailed functional profile of hematopoietic cells in these two patients as was done with patient #3.DiscussionOur third patient does not, as of yet, have any evidence of severe inflammation and the presentation was more consistent with pediatric CVID.", [["hematopoietic cells", "ANATOMY", 107, 126], ["inflammation", "DISEASE", 254, 266], ["CVID", "DISEASE", 323, 327], ["hematopoietic cells", "CELL", 107, 126], ["patients", "ORGANISM", 140, 148], ["patient", "ORGANISM", 166, 173], ["patient", "ORGANISM", 197, 204], ["hematopoietic cells", "CELL_TYPE", 107, 126], ["patients", "SPECIES", 140, 148], ["patient", "SPECIES", 166, 173], ["patient", "SPECIES", 197, 204], ["our study", "TEST", 26, 35], ["severe inflammation", "PROBLEM", 247, 266], ["pediatric CVID", "PROBLEM", 313, 327], ["hematopoietic cells", "OBSERVATION", 107, 126], ["severe", "OBSERVATION_MODIFIER", 247, 253], ["inflammation", "OBSERVATION", 254, 266]]], ["The association between PLCG2 mutations and CVID is further supported by a recent study of 185 CVID cases, which revealed 12 missense variants of PLCG2 [33].", [["CVID", "DISEASE", 44, 48], ["CVID", "DISEASE", 95, 99], ["PLCG2", "GENE_OR_GENE_PRODUCT", 24, 29], ["PLCG2", "PROTEIN", 24, 29], ["PLCG2 mutations", "PROBLEM", 24, 39], ["CVID", "PROBLEM", 44, 48], ["a recent study", "TEST", 73, 87], ["CVID cases", "TEST", 95, 105], ["12 missense variants of PLCG2", "PROBLEM", 122, 151]]], ["Overexpression studies in a PLCG2 deficient DT40 B cell line, as done in our study, showed enhanced ERK phosphorylation and enhanced activation following IgM stimulation.DiscussionInterestingly, the B cell defects of the third patient more closely resembled those observed in PLC\u03b32-deficient mice despite completely opposing effects on BCR-stimulated ERK phosphorylation and calcium flux [34].", [["DT40 B cell line", "ANATOMY", 44, 60], ["B cell", "ANATOMY", 199, 205], ["calcium", "CHEMICAL", 375, 382], ["calcium", "CHEMICAL", 375, 382], ["PLCG2", "GENE_OR_GENE_PRODUCT", 28, 33], ["DT40 B cell line", "CELL", 44, 60], ["ERK", "GENE_OR_GENE_PRODUCT", 100, 103], ["IgM", "GENE_OR_GENE_PRODUCT", 154, 157], ["B cell", "CELL", 199, 205], ["patient", "ORGANISM", 227, 234], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 276, 281], ["mice", "ORGANISM", 292, 296], ["BCR", "GENE_OR_GENE_PRODUCT", 336, 339], ["ERK", "GENE_OR_GENE_PRODUCT", 351, 354], ["calcium", "SIMPLE_CHEMICAL", 375, 382], ["PLCG2 deficient DT40 B cell line", "CELL_LINE", 28, 60], ["ERK", "PROTEIN", 100, 103], ["IgM", "PROTEIN", 154, 157], ["PLC\u03b32", "PROTEIN", 276, 281], ["BCR", "PROTEIN", 336, 339], ["ERK", "PROTEIN", 351, 354], ["patient", "SPECIES", 227, 234], ["mice", "SPECIES", 292, 296], ["mice", "SPECIES", 292, 296], ["Overexpression studies", "TEST", 0, 22], ["a PLCG2 deficient DT40 B cell line", "TREATMENT", 26, 60], ["our study", "TEST", 73, 82], ["enhanced ERK phosphorylation", "PROBLEM", 91, 119], ["IgM stimulation", "TREATMENT", 154, 169], ["the B cell defects", "PROBLEM", 195, 213], ["BCR", "TEST", 336, 339], ["ERK phosphorylation", "TEST", 351, 370], ["calcium flux", "TEST", 375, 387], ["cell line", "OBSERVATION", 51, 60], ["ERK phosphorylation", "OBSERVATION", 100, 119], ["cell defects", "OBSERVATION", 201, 213]]], ["These mice were viable but had decreased mature B cells, a block in pro-B cell differentiation, and B1 B cell deficiency.", [["B cells", "ANATOMY", 48, 55], ["pro-B cell", "ANATOMY", 68, 78], ["B cell", "ANATOMY", 103, 109], ["mice", "ORGANISM", 6, 10], ["B cells", "CELL", 48, 55], ["pro-B cell", "CELL", 68, 78], ["B1 B cell", "CELL", 100, 109], ["mature B cells", "CELL_TYPE", 41, 55], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["decreased mature B cells", "PROBLEM", 31, 55], ["a block in pro", "PROBLEM", 57, 71], ["B1 B cell deficiency", "PROBLEM", 100, 120], ["decreased", "OBSERVATION_MODIFIER", 31, 40], ["mature", "OBSERVATION_MODIFIER", 41, 47], ["B cells", "OBSERVATION", 48, 55], ["cell differentiation", "OBSERVATION", 74, 94], ["B1 B cell deficiency", "OBSERVATION", 100, 120]]], ["IgM receptor-induced Ca2+ flux and proliferation in response to B cell mitogens was absent.", [["B cell", "ANATOMY", 64, 70], ["Ca2", "CHEMICAL", 21, 24], ["Ca2+", "CHEMICAL", 21, 25], ["IgM receptor", "GENE_OR_GENE_PRODUCT", 0, 12], ["Ca2+", "SIMPLE_CHEMICAL", 21, 25], ["B cell", "CELL", 64, 70], ["IgM receptor", "PROTEIN", 0, 12], ["Ca2", "PROTEIN", 21, 24], ["B cell mitogens", "PROTEIN", 64, 79], ["IgM receptor", "TEST", 0, 12], ["Ca2+ flux", "PROBLEM", 21, 30], ["proliferation", "PROBLEM", 35, 48], ["B cell mitogens", "TEST", 64, 79], ["cell mitogens", "OBSERVATION", 66, 79]]], ["Ig levels were reduced and T cell\u2013independent antibody production was absent.", [["Ig", "GENE_OR_GENE_PRODUCT", 0, 2], ["T cell\u2013independent antibody", "GENE_OR_GENE_PRODUCT", 27, 54], ["Ig", "PROTEIN", 0, 2], ["Ig levels", "TEST", 0, 9], ["T cell\u2013independent antibody production", "TEST", 27, 65]]], ["Fc\u03b3R signaling was also defective, resulting in a loss of collagen-induced platelet aggregation, mast cell Fc\u03b5R function, and NK cell Fc\u03b3RIII and 2B4 function [35].", [["platelet", "ANATOMY", 75, 83], ["mast cell", "ANATOMY", 97, 106], ["NK cell", "ANATOMY", 126, 133], ["platelet aggregation", "DISEASE", 75, 95], ["Fc\u03b3R", "GENE_OR_GENE_PRODUCT", 0, 4], ["collagen", "GENE_OR_GENE_PRODUCT", 58, 66], ["platelet", "CELL", 75, 83], ["mast cell Fc\u03b5R", "GENE_OR_GENE_PRODUCT", 97, 111], ["NK cell Fc\u03b3RIII", "GENE_OR_GENE_PRODUCT", 126, 141], ["2B4", "GENE_OR_GENE_PRODUCT", 146, 149], ["Fc\u03b3R", "PROTEIN", 0, 4], ["collagen", "PROTEIN", 58, 66], ["2B4", "PROTEIN", 146, 149], ["also defective", "PROBLEM", 19, 33], ["a loss of collagen-induced platelet aggregation", "PROBLEM", 48, 95], ["mast cell Fc", "TEST", 97, 109], ["R function", "TEST", 110, 120], ["NK cell Fc", "TEST", 126, 136], ["RIII", "TEST", 137, 141], ["defective", "OBSERVATION", 24, 33], ["platelet aggregation", "OBSERVATION", 75, 95], ["mast cell", "OBSERVATION", 97, 106], ["NK cell", "OBSERVATION", 126, 133]]], ["Targeted deletion of Plc\u03b32 in germinal center B cells demonstrated an additional essential role in the maintenance of memory B cells [36].", [["germinal center B cells", "ANATOMY", 30, 53], ["memory B cells", "ANATOMY", 118, 132], ["Plc\u03b32", "GENE_OR_GENE_PRODUCT", 21, 26], ["germinal center B cells", "CELL", 30, 53], ["memory B cells", "CELL", 118, 132], ["Plc\u03b32", "PROTEIN", 21, 26], ["germinal center B cells", "CELL_TYPE", 30, 53], ["memory B cells", "CELL_TYPE", 118, 132], ["Targeted deletion of Plc\u03b32 in germinal center B cells", "PROBLEM", 0, 53], ["essential", "OBSERVATION_MODIFIER", 81, 90]]], ["To date, there are no reported cases of humans with PLC\u03b32 deficiency.", [["humans", "ORGANISM", 40, 46], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 52, 57], ["PLC\u03b32", "PROTEIN", 52, 57], ["humans", "SPECIES", 40, 46], ["humans", "SPECIES", 40, 46], ["PLC\u03b32 deficiency", "PROBLEM", 52, 68]]], ["This suggests that PLC\u03b32 activity may be tightly regulated in normal B cell development; a decrease in PLC\u03b32 activity results in diminished BCR signaling that strongly impairs development of transitional B cells [37], while BCR hyper-reactivity causes B cell apoptosis.", [["B cell", "ANATOMY", 69, 75], ["transitional B cells", "ANATOMY", 191, 211], ["B cell", "ANATOMY", 252, 258], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 19, 24], ["B cell", "CELL", 69, 75], ["PLC\u03b32", "GENE_OR_GENE_PRODUCT", 103, 108], ["BCR", "GENE_OR_GENE_PRODUCT", 140, 143], ["transitional B cells", "CELL", 191, 211], ["BCR", "GENE_OR_GENE_PRODUCT", 224, 227], ["B cell", "CELL", 252, 258], ["PLC\u03b32", "PROTEIN", 19, 24], ["PLC\u03b32", "PROTEIN", 103, 108], ["BCR", "PROTEIN", 140, 143], ["transitional B cells", "CELL_TYPE", 191, 211], ["BCR", "PROTEIN", 224, 227], ["PLC\u03b32 activity", "PROBLEM", 19, 33], ["a decrease in PLC\u03b32 activity", "PROBLEM", 89, 117], ["diminished BCR signaling", "PROBLEM", 129, 153], ["transitional B cells", "PROBLEM", 191, 211], ["BCR", "TEST", 224, 227], ["B cell apoptosis", "PROBLEM", 252, 268], ["normal B cell", "OBSERVATION", 62, 75], ["decrease", "OBSERVATION_MODIFIER", 91, 99], ["diminished", "OBSERVATION_MODIFIER", 129, 139], ["BCR", "OBSERVATION", 140, 143], ["transitional B cells", "OBSERVATION", 191, 211], ["B cell apoptosis", "OBSERVATION", 252, 268]]], ["Either way, there is a defect in B cell development.DiscussionIn this study, we report the same PLCG2 mutation in three patients with different phenotypes.", [["B cell", "ANATOMY", 33, 39], ["B cell", "CELL", 33, 39], ["PLCG2", "GENE_OR_GENE_PRODUCT", 96, 101], ["patients", "ORGANISM", 120, 128], ["PLCG2", "DNA", 96, 101], ["patients", "SPECIES", 120, 128], ["a defect in B cell development", "PROBLEM", 21, 51], ["this study", "TEST", 65, 75], ["different phenotypes", "PROBLEM", 134, 154], ["defect", "OBSERVATION", 23, 29], ["B cell development", "OBSERVATION", 33, 51]]], ["The reasons for this may include variable expressivity of the genotype in various hematopoietic cell subsets leading to overdominance of the gain-of-function allele in certain cells.", [["hematopoietic cell", "ANATOMY", 82, 100], ["cells", "ANATOMY", 176, 181], ["hematopoietic cell subsets", "CELL", 82, 108], ["cells", "CELL", 176, 181], ["hematopoietic cell subsets", "CELL_TYPE", 82, 108], ["gain-of-function allele", "DNA", 141, 164], ["the genotype in various hematopoietic cell subsets", "PROBLEM", 58, 108], ["the gain", "PROBLEM", 137, 145], ["various hematopoietic cell subsets", "OBSERVATION", 74, 108]]], ["For example, the B cell lineage in our third case may have had increased mutant allele transcription and gene activity resulting in a more pronounced effect on BCR signaling in early B cell development.", [["B cell lineage", "ANATOMY", 17, 31], ["B cell", "ANATOMY", 183, 189], ["B cell lineage", "CELL", 17, 31], ["BCR", "GENE_OR_GENE_PRODUCT", 160, 163], ["B cell", "CELL", 183, 189], ["B cell lineage", "CELL_TYPE", 17, 31], ["mutant allele", "DNA", 73, 86], ["BCR", "PROTEIN", 160, 163], ["increased mutant allele transcription", "PROBLEM", 63, 100], ["BCR signaling", "PROBLEM", 160, 173], ["cell lineage", "OBSERVATION", 19, 31], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["mutant allele transcription", "OBSERVATION", 73, 100], ["more pronounced", "OBSERVATION_MODIFIER", 134, 149], ["BCR", "OBSERVATION", 160, 163], ["early B cell development", "OBSERVATION", 177, 201]]], ["Further, yet unknown modifier genes and environmental factors may affect this phenotype.DiscussionOur study highlights the utility of the whole genome/exome sequencing approach in elucidating genetic causes of autoinflammatory syndromes and CVID and provide further insight into the mechanism of BCR signaling in human B cells.", [["B cells", "ANATOMY", 319, 326], ["autoinflammatory syndromes", "DISEASE", 210, 236], ["CVID", "DISEASE", 241, 245], ["BCR", "GENE_OR_GENE_PRODUCT", 296, 299], ["human", "ORGANISM", 313, 318], ["B cells", "CELL", 319, 326], ["modifier genes", "DNA", 21, 35], ["BCR", "PROTEIN", 296, 299], ["human B cells", "CELL_TYPE", 313, 326], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 313, 318], ["this phenotype", "PROBLEM", 73, 87], ["DiscussionOur study", "TEST", 88, 107], ["the whole genome/exome sequencing approach", "TREATMENT", 134, 176], ["autoinflammatory syndromes", "PROBLEM", 210, 236], ["CVID", "PROBLEM", 241, 245], ["BCR signaling in human B cells", "PROBLEM", 296, 326], ["autoinflammatory", "OBSERVATION", 210, 226], ["BCR", "OBSERVATION", 296, 299]]], ["Moreover, this work emphasizes the ongoing critical need for functional studies to link genotype to phenotype.", [["functional studies", "TEST", 61, 79]]], ["Our results also expand the clinical spectrum of diseases resulting from PLCG2 mutations, while observing similarities such as impaired B cell memory and antibody production.", [["B cell", "ANATOMY", 136, 142], ["PLCG2", "GENE_OR_GENE_PRODUCT", 73, 78], ["B cell", "CELL", 136, 142], ["PLCG2", "PROTEIN", 73, 78], ["diseases", "PROBLEM", 49, 57], ["PLCG2 mutations", "PROBLEM", 73, 88], ["impaired B cell memory", "PROBLEM", 127, 149], ["diseases", "OBSERVATION", 49, 57], ["cell memory", "OBSERVATION", 138, 149]]]], "b14bf388bff34623d1cf1ec54dd10f4e04e4c96d": [["IntroductionThe human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) pandemic (pandemic) was a major crisis at the end of the 20th and beginning of the 21st century.", [["human immunodeficiency virus/acquired immune deficiency syndrome", "DISEASE", 16, 80], ["HIV/AIDS) pandemic", "DISEASE", 82, 100], ["pandemic", "DISEASE", 102, 110], ["human immunodeficiency virus", "ORGANISM", 16, 44], ["human", "SPECIES", 16, 21], ["immunodeficiency virus", "SPECIES", 22, 44], ["human immunodeficiency virus", "SPECIES", 16, 44], ["HIV", "SPECIES", 82, 85], ["The human immunodeficiency virus", "PROBLEM", 12, 44], ["acquired immune deficiency syndrome", "PROBLEM", 45, 80], ["HIV/AIDS)", "PROBLEM", 82, 91], ["pandemic", "PROBLEM", 92, 100], ["a major crisis", "PROBLEM", 116, 130], ["immune deficiency", "OBSERVATION", 54, 71]]], ["Such a defining moment in the history of healthrelated infections led to transformations in its proponents, as well as their medical practice.", [["infections", "DISEASE", 55, 65], ["healthrelated infections", "PROBLEM", 41, 65], ["infections", "OBSERVATION", 55, 65]]], ["This research article aims to offer insights into the lived trajectories/experiences (journeys) of six Canadian gay physicians while they attempted to treat, care for, and cure/heal (treat) gay HIV/AIDS patients from 1981 to 2009.", [["HIV/AIDS", "DISEASE", 194, 202], ["HIV", "ORGANISM", 194, 197], ["patients", "ORGANISM", 203, 211], ["HIV", "SPECIES", 194, 197], ["patients", "SPECIES", 203, 211], ["cure/heal", "TREATMENT", 172, 181]]], ["According to Valdiserri (2011) , in June 1981, a major event, referred to as a tempest, crisis, lethal threat, or new outbreak (among other terms), shocked the world and baffled the medical establishment (Bayer & Oppenheimer, 2000; Finkelstein, 2018 ; Joint United Nations Programme on HIV/ AIDS, 2002; L\u00e9vy & Qu\u00e9villon, 2014 -2015 Piot & Quinn, 2013; U.S. Department of Health and Human Services, 2018 ).", [["HIV/ AIDS", "DISEASE", 286, 295], ["Human", "ORGANISM", 382, 387], ["Human", "SPECIES", 382, 387], ["crisis", "PROBLEM", 88, 94], ["lethal threat", "PROBLEM", 96, 109], ["HIV/ AIDS", "TREATMENT", 286, 295], ["Joint", "ANATOMY", 252, 257]]], ["An unknown virus, disease, or infection was reported for the first time by the Centers for Disease Control and Prevention (CDC) in the Morbidity and Mortality Weekly Report (U.S Department of Health and Human Services, 2018) .", [["infection", "DISEASE", 30, 39], ["Human", "ORGANISM", 203, 208], ["Human", "SPECIES", 203, 208], ["An unknown virus", "PROBLEM", 0, 16], ["disease", "PROBLEM", 18, 25], ["infection", "PROBLEM", 30, 39], ["Disease Control", "TREATMENT", 91, 106], ["unknown", "UNCERTAINTY", 3, 10], ["virus", "OBSERVATION", 11, 16], ["disease", "OBSERVATION", 18, 25], ["infection", "OBSERVATION", 30, 39]]], ["It was first called gay cancer or gay plague by the media, and gay-related immune deficiency (GRID) by the CDC (Altman, 1982; Chibbaro, 1982; Cichocki, 2009; Kher, 1982) .", [["cancer", "ANATOMY", 24, 30], ["gay cancer", "DISEASE", 20, 30], ["gay plague", "DISEASE", 34, 44], ["immune deficiency", "DISEASE", 75, 92], ["GRID", "DISEASE", 94, 98], ["gay cancer", "CANCER", 20, 30], ["immune deficiency", "PROBLEM", 75, 92], ["immune deficiency", "OBSERVATION", 75, 92]]], ["In 1982, the CDC renamed the infection AIDS.", [["infection", "DISEASE", 29, 38], ["AIDS", "DISEASE", 39, 43], ["the infection AIDS", "PROBLEM", 25, 43], ["infection", "OBSERVATION", 29, 38]]], ["1 It was not until 1986 that HIV was termed (Aldrich & Wotherspoon, 2001) .", [["HIV", "ORGANISM", 29, 32], ["HIV", "SPECIES", 29, 32], ["HIV", "SPECIES", 29, 32], ["HIV", "PROBLEM", 29, 32]]], ["The infection soon grew into an epidemic, as it was prevalent within a larger community, mostly gay (Bayer & Oppenheimer, 2000; Ungvarski, 2001) .", [["infection", "DISEASE", 4, 13], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["As cases appeared in other parts of the world, besides North America, such as Europe and Africa, it was eventually recognized as a pandemic (Altman, 2011; Smith, 2001) .IntroductionThroughout the more than four decades since the appearance of the HIV infection, many narratives have been published (e.g., Alderman & Frey, 1997; Boulanger & Thomas, 2008; McCoy, 2005; Scannell, 1999; Smith, 2001) .", [["HIV infection", "DISEASE", 247, 260], ["HIV", "ORGANISM", 247, 250], ["HIV", "SPECIES", 247, 250], ["HIV", "SPECIES", 247, 250], ["Introduction", "TREATMENT", 169, 181], ["the HIV infection", "PROBLEM", 243, 260], ["HIV", "OBSERVATION_MODIFIER", 247, 250], ["infection", "OBSERVATION", 251, 260]]], ["They speak of \"courage, cowardice, hope, despair, compassion, and bigotry\" (Ungvarski, 2001, p.", [["bigotry", "DISEASE", 66, 73]]], ["They describe the fear of the unknown, the spread of the disease, death, sexuality, and alternative lifestyles, such as bisexuality, homosexuality, transgender, and drug use (Witt Sherman, 2000; Witt Sherman & Ouellette, 2000) .", [["death", "DISEASE", 66, 71], ["the disease", "PROBLEM", 53, 64]]], ["Because of the attitudes, beliefs, interpretations, opinions, perceptions, and values that individuals held about HIV/AIDS, many social problems arose, such as stigmatization, discrimination, and prejudice (De Oliveira Almeida, Vandenplas-Holper, & De Ketele, 1992; Witt Sherman, 2000; Witt Sherman & Ouellette, 2000) .", [["HIV/AIDS", "DISEASE", 114, 122], ["HIV", "SPECIES", 114, 117], ["HIV", "SPECIES", 114, 117], ["Vandenplas-Holper, & De Ketele, 1992; Witt Sherman, 2000; Witt Sherman & Ouellette, 2000)", "SPECIES", 228, 317], ["HIV/AIDS", "PROBLEM", 114, 122]]], ["Moreover, because of the convergence of the myriad of uncertainties regarding HIV prevention, HIV/AIDS treatment, and opportunistic infections, many HIV-infected patients developed comorbidities with the above-mentioned issues or fears.", [["HIV/AIDS", "DISEASE", 94, 102], ["opportunistic infections", "DISEASE", 118, 142], ["HIV-infected", "DISEASE", 149, 161], ["HIV", "ORGANISM", 78, 81], ["HIV", "ORGANISM", 94, 97], ["HIV", "ORGANISM", 149, 152], ["patients", "ORGANISM", 162, 170], ["HIV", "SPECIES", 78, 81], ["HIV", "SPECIES", 94, 97], ["HIV-", "SPECIES", 149, 153], ["patients", "SPECIES", 162, 170], ["HIV", "SPECIES", 78, 81], ["HIV", "SPECIES", 94, 97], ["HIV", "SPECIES", 149, 152], ["HIV prevention", "TREATMENT", 78, 92], ["HIV/AIDS treatment", "TREATMENT", 94, 112], ["opportunistic infections", "PROBLEM", 118, 142], ["comorbidities", "PROBLEM", 181, 194]]], ["Furthermore, some health professionals \"succumb[ed] to hysteria and abandon [ed] their objectivity and compassion in the care of patients with HIV/AIDS\" (Dunkel & Harfield, 1986, p.", [["hysteria", "DISEASE", 55, 63], ["HIV/AIDS", "DISEASE", 143, 151], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["hysteria", "PROBLEM", 55, 63]]], ["114; Witt Sherman, 2000; Witt Sherman & Ouellette, 2000) .IntroductionIn response to the shock provoked by the sudden and still unknown infection, as well as the hysteria, abandonment, and victimization of some HIV-infected gay members by their community, \"the gay, lesbian, bisexual, and transgender (LGBT) communities quickly came to realize that if they didn't take action, nobody would\" (U.S. Department of Health and Human Services, 2018, p.", [["shock", "DISEASE", 89, 94], ["infection", "DISEASE", 136, 145], ["hysteria", "DISEASE", 162, 170], ["HIV-infected", "DISEASE", 211, 223], ["Human", "ORGANISM", 422, 427], ["HIV", "SPECIES", 211, 214], ["Human", "SPECIES", 422, 427], ["HIV", "SPECIES", 211, 214], ["the shock", "PROBLEM", 85, 94], ["unknown infection", "PROBLEM", 128, 145], ["the hysteria", "PROBLEM", 158, 170], ["infection", "OBSERVATION", 136, 145]]], ["They responded to the call to action because they had friends or family members who were HIV-infected, or as a personal response to the abandonment and rejection of their patients who were either gay, or HIV-infected, or both simultaneously (Pascreta & Jacobsen, 1989) .", [["HIV-infected", "DISEASE", 89, 101], ["HIV-infected", "DISEASE", 204, 216], ["patients", "ORGANISM", 171, 179], ["HIV", "ORGANISM", 204, 207], ["HIV", "SPECIES", 89, 92], ["patients", "SPECIES", 171, 179], ["HIV", "SPECIES", 204, 207], ["HIV", "SPECIES", 89, 92], ["HIV", "SPECIES", 204, 207], ["HIV", "PROBLEM", 204, 207], ["infected", "PROBLEM", 208, 216], ["infected", "OBSERVATION", 208, 216]]], ["They came out of their professional sexual neutrality and became \"openly\" gay physicians, profoundly implicated in the political, social, and medical causes of their patients, friends, and community (Jacob, 2012) .IntroductionUnfortunately, over time, memories of what it was like to meet head-on a grim, contagious, disfiguring, lethal, and sexually transmitted threat like HIV/AIDS have begun to fade.", [["head", "ANATOMY", 289, 293], ["sexually transmitted threat like HIV/AIDS", "DISEASE", 342, 383], ["patients", "ORGANISM", 166, 174], ["head", "ORGANISM_SUBDIVISION", 289, 293], ["HIV", "ORGANISM", 375, 378], ["patients", "SPECIES", 166, 174], ["HIV", "SPECIES", 375, 378], ["HIV", "SPECIES", 375, 378], ["HIV/AIDS", "PROBLEM", 375, 383]]], ["3) and when \"people with HIV [/AIDS] were fired from their jobs, kicked out of their apartments, denied health care and abandoned by their families\" (AIDS Legal Council of Chicago, 2013, p.", [["HIV [/AIDS", "DISEASE", 25, 35], ["AIDS", "DISEASE", 150, 154], ["people", "ORGANISM", 13, 19], ["HIV", "ORGANISM", 25, 28], ["people", "SPECIES", 13, 19], ["HIV", "SPECIES", 25, 28], ["HIV", "SPECIES", 25, 28], ["HIV", "PROBLEM", 25, 28], ["AIDS", "PROBLEM", 31, 35]]], ["There is a new generation of activists, archivists, artists, historians, and researchers, among others, who were born during the HIV/AIDS pandemic, who now need to make sense of this grim period (Finkelstein, 2018) .", [["HIV/AIDS pandemic", "DISEASE", 129, 146], ["HIV", "SPECIES", 129, 132], ["new", "OBSERVATION_MODIFIER", 11, 14], ["generation", "OBSERVATION_MODIFIER", 15, 25]]], ["Moreover, there is a growing number of archival projects, books, documentaries, and gallery exhibitions that are now devoted to the topic, with more underway.IntroductionOne such undertaking is this scientific research article which presents an unpublished study conducted between 2008 and 2009 with six Canadian gay HIV/AIDS physicians (study).", [["HIV/AIDS", "DISEASE", 317, 325], ["an unpublished study", "TEST", 242, 262], ["growing", "OBSERVATION_MODIFIER", 21, 28], ["number", "OBSERVATION_MODIFIER", 29, 35]]], ["While it aims to offer insights into the lived journeys of unsung heroes (physicians), it also serves as a reminder of their courage as lobbyists and advocates (militants) for their HIV/AIDS patients (patients) during the pandemic.Literature ReviewAt the time of the study, only two types of literature pertaining to the study's topic, that is, The Use of Experiential Learning in the Transformation of the Medical Practice of Six Professionals in the Context of the HIV/AIDS Pandemic, 2 were available.", [["HIV/AIDS", "DISEASE", 182, 190], ["AIDS", "DISEASE", 471, 475], ["HIV", "ORGANISM", 182, 185], ["AIDS", "ORGANISM", 186, 190], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 201, 209], ["HIV", "SPECIES", 182, 185], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 201, 209], ["HIV", "SPECIES", 182, 185], ["the pandemic", "PROBLEM", 218, 230], ["the study", "TEST", 263, 272], ["the study", "TEST", 317, 326]]], ["These two types of literature served to establish a preliminary understanding of the patients' trajectories from the onset of the infection to the patients' death.", [["infection", "DISEASE", 130, 139], ["death", "DISEASE", 157, 162], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 147, 155], ["the infection", "PROBLEM", 126, 139], ["the patients' death", "PROBLEM", 143, 162], ["infection", "OBSERVATION", 130, 139]]], ["They also provided an account of physicians' journeys from the onset of the infection to their patients' death and beyond, including attending their funerals, for example, at different key periods of the pandemic's trajectory.", [["infection", "DISEASE", 76, 85], ["death", "DISEASE", 105, 110], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["the infection", "PROBLEM", 72, 85], ["infection", "OBSERVATION", 76, 85]]], ["These key periods were identified as follows: Period 1, HIV/AIDS Emergence; Period 2, Recognized Pandemic and Militancy Rise; and Period 3, HIV Chronicity and Militancy Decrease (see appendix-HIV-AIDS Pandemic Trajectory: Three Periods).", [["AIDS", "DISEASE", 60, 64], ["Pandemic", "DISEASE", 97, 105], ["HIV Chronicity", "DISEASE", 140, 154], ["AIDS", "DISEASE", 196, 200], ["HIV", "SPECIES", 140, 143], ["HIV", "SPECIES", 140, 143], ["HIV Chronicity", "PROBLEM", 140, 154], ["Militancy Decrease", "PROBLEM", 159, 177], ["appendix", "ANATOMY", 183, 191]]], ["A few examples of the books and autobiographies from nonmedical and medical authors are highlighted here for their significant input into the study.Literature ReviewIn their book titled Good Doctor Good Patients: Partners in the HIV Treatment, Rabkin, Remien, and Wilson (1994) present patients' and their physicians' beliefs about the characteristics of and expectations from the physician-patient therapeutic relationship.", [["Patients", "ORGANISM", 203, 211], ["patients", "ORGANISM", 286, 294], ["patient", "ORGANISM", 391, 398], ["Patients", "SPECIES", 203, 211], ["patients", "SPECIES", 286, 294], ["patient", "SPECIES", 391, 398], ["the study", "TEST", 138, 147], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["They discuss medical and psychological challenges faced by both physicians and patients from the initial HIV/AIDS diagnosis up to and including the end-stage of the disease, and the dying process.", [["AIDS", "DISEASE", 109, 113], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["HIV", "SPECIES", 105, 108], ["medical and psychological challenges", "TREATMENT", 13, 49], ["the disease", "PROBLEM", 161, 172], ["disease", "OBSERVATION", 165, 172]]], ["They also describe specific skills and strategies that physicians can use to meet these challenges and discuss the role that friends, family, and professional counselors play in addressing the ongoing challenges of living with HIV/AIDS.", [["HIV/AIDS", "DISEASE", 227, 235], ["HIV", "SPECIES", 227, 230]]], ["In Reports From the Holocaust: The Story of an AIDS Activist, Kramer (1994) shares his views as an AIDS activist and advocate, as well as on AIDS and LGBT civil rights from the beginning of the pandemic.", [["AIDS", "DISEASE", 47, 51], ["AIDS", "DISEASE", 99, 103], ["AIDS", "DISEASE", 141, 145], ["his views", "TEST", 83, 92], ["AIDS", "TREATMENT", 141, 145], ["LGBT civil rights", "TREATMENT", 150, 167]]], ["In addition, he documents his time spent working in community organizations against HIV/AIDS (e.g., Gay Men's Health Crisis and ACT UP) and beyond.", [["HIV/AIDS", "DISEASE", 84, 92], ["HIV", "ORGANISM", 84, 87], ["HIV", "SPECIES", 84, 87], ["HIV/AIDS", "PROBLEM", 84, 92]]], ["As for Shilts (1988) , in his book titled And the Band Played On: Politics, People and the AIDS Epidemic, he discusses the discovery and spread of HIV/AIDS and comments on the government's indifference and political infighting during the early 1980s.Literature ReviewIn his autobiography titled To the Friend Who Did Not Save My Life, Guibert (1993) shares his own journey on his AIDSrelated physical and psychological suffering, and reveals his physician-patient therapeutic relationship.", [["AIDS", "DISEASE", 91, 95], ["HIV/AIDS", "DISEASE", 147, 155], ["AIDSrelated physical and psychological suffering", "DISEASE", 380, 428], ["patient", "ORGANISM", 456, 463], ["People", "SPECIES", 76, 82], ["patient", "SPECIES", 456, 463], ["HIV", "SPECIES", 147, 150], ["HIV/AIDS", "PROBLEM", 147, 155]]], ["Hodge-Wright (2004) , in her autobiography titled Life Lessons: Stories of Hope, Love and Laughter in the Face of AIDS, discloses stories of love, betrayal, forgiveness, and joy from the counseling experiences which impacted her life.", [["AIDS", "DISEASE", 114, 118]]], ["She also reveals her efforts to find meaning in every positive and negative life experiences, including when individuals are confronted with AIDS.", [["AIDS", "DISEASE", 141, 145]]], ["As for Whitmore (1988) , in Someone Was Here: Profiles in the AIDS Epidemic, he tries to humanize the notions of illness, epidemic, and courage by reaching out to men and women whose lives were changed by the HIV/AIDS epidemic.", [["AIDS", "DISEASE", 62, 66], ["illness", "DISEASE", 113, 120], ["HIV/AIDS", "DISEASE", 209, 217], ["men", "ORGANISM", 163, 166], ["women", "ORGANISM", 171, 176], ["men", "SPECIES", 163, 166], ["women", "SPECIES", 171, 176], ["HIV", "SPECIES", 209, 212], ["illness", "PROBLEM", 113, 120]]], ["In fact, these autobiographies, and many more, present the human toll of the HIV/AIDS pandemic (see also Bluestein, 1997; Callwood, 1988; Cox, 1990; G\u00e9linas-O'Meara, 1994; Kavanagh, 2007; Monette, 1988; Oyler, 1988) .Literature ReviewIn his autobiography titled The Least of These My Brethren: A Doctor's Story of Hope and Miracles on an Inner-City AIDS Ward, Baxter (1997) shares the life stories of suffering and redemption of HIV/AIDS patients.", [["HIV/AIDS pandemic", "DISEASE", 77, 94], ["AIDS", "DISEASE", 349, 353], ["HIV/AIDS", "DISEASE", 429, 437], ["human", "ORGANISM", 59, 64], ["HIV", "ORGANISM", 77, 80], ["HIV", "ORGANISM", 429, 432], ["patients", "ORGANISM", 438, 446], ["human", "SPECIES", 59, 64], ["HIV", "SPECIES", 77, 80], ["HIV", "SPECIES", 429, 432], ["patients", "SPECIES", 438, 446], ["human", "SPECIES", 59, 64], ["HIV", "SPECIES", 429, 432], ["these autobiographies", "TEST", 9, 30], ["Cox", "TEST", 138, 141], ["G\u00e9linas", "TEST", 149, 156]]], ["These stories capture the hope and miracles he encountered while attempting to treat HIV/AIDS patients during his three and a half years in a New York AIDS center.", [["HIV/AIDS", "DISEASE", 85, 93], ["AIDS", "DISEASE", 151, 155], ["HIV", "ORGANISM", 85, 88], ["patients", "ORGANISM", 94, 102], ["HIV", "SPECIES", 85, 88], ["patients", "SPECIES", 94, 102], ["HIV", "SPECIES", 85, 88]]], ["In My Own Country: A Doctor's Story of a Town and Its People in the Age of AIDS, Verghese (1985) tells a story of the AIDS epidemic inside a hospital in rural America while confronting his own prejudices and fears.", [["AIDS", "DISEASE", 75, 79], ["AIDS", "DISEASE", 118, 122], ["People", "SPECIES", 54, 60]]], ["In Strong Shadows: Scenes From an Inner City AIDS Clinic, Zuger (1995) presents stories of HIV/ AIDS patients she attempted to treat by illustrating their struggles with infections and medications, as well as the effects on them and their families.", [["AIDS", "DISEASE", 45, 49], ["HIV/ AIDS", "DISEASE", 91, 100], ["infections", "DISEASE", 170, 180], ["HIV", "ORGANISM", 91, 94], ["patients", "ORGANISM", 101, 109], ["HIV", "SPECIES", 91, 94], ["patients", "SPECIES", 101, 109], ["HIV", "SPECIES", 91, 94], ["infections", "PROBLEM", 170, 180], ["medications", "TREATMENT", 185, 196], ["Strong", "OBSERVATION_MODIFIER", 3, 9], ["Shadows", "OBSERVATION", 10, 17]]], ["As for the book titled AIDS Doctors: Voices From the Epidemic.", [["AIDS", "DISEASE", 23, 27]]], ["An Oral History, authors Bayer and Oppenheimer (2000) recount the stories of 73 physicians whose lives were centered on the HIV/AIDS pandemic (see also Boulanger & Thomas, 2008; Cyr, 2001; McCoy, 2005; Olivier, 1996; Scannell, 1999; Selwyn, 1998) .ThemesThe books and autobiographies mentioned in the literature review helped to identify the themes needed for the preparation of the semi-structured interview grid and the creation of the initial conceptual taxonomy that was used to organize and analyze data.", [["HIV/AIDS pandemic", "DISEASE", 124, 141], ["HIV/AIDS pandemic (see also Boulanger & Thomas, 2008; Cyr, 2001; McCoy, 2005; Olivier, 1996; Scannell, 1999; Selwyn, 1998)", "SPECIES", 124, 246]]], ["Physicians highlighted the impact of the emergence of HIV/ AIDS, their recognition of the epidemic and the pandemic on them, their patients, and their profession.", [["HIV/ AIDS", "DISEASE", 54, 63], ["HIV", "ORGANISM", 54, 57], ["patients", "ORGANISM", 131, 139], ["HIV", "SPECIES", 54, 57], ["patients", "SPECIES", 131, 139], ["HIV", "SPECIES", 54, 57], ["HIV/ AIDS", "TREATMENT", 54, 63]]], ["They mentioned, among other themes, the uncertainties generated by a multiplication of scientific and medical discoveries/findings, as well as the developments in the treatment of opportunistic infections related to the HIV infection.", [["opportunistic infections", "DISEASE", 180, 204], ["HIV infection", "DISEASE", 220, 233], ["HIV", "ORGANISM", 220, 223], ["HIV", "SPECIES", 220, 223], ["HIV", "SPECIES", 220, 223], ["opportunistic infections", "PROBLEM", 180, 204], ["the HIV infection", "PROBLEM", 216, 233], ["HIV", "OBSERVATION_MODIFIER", 220, 223], ["infection", "OBSERVATION", 224, 233]]], ["Physicians also talked about the perceptions they and other physicians held about sexuality, drug use, and HIV/AIDS.", [["HIV/AIDS", "DISEASE", 107, 115], ["HIV", "SPECIES", 107, 110], ["HIV", "SPECIES", 107, 110]]], ["Finally, they disclosed how they modified the way they practiced medicine at the outset of their careers, moving from a physician-centered practice toward a more patient-centered practice.Study MethodologyThe data presented in this research article were gathered through the descriptive, interpretive, and exploratory qualitative case study conducted by Jacob (2012) .", [["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["exploratory qualitative case study", "TEST", 306, 340]]], ["It was also preferred because the study was situated at the heart of physicians' everyday life while interacting with and attempting to treat their patients.", [["heart", "ANATOMY", 60, 65], ["heart", "ORGAN", 60, 65], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["the study", "TEST", 30, 39], ["heart", "ANATOMY", 60, 65]]], ["Finally, it was privileged because the HIV/AIDS pandemic is a contemporary event with facts and meaning related to the physicians' journeys inserted into their professional-patient relationships.Study MethodologyThe study conducted by Jacob (2012) identified six Canadian gay HIV/AIDS dedicated physicians' experiential learning and captured their transformations during the moments they recalled while attempting to treat their patients.", [["HIV/AIDS", "DISEASE", 39, 47], ["HIV/AIDS", "DISEASE", 276, 284], ["patient", "ORGANISM", 173, 180], ["patients", "ORGANISM", 429, 437], ["patient", "SPECIES", 173, 180], ["HIV", "SPECIES", 276, 279], ["patients", "SPECIES", 429, 437], ["HIV", "SPECIES", 39, 42], ["the HIV/AIDS pandemic", "PROBLEM", 35, 56], ["The study", "TEST", 212, 221]]], ["Jacob outlines how they rethought their relationship with their patients, other professionals, and community networks during those same gripping moments.Study MethodologyThe approach adopted when recruiting physicians for that study was purposive because it selected as participants Canadian gay dedicated HIV/AIDS physicians who met specific criteria (Bernard, 2002; Lewis & Sheppard, 2006) .", [["HIV/AIDS", "DISEASE", 306, 314], ["patients", "ORGANISM", 64, 72], ["HIV", "ORGANISM", 306, 309], ["patients", "SPECIES", 64, 72], ["participants", "SPECIES", 270, 282], ["that study", "TEST", 222, 232]]], ["These criteria were inspired by the criteria used by patients when choosing to consult a physician during the pandemic (Jacob, 2012) .", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["They mainly sought out physicians who could and were willing to provide information by virtue of their expertise and competence in sexually and blood-transmitted infections and in the HIV/AIDS prevention and treatment field.", [["blood", "ANATOMY", 144, 149], ["sexually and blood-transmitted infections", "DISEASE", 131, 172], ["HIV/AIDS", "DISEASE", 184, 192], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["HIV", "SPECIES", 184, 187], ["transmitted infections", "PROBLEM", 150, 172], ["the HIV/AIDS prevention", "TREATMENT", 180, 203], ["treatment field", "TREATMENT", 208, 223]]], ["They looked for those who were involved and had experience, since the beginning of the pandemic, in the treatment of patients, and who had the reputation of having been confronted by the devastating effects of the pandemic throughout its trajectory by the HIV/AIDS research community.", [["AIDS", "DISEASE", 260, 264], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["HIV", "SPECIES", 256, 259], ["the pandemic", "PROBLEM", 210, 222]]], ["Moreover, they sought out physicians with the same sexual preference as theirs and identified as being gay, as well as individuals who possessed a militancy background, that is to say, mobilized and advocated for their patients and their community.", [["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227]]], ["Finally, patients migrated toward locations where these specific physicians had established their practice in large Canadian urban centers, mainly in private and public health clinics specialized in the treatment of patients with sexually and blood-transmitted infections, and in the HIV/ AIDS prevention and treatment field.Study MethodologyAn invitation to participate in semi-structured interviews was sent via email to a pool of physicians who met the above selection criteria.", [["blood", "ANATOMY", 243, 248], ["sexually and blood-transmitted infections", "DISEASE", 230, 271], ["HIV/ AIDS", "DISEASE", 284, 293], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 216, 224], ["blood", "ORGANISM_SUBSTANCE", 243, 248], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 216, 224], ["HIV", "SPECIES", 284, 287], ["sexually and blood-transmitted infections", "PROBLEM", 230, 271], ["the HIV/ AIDS prevention", "TREATMENT", 280, 304], ["treatment field", "TREATMENT", 309, 324], ["semi-structured interviews", "TEST", 374, 400], ["infections", "OBSERVATION", 261, 271]]], ["Their credentials and reputation were well-known by the HIV/AIDS research community through prior research studies conducted with them and/or through the physicians' presentations at national and international conferences (e.g., Canadian Conference on HIV/AIDS Research, and the International AIDS Conference).", [["AIDS", "DISEASE", 60, 64], ["HIV/AIDS", "DISEASE", 252, 260], ["AIDS", "DISEASE", 293, 297], ["HIV", "SPECIES", 56, 59], ["HIV", "SPECIES", 252, 255], ["prior research studies", "TEST", 92, 114]]], ["Their median age was 48 years old and their experience in the treatment of HIV/AIDS patients spanned an average of 19 years, with their medical practice consisting of 200 HIV/AIDS patients, in mean terms.", [["HIV/AIDS", "DISEASE", 75, 83], ["HIV/AIDS", "DISEASE", 171, 179], ["HIV", "ORGANISM", 75, 78], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 180, 188], ["HIV", "SPECIES", 75, 78], ["patients", "SPECIES", 84, 92], ["HIV", "SPECIES", 171, 174], ["patients", "SPECIES", 180, 188], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 171, 174], ["HIV/AIDS", "PROBLEM", 75, 83]]], ["Finally, the six physicians practiced medicine in large Canadian urban centers: four in private health clinics and two in public health clinics specialized in the prevention, treatment, and care of patients with sexually and blood-transmitted infections (e.g., HIV).Study MethodologyThe following sections explain the interview process, as well as the data collection, production, and analysis as it is suggested by many specialists in the case study methodology (Hlady, 2002a (Hlady, , 2002b Karsenti & Savoie-Zajc, 2000; Miles & Huberman, 2005) .", [["blood", "ANATOMY", 225, 230], ["sections", "ANATOMY", 297, 305], ["sexually and blood-transmitted infections", "DISEASE", 212, 253], ["patients", "ORGANISM", 198, 206], ["blood", "ORGANISM_SUBSTANCE", 225, 230], ["patients", "SPECIES", 198, 206], ["HIV", "SPECIES", 261, 264], ["HIV", "SPECIES", 261, 264], ["treatment", "TREATMENT", 175, 184], ["sexually and blood-transmitted infections", "PROBLEM", 212, 253], ["the data collection", "TEST", 348, 367]]], ["After the standard procedures for qualitative studies, that is, explanation of the study, interview procedure, and consent form, the second phase of study began, that is, data collection through interviews.", [["qualitative studies", "TEST", 34, 53], ["the study", "TEST", 79, 88], ["interview procedure", "TREATMENT", 90, 109], ["the second phase of study", "TEST", 129, 154]]], ["The interviews were conducted using an interview grid, that is, closed-ended questions for quantitative information gathering (e.g., age, number of years of experience, number of HIV/AIDS patients, and work environment) and open-ended questions for qualitative information gathering about the physicians' lived journeys.", [["HIV/AIDS", "DISEASE", 179, 187], ["patients", "ORGANISM", 188, 196], ["HIV", "SPECIES", 179, 182], ["patients", "SPECIES", 188, 196], ["HIV", "SPECIES", 179, 182]]], ["The study used the period that included the start of the epidemic (around 1981) through to the said infection chronicity (around 1998), as well as up to the interview period, 2008-2009.", [["infection", "DISEASE", 100, 109], ["The study", "TEST", 0, 9], ["the said infection chronicity", "PROBLEM", 91, 120], ["infection", "OBSERVATION", 100, 109]]], ["To allow for a preliminary analysis, the complete transcription of the audio tape for each interview was performed within 24 hr following the interview.Study MethodologyBased on Merriam (1988) , as well as her peers (Hlady, 2002a (Hlady, , 2002b Karsenti & Savoie-Zajc, 2000; Miles & Huberman, 2005) , the data analysis steps included, in a successive and cumulative manner, reading over the interview transcript (verbatim) and researcher journal after each interview session, to develop a certain familiarity with the data; creating headings manually and using a data processing software (e.g., Atlas-ti); and indicating recurrent ideas, that is, notions, concepts, themes, and so on.", [["audio tape", "DNA", 71, 81], ["a preliminary analysis", "TEST", 13, 35], ["the audio tape", "TREATMENT", 67, 81]]], ["This back-and-forth movement between data collection and analysis was maintained throughout the data collection phases.Study MethodologyDuring the data analysis for each transcript, an iterative process was used to separate the data into the following categories: units of meaning, coding, categorization, and established relationships between them (e.g., commonalities, differences, and patterns) (Jacob, 2012) .", [["This back", "TEST", 0, 9], ["data collection", "TEST", 37, 52], ["analysis", "TEST", 57, 65], ["the data collection phases", "TEST", 92, 118], ["the data analysis", "TEST", 143, 160], ["an iterative process", "TREATMENT", 182, 202]]], ["Following the last interview, an in-depth data analysis was conducted for each transcript and between transcripts.Study MethodologyThe study's scientific rigor and trustworthiness were established (Merriam, 1988 ) through a process which included peer reviews (the research team) of every interview transcript, discussions of the research process, and presentations of the data's interpretation.", [["an in-depth data analysis", "TEST", 30, 55], ["The study", "TEST", 131, 140], ["the data's interpretation", "TEST", 369, 394]]], ["Two physicians presented their comments and suggestions.ResultsThe following two broad-meaning categories emerged from the data analysis of the semi-structured interviews conducted during Jacob's (2012) study: namely, Category 1: the transformation of the physicians' identities, both personal and professional; and Category 2: the transformation of the relationships physicians nurtured with their patients (e.g., physician-patient therapeutic relationship) and with various networks (e.g., professional, pharmaceutical, and community networks).", [["patients", "ORGANISM", 399, 407], ["patient", "ORGANISM", 425, 432], ["patients", "SPECIES", 399, 407], ["patient", "SPECIES", 425, 432], ["the data analysis", "TEST", 119, 136]]], ["These categories are explained and illustrated in the following sections.Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalFollowing the growth of the pandemic, physicians reported noticing the transformation of the perspective they held of their personal and professional identities.", [["sections", "ANATOMY", 64, 72]]], ["For some physicians, this meant, first, that they would devote more time to the treatment and care of patients from the gay community to which they belonged and, second, that they would demonstrate their commitment to and solidarity with their community by advocating and lobbying personally on their behalf.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110]]], ["I was no longer scared of being an openly gay physician . . .", [["no longer", "UNCERTAINTY", 6, 15]]], ["There were many gay physicians who decided to get involved in the treatment of HIVinfected gay patients.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103]]], ["We took control of our patients.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["First, they became committed to the development of professional knowledge related to medications (drugs) and treatments.", [["medications (drugs", "TREATMENT", 85, 103], ["treatments", "TREATMENT", 109, 119]]], ["They started conducting research protocols with the patients' voluntary participation.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["research protocols", "TREATMENT", 24, 42]]], ["I talk to them about the potential risks to themselves, such as being contaminated by another HIV strain during unprotected sex.", [["HIV", "SPECIES", 94, 97], ["HIV", "SPECIES", 94, 97], ["another HIV strain", "PROBLEM", 86, 104]]], ["I then talk to them about the possible impacts that they were not aware of, one day, that they may have transmitted the HIV infection to someone else.", [["HIV infection", "DISEASE", 120, 133], ["HIV", "ORGANISM", 120, 123], ["HIV", "SPECIES", 120, 123], ["HIV", "SPECIES", 120, 123], ["the HIV infection", "PROBLEM", 116, 133]]], ["167) Because of the unusual high occurrence of death among their patients, physicians faced disorienting dilemmas that led them to modify some of the perceptions that they held about their medical practice.", [["death", "DISEASE", 47, 52], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73]]], ["The following are examples of various dilemmas they encountered.Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalA dilemma about their perception of death and time.", [["death", "DISEASE", 183, 188], ["various dilemmas", "PROBLEM", 30, 46]]], ["This dilemma takes into account their felt inability to do anything within their medical practice to reduce the infection's occurrence or mitigate its psychological and physical effects on their patients.Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalWe saw what it was like to lose patients, as we lost many.", [["infection", "DISEASE", 112, 121], ["patients", "ORGANISM", 195, 203], ["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 319, 327], ["the infection", "PROBLEM", 108, 121], ["infection", "OBSERVATION", 112, 121]]], ["My worst episode was when I lost fourteen patients in ten days.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["It meant that when a patient who entered your office was sick, you would send him to the hospital.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28]]], ["The next patient was the friend of the previous patient.", [["patient", "ORGANISM", 9, 16], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 9, 16], ["patient", "SPECIES", 48, 55]]], ["He would tell you that the previous patient died.", [["He", "ORGANISM", 0, 2], ["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43]]], ["Afterward, it was the hospital staff who would call you to tell you that one of your patients died. . . .", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93]]], ["I learned to live one day at a time (Doctor Antoine). (pp. 152-153) There was this kind of fatalism in the air non-stop (Doctor Bernard). (p.", [["fatalism", "DISEASE", 91, 99], ["air", "ANATOMY", 107, 110]]], ["152) What we told patients was that they were going to die in a few months, or in a few years, if all went well.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["153) A dilemma about their perception of euthanasia.", [["euthanasia", "PROBLEM", 41, 51], ["euthanasia", "OBSERVATION", 41, 51]]], ["This dilemma led them to consider, at the risk of their own career, the demands made by their patients, their patients' friends, or their relatives, to assist them in dying so they may die in dignity.Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalWhat are they [the patient's friends] going to do with what I gave them?", [["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 110, 118], ["patient", "ORGANISM", 302, 309], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 110, 118], ["patient", "SPECIES", 302, 309]]], ["Are they going to cause the patient's death?", [["death", "DISEASE", 38, 43], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["the patient's death", "PROBLEM", 24, 43]]], ["At the same time, I was thinking, if the patient is not well, maybe it is better that he dies.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48]]], ["Physicians realized that they would incur risk in exercising their profession as long as lasted the scientific and medical uncertainties, at the time of the pandemic, concerning the way that the infection was transmitted, often placing themselves in situations that could possibly endanger their own health and life.", [["infection", "DISEASE", 195, 204], ["the infection", "PROBLEM", 191, 204], ["infection", "OBSERVATION", 195, 204]]], ["I was scared for my own health every time I was in contact with a patient because at that time, I did not know the modes of transmission (Doctor Claude A dilemma about their perception of aggressive and futile therapies.", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["aggressive and futile therapies", "TREATMENT", 188, 219]]], ["Physicians realized that they should cease to impose their will on their patients and begin to determine when they should stop therapies, treatments, and medications as they did not improve the patient's health.Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalAt a certain moment, I realized that I had to stop wanting to cure a patient at all cost.", [["patients", "ORGANISM", 73, 81], ["patient", "ORGANISM", 194, 201], ["patient", "ORGANISM", 363, 370], ["patients", "SPECIES", 73, 81], ["patient", "SPECIES", 194, 201], ["patient", "SPECIES", 363, 370], ["therapies", "TREATMENT", 127, 136], ["treatments", "TREATMENT", 138, 148], ["medications", "TREATMENT", 154, 165]]], ["As long as I thought that there was a chance that I could cure the patient, I would try other medications.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["other medications", "TREATMENT", 88, 105]]], ["I would behave this way because when I would succeed in healing a patient, it was well perceived by other doctors (Doctor Denis). (p.", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73]]], ["154) I thought that it was important to realize that there was a limit to how much medication I could administer to a patient when the medication was no longer efficient to cure the disease (Doctor Edgar). (p.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["the medication", "TREATMENT", 131, 145]]], ["154) A dilemma about the traditional images that physicians held about places to practice medicine.", [["practice medicine", "TREATMENT", 81, 98]]], ["Physicians became aware that they had to go back and forth between private clinics, local community health centers and hospitals, and less conventional places to treat their patients, such as shelters, homes and hospices, private residences, and prisons.", [["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182]]], ["In a context where the number of HIV/AIDS cases was constantly increasing, physicians became acutely aware of their limitations as their patients were dying, and they neither knew the virus that infected them nor the many opportunistic diseases that were affecting them.", [["HIV/AIDS", "DISEASE", 33, 41], ["opportunistic diseases", "DISEASE", 222, 244], ["HIV", "ORGANISM", 33, 36], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["HIV", "SPECIES", 33, 36], ["HIV/AIDS cases", "PROBLEM", 33, 47], ["the virus", "PROBLEM", 180, 189], ["the many opportunistic diseases", "PROBLEM", 213, 244], ["opportunistic", "OBSERVATION_MODIFIER", 222, 235], ["diseases", "OBSERVATION", 236, 244]]], ["Physicians were practicing in an environment where medication was more and more numerous and constantly changing (Garfield, 1993) , where data (evidence-based) to support the decisions they were making (e.g., on the start and stop of treatment) were missing, and where the knowledge about the medication they were prescribing and its food interactions was not available.Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalOften, I would tell my patients that the drug they are taking now has a specific value in time.", [["patients", "ORGANISM", 476, 484], ["patients", "SPECIES", 476, 484], ["medication", "TREATMENT", 51, 61], ["treatment", "TREATMENT", 234, 243], ["the medication", "TREATMENT", 289, 303]]], ["159)Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalWhen I did not have information on the interaction between a drug I was prescribing and certain foods, such as garlic, I would tell my patients that it was better to be careful and not to eat it every day (Doctor Antoine A dilemma about medicine in general.", [["garlic", "SIMPLE_CHEMICAL", 198, 204], ["patients", "ORGANISM", 222, 230], ["garlic", "SPECIES", 198, 204], ["patients", "SPECIES", 222, 230]]], ["According to these physicians, the medical profession was still paternalistic (Emanuel & Emanuel, 1992) , often blaming patients for their mishaps and sustaining prejudice against the gay community.Category 1: Transformation of the Physicians' Identities: Personal and ProfessionalMedicine is quite paternalistic.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128]]], ["The doctor in his medical practice is quite paternalistic. . . . in the medical domain, patients are often blamed for what happens to them (Doctor Edgar). (p.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["You went with a girl, you went alone, or you didn't go at all (Doctor Denis). (p.", [["girl", "SPECIES", 16, 20]]], ["160)Category 2: Physician-Patient, Professional, Pharmaceutical, and Community Network RelationshipsFollowing the growth of the pandemic, physicians mentioned perspective transformations in the physician-patient therapeutic relationship, patient empowerment, and medical therapeutic conversations, as well as in their professional, pharmaceutical, and community network relationships.Category 2: Physician-Patient, Professional, Pharmaceutical, and Community Network RelationshipsIn their medical practice, physicians were compelled to transform the physician-patient therapeutic relationship because of the significant role social movements against HIV/AIDS played in HIV/AIDS information dissemination to its membership, and the growing number of informed and empowered patients they treated.", [["HIV/AIDS", "DISEASE", 650, 658], ["AIDS", "DISEASE", 673, 677], ["patient", "ORGANISM", 204, 211], ["patient", "ORGANISM", 238, 245], ["patient", "ORGANISM", 560, 567], ["HIV", "ORGANISM", 650, 653], ["patients", "ORGANISM", 772, 780], ["Patient", "SPECIES", 26, 33], ["patient", "SPECIES", 204, 211], ["patient", "SPECIES", 238, 245], ["Patient", "SPECIES", 406, 413], ["patient", "SPECIES", 560, 567], ["HIV", "SPECIES", 650, 653], ["patients", "SPECIES", 772, 780], ["HIV", "SPECIES", 650, 653], ["HIV", "SPECIES", 669, 672], ["HIV/AIDS", "PROBLEM", 650, 658]]], ["In fact, they started engaging in sustained and challenging therapeutic conversations with their patients.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105]]], ["Therefore, they had to explain the decisions they made regarding their patients' health and pay more attention to their choice of words when having to provide advice, discuss options, and negotiate treatments and medications, as well as the start or cessation of a treatment and/or medication.Category 2: Physician-Patient, Professional, Pharmaceutical, and Community Network RelationshipsWhen you treat those patients, it is more stimulating.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 410, 418], ["patients", "SPECIES", 71, 79], ["Patient", "SPECIES", 315, 322], ["patients", "SPECIES", 410, 418], ["negotiate treatments", "TREATMENT", 188, 208], ["medications", "TREATMENT", 213, 224], ["a treatment", "TREATMENT", 263, 274], ["medication", "TREATMENT", 282, 292]]], ["When you tell those patients to take such and such a drug, they ask you why they must take that one and not another one.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["207) I explain more my train of thought and the drug that I am going to prescribe when I treat those patients.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109]]], ["I take more time to explain how I arrived at that decision (Doctor Bernard). (p.207)What I learned is that it is important to be careful not to be confrontational with those patients. . . .", [["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182]]], ["I am sometimes in a situation where I must learn to negotiate with those patients, for example, when to start or to end a treatment (Doctor Claude).", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["Physicians also modified their medical practice to strengthen the criteria surrounding privacy, while continuing to comply with the requirements prescribed by law (mandatory reporting), to address the new patients' demand (non-disclosure).207)The doctor-patient relationship is one that stays between four walls.", [["patients", "ORGANISM", 205, 213], ["patient", "ORGANISM", 254, 261], ["patients", "SPECIES", 205, 213], ["patient", "SPECIES", 254, 261]]], ["Very often, we are the only ones who know that someone is HIV-positive.", [["HIV", "ORGANISM", 58, 61], ["HIV", "SPECIES", 58, 61]]], ["165)207)The patient did not want the reason for his death mentioned on his death certificate (Doctor Denis). (p.", [["death", "DISEASE", 52, 57], ["death", "DISEASE", 75, 80], ["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19], ["his death", "PROBLEM", 48, 57]]], ["165) Physicians realized that the border (therapeutic distance) between themselves and their patients was gradually blurring as more and more of the patients who sought their HIV/ AIDS expertise had often been their friends, lovers, colleagues, or co-gay community members.207)It was a clientele to which I identified a lot with because these men were like me, at that time, young gay men who were discovering themselves a little, who were starting to live their gay life (Doctor Claude). (p.", [["AIDS", "DISEASE", 180, 184], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 149, 157], ["men", "ORGANISM", 343, 346], ["men", "ORGANISM", 385, 388], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 149, 157], ["HIV", "SPECIES", 175, 178], ["men", "SPECIES", 343, 346], ["men", "SPECIES", 385, 388], ["HIV", "SPECIES", 175, 178]]], ["They were their patients before they were diagnosed, up to their death and beyond, as many physicians started attending their patients' funerals, a rare occurrence before the pandemic.", [["death", "DISEASE", 65, 70], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 126, 134]]], ["They also learned about their patients' rejection, on a regular basis.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["rejection", "OBSERVATION", 40, 49]]], ["In Doctor Edgar's words, \"Patients would tell me about the rejection they face from society in general and from the gay community in particular . . .\" (p.", [["Patients", "ORGANISM", 26, 34], ["Patients", "SPECIES", 26, 34]]], ["171).207)At some point during the pandemic, some physicians understood that they had to start rebuilding the boarder (therapeutic distance) which had once existed between themselves and their patients to be more effective and efficient.", [["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200]]], ["In fact, this therapeutic distance was essential in repositioning the physicians' role, in changing certain habits, or to educate their patients on health, sexuality, and blood-transmitted infections, among other topics. . . . physicians had to start rebuilding the therapeutic distance, a distance between a doctor and the infection of his patients, the distance between a doctor and his patients . . .", [["blood", "ANATOMY", 171, 176], ["blood-transmitted infections", "DISEASE", 171, 199], ["infection", "DISEASE", 324, 333], ["patients", "ORGANISM", 136, 144], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["patients", "ORGANISM", 341, 349], ["patients", "ORGANISM", 389, 397], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 341, 349], ["patients", "SPECIES", 389, 397], ["transmitted infections", "PROBLEM", 177, 199], ["infection", "OBSERVATION", 324, 333]]], ["At times, the traditional physician-patient role was reversed when patients became aware that their physician was possibly more ill (e.g., workload or HIV-infected) than they were, or when they were simply concerned about their physician's physical and mental well-being.", [["HIV-infected", "DISEASE", 151, 163], ["patient", "ORGANISM", 36, 43], ["patients", "ORGANISM", 67, 75], ["patient", "SPECIES", 36, 43], ["patients", "SPECIES", 67, 75], ["HIV", "SPECIES", 151, 154], ["HIV", "PROBLEM", 151, 154]]], ["They had to develop new contacts with professionals who were sympathetic to their cause, fighting HIV/ AIDS (e.g., pharmacists and medical specialists), not only to find technically relevant information but also to obtain reliable and supportive collaborations.207). . it was really through those years that we learned which doctors were sympathetic to our cause.", [["HIV/ AIDS", "DISEASE", 98, 107]]], ["They were the doctors who were not prejudicial to our patients.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["We developed a network, people we knew, teams or specialists to whom we had easier access. . . .", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30]]], ["I had to let go of control to enable the specialists to do what needed to be done (Doctor Denis). (pp. 173-174) The neurologist who evaluated the patient was very good with patients who were HIV-infected (Doctor Antoine). (p.", [["HIV-infected", "DISEASE", 191, 203], ["patient", "ORGANISM", 146, 153], ["patients", "ORGANISM", 173, 181], ["patient", "SPECIES", 146, 153], ["patients", "SPECIES", 173, 181], ["HIV", "SPECIES", 191, 194], ["HIV", "SPECIES", 191, 194], ["HIV", "PROBLEM", 191, 194]]], ["However, they needed to modify the perception they held about them, from an industry whose primary focus was profit maximization to one whose focus was more humanitarian, focused on patients.", [["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190]]], ["They also needed to realize that the pharmaceutical industry was moving from an industry reliant on universities and private sector medical research and development to one more reliant on physicians for the same purpose.207)If you have a new patient who does not yet have access to the drugs he needs, the pharmaceutical companies are there to help.", [["patient", "ORGANISM", 242, 249], ["patient", "SPECIES", 242, 249], ["the drugs", "TREATMENT", 282, 291]]], ["I once phoned all the pharmaceutical companies to get access to a drug before it was available because I had a patient who was really sick. . . .", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118]]], ["174) . . . if we hadn't participated in that research protocol, if we didn't have a structure that allowed us to do research, which is not always possible in a private clinic, our patients would have had to wait three years.", [["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["research protocol", "TREATMENT", 45, 62]]], ["Some would have died because of the lack of access to medication.", [["medication", "TREATMENT", 54, 64]]], ["Therefore, it was fantastic to save all those patients . . .", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["175) Finally, physicians also had to add to their networks gay community organizations, as they were also involved in the prevention and fight against HIV/AIDS.", [["HIV/AIDS", "DISEASE", 151, 159], ["HIV", "ORGANISM", 151, 154], ["HIV", "SPECIES", 151, 154], ["HIV", "SPECIES", 151, 154], ["HIV/AIDS", "PROBLEM", 151, 159]]], ["We kept in contact, with the gay community organizations against HIV and we worked with them (Doctor Denis). (p.", [["HIV", "ORGANISM", 65, 68], ["HIV", "SPECIES", 65, 68], ["HIV", "SPECIES", 65, 68], ["HIV", "PROBLEM", 65, 68]]], ["I did many information sessions directly to patients, thanks to that organization . . .", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["177) To sum up, the data showed that the physicians transformed their personal and professional identities, as well as their practice to take into account the growing number of HIV-infected patients they treated who were empowered and informed, because of the social movements against HIV/ AIDS that supported them.207)They also transformed the relationships they nurtured with their patients (e.g., physician-patient therapeutic relationship) and with various networks (e.g., professional, pharmaceutical, and community networks).DiscussionThe following section brings together three types of findings for discussion.", [["HIV-infected", "DISEASE", 177, 189], ["HIV/ AIDS", "DISEASE", 285, 294], ["HIV", "ORGANISM", 177, 180], ["patients", "ORGANISM", 190, 198], ["HIV", "ORGANISM", 285, 288], ["patients", "ORGANISM", 384, 392], ["patient", "ORGANISM", 410, 417], ["patients", "SPECIES", 190, 198], ["HIV", "SPECIES", 285, 288], ["patients", "SPECIES", 384, 392], ["patient", "SPECIES", 410, 417], ["HIV", "SPECIES", 177, 180], ["HIV", "SPECIES", 285, 288], ["HIV/ AIDS", "PROBLEM", 285, 294]]], ["The first section compares differences between the themes that emerged from the study and those that resulted from the analysis of the previously mentioned autobiographies.", [["the study", "TEST", 76, 85], ["the analysis", "TEST", 115, 127]]], ["The second one presents new findings obtained through a recent literature review.", [["a recent literature review", "TEST", 54, 80], ["new", "OBSERVATION_MODIFIER", 24, 27]]], ["Finally, the third section shows that some themes raised by this research article still persist today (recurring themes).DifferencesThe themes (identified in the autobiographies that were used to prepare the semi-structured interview grid and to create the initial conceptual taxonomy that was used to organize and analyze data) are almost a mirror image of the themes that emerged from the data analysis of the interviews.", [["the third section", "TEST", 9, 26], ["the data analysis", "TEST", 387, 404]]], ["These themes highlighted the impact of the emergence of HIV/ AIDS; emphasized the uncertainties generated by a multiplication of scientific and medical discoveries/findings; talked about the perceptions physicians held about sexuality, drug use, and HIV/AIDS; and have drawn attention to the way they practiced medicine, going from a physician-centered practice toward a patient-centered practice.DifferencesHowever, the following themes emerged from the data of the study of some Canadian gay HIV/AIDS dedicated physicians' journeys but did not appear in the physicians' autobiographies.", [["HIV/ AIDS", "DISEASE", 56, 65], ["HIV/AIDS", "DISEASE", 250, 258], ["HIV/AIDS", "DISEASE", 494, 502], ["HIV", "ORGANISM", 56, 59], ["patient", "ORGANISM", 371, 378], ["HIV", "SPECIES", 250, 253], ["patient", "SPECIES", 371, 378], ["HIV", "SPECIES", 494, 497], ["HIV", "SPECIES", 56, 59], ["HIV", "SPECIES", 250, 253], ["HIV/ AIDS", "TREATMENT", 56, 65], ["HIV/AIDS", "PROBLEM", 250, 258], ["the study", "TEST", 463, 472]]], ["Under the first category mentioned in the study, the transformation of the physician's personal and professional identities, the study brought to light the militant implication of these gay physicians as they advocated and lobbied for their HIV/AIDS gay patients.", [["HIV/AIDS gay", "DISEASE", 241, 253], ["HIV", "ORGANISM", 241, 244], ["patients", "ORGANISM", 254, 262], ["HIV", "SPECIES", 241, 244], ["patients", "SPECIES", 254, 262], ["HIV", "SPECIES", 241, 244], ["the study", "TEST", 38, 47], ["the study", "TEST", 125, 134]]], ["As they recognized themselves as being gay physicians, they reconsidered and altered their involvement in their patients' medical, political, and social causes/battles (e.g., treatment, medication, and rights).", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["treatment", "TREATMENT", 175, 184], ["medication", "TREATMENT", 186, 196]]], ["To strengthen their ties with their community, they also modified their medical practice by treating their patients in conventional (e.g., private clinics, community health centers, and hospitals) and unconventional work environments, namely, in their patients' residences/homes.DifferencesThe study also underlines that during the pandemic, these gay physicians recognized that pharmaceutical companies had acquired a more open attitude regarding their participation in research protocols.", [["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 252, 260], ["The study", "TEST", 290, 299], ["research protocols", "TREATMENT", 471, 489]]], ["They became committed to the development of professional knowledge related to medications (drugs) and treatments.DifferencesFinally, as they were constantly confronted with a fatal disease, they recognized that there might be a place and a time where euthanasia would be appropriate, even though it was still illegal at the time.DifferencesUnder the second category mentioned in the study, the transformation of the physician-patient relationship, as well as the professional, pharmaceutical and community networks, the study brought to light how gay HIV/AIDS dedicated physicians made more place for discussion about the HIV/AIDS patients' lifestyle (e.g., sexuality, homosexuality, cruising, raves, drugs, and saunas).", [["HIV/AIDS", "DISEASE", 551, 559], ["HIV/AIDS", "DISEASE", 622, 630], ["patient", "ORGANISM", 426, 433], ["HIV", "ORGANISM", 551, 554], ["HIV", "ORGANISM", 622, 625], ["patients", "ORGANISM", 631, 639], ["patient", "SPECIES", 426, 433], ["HIV", "SPECIES", 622, 625], ["patients", "SPECIES", 631, 639], ["HIV", "SPECIES", 551, 554], ["HIV", "SPECIES", 622, 625], ["medications (drugs", "TREATMENT", 78, 96], ["treatments", "TREATMENT", 102, 112], ["a fatal disease", "PROBLEM", 173, 188], ["euthanasia", "PROBLEM", 251, 261], ["the study", "TEST", 379, 388], ["the study", "TEST", 516, 525], ["drugs", "TREATMENT", 701, 706], ["fatal", "OBSERVATION_MODIFIER", 175, 180], ["disease", "OBSERVATION", 181, 188]]], ["They also modified their therapeutic conversations by being less paternalistic, refraining from blaming patients for what happened to them, and by not discriminating and stigmatizing their patients.", [["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 189, 197]]], ["While doing so, they also blurred the traditional border that existed between themselves and their patients, such as by going to their patients' funerals.", [["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 135, 143]]], ["They built networks of professionals who were sympathetic to their causes/battles and developed links with social movements to increase the support networks for their patients.", [["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175]]], ["They became directly involved in gay community organizations against HIV/AIDS and learned to play an active role as openly gay informants and activists to disseminate information about HIV/AIDS.DifferencesThe results from the study, unlike the physician's autobiographies, make no mention of the role spirituality or religion played while patients were facing a life-threatening and limiting infection such as HIV/AIDS, neither did it mention the reflections patients and physicians provided in relation to it.", [["HIV/AIDS", "DISEASE", 69, 77], ["HIV/AIDS", "DISEASE", 185, 193], ["infection", "DISEASE", 392, 401], ["HIV/AIDS", "DISEASE", 410, 418], ["HIV", "ORGANISM", 69, 72], ["HIV", "ORGANISM", 185, 188], ["patients", "ORGANISM", 339, 347], ["patients", "ORGANISM", 459, 467], ["HIV", "SPECIES", 69, 72], ["HIV", "SPECIES", 185, 188], ["patients", "SPECIES", 339, 347], ["patients", "SPECIES", 459, 467], ["HIV", "SPECIES", 69, 72], ["HIV", "SPECIES", 185, 188], ["HIV", "SPECIES", 410, 413], ["HIV/AIDS", "PROBLEM", 185, 193], ["the study", "TEST", 222, 231], ["the physician's autobiographies", "TEST", 240, 271], ["limiting infection", "PROBLEM", 383, 401], ["HIV/AIDS", "PROBLEM", 410, 418]]], ["Yet, the place of spirituality and religion in the lives of patients facing a life-threatening and limiting infection such as HIV/ AIDS and their physicians is often mentioned in the autobiographies examined for the study (e.g., Baxter, 1997; Boulanger & Thomas, 2008; Scannell, 1999; Verghese, 1985) .DifferencesThen, one day, tired of seeing my friends and patients who were only 25, 30, 35 years old die one after the other from AIDS, I questioned my faith and felt anger towards God.", [["infection", "DISEASE", 108, 117], ["HIV/ AIDS", "DISEASE", 126, 135], ["AIDS", "DISEASE", 432, 436], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 60, 68], ["HIV", "SPECIES", 126, 129], ["patients", "SPECIES", 359, 367], ["HIV", "SPECIES", 126, 129], ["limiting infection", "PROBLEM", 99, 117], ["HIV/ AIDS", "PROBLEM", 126, 135], ["the study", "TEST", 212, 221], ["infection", "OBSERVATION", 108, 117]]], ["(Boulanger & Thomas, 2008, pp. 59-60)New FindingsThrough a recent literature review pertaining to gay nurses caring for gay HIV-infected patients, three research papers surfaced about physicians who attempted to treat patients in the context of the pandemic.", [["HIV-infected", "DISEASE", 124, 136], ["gay HIV", "ORGANISM", 120, 127], ["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 218, 226], ["HIV", "SPECIES", 124, 127], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 218, 226], ["HIV", "SPECIES", 124, 127], ["the pandemic", "PROBLEM", 245, 257], ["pandemic", "OBSERVATION", 249, 257]]], ["The second one, by Murbach (1991) , speaks about M\u00e9decins et patients au temps du sida: le cas de Montr\u00e9al; and the third one, by L\u00e9vy and Qu\u00e9villon (2014-2015) , addresses the Pratiques professionnelles m\u00e9dicales et VIH/sida: des t\u00e9moignages \u00e0 la fiction romanesque.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69]]], ["However, they never openly breach the topic from the same specific angle as Jacob's study, namely, the lived experiences of gay HIV/ AIDS dedicated physicians attempting to treat gay HIV/ AIDS patients.New FindingsWitt Sherman and Ouellette (2000) present the physicians' reflection on \"their professional histories in caring for patients with AIDS\" (p.", [["HIV/ AIDS", "DISEASE", 128, 137], ["HIV/ AIDS", "DISEASE", 183, 192], ["AIDS", "DISEASE", 344, 348], ["HIV", "ORGANISM", 128, 131], ["HIV", "ORGANISM", 183, 186], ["AIDS", "ORGANISM", 188, 192], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 330, 338], ["HIV", "SPECIES", 183, 186], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 330, 338], ["HIV", "SPECIES", 128, 131], ["Jacob's study", "TEST", 76, 89]]], ["Even though the physicians they interviewed included one gay physician, the data were not segregated using that variable.", [["the data", "TEST", 72, 80]]], ["This research article's interest resides in the additional information pertaining to the following categories that are described below.New FindingsReasons for entering the AIDS care frontline.", [["AIDS", "DISEASE", 172, 176], ["the AIDS care frontline", "TREATMENT", 168, 191]]], ["These physicians adopted the AIDS care domain as a natural progression of knowledge and skills as they had \"prior experience and knowledge in virology, epidemiology, or infectious disease\" (p.", [["AIDS", "DISEASE", 29, 33], ["infectious disease", "DISEASE", 169, 187], ["the AIDS care", "TREATMENT", 25, 38]]], ["They also mentioned that they chose that domain of work because they felt that \"there was a heightened sense of connection with themselves, their patients, and the personal and professional values and beliefs that guided their lives and medical practices\" (p.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154]]], ["279).New FindingsRewarding aspects of AIDS care.", [["AIDS", "DISEASE", 38, 42], ["AIDS care", "TREATMENT", 38, 47], ["AIDS", "OBSERVATION", 38, 42]]], ["Once physicians had learned to deal with the numerous stressors and emotional consequences of AIDS care, they felt that \"the rewards in caring for patients with AIDS outweighed the stressors\" (p.", [["AIDS", "DISEASE", 94, 98], ["AIDS", "DISEASE", 161, 165], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["AIDS care", "TREATMENT", 94, 103]]], ["The rewards that they mentioned included \"developing long-term, reciprocal relationships with patients, developing partnerships in care, experiencing personal and professional growth, and a sense of gratification\" (pp. 281-282).New FindingsAspects of the physician-patient therapeutic relationship and patient characteristics that promote a willingness and commitment to care.", [["patients", "ORGANISM", 94, 102], ["patient", "ORGANISM", 265, 272], ["patient", "ORGANISM", 302, 309], ["patients", "SPECIES", 94, 102], ["patient", "SPECIES", 265, 272], ["patient", "SPECIES", 302, 309]]], ["Physicians mentioned that many aspects of the physician-patient therapeutic relationship and patients' characteristics may influence a physician's willingness, desire, and commitment to attempting to treat patients, such as \"'patients who demonstrate self-care,' 'patients who trust my [their] care,' 'patients who value our [their] relationship,' and 'patients who teach us [them] how to die with grace and dignity'\" (p.", [["patient", "ORGANISM", 56, 63], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 226, 234], ["patients", "ORGANISM", 264, 272], ["patients", "ORGANISM", 302, 310], ["patients", "ORGANISM", 353, 361], ["patient", "SPECIES", 56, 63], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 226, 234], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 302, 310], ["patients", "SPECIES", 353, 361]]], ["283).New FindingsRecommendations offered by physicians specializing in the AIDS care domain.", [["AIDS", "DISEASE", 75, 79]]], ["Physicians offered many recommendations to their colleagues considering the AIDS care domain as a future profession.", [["AIDS", "DISEASE", 76, 80], ["the AIDS care", "TREATMENT", 72, 85]]], ["Such examples include working on caring (e.g., empowering patients, listening to them, and talking to them in a language they can understand), learning to turn mistakes into lessons (e.g., using reflection on action, and realizing that one is human), being realistic yet optimistic (e.g., admitting that one doesn't have all the answers, and dealing with uncertainty about the patient's condition with honesty), and learning to say no when you need to protect oneself (e.g., valuing and augmenting one's personal relationships) (Witt Sherman & Ouellette, 2000) .New FindingsLessons learned.", [["patients", "ORGANISM", 58, 66], ["human", "ORGANISM", 243, 248], ["patient", "ORGANISM", 377, 384], ["patients", "SPECIES", 58, 66], ["human", "SPECIES", 243, 248], ["patient", "SPECIES", 377, 384], ["human", "SPECIES", 243, 248]]], ["284), and as such, the virus did not discriminate.", [["the virus", "PROBLEM", 19, 28]]], ["Such realization helped them to accept patients the way they were and, more importantly, that all patients deserved to be treated and cared for, and to receive quality care.", [["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 98, 106]]], ["As there was no mention of God or spirituality-like in Jacob's study-in either \"causing the epidemic, or alleviating the suffering\" (p.", [["Jacob's study", "TEST", 55, 68], ["no mention", "UNCERTAINTY", 13, 23]]], ["However, such a life choice and dedication did not prevent them from burning out, experiencing depression, or marital conflicts.", [["depression", "DISEASE", 95, 105], ["depression", "PROBLEM", 95, 105]]], ["Murbach (1991) presents a study conducted in Montreal, in 1989 Montreal, in -1990 , where the data were not segregated using the variable of homosexuality.", [["a study", "TEST", 24, 31]]], ["It attempted to comprehend how physicians and patients perceive their relation, the disease and death, and care and medical research.", [["death", "DISEASE", 96, 101], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the disease and death", "PROBLEM", 80, 101]]], ["The interest of this research resides in the fact that it mentions experiences not previously accounted for in other studies.New FindingsMedical personnel obligations.", [["other studies", "TEST", 111, 124]]], ["During the pandemic, a large societal debate was underway to determine the medical personnel's obligations, and, in particular, the physician's obligation to attempt to treat patients, as well as their freedom to choose their patients.", [["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 226, 234], ["large", "OBSERVATION_MODIFIER", 23, 28]]], ["(2000), Murbach (1991) provides reasons why physicians would decide to specialize in the AIDS-care domain.", [["AIDS", "DISEASE", 89, 93]]], ["They perceived that they would have access to interesting medical cases, as AIDS was a major scientific event that could bring them peer recognition.", [["AIDS", "DISEASE", 76, 80]]], ["Finally, some new specialists considered the AIDS domain as a means to access research funds and consolidate their research notoriety.Reasons physicians entered the AIDS care domain.", [["AIDS", "DISEASE", 45, 49], ["AIDS", "DISEASE", 165, 169], ["research funds", "TREATMENT", 78, 92]]], ["Like Witt Sherman and OuelletteCultural differences and alternative medicine.", [["alternative medicine", "TREATMENT", 56, 76], ["Sherman", "OBSERVATION", 10, 17]]], ["It was noted that most physicians adopted a degree of openness to diverse alternative medicines, and even supposedly \"miracle medications\" (p.", [["diverse alternative medicines", "TREATMENT", 66, 95], ["miracle medications", "TREATMENT", 118, 137]]], ["77), but without severing bridges with traditional medicine.", [["traditional medicine", "TREATMENT", 39, 59]]], ["However, there might have been a cultural bias in looking for such alternatives, as Francophone physicians were more prone to have confidence in \"natural\" treatments then their Anglophone counterparts.Reasons physicians entered the AIDS care domain.", [["AIDS", "DISEASE", 232, 236], ["natural\" treatments", "TREATMENT", 146, 165]]], ["Like Witt Sherman and OuelletteHonesty in the context of research trials.", [["research trials", "TREATMENT", 57, 72], ["Sherman", "OBSERVATION", 10, 17]]], ["80) with HIV patients was more than necessary, as new research trials had a \"50/50 chance\" of success (p.", [["HIV", "ORGANISM", 9, 12], ["patients", "ORGANISM", 13, 21], ["HIV", "SPECIES", 9, 12], ["patients", "SPECIES", 13, 21], ["HIV", "SPECIES", 9, 12], ["HIV", "PROBLEM", 9, 12]]], ["In this sphere of uncertainty, physicians, as well as patients, were desperate to try something-anything new.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["They had to be honest to themselves, as physicians, and their patients needed to be at the forefront of these research trials because they had never been done before.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["L\u00e9vy and Qu\u00e9villon (2014-2015) present a paper that triangulates sociological, autobiographies, and novel narratives to extract the transformations of the medical practice, the place of the affect related to the illness and death, the physician-patient therapeutic relationship, and its representation during the pandemic's evolution.Reasons physicians entered the AIDS care domain.", [["illness", "DISEASE", 212, 219], ["death", "DISEASE", 224, 229], ["AIDS", "DISEASE", 365, 369], ["patient", "ORGANISM", 245, 252], ["patient", "SPECIES", 245, 252]]], ["This research is interesting because it speaks about the emotional sphere in terms of its connection to the disease, death, and the relationship with their patients.Reasons physicians entered the AIDS care domain.", [["death", "DISEASE", 117, 122], ["AIDS", "DISEASE", 196, 200], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["the disease", "PROBLEM", 104, 115]]], ["Like Witt Sherman and OuelletteAffective challenges.", [["OuelletteAffective challenges", "TREATMENT", 22, 51]]], ["The emotional sphere mentioned above speaks directly to the ambivalent feelings physicians experienced while attempting to treat their patients.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143]]], ["While these feelings are comparable to those mentioned by patients, such as rage, agony, dissension, sadness, acceptance, revolt, and hope, they also include compassion, fear, and culpability.Reasons physicians entered the AIDS care domain.", [["dissension", "DISEASE", 89, 99], ["AIDS", "DISEASE", 223, 227], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["dissension", "PROBLEM", 89, 99], ["sadness", "PROBLEM", 101, 108]]], ["Like Witt Sherman and OuelletteThrough the same literature review, two books also surfaced: one by Dr. Johnson, titled Working on a Miracle, explaining his combat against the HIV infection and his search for a treatment, and the other by Dr. Waddell, called Gay Olympian: The Life and Death of Dr. Tom Waddell, describing his life quests (e.g., \"coming out,\" a career, a family), as well as his battle against the infection.Reasons physicians entered the AIDS care domain.", [["HIV infection", "DISEASE", 175, 188], ["infection", "DISEASE", 414, 423], ["AIDS", "DISEASE", 455, 459], ["HIV", "SPECIES", 175, 178], ["HIV", "SPECIES", 175, 178], ["the HIV infection", "PROBLEM", 171, 188], ["a treatment", "TREATMENT", 208, 219], ["the infection", "PROBLEM", 410, 423], ["infection", "OBSERVATION", 414, 423]]], ["Like Witt Sherman and OuelletteIn his book, Johnson (1997) describes his odyssey and \"apparently successful fight against HIV\" (Campbell, 1997, p.", [["HIV", "ORGANISM", 122, 125], ["HIV", "SPECIES", 122, 125], ["HIV", "SPECIES", 122, 125]]], ["Four years earlier, \"an autopsy on an HIV-infected corpse\" (p.", [["corpse", "ANATOMY", 51, 57], ["HIV-infected", "DISEASE", 38, 50], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41]]], ["When his scalpel slipped, he went from being a doctor to being a patient (Johnson, 1997) .Reasons physicians entered the AIDS care domain.", [["AIDS", "DISEASE", 121, 125], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72]]], ["1) , which \"ran contrary to conventional treatments\" (p.", [["conventional treatments", "TREATMENT", 28, 51]]], ["It consisted in immediately starting an aggressive treatment, at a time when the tendency was not to start treatment immediately, of a \"veritable alphabet soup of drug therapies\" (p.", [["an aggressive treatment", "TREATMENT", 37, 60], ["treatment", "TREATMENT", 107, 116], ["drug therapies", "TREATMENT", 163, 177]]], ["4 Johnson did not allege having found a cure for AIDS.", [["AIDS", "DISEASE", 49, 53], ["AIDS", "PROBLEM", 49, 53]]], ["In fact, at the time of Johnson's discovery, other AIDS experts, Warn[ed] against unrealistic optimism, fearing the disease may be dormant or hiding out in another part of his body, such as the lymph nodes.", [["body", "ANATOMY", 176, 180], ["lymph nodes", "ANATOMY", 194, 205], ["AIDS", "DISEASE", 51, 55], ["body", "ORGANISM_SUBDIVISION", 176, 180], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 194, 205], ["the disease", "PROBLEM", 112, 123], ["the lymph nodes", "PROBLEM", 190, 205], ["disease", "OBSERVATION", 116, 123], ["may be", "UNCERTAINTY", 124, 130], ["body", "ANATOMY", 176, 180], ["lymph nodes", "OBSERVATION", 194, 205]]], ["2) Twenty-one years later, Dr. Johnson is still working as a pathologist and a Professor at the University of Rochester School of Medicine & Dentistry in Rochester, New York.Reasons physicians entered the AIDS care domain.", [["AIDS", "DISEASE", 205, 209]]], ["Like Witt Sherman and OuelletteFinally, Waddell and Schaap's (1996) book presents, in the first person, the trials and tribulations of a teenager realizing that he might be gay, and his subsequent coming out, as a gay physician, once he had full-blown AIDS.", [["AIDS", "DISEASE", 252, 256], ["person", "SPECIES", 96, 102]]], ["This book is interesting because it is written by a gay physician who passed away from an AIDS-related infection.", [["AIDS", "DISEASE", 90, 94], ["infection", "DISEASE", 103, 112], ["an AIDS", "PROBLEM", 87, 94], ["related infection", "PROBLEM", 95, 112], ["AIDS", "OBSERVATION", 90, 94], ["infection", "OBSERVATION", 103, 112]]], ["Waddell explains the full chronology of the progression of the infection and his attempts to cure/heal it.", [["infection", "DISEASE", 63, 72], ["the infection", "PROBLEM", 59, 72], ["cure/heal", "TREATMENT", 93, 102], ["progression", "OBSERVATION_MODIFIER", 44, 55], ["infection", "OBSERVATION", 63, 72]]], ["He also gives explicit examples of his lifestyle before and during the epidemic, up until his death.", [["death", "DISEASE", 94, 99], ["his death", "PROBLEM", 90, 99]]], ["The book also confirms that Waddell, like some gay physicians, wrote \"articles on the subject for the California Voice, and I am trying [tried] to bring some common sense to the crisis and offer [offered] people ways to begin to alter their behaviour in the least traumatic way\" (p.", [["traumatic", "DISEASE", 264, 273], ["people", "SPECIES", 205, 211]]], ["There was discrimination, stigmatization, and prejudice toward AIDS victims but, as Waddell points out, there were also poignant reunions with past lovers and friends because of the disease.", [["AIDS", "DISEASE", 63, 67], ["stigmatization", "PROBLEM", 26, 40], ["prejudice toward AIDS victims", "PROBLEM", 46, 75], ["the disease", "PROBLEM", 178, 189], ["disease", "OBSERVATION", 182, 189]]], ["His book also eloquently presents the state of panic that was present, at that time, in Castro's gay community, in San Francisco, California.Reasons physicians entered the AIDS care domain.", [["panic", "DISEASE", 47, 52], ["AIDS", "DISEASE", 172, 176], ["panic", "PROBLEM", 47, 52]]], ["\"In this era of AIDS, it's sensible to be monogamous or even celibate\" (p.", [["AIDS", "DISEASE", 16, 20]]], ["Spirituality, or the lack thereof, was also commented on by the author in the following manner, before closing his eyes for the last time, \"Well this should be interesting\" (p.", [["eyes", "ANATOMY", 115, 119], ["eyes", "ORGAN", 115, 119]]], ["223).Reasons physicians entered the AIDS care domain.", [["AIDS", "DISEASE", 36, 40]]], ["Like Witt Sherman and OuelletteWithout a doubt, these narratives, and the information they contain, would have positively impacted Jacob's (2012) study, by providing more information in the preparation of the interview grid, the categorization for data analysis, and more opportunity for disclosure.Recurring ThemesSome themes raised by this research article still persist today (recurring themes).", [["data analysis", "TEST", 248, 261], ["Recurring Themes", "PROBLEM", 299, 315]]], ["Among them are the absence of services to key populations, discrimination and stigmatization, the lack of regulatory framework, and the importance of communication in the physician-patient therapeutic relationship.", [["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 181, 188]]], ["As well, they do not address their practical constraints.Recurring ThemesFurther in the report, WHO recognized that structural barriers to health services, such as stigmatization and discrimination, continue to exist and they must be removed to improve the knowledge of \"serostatus\" in sex workers, men who have sex with men, transgender people, and drug injection users (key populations), while promoting and protecting human rights and promoting access to health services.Recurring ThemesIn the same report, WHO highlighted that many countries lack a regulatory framework, such as laws, policies, regulations, or interventions to protect human rights, to enable the rapid regulatory approval of new and generic medicines and diagnostics, and to expedite their marketing approval.Recurring ThemesFinally, in 2014, a study by Young reminded us of the importance of a physician-patient therapeutic relationship based on communication.Recurring Themes. . . optimal health requires attention to provider-patient communication across the entire HIV care cascade.", [["men", "ORGANISM", 299, 302], ["men", "ORGANISM", 321, 324], ["human", "ORGANISM", 421, 426], ["human", "ORGANISM", 640, 645], ["patient", "ORGANISM", 877, 884], ["patient", "ORGANISM", 1001, 1008], ["men", "SPECIES", 299, 302], ["men", "SPECIES", 321, 324], ["people", "SPECIES", 338, 344], ["human", "SPECIES", 421, 426], ["human", "SPECIES", 640, 645], ["patient", "SPECIES", 877, 884], ["patient", "SPECIES", 1001, 1008], ["human", "SPECIES", 421, 426], ["human", "SPECIES", 640, 645], ["HIV", "SPECIES", 1041, 1044], ["Recurring Themes", "PROBLEM", 474, 490], ["interventions", "TREATMENT", 615, 628], ["new and generic medicines", "TREATMENT", 697, 722], ["a study", "TEST", 815, 822]]], ["While care cascade metrics begin with testing and end with viral suppression, healthy aging with HIV requires attention to aspects of health and healthcare communication. (p.", [["viral suppression", "DISEASE", 59, 76], ["HIV", "SPECIES", 97, 100], ["testing", "TEST", 38, 45], ["viral suppression", "PROBLEM", 59, 76]]], ["1) These recurrent themes converge toward one central theme that is the patient's needs.", [["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79]]], ["It is through the patient's needs that health and social services are recognized and should be improved; that discrimination and stigmatization happen and should be addressed; that human rights are challenged and should be fought; and that communication with physicians occurs and should be evaluated.Research ImplicationsIt is important to emphasize that the study conducted by Jacob in 2012, and on which this research article is based, revealed research implications that are equivalently associated with the patients' needs, the medical practice, and various stakeholders.", [["patient", "ORGANISM", 18, 25], ["human", "ORGANISM", 181, 186], ["patients", "ORGANISM", 512, 520], ["patient", "SPECIES", 18, 25], ["human", "SPECIES", 181, 186], ["patients", "SPECIES", 512, 520], ["human", "SPECIES", 181, 186], ["the study", "TEST", 356, 365]]], ["A closer look at these research implications shows that the treatment of patients, especially in time of crisis, challenges the traditional evidence-based medicine and provokes new practices.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["crisis", "PROBLEM", 105, 111]]], ["As seen in this research article, these practices, based on lived journeys, have produced new scientific knowledge that increases the professional-patient relationship and the value of the patient who becomes more involved in the process of healing (patient informant and patient empowerment).Research ImplicationsThe lived journeys of these six Canadian gay physicians will serve the medical community and the public health domain when they attempt to treat, care for, and cure/heal patients who are infected with future diseases.", [["patient", "ORGANISM", 147, 154], ["patient", "ORGANISM", 189, 196], ["patient", "ORGANISM", 250, 257], ["patient", "ORGANISM", 272, 279], ["patients", "ORGANISM", 484, 492], ["patient", "SPECIES", 147, 154], ["patient", "SPECIES", 189, 196], ["patient", "SPECIES", 250, 257], ["patient", "SPECIES", 272, 279], ["patients", "SPECIES", 484, 492], ["future diseases", "PROBLEM", 515, 530], ["new", "OBSERVATION_MODIFIER", 90, 93]]], ["This is especially true where at first, little institutionalized, evidence-based, knowledge is available and patient stigmatization and discrimination is prevalent, for instance, the severe acute respiratory syndrome (SARS), the human infected H1N1 influenza, and the mosquito-borne ZIKA.", [["acute respiratory syndrome", "DISEASE", 190, 216], ["SARS", "DISEASE", 218, 222], ["infected H1N1 influenza", "DISEASE", 235, 258], ["patient", "ORGANISM", 109, 116], ["human", "ORGANISM", 229, 234], ["H1N1 influenza", "ORGANISM", 244, 258], ["patient", "SPECIES", 109, 116], ["human", "SPECIES", 229, 234], ["H1N1 influenza", "SPECIES", 244, 258], ["human infected H1N1 influenza", "SPECIES", 229, 258], ["the severe acute respiratory syndrome", "PROBLEM", 179, 216], ["SARS", "PROBLEM", 218, 222], ["the human infected H1N1 influenza", "PROBLEM", 225, 258], ["severe", "OBSERVATION_MODIFIER", 183, 189], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["respiratory syndrome", "OBSERVATION", 196, 216], ["infected", "OBSERVATION_MODIFIER", 235, 243], ["H1N1 influenza", "OBSERVATION", 244, 258]]], ["This reference to past outbreaks will help today's physicians approach these new diseases with a more human touch and a view to the possibility of being transformed personally and professionally (e.g., militancy and researcher practitioner).", [["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["these new diseases", "PROBLEM", 71, 89]]], ["It will also encourage them to remain open to modified relationships (e.g., a new approach to their patients as informants and trainers, their colleagues, other professionals, and community organizations) that could help them in their battle against the infection.Other Research InterestsBecause of the interest created by Jacob's (2012) study, as well as the research papers and books that surfaced since, we are now moving our research interest from gay physicians to gay nurses' lived journeys while caring for gay HIV-infected patients during the HIV/AIDS pandemic.", [["infection", "DISEASE", 254, 263], ["HIV-infected", "DISEASE", 518, 530], ["HIV/AIDS pandemic", "DISEASE", 551, 568], ["patients", "ORGANISM", 100, 108], ["gay HIV", "ORGANISM", 514, 521], ["patients", "ORGANISM", 531, 539], ["patients", "SPECIES", 100, 108], ["HIV", "SPECIES", 518, 521], ["patients", "SPECIES", 531, 539], ["HIV", "SPECIES", 551, 554], ["HIV", "SPECIES", 518, 521], ["HIV", "SPECIES", 551, 554], ["the infection", "PROBLEM", 250, 263], ["pandemic", "PROBLEM", 560, 568], ["infection", "OBSERVATION", 254, 263]]], ["This new research article's interest lies in the fact that nurses have an increased proximity with patients; therefore, they may have had similar or different lived experiences with gay HIV-infected patients than their gay physician counterparts.Other Research InterestsOur literature review has already uncovered one book written by a gay nurse and one written by a lesbian nurse (Czerwiec, 2017; Varsalone & Deering, 2016) .", [["HIV-infected", "DISEASE", 186, 198], ["patients", "ORGANISM", 99, 107], ["gay HIV", "ORGANISM", 182, 189], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 99, 107], ["HIV", "SPECIES", 186, 189], ["patients", "SPECIES", 199, 207], ["HIV", "SPECIES", 186, 189], ["increased", "OBSERVATION_MODIFIER", 74, 83]]], ["However, one book and a few articles were found with nurses caring for HIV/AIDS patients as subjects (Bennett, 1992; McGarrahan, 1994; Witt Sherman, 2000) .ConclusionThe objective of this research article was to provide the lived journeys of Canadian gay HIV/AIDS dedicated physicians in the context of the HIV/AIDS pandemic in an effort to draw a better picture of what it was like to be a gay physician during that particular period.", [["HIV/AIDS", "DISEASE", 71, 79], ["HIV/AIDS", "DISEASE", 255, 263], ["HIV/AIDS", "DISEASE", 307, 315], ["HIV", "ORGANISM", 71, 74], ["patients", "ORGANISM", 80, 88], ["HIV", "SPECIES", 71, 74], ["patients", "SPECIES", 80, 88], ["HIV", "SPECIES", 255, 258], ["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 255, 258], ["HIV", "SPECIES", 307, 310], ["the HIV/AIDS pandemic", "PROBLEM", 303, 324]]], ["The research background was based on books and autobiographies that set the stage for the HIV/ AIDS context.", [["AIDS", "DISEASE", 95, 99], ["HIV", "SPECIES", 90, 93], ["autobiographies", "TREATMENT", 47, 62], ["the HIV/ AIDS context", "PROBLEM", 86, 107]]], ["In addition, they provided an account of the physicians' trajectories/journeys/experiences as they to treat, care for, and cure/heal HIV-infected patients throughout the pandemic.ConclusionIn the context of the HIV/AIDS pandemic, the Canadian gay physicians' personal and professional identities and the way they viewed their practice were transformed by their lived journeys.", [["HIV-infected", "DISEASE", 133, 145], ["HIV/AIDS", "DISEASE", 211, 219], ["HIV", "ORGANISM", 133, 136], ["patients", "ORGANISM", 146, 154], ["HIV", "SPECIES", 133, 136], ["patients", "SPECIES", 146, 154], ["HIV", "SPECIES", 133, 136], ["HIV", "SPECIES", 211, 214], ["heal HIV", "PROBLEM", 128, 136]]], ["They became openly gay HIV/AIDS dedicated and militant physicians, advocating and lobbying for their patients.", [["HIV/AIDS", "DISEASE", 23, 31], ["patients", "ORGANISM", 101, 109], ["HIV", "SPECIES", 23, 26], ["patients", "SPECIES", 101, 109], ["HIV", "SPECIES", 23, 26]]], ["They altered their physician-patient therapeutic relationship, making it more open and egalitarian.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36]]], ["They modified their relationship to their networks, namely, community organizations, other colleagues, pharmacists, and the pharmaceutical industry, by increasing their personal and professional involvement in gay community organizations against HIV/AIDS, building a network of professionals able and willing to care for their patients, and becoming physician researchers practitioners.ConclusionThe data presented and the results interpreted offered a candid insight into the lives of Canadian gay HIV/AIDS physicians, at a time when the medical world was not prepared for such a devastating disease.", [["HIV/AIDS", "DISEASE", 246, 254], ["HIV/AIDS", "DISEASE", 499, 507], ["patients", "ORGANISM", 327, 335], ["HIV", "SPECIES", 246, 249], ["patients", "SPECIES", 327, 335], ["HIV", "SPECIES", 499, 502], ["HIV", "SPECIES", 246, 249], ["a devastating disease", "PROBLEM", 579, 600], ["devastating", "OBSERVATION_MODIFIER", 581, 592], ["disease", "OBSERVATION", 593, 600]]], ["The therapeutic relationship between physicians and patients is a good example of this type of change, as both, physicians and patients, had to re-define what to expect from each other.ConclusionAs people read these physicians' lived journeys, they are reminded of a time when gay physicians who practiced during the HIV/AIDS pandemic were militants, advocated for their gay HIV/AIDS patients, and lobbied for a cure.", [["HIV/AIDS pandemic", "DISEASE", 317, 334], ["HIV/AIDS", "DISEASE", 375, 383], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 127, 135], ["people", "ORGANISM", 198, 204], ["HIV", "ORGANISM", 375, 378], ["patients", "ORGANISM", 384, 392], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 127, 135], ["people", "SPECIES", 198, 204], ["HIV", "SPECIES", 375, 378], ["patients", "SPECIES", 384, 392], ["HIV", "SPECIES", 317, 320], ["HIV", "SPECIES", 375, 378]]], ["This article lifted the veil of darkness that shrouded the contribution made by these unsung heroes, shining of spotlight on their selfless dedication to their patients in the hope that readers will recognize their sacrifices and come to realize that they were personally and professionally affected and forever transformed because of their involvement in their attempts to treat, care of, and cure/heal gay HIV-infected patients during the HIV/AIDS pandemic.ConclusionFinally, according to Finkelstein (2018) , these narratives are a reminder that the full \"story of [HIV/] AIDS cannot be written yet [until a] cure, curative, functional cure, or vaccine\" (pp. 219-220) against HIV/AIDS is found, there is a need to re-count the way it was and how it is now translated into our present.", [["HIV-infected", "DISEASE", 408, 420], ["HIV/AIDS pandemic", "DISEASE", 441, 458], ["AIDS", "DISEASE", 575, 579], ["pp. 219-220", "CHEMICAL", 658, 669], ["HIV/AIDS", "DISEASE", 679, 687], ["patients", "ORGANISM", 160, 168], ["HIV", "ORGANISM", 408, 411], ["patients", "ORGANISM", 421, 429], ["HIV", "ORGANISM", 679, 682], ["patients", "SPECIES", 160, 168], ["HIV", "SPECIES", 408, 411], ["patients", "SPECIES", 421, 429], ["HIV", "SPECIES", 441, 444], ["HIV", "SPECIES", 679, 682], ["HIV", "SPECIES", 408, 411], ["HIV", "SPECIES", 441, 444], ["HIV", "SPECIES", 679, 682], ["HIV", "PROBLEM", 408, 411], ["pandemic", "PROBLEM", 450, 458], ["AIDS", "PROBLEM", 575, 579], ["curative", "TREATMENT", 618, 626], ["HIV/AIDS", "PROBLEM", 679, 687]]]], "29751adb696a77863772a4fcd8ff80bb82e242fa": [["Background COVID-19, a mild to severe respiratory syndrome that follows infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China in December 2019 and rapidly became a pandemic that affected millions of people, causing substantial mortality around the world.", [["respiratory syndrome", "DISEASE", 38, 58], ["infection", "DISEASE", 72, 81], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 94, 132], ["SARS-CoV-2", "ORGANISM", 136, 146], ["people", "ORGANISM", 259, 265], ["people", "SPECIES", 259, 265], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 87, 146], ["Background COVID", "TEST", 0, 16], ["a mild to severe respiratory syndrome", "PROBLEM", 21, 58], ["infection", "PROBLEM", 72, 81], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 87, 132], ["SARS-CoV", "TEST", 136, 144], ["mild", "OBSERVATION_MODIFIER", 23, 27], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["respiratory syndrome", "OBSERVATION", 38, 58], ["Severe", "OBSERVATION_MODIFIER", 87, 93], ["Acute", "OBSERVATION_MODIFIER", 94, 99], ["Respiratory Syndrome", "OBSERVATION", 100, 120], ["substantial", "OBSERVATION_MODIFIER", 275, 286], ["mortality", "OBSERVATION", 287, 296]]], ["Most individuals infected with SARS-CoV-2 develop a flu-like, mild clinical syndrome (non-pneumonia or a mild atypical pneumonia), and a sizeable proportion (~20%) require hospitalization (dyspnea, low oxygen saturation), with a substantial proportion leading to a critical illness (respiratory failure, septic shock, and/or multiple organ dysfunction) and death [1, 2] .", [["respiratory", "ANATOMY", 283, 294], ["organ", "ANATOMY", 334, 339], ["SARS", "DISEASE", 31, 35], ["flu", "DISEASE", 52, 55], ["non-pneumonia", "DISEASE", 86, 99], ["pneumonia", "DISEASE", 119, 128], ["dyspnea", "DISEASE", 189, 196], ["oxygen", "CHEMICAL", 202, 208], ["respiratory failure", "DISEASE", 283, 302], ["septic shock", "DISEASE", 304, 316], ["organ dysfunction", "DISEASE", 334, 351], ["death", "DISEASE", 357, 362], ["oxygen", "CHEMICAL", 202, 208], ["SARS-CoV-2", "ORGANISM", 31, 41], ["oxygen", "SIMPLE_CHEMICAL", 202, 208], ["organ", "ORGAN", 334, 339], ["CoV-", "SPECIES", 36, 40], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["a flu", "PROBLEM", 50, 55], ["mild clinical syndrome", "PROBLEM", 62, 84], ["non-pneumonia", "PROBLEM", 86, 99], ["a mild atypical pneumonia", "PROBLEM", 103, 128], ["dyspnea", "PROBLEM", 189, 196], ["low oxygen saturation", "PROBLEM", 198, 219], ["a critical illness", "PROBLEM", 263, 281], ["respiratory failure", "PROBLEM", 283, 302], ["septic shock", "PROBLEM", 304, 316], ["multiple organ dysfunction", "PROBLEM", 325, 351], ["death", "PROBLEM", 357, 362], ["infected", "OBSERVATION", 17, 25], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["atypical", "OBSERVATION_MODIFIER", 110, 118], ["pneumonia", "OBSERVATION", 119, 128], ["sizeable", "OBSERVATION_MODIFIER", 137, 145], ["proportion", "OBSERVATION_MODIFIER", 146, 156], ["respiratory failure", "OBSERVATION", 283, 302], ["septic shock", "OBSERVATION", 304, 316], ["organ", "ANATOMY", 334, 339], ["dysfunction", "OBSERVATION", 340, 351]]]], "f5126a5111f9c53cf3f621c9ab6d54b6b57ab95a": [["are generally recognized to cause mild upper respiratory tract diseases and, rarely, lower respiratory tract diseases [2] .", [["upper respiratory tract", "ANATOMY", 39, 62], ["lower respiratory tract", "ANATOMY", 85, 108], ["upper respiratory tract diseases", "DISEASE", 39, 71], ["respiratory tract diseases", "DISEASE", 91, 117], ["tract", "ORGANISM_SUBDIVISION", 57, 62], ["mild upper respiratory tract diseases", "PROBLEM", 34, 71], ["lower respiratory tract diseases", "PROBLEM", 85, 117], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["upper", "ANATOMY_MODIFIER", 39, 44], ["respiratory tract", "ANATOMY", 45, 62], ["lower", "ANATOMY_MODIFIER", 85, 90], ["respiratory tract", "ANATOMY", 91, 108]]], ["Phylogenetic analyses show that SARS-CoV is not closely related to any of the previously characterized CoVs [3] .", [["SARS", "DISEASE", 32, 36], ["SARS-CoV", "ORGANISM", 32, 40], ["SARS-CoV", "SPECIES", 32, 40], ["Phylogenetic analyses", "TEST", 0, 21], ["SARS-CoV", "PROBLEM", 32, 40]]], ["However, some investigators, using SARS-CoV-infected Vero cells in immunohistochemical antibody tests, have observed cross-reactions between SARS-CoV and group I CoVs, but seroepidemiological studies revealed that there were no cross-reactions with SARS-CoV-infected Vero cells in 13 and 14 paired serum samples from patients with HCoV-OC43 and HCoV-229E, respectively [1] .", [["Vero cells", "ANATOMY", 53, 63], ["Vero cells", "ANATOMY", 267, 277], ["serum samples", "ANATOMY", 298, 311], ["HCoV-229E", "ANATOMY", 345, 354], ["SARS", "DISEASE", 249, 253], ["SARS-CoV", "ORGANISM", 35, 43], ["Vero cells", "CELL", 53, 63], ["SARS-CoV", "ORGANISM", 141, 149], ["CoVs", "GENE_OR_GENE_PRODUCT", 162, 166], ["SARS-CoV", "ORGANISM", 249, 257], ["Vero cells", "CELL", 267, 277], ["serum samples", "ORGANISM_SUBSTANCE", 298, 311], ["patients", "ORGANISM", 317, 325], ["HCoV-OC43", "CELL", 331, 340], ["HCoV-229E", "CELL", 345, 354], ["SARS-CoV-infected Vero cells", "CELL_LINE", 35, 63], ["SARS-CoV-infected Vero cells", "CELL_LINE", 249, 277], ["patients", "SPECIES", 317, 325], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 141, 149], ["SARS-CoV", "SPECIES", 249, 257], ["HCoV", "SPECIES", 331, 335], ["HCoV-229E", "SPECIES", 345, 354], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["infected Vero cells", "PROBLEM", 44, 63], ["immunohistochemical antibody tests", "TEST", 67, 101], ["cross-reactions", "PROBLEM", 117, 132], ["SARS", "PROBLEM", 141, 145], ["group I CoVs", "PROBLEM", 154, 166], ["seroepidemiological studies", "TEST", 172, 199], ["cross-reactions", "PROBLEM", 228, 243], ["SARS", "PROBLEM", 249, 253], ["CoV", "TEST", 254, 257], ["infected Vero cells", "PROBLEM", 258, 277], ["serum samples", "TEST", 298, 311], ["HCoV", "TEST", 331, 335], ["OC43", "TEST", 336, 340], ["HCoV", "TEST", 345, 349], ["Vero cells", "OBSERVATION", 53, 63]]], ["Serum samples from group I CoV-infected animals also cross-reacted with the recombinant nucleocapsid protein of SARS-CoV [4] .", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["CoV", "ORGANISM", 27, 30], ["animals", "ORGANISM", 40, 47], ["SARS-CoV", "ORGANISM", 112, 120], ["recombinant nucleocapsid protein", "PROTEIN", 76, 108], ["I CoV", "SPECIES", 25, 30], ["SARS-CoV", "SPECIES", 112, 120], ["Serum samples", "TEST", 0, 13], ["group I CoV", "TEST", 19, 30], ["infected animals", "PROBLEM", 31, 47], ["SARS", "PROBLEM", 112, 116]]], ["Results of the recombinant nucleocapsid protein-based ELISA were positive in 1.04% of serum samples from healthy blood donors [5] .", [["serum samples", "ANATOMY", 86, 99], ["blood", "ANATOMY", 113, 118], ["serum samples", "ORGANISM_SUBSTANCE", 86, 99], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["recombinant nucleocapsid protein", "PROTEIN", 15, 47], ["the recombinant nucleocapsid protein", "TEST", 11, 47], ["ELISA", "TEST", 54, 59], ["serum samples", "TEST", 86, 99], ["healthy blood donors", "TEST", 105, 125]]], ["The nature of this antigenic cross-reactivity is still unknown.", [["this antigenic cross-reactivity", "TEST", 14, 45]]], ["In the present study, we cloned the nucleocapsid genes of SARS-CoV, HCoV-229E, and HCoV-OC43 and produced specific animal antisera to determine if the nucleocapsid protein is responsible for the observed antigenic cross-reactivity.", [["SARS-CoV", "ORGANISM", 58, 66], ["HCoV-229E", "CELL", 68, 77], ["HCoV-OC43", "CELL", 83, 92], ["nucleocapsid genes", "DNA", 36, 54], ["HCoV", "DNA", 83, 87], ["OC43", "DNA", 88, 92], ["nucleocapsid protein", "PROTEIN", 151, 171], ["SARS-CoV", "SPECIES", 58, 66], ["HCoV-229E", "SPECIES", 68, 77], ["HCoV-OC43", "SPECIES", 83, 92], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["HCoV", "TEST", 68, 72], ["HCoV", "TEST", 83, 87], ["specific animal antisera", "TEST", 106, 130], ["the nucleocapsid protein", "TEST", 147, 171], ["the observed antigenic cross-reactivity", "PROBLEM", 191, 230]]], ["In addition, the antigenic relationships among SARS-CoV, HCoV-229E, and HCoV-OC43 were further studied using serum samples from healthy donors and patients with SARS.", [["serum samples", "ANATOMY", 109, 122], ["SARS", "DISEASE", 161, 165], ["SARS-CoV", "ORGANISM", 47, 55], ["HCoV-229E", "ORGANISM", 57, 66], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 72, 81], ["serum samples", "ORGANISM_SUBSTANCE", 109, 122], ["donors", "ORGANISM", 136, 142], ["patients", "ORGANISM", 147, 155], ["SARS-CoV, HCoV-229E, and HCoV-OC43", "DNA", 47, 81], ["patients", "SPECIES", 147, 155], ["SARS-CoV", "SPECIES", 47, 55], ["HCoV-229E", "SPECIES", 57, 66], ["HCoV", "SPECIES", 72, 76], ["the antigenic relationships", "TEST", 13, 40], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["HCoV", "TEST", 57, 61], ["HCoV", "TEST", 72, 76], ["serum samples", "TEST", 109, 122], ["SARS", "PROBLEM", 161, 165]]]], "76b09383740476d96a3e63ae0f265e2897e9a194": [["INTRODUCTIONMankind has held a centuries-long fascination with the cat.", [["cat", "ORGANISM", 67, 70]]], ["The earliest arch eological records that have been linked to the domestication of Felis catus date to approximately 9500 years ago from Cyprus, 1 with recent molecular genetic analyses in our laboratory suggesting a Middle Eastern origin for domestication (C. Driscoll et al., unpublished observations) .", [["Felis catus", "ORGANISM", 82, 93], ["Felis catus", "SPECIES", 82, 93], ["Felis catus", "SPECIES", 82, 93], ["recent molecular genetic analyses", "PROBLEM", 151, 184], ["arch", "ANATOMY", 13, 17], ["Middle", "ANATOMY_MODIFIER", 216, 222]]], ["Currently the most numerous of companion animals, numbering close to 90 million in households across the United States (http://www.appma.org/ press_industrytrends.asp), the cat enjoys a medical surveillance second only to the dog and humankind.", [["cat", "ORGANISM", 173, 176], ["dog", "ORGANISM", 226, 229], ["dog", "SPECIES", 226, 229], ["most numerous", "OBSERVATION_MODIFIER", 14, 27]]], ["In this chapter we review the promise of the cat as an important model for the advancement of human hereditary and infectious disease and the genomic tools that have been developed for the identification, and characterization of genes of interest.INTRODUCTIONFor many years we have sought to characterize genetic organization in the domestic cat and to develop genomic resources that establish F. catus as a useful animal model for human hereditary disease analogues, neoplasia, genetic factors associated with host response to infectious disease, and mammalian genome evolution.", [["neoplasia", "ANATOMY", 468, 477], ["hereditary and infectious disease", "DISEASE", 100, 133], ["hereditary disease", "DISEASE", 438, 456], ["neoplasia", "DISEASE", 468, 477], ["infectious disease", "DISEASE", 528, 546], ["cat", "ORGANISM", 45, 48], ["human", "ORGANISM", 94, 99], ["cat", "ORGANISM", 342, 345], ["F. catus", "ORGANISM", 394, 402], ["human", "ORGANISM", 432, 437], ["neoplasia", "CANCER", 468, 477], ["human", "SPECIES", 94, 99], ["cat", "SPECIES", 342, 345], ["human", "SPECIES", 432, 437], ["human", "SPECIES", 94, 99], ["F. catus", "SPECIES", 394, 402], ["human", "SPECIES", 432, 437], ["human hereditary and infectious disease", "PROBLEM", 94, 133], ["the genomic tools", "TEST", 138, 155], ["the identification", "TEST", 185, 203], ["human hereditary disease analogues", "PROBLEM", 432, 466], ["neoplasia", "PROBLEM", 468, 477], ["genetic factors", "PROBLEM", 479, 494], ["infectious disease", "PROBLEM", 528, 546], ["infectious", "OBSERVATION", 115, 125], ["infectious", "OBSERVATION", 528, 538], ["mammalian genome", "OBSERVATION", 552, 568]]], ["2, 3 To identify genes associated with inherited pathologies that mirror inherited human conditions and interesting pheno-types in the domestic cat, we have produced genetic maps of sufficient density to allow linkage or association-based mapping exercises.", [["inherited pathologies", "DISEASE", 39, 60], ["human", "ORGANISM", 83, 88], ["cat", "ORGANISM", 144, 147], ["human", "SPECIES", 83, 88], ["cat", "SPECIES", 144, 147], ["human", "SPECIES", 83, 88], ["inherited pathologies", "PROBLEM", 39, 60], ["mirror inherited human conditions", "PROBLEM", 66, 99], ["based mapping exercises", "TREATMENT", 233, 256]]], ["[4] [5] [6] [7] [8] [9] [10] [11] The first genetic map of the cat, a physical map generated from a somatic-cell hybrid panel, demonstrated the cat's high level of conserved synteny with the human genome, which offered much promise for the future application of comparative genomic inference in felid mapping and association exercises.", [["[4] [5] [6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 33], ["cat", "ORGANISM", 63, 66], ["cat", "ORGANISM", 144, 147], ["human", "ORGANISM", 191, 196], ["somatic-cell hybrid panel", "CELL_LINE", 100, 125], ["human genome", "DNA", 191, 203], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["the cat", "TEST", 59, 66], ["a physical map", "TEST", 68, 82], ["a somatic-cell hybrid panel", "TEST", 98, 125], ["the human genome", "TREATMENT", 187, 203]]], ["12 Several radiation hybrid (RH) and genetic linkage (GL) maps have since been published.", [["Several radiation hybrid (RH", "TREATMENT", 3, 31], ["genetic linkage (GL) maps", "TREATMENT", 37, 62], ["radiation hybrid", "OBSERVATION", 11, 27]]], ["[4] [5] [6] [7] [8] [9] 11, 13, 14THE DOMESTIC CAT RADIATION HYBRID MAPAlthough previous versions of the cat gene map, based on somatic cell hybrid and ZOO FISH analysis, 15 ,16 revealed considerable conservation of synteny with the human genome, these maps provided no knowledge of gene order or intrachromosomal genome rearrangement between the two species, information that is critical to applying comparative map inference to gene dis covery in gene-poor model systems.", [["cell", "ANATOMY", 136, 140], ["[4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 0, 23], ["cat", "ORGANISM", 105, 108], ["somatic cell", "CELL", 128, 140], ["human", "ORGANISM", 233, 238], ["cat gene map", "DNA", 105, 117], ["human genome", "DNA", 233, 245], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 233, 238], ["the cat gene map", "TEST", 101, 117], ["somatic cell hybrid", "TEST", 128, 147], ["ZOO FISH analysis", "TEST", 152, 169], ["the human genome", "TREATMENT", 229, 245], ["these maps", "TEST", 247, 257], ["intrachromosomal genome rearrangement", "PROBLEM", 297, 334], ["genome rearrangement", "OBSERVATION", 314, 334]]], ["Radiation hybrid (RH) mapping has emerged as a powerful tool for constructing moderate-to high-density gene maps in vertebrates by obviating the need to identify interspecific polymorphisms critical for the generation of genetic linkage maps.", [["Radiation hybrid (RH) mapping", "TREATMENT", 0, 29], ["interspecific polymorphisms", "PROBLEM", 162, 189]]], ["7 The most recent RH map of the cat 8 includes 1793 markers: 662 coding loci, 335 selected markers derived from the cat 2X whole genome sequence targeted at breakpoints in conserved synteny between human and cat, and 797 short tandem repeat (STR) loci.", [["cat", "ORGANISM", 32, 35], ["human", "ORGANISM", 198, 203], ["cat 8", "DNA", 32, 37], ["cat 2X whole genome sequence", "DNA", 116, 144], ["human and cat, and 797 short tandem repeat (STR) loci", "DNA", 198, 251], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["The most recent RH map", "TEST", 2, 24], ["coding loci", "TEST", 65, 76], ["selected markers", "TEST", 82, 98], ["the cat 2X whole genome sequence", "TREATMENT", 112, 144], ["short tandem repeat (STR) loci", "PROBLEM", 221, 251]]], ["The strategy used in developing the current RH map was to target gaps in the feline-human comparative map, and to provide more definition in breakpoints in regions of conserved synteny between cat and human.", [["feline", "ORGANISM", 77, 83], ["human", "ORGANISM", 84, 89], ["cat", "ORGANISM", 193, 196], ["human", "ORGANISM", 201, 206], ["RH map", "DNA", 44, 50], ["feline-human comparative map", "DNA", 77, 105], ["human", "SPECIES", 84, 89], ["cat", "SPECIES", 193, 196], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 201, 206], ["the current RH map", "TEST", 32, 50]]], ["The 1793 markers cover the length of the 18 feline autosomes and the X chromosome at an average spacing of one marker every 1.5 Mb (megabase), with fairly uniform marker density.", [["X chromosome", "ANATOMY", 69, 81], ["feline", "ORGANISM", 44, 50], ["autosomes", "CELLULAR_COMPONENT", 51, 60], ["X chromosome", "CELLULAR_COMPONENT", 69, 81], ["1793 markers", "DNA", 4, 16], ["18 feline autosomes", "DNA", 41, 60], ["X chromosome", "DNA", 69, 81], ["the 18 feline autosomes", "TREATMENT", 37, 60], ["the X chromosome", "TREATMENT", 65, 81], ["uniform", "OBSERVATION_MODIFIER", 155, 162], ["marker density", "OBSERVATION", 163, 177]]], ["8 An enhanced comparative map demonstrates that the current map provides 86% and 85% comparative coverage of the human and canine genomes, respectively.", [["human", "ORGANISM", 113, 118], ["canine", "ORGANISM", 123, 129], ["human and canine genomes", "DNA", 113, 137], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["canine", "SPECIES", 123, 129], ["the current map", "TEST", 48, 63]]], ["8 Ninety-six percent of the 1793 cat markers have identifi able orthologues in the canine and human genome sequences, providing a rich comparative tool, which is critical in linkage mapping exercises for the identification of genes controlling feline phenotypes.", [["cat", "ORGANISM", 33, 36], ["canine", "ORGANISM", 83, 89], ["human", "ORGANISM", 94, 99], ["feline", "ORGANISM", 244, 250], ["canine and human genome sequences", "DNA", 83, 116], ["canine", "SPECIES", 83, 89], ["human", "SPECIES", 94, 99], ["canine", "SPECIES", 83, 89], ["human", "SPECIES", 94, 99], ["linkage mapping exercises", "TREATMENT", 174, 199], ["genes controlling feline phenotypes", "PROBLEM", 226, 261]]], ["Figure 25 -1 presents a graphic display of each cat chromosome and blocks of conserved syntenic order with the human and canine genomes.", [["chromosome", "ANATOMY", 52, 62], ["cat", "ORGANISM", 48, 51], ["chromosome", "CELLULAR_COMPONENT", 52, 62], ["human", "ORGANISM", 111, 116], ["canine", "ORGANISM", 121, 127], ["cat chromosome", "DNA", 48, 62], ["human and canine genomes", "DNA", 111, 135], ["human", "SPECIES", 111, 116], ["canine", "SPECIES", 121, 127], ["human", "SPECIES", 111, 116], ["canine", "SPECIES", 121, 127]]], ["8 One hundred and fifty-two cat-human and 134 cat-dog homologous synteny blocks were identified.", [["cat-human", "CANCER", 28, 37], ["cat", "ORGANISM", 46, 49], ["dog", "ORGANISM", 50, 53], ["cat-human and 134 cat-dog homologous synteny blocks", "DNA", 28, 79], ["cat-dog", "SPECIES", 46, 53], ["134 cat-dog homologous synteny blocks", "TREATMENT", 42, 79]]], ["Alignment of cat, dog, and human chromosomes demonstrated different patterns of chromosomal rearrangement with a marked increase in interchromosomal rearrangements relative to human in the canid lineage (89% of all rearrangements), as opposed to the more frequent intrachromosomal rearrangements in the felid lineage (95% of all rearrangements) since divergence from a common carnivore ancestor 55 My ago.THE DOMESTIC CAT RADIATION HYBRID MAPWith an average spacing of 1 marker every 1.5 Mb in the feline euchromatic sequence, the map provided a solid framework for the chromosomal assignment of feline contigs and scaffolds during assembly of the cat genome assembly, 17 and served as a comparative tool to aid in the identification of genes controlling feline phenotypes.THE DOMESTIC CAT GENETIC LINKAGE MAPAs a complement to the RH map of the cat, a third generation linkage map of 625 STRs is currently nearing completion.", [["chromosomes", "ANATOMY", 33, 44], ["chromosomal", "ANATOMY", 80, 91], ["canid lineage", "ANATOMY", 189, 202], ["felid lineage", "ANATOMY", 303, 316], ["chromosomal", "ANATOMY", 570, 581], ["cat", "ORGANISM", 13, 16], ["dog", "ORGANISM", 18, 21], ["human", "ORGANISM", 27, 32], ["chromosomal", "CELLULAR_COMPONENT", 80, 91], ["interchromosomal", "CELLULAR_COMPONENT", 132, 148], ["human", "ORGANISM", 176, 181], ["canid lineage", "CELL", 189, 202], ["felid lineage", "CELL", 303, 316], ["feline", "ORGANISM", 498, 504], ["chromosomal", "CELLULAR_COMPONENT", 570, 581], ["feline", "ORGANISM", 596, 602], ["cat", "ORGANISM", 648, 651], ["feline", "ORGANISM", 755, 761], ["cat", "ORGANISM", 846, 849], ["cat, dog, and human chromosomes", "DNA", 13, 44], ["canid lineage", "CELL_TYPE", 189, 202], ["felid lineage", "CELL_TYPE", 303, 316], ["DOMESTIC CAT RADIATION HYBRID MAPWith", "DNA", 409, 446], ["feline euchromatic sequence", "DNA", 498, 525], ["feline contigs", "DNA", 596, 610], ["cat genome", "DNA", 648, 658], ["DOMESTIC CAT GENETIC LINKAGE MAPAs", "DNA", 777, 811], ["RH map", "DNA", 832, 838], ["625 STRs", "DNA", 885, 893], ["dog", "SPECIES", 18, 21], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 176, 181], ["chromosomal rearrangement", "PROBLEM", 80, 105], ["a marked increase in interchromosomal rearrangements", "PROBLEM", 111, 163], ["a solid framework", "TREATMENT", 544, 561], ["feline contigs", "TREATMENT", 596, 610], ["scaffolds", "TREATMENT", 615, 624], ["genes controlling feline phenotypes", "PROBLEM", 737, 772], ["the RH map", "TEST", 828, 838], ["a third generation linkage map", "TREATMENT", 851, 881], ["chromosomal rearrangement", "OBSERVATION", 80, 105], ["marked", "OBSERVATION_MODIFIER", 113, 119], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["interchromosomal rearrangements", "OBSERVATION", 132, 163], ["intrachromosomal rearrangements", "OBSERVATION", 264, 295], ["felid lineage", "OBSERVATION", 303, 316], ["RADIATION HYBRID", "OBSERVATION", 422, 438], ["average", "OBSERVATION_MODIFIER", 450, 457], ["spacing", "OBSERVATION_MODIFIER", 458, 465]]], ["The map has been generated in a large multigeneration domestic cat pedigree (n = 483 informative meioses).", [["cat", "ORGANISM", 63, 66], ["The map", "TEST", 0, 7], ["large", "OBSERVATION_MODIFIER", 32, 37]]], ["18 Previous first-and second-generation linkage maps of the cat were generated in a multigeneration interspecies pedigree generated between the domestic cat and the Asian leopard cat, Prionailurus bengalensis, 7 to facilitate the mapping and integration of Type I (coding) and Type II (polymorphic STR) loci.", [["cat", "ORGANISM", 60, 63], ["cat", "ORGANISM", 153, 156], ["cat", "ORGANISM", 179, 182], ["Prionailurus bengalensis", "ORGANISM", 184, 208], ["Type I (coding)", "GENE_OR_GENE_PRODUCT", 257, 272], ["Type II", "GENE_OR_GENE_PRODUCT", 277, 284], ["Type I (coding) and Type II (polymorphic STR) loci", "DNA", 257, 307], ["cat", "SPECIES", 153, 156], ["cat", "SPECIES", 179, 182], ["Prionailurus bengalensis", "SPECIES", 184, 208], ["Asian leopard cat", "SPECIES", 165, 182], ["Prionailurus bengalensis", "SPECIES", 184, 208], ["Prionailurus bengalensis", "TREATMENT", 184, 208], ["the mapping", "TEST", 226, 237], ["Type I (coding)", "PROBLEM", 257, 272], ["Type II (polymorphic STR) loci", "PROBLEM", 277, 307]]], ["7 The current map, which spans all 18 autosomes with single linkage groups, has twice the STR density of previous maps, providing a 5-cM resolution.", [["autosomes", "DNA", 38, 47], ["The current map", "TEST", 2, 17], ["previous maps", "TEST", 105, 118], ["a 5-cM resolution", "TREATMENT", 130, 147], ["5-cM", "OBSERVATION_MODIFIER", 132, 136]]], ["There is also greatly expanded coverage of the X chromosome, with some 75 STR loci.", [["X chromosome", "ANATOMY", 47, 59], ["X chromosome", "CELLULAR_COMPONENT", 47, 59], ["X chromosome", "DNA", 47, 59], ["75 STR loci", "DNA", 71, 82], ["some 75 STR loci", "PROBLEM", 66, 82], ["greatly", "OBSERVATION_MODIFIER", 14, 21], ["expanded", "OBSERVATION_MODIFIER", 22, 30], ["coverage", "OBSERVATION_MODIFIER", 31, 39], ["X chromosome", "OBSERVATION_MODIFIER", 47, 59], ["STR loci", "OBSERVATION", 74, 82]]], ["Marker order between the current generation RH and GL maps is highly concordant.", [["GL maps", "DNA", 51, 58], ["GL maps", "TEST", 51, 58], ["concordant", "OBSERVATION", 69, 79]]], ["8 Approximately 85% of the STRs are mapped in the most current RH map of the cat, 8 which provides reference and integration with Type I loci.", [["cat", "ORGANISM", 77, 80], ["Type I loci", "DNA", 130, 141], ["the STRs", "TEST", 23, 31], ["Type I loci", "PROBLEM", 130, 141]]], ["Whereas the third-generation linkage map is composed entirely of STR loci, the sequence homology of extended genomic regions adjacent to the STR loci in the cat 2X whole genome sequence, 17 to the dog's homologous region, 19 has enabled us to obtain identifiable orthologues in the canine and human genome sequences for over 95% of the STRs.", [["cat 2X", "ORGANISM", 157, 163], ["canine", "ORGANISM", 282, 288], ["human", "ORGANISM", 293, 298], ["third-generation linkage map", "DNA", 12, 40], ["STR loci", "DNA", 65, 73], ["extended genomic regions", "DNA", 100, 124], ["STR loci", "DNA", 141, 149], ["cat 2X whole genome sequence", "DNA", 157, 185], ["dog's homologous region", "DNA", 197, 220], ["canine and human genome sequences", "DNA", 282, 315], ["STRs", "DNA", 336, 340], ["dog", "SPECIES", 197, 200], ["canine", "SPECIES", 282, 288], ["human", "SPECIES", 293, 298], ["canine", "SPECIES", 282, 288], ["human", "SPECIES", 293, 298], ["STR loci", "PROBLEM", 65, 73], ["the STRs", "TEST", 332, 340]]], ["Thus, practically every STR acts as a \"virtual\" Type 1 locus, with both comparative anchoring and linkage map utility.", [["STR", "CHEMICAL", 24, 27], ["STR", "DNA", 24, 27], ["Type 1 locus", "DNA", 48, 60]]], ["Combined with the cat RH map, these genomic tools provide us with the comparative reference to other mammalian genomes critical for linkage and association mapping.THE DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEThe domestic cat is one of 26 mammalian species endorsed by the National Human Genome Research Institute (NHGRI) Human Genome Annotation committee for a \"light\" 2-fold whole genome sequence, largely to capture the pattern of genome variation and divergence that characterizes the mammalian radiations (http:// www.hgsc.bcm.tmc.edu/projects/bovine/, http://www.broad.mit. edu/mammals/).", [["cat", "ORGANISM", 220, 223], ["Human", "ORGANISM", 280, 285], ["Human", "ORGANISM", 320, 325], ["cat RH map", "DNA", 18, 28], ["mammalian genomes", "DNA", 101, 118], ["cat", "SPECIES", 220, 223], ["Human", "SPECIES", 280, 285], ["Human", "SPECIES", 320, 325], ["the cat RH map", "TEST", 14, 28], ["a \"light\" 2-fold whole genome sequence", "TREATMENT", 358, 396], ["genome variation", "PROBLEM", 432, 448], ["genome variation", "OBSERVATION", 432, 448]]], ["Although light genome coverage provides limited sequence representation, (\u223c80%), 20 one of the rationales for these light genome sequences included \"enhancing opportunities for research on species providing human medical models.\"", [["human", "ORGANISM", 207, 212], ["light genome sequences", "DNA", 116, 138], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 207, 212], ["light genome coverage", "TREATMENT", 9, 30], ["these light genome sequences", "TEST", 110, 138]]], ["The 2-fold assembly of the domestic cat genome has recently been completed for a female Abyssinian cat, \"Cinnamon,\" 17 and a 7X whole genome sequencing effort is planned in the near future.THE DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEA total of 9,161,674 reads were assembled to 817,956 contigs, covering 1.642 Gb with an N50 (i.e., half of the sequenced base pairs are in contigs <N50) contig length of 2378 bp.", [["cat", "ORGANISM", 36, 39], ["cat", "ORGANISM", 99, 102], ["domestic cat genome", "DNA", 27, 46], ["817,956 contigs", "DNA", 277, 292], ["N50", "DNA", 320, 323], ["sequenced base pairs", "DNA", 343, 363], ["cat", "SPECIES", 99, 102], ["Gb", "TEST", 309, 311], ["an N50", "TEST", 317, 323], ["contig length", "TEST", 385, 398], ["bp", "TEST", 407, 409]]], ["Assembled supercontigs (N = 217,790) had an N50 length of 117 kb 17 (http:// hosted. abcc.ncifcrf.gov/cgi-gin/gbrowse/cat/).", [["N50 length", "DNA", 44, 54], ["117 kb 17", "DNA", 58, 67], ["an N50 length", "TEST", 41, 54], ["kb", "TEST", 62, 64]]], ["The estimated size of the genome was 2.7 Gb and the genome coverage was approximately 2-fold, predicting an average inclusion of 80-85% of the eukaryotic genome sequence.", [["genome", "CELLULAR_COMPONENT", 26, 32], ["eukaryotic genome sequence", "DNA", 143, 169], ["the genome coverage", "TEST", 48, 67], ["size", "OBSERVATION_MODIFIER", 14, 18], ["genome", "OBSERVATION_MODIFIER", 26, 32], ["2.7 Gb", "OBSERVATION_MODIFIER", 37, 43], ["genome", "OBSERVATION_MODIFIER", 52, 58], ["coverage", "OBSERVATION_MODIFIER", 59, 67], ["average", "OBSERVATION_MODIFIER", 108, 115], ["eukaryotic genome", "OBSERVATION", 143, 160]]], ["21 Feline coding genes were identified using a comparative approach based upon sequence homology and syntenic orthology of neighboring gene homologues in the genomes of six index mammal species (human, chimp, mouse, rat, cow, and dog).", [["Feline", "ORGANISM", 3, 9], ["human", "ORGANISM", 195, 200], ["chimp", "ORGANISM", 202, 207], ["mouse", "ORGANISM", 209, 214], ["rat", "ORGANISM", 216, 219], ["cow", "ORGANISM", 221, 224], ["dog", "ORGANISM", 230, 233], ["Feline coding genes", "DNA", 3, 22], ["neighboring gene homologues", "DNA", 123, 150], ["human", "SPECIES", 195, 200], ["mouse", "SPECIES", 209, 214], ["rat", "SPECIES", 216, 219], ["cow", "SPECIES", 221, 224], ["dog", "SPECIES", 230, 233], ["human", "SPECIES", 195, 200], ["mouse", "SPECIES", 209, 214], ["rat", "SPECIES", 216, 219], ["cow", "SPECIES", 221, 224], ["a comparative approach", "TREATMENT", 45, 67]]], ["The results revealed nearly 21,080 feline genes plus 132,493 conserved sequence blocks (CSBs) used to build the gene map, 17 depending upon the framework RH map of 1794 ordered Type 1 markers.", [["feline", "ORGANISM", 35, 41], ["feline genes", "DNA", 35, 47], ["132,493 conserved sequence blocks", "DNA", 53, 86], ["CSBs", "DNA", 88, 92], ["1794 ordered Type 1 markers", "DNA", 164, 191], ["CSBs", "TEST", 88, 92], ["the framework RH map", "TEST", 140, 160]]], ["8 The 2X feline genome sequence detects 83% of human genes, 89% of chimp or cattle genes, and 92% of dog genes based upon sequence identity to approximately 1000 bp of reciprocal base match 17 between the cat sequence and the genome sequence of the six index mammals.THE DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEA genome browser has been developed from the cat assembly, named Genome Annotation Region FIELD (GARFIELD), which provides a physical map of the 18 autosomes and the X chromosome, which can be inspected for sequence representation, including genes and the proportion of that gene available in the 2X cover, single nucleotide polymorphisms (SNPs), and STRs, which can be used in linkage and association mapping, and other genome features (http://ccr.cancer.gov/ labs/lab).", [["X chromosome", "ANATOMY", 476, 488], ["2X feline", "ORGANISM", 6, 15], ["human", "ORGANISM", 47, 52], ["chimp", "ORGANISM", 67, 72], ["cattle", "ORGANISM", 76, 82], ["dog", "ORGANISM", 101, 104], ["cat", "ORGANISM", 205, 208], ["cat", "ORGANISM", 355, 358], ["autosomes", "CELLULAR_COMPONENT", 458, 467], ["X chromosome", "CELLULAR_COMPONENT", 476, 488], ["2X feline genome sequence", "DNA", 6, 31], ["human genes", "DNA", 47, 58], ["chimp or cattle genes", "DNA", 67, 88], ["dog genes", "DNA", 101, 110], ["cat sequence", "DNA", 205, 217], ["DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEA genome browser", "DNA", 271, 326], ["18 autosomes", "DNA", 455, 467], ["X chromosome", "DNA", 476, 488], ["2X cover", "DNA", 607, 615], ["SNPs", "DNA", 650, 654], ["STRs", "DNA", 661, 665], ["human", "SPECIES", 47, 52], ["cattle", "SPECIES", 76, 82], ["human", "SPECIES", 47, 52], ["cattle", "SPECIES", 76, 82], ["The 2X feline genome sequence", "TEST", 2, 31], ["human genes", "TEST", 47, 58], ["chimp", "TEST", 67, 72], ["the cat sequence", "TEST", 201, 217], ["a physical map", "TEST", 433, 447], ["the X chromosome", "TEST", 472, 488], ["sequence representation", "TEST", 517, 540], ["single nucleotide polymorphisms (SNPs)", "TREATMENT", 617, 655], ["STRs", "TREATMENT", 661, 665], ["association mapping", "TEST", 700, 719]]], ["FigureSINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS DEMONSTRATES POTENTIAL OF LINKAGE DISEQUILIBRIUM MAPPING IN CAT BREEDSA total of 421,000 SNP variants were identified in Cinnamon's sequence, representing an incidence of 1/600 bp.", [["SNP", "CHEMICAL", 135, 138], ["CAT BREEDSA total of 421,000 SNP variants", "DNA", 106, 147], ["Cinnamon's sequence", "DNA", 167, 186], ["FigureSINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS", "TEST", 0, 45], ["SNP variants", "PROBLEM", 135, 147], ["Cinnamon's sequence", "TEST", 167, 186], ["LINKAGE DISEQUILIBRIUM", "OBSERVATION", 72, 94]]], ["17 Approximately 43% of Cinnamon's genome was heterozygous and 57% homozygous, which was not unexpected in a breed cat that is also the member of a highly inbred pedigree for retinal atrophy.", [["retinal", "ANATOMY", 175, 182], ["retinal atrophy", "DISEASE", 175, 190], ["cat", "ORGANISM", 115, 118], ["retinal", "MULTI-TISSUE_STRUCTURE", 175, 182], ["Cinnamon's genome", "DNA", 24, 41], ["heterozygous", "PROBLEM", 46, 58], ["57% homozygous", "PROBLEM", 63, 77], ["retinal atrophy", "PROBLEM", 175, 190], ["43%", "OBSERVATION_MODIFIER", 17, 20], ["retinal", "ANATOMY", 175, 182], ["atrophy", "OBSERVATION", 183, 190]]], ["17, 22 Long stretches of alternating homozygous and heterozygous segments were observed ( Figure 25 -3), which represent the consequences of close inbreeding during the domestication process, and the more recent generation of fancy breeds and inbred disease pedigree.", [["alternating homozygous and heterozygous segments", "PROBLEM", 25, 73], ["fancy breeds", "PROBLEM", 226, 238], ["inbred disease pedigree", "PROBLEM", 243, 266], ["alternating homozygous", "OBSERVATION", 25, 47], ["heterozygous", "OBSERVATION", 52, 64], ["segments", "ANATOMY_MODIFIER", 65, 73]]], ["22 Similar patches of homozygous/heterozygous segments were observed in the recently released whole genome sequence of the dog.", [["dog", "ORGANISM", 123, 126], ["whole genome sequence", "DNA", 94, 115], ["dog", "SPECIES", 123, 126], ["homozygous/heterozygous segments", "PROBLEM", 22, 54], ["Similar", "OBSERVATION_MODIFIER", 3, 10], ["patches", "OBSERVATION_MODIFIER", 11, 18], ["homozygous", "OBSERVATION", 22, 32], ["heterozygous segments", "OBSERVATION", 33, 54], ["dog", "ANATOMY", 123, 126]]], ["19 The length of the segments is influenced by breedspecifi c history including effective population sizes, use of popular sires, and population bottlenecks.", [["effective population sizes", "TREATMENT", 80, 106], ["popular sires", "TREATMENT", 115, 128], ["length", "OBSERVATION_MODIFIER", 7, 13], ["segments", "ANATOMY_MODIFIER", 21, 29], ["effective", "OBSERVATION_MODIFIER", 80, 89], ["population", "OBSERVATION_MODIFIER", 90, 100], ["sizes", "OBSERVATION_MODIFIER", 101, 106], ["popular sires", "OBSERVATION", 115, 128]]], ["23, 24 Linkage disequilibrium (LD) mapping has recently emerged as a powerful approach in humans for association mapping.", [["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["Linkage disequilibrium (LD) mapping", "PROBLEM", 7, 42]]], ["25 Long stretches of linkage disequilibrium in the target population greatly facilitate the success of the strategy and decrease the number of markers required for analysis.", [["Long stretches of linkage disequilibrium", "PROBLEM", 3, 43], ["the strategy", "TREATMENT", 103, 115], ["analysis", "TEST", 164, 172], ["linkage disequilibrium", "OBSERVATION", 21, 43]]], ["25 The extended LDs observed in dog breeds, up to one hundred times the length observed in human populations, 26 is proving to be a powerful mapping strategy for identification of genes associated with breedspecifi c phenotypes, 27 including hereditary pathologies.", [["hereditary pathologies", "DISEASE", 242, 264], ["dog", "ORGANISM", 32, 35], ["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["a powerful mapping strategy", "TREATMENT", 130, 157], ["breedspecifi c phenotypes", "PROBLEM", 202, 227], ["hereditary pathologies", "PROBLEM", 242, 264], ["dog breeds", "OBSERVATION", 32, 42]]], ["28, 29 The potential of this mapping approach in cat breeds was evaluated by examining breed-specific patterns of common segment homozygosity in 24 Cat Fancier Association (CFA) (http://www.cfainc.org) breeds.", [["cat", "ORGANISM", 49, 52], ["this mapping approach", "TREATMENT", 24, 45], ["common segment homozygosity", "PROBLEM", 114, 141], ["common segment", "ANATOMY", 114, 128]]], ["17 The level of homozygosity refl ected in a group of 665 SNPs was roughly half that seen in dogs, 26 likely reflecting a more extensive recent inbreeding within Heterozygosity across Cinnamon's chromosomes is represented in nonoverlapping windows of 100 kb.", [["chromosomes", "ANATOMY", 195, 206], ["chromosomes", "CELLULAR_COMPONENT", 195, 206], ["Cinnamon's chromosomes", "DNA", 184, 206], ["dogs", "SPECIES", 93, 97], ["a more extensive recent inbreeding within Heterozygosity", "PROBLEM", 120, 176], ["Cinnamon's chromosomes", "TREATMENT", 184, 206], ["extensive", "OBSERVATION_MODIFIER", 127, 136]]], ["Black represents regions with more than two SNPs per 100 kb while gray represents the homozygous region (less than two SNP, 0/100 kb).", [["homozygous region", "DNA", 86, 103], ["the homozygous region", "PROBLEM", 82, 103], ["homozygous", "OBSERVATION", 86, 96]]], ["White represents gaps in the chromosome assembly.SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS DEMONSTRATES POTENTIAL OF LINKAGE DISEQUILIBRIUM MAPPING IN CAT BREEDSdog versus cat breeds.", [["chromosome", "ANATOMY", 29, 39], ["chromosome", "CELLULAR_COMPONENT", 29, 39], ["cat", "ORGANISM", 170, 173], ["CAT BREEDSdog", "PROTEIN", 149, 162], ["SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS", "TEST", 49, 88], ["LINKAGE DISEQUILIBRIUM MAPPING", "PROBLEM", 115, 145], ["gaps", "OBSERVATION", 17, 21], ["LINKAGE DISEQUILIBRIUM", "OBSERVATION", 115, 137]]], ["30 This level of homozygosity was used to estimate 19 that some 45,000 equivalently spaced SNP variants would be required for a linkage disequilibrium/haplotype-based association genome search of a complex heritable disease within cat breeds.SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS DEMONSTRATES POTENTIAL OF LINKAGE DISEQUILIBRIUM MAPPING IN CAT BREEDSRecently, tyrosinase-related protein 1 (TYRP1), one of the key enzymes in the melanogenic pathway, was linked to two coat color variants in the cat by association mapping in 38 cat breeds due to extensive LD.", [["SNP", "CHEMICAL", 91, 94], ["cat", "ORGANISM", 231, 234], ["tyrosinase-related protein 1", "GENE_OR_GENE_PRODUCT", 362, 390], ["TYRP1", "GENE_OR_GENE_PRODUCT", 392, 397], ["cat", "ORGANISM", 496, 499], ["cat", "ORGANISM", 529, 532], ["CAT", "PROTEIN", 342, 345], ["tyrosinase-related protein 1", "PROTEIN", 362, 390], ["TYRP1", "PROTEIN", 392, 397], ["some 45,000 equivalently spaced SNP variants", "PROBLEM", 59, 103], ["a linkage disequilibrium/haplotype", "PROBLEM", 126, 160], ["a complex heritable disease", "PROBLEM", 196, 223], ["SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS", "TEST", 242, 281], ["LINKAGE DISEQUILIBRIUM MAPPING", "PROBLEM", 308, 338], ["CAT BREEDSRecently", "TEST", 342, 360], ["tyrosinase", "TEST", 362, 372], ["protein", "TEST", 381, 388], ["the key enzymes", "TEST", 407, 422], ["extensive LD", "PROBLEM", 547, 559], ["complex", "OBSERVATION_MODIFIER", 198, 205], ["heritable", "OBSERVATION_MODIFIER", 206, 215], ["disease", "OBSERVATION", 216, 223], ["LINKAGE DISEQUILIBRIUM", "OBSERVATION", 308, 330]]], ["31 Two DNA polymorphisms in TYRP1, an A3G substitution in the signal peptide and an in-frame insertion TYRP1-421ins17/18, were associated with the chocolate (b) allele.", [["DNA", "CELLULAR_COMPONENT", 7, 10], ["TYRP1", "GENE_OR_GENE_PRODUCT", 28, 33], ["A3G", "GENE_OR_GENE_PRODUCT", 38, 41], ["chocolate (b)", "GENE_OR_GENE_PRODUCT", 147, 160], ["TYRP1", "DNA", 28, 33], ["TYRP1", "DNA", 103, 108], ["421ins17/18", "DNA", 109, 120], ["chocolate (b) allele", "DNA", 147, 167], ["Two DNA polymorphisms in TYRP1", "PROBLEM", 3, 33], ["an A3G substitution", "TREATMENT", 35, 54], ["the signal peptide", "TEST", 58, 76], ["A3G substitution", "OBSERVATION", 38, 54]]], ["A premature UAG stop codon at position 100 of TYRP1 was associated with a second allele of the B locus, cinnamon (bl).", [["TYRP1", "GENE_OR_GENE_PRODUCT", 46, 51], ["B", "GENE_OR_GENE_PRODUCT", 95, 96], ["cinnamon", "SIMPLE_CHEMICAL", 104, 112], ["premature UAG stop codon", "DNA", 2, 26], ["TYRP1", "DNA", 46, 51], ["allele", "DNA", 81, 87], ["B locus", "DNA", 95, 102], ["cinnamon (bl)", "DNA", 104, 117], ["A premature UAG stop codon", "TREATMENT", 0, 26], ["TYRP1", "PROBLEM", 46, 51], ["premature", "OBSERVATION_MODIFIER", 2, 11], ["UAG", "OBSERVATION", 12, 15], ["stop codon", "OBSERVATION", 16, 26]]], ["32 SNP discovery is planned in the 7X whole genome sequencing of the cat through a resequencing strategy of selected genomic regions in several cat breeds as was recently performed in the 7X whole genome sequencing of the dog.", [["SNP", "CHEMICAL", 3, 6], ["cat", "ORGANISM", 69, 72], ["cat", "ORGANISM", 144, 147], ["dog", "ORGANISM", 222, 225], ["genomic regions", "DNA", 117, 132], ["dog", "SPECIES", 222, 225], ["cat breeds", "OBSERVATION", 144, 154]]], ["19THE MATURITY OF CURRENT FELID MAPPING RESOURCES DEMONSTRATED IN SUCCESSFUL WHOLE GENOME AND ASSOCIATION MAPPING EXERCISESThe majority of hereditary pathologies in the domestic cat for which the gene defect has been elucidated have resulted from the analysis of candidate genes (Table 25-1) .", [["hereditary pathologies", "DISEASE", 139, 161], ["cat", "ORGANISM", 178, 181], ["candidate genes", "DNA", 263, 278], ["Table 25-1", "DNA", 280, 290], ["cat", "SPECIES", 178, 181], ["hereditary pathologies", "PROBLEM", 139, 161], ["the gene defect", "PROBLEM", 192, 207], ["hereditary", "OBSERVATION_MODIFIER", 139, 149], ["pathologies", "OBSERVATION", 150, 161], ["defect", "OBSERVATION", 201, 207]]], ["However, with the availability of a detailed comparative map, and integration with developing GL and RH maps, and the cat 2X whole genome sequence, linkage and association-based mapping techniques have recently identified causative mutations for hereditary disease genes, 33, 34 as well as several feline phenotypes (Table 25-1) .", [["hereditary disease", "DISEASE", 246, 264], ["GL", "CELL", 94, 96], ["feline", "ORGANISM", 298, 304], ["GL and RH maps", "DNA", 94, 108], ["cat 2X whole genome sequence", "DNA", 118, 146], ["hereditary disease genes", "DNA", 246, 270], ["developing GL and RH maps", "TEST", 83, 108], ["the cat 2X whole genome sequence", "TEST", 114, 146], ["causative mutations", "PROBLEM", 222, 241], ["hereditary disease genes", "PROBLEM", 246, 270], ["several feline phenotypes", "TEST", 290, 315]]], ["18, 32, Once a genomic region is implicated from association-based or linkage mapping exercises, fine mapping has been accomplished by development of new STRs or SNPs in the targeted region using the cat 2X whole genome sequence data accessed sequence tagged sites (STS), utilizing sequence information from the cat 2X whole genome sequencing effort, which ultimately identifi ed an \u223c140 kb deletion and a novel gene candidate, LIX1 34 ( Figure 25-4) .", [["genomic region", "DNA", 15, 29], ["STRs", "DNA", 154, 158], ["SNPs", "DNA", 162, 166], ["cat 2X whole genome sequence", "DNA", 200, 228], ["\u223c140 kb deletion", "DNA", 383, 399], ["novel gene candidate", "DNA", 406, 426], ["LIX1 34", "DNA", 428, 435], ["Figure 25-4", "DNA", 438, 449], ["linkage mapping exercises", "TREATMENT", 70, 95], ["fine mapping", "TEST", 97, 109], ["new STRs or SNPs", "PROBLEM", 150, 166], ["LIX1", "TEST", 428, 432], ["new", "OBSERVATION_MODIFIER", 150, 153]]], ["Though the function of LIX1 is unknown, the predicted secondary structure is compatible with a role in RNA metabolism.", [["LIX1", "GENE_OR_GENE_PRODUCT", 23, 27], ["LIX1", "PROTEIN", 23, 27], ["a role in RNA metabolism", "PROBLEM", 93, 117], ["secondary structure", "OBSERVATION", 54, 73], ["compatible with", "UNCERTAINTY", 77, 92], ["RNA metabolism", "OBSERVATION", 103, 117]]], ["An exon sequence screen of 25 human SMA cases, not otherwise explicable by mutations at the SMN1 locus, failed to identify comparable LIX1 mutations.", [["human", "ORGANISM", 30, 35], ["SMA", "GENE_OR_GENE_PRODUCT", 36, 39], ["SMN1", "GENE_OR_GENE_PRODUCT", 92, 96], ["LIX1", "GENE_OR_GENE_PRODUCT", 134, 138], ["SMN1 locus", "DNA", 92, 102], ["LIX1", "DNA", 134, 138], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["An exon sequence screen", "TEST", 0, 23], ["mutations at the SMN1 locus", "PROBLEM", 75, 102], ["SMA", "ANATOMY", 36, 39]]], ["34 The SMN1 gene product, SMN, is a ubiquitously expressed protein member of multiple ribonucleoprotein complexes with diverse roles in RNA metabolism, splicing, and transport in all cells.", [["cells", "ANATOMY", 183, 188], ["SMN1", "GENE_OR_GENE_PRODUCT", 7, 11], ["SMN", "GENE_OR_GENE_PRODUCT", 26, 29], ["cells", "CELL", 183, 188], ["SMN1 gene product", "PROTEIN", 7, 24], ["SMN", "PROTEIN", 26, 29], ["ubiquitously expressed protein member", "PROTEIN", 36, 73], ["multiple ribonucleoprotein complexes", "PROTEIN", 77, 113], ["multiple ribonucleoprotein complexes", "PROBLEM", 77, 113], ["SMN", "ANATOMY", 26, 29], ["multiple", "OBSERVATION_MODIFIER", 77, 85], ["ribonucleoprotein complexes", "OBSERVATION", 86, 113], ["RNA metabolism", "OBSERVATION", 136, 150]]], ["62, 63 A central focus of SMA research remains to discern the disease mechanism(s) and to understand why the primary disease pathology is localized to spinal lower motor neurons when all cells require SMN function.", [["spinal lower motor neurons", "ANATOMY", 151, 177], ["cells", "ANATOMY", 187, 192], ["SMA", "MULTI-TISSUE_STRUCTURE", 26, 29], ["neurons", "CELL", 170, 177], ["cells", "CELL", 187, 192], ["SMN", "GENE_OR_GENE_PRODUCT", 201, 204], ["spinal lower motor neurons", "CELL_TYPE", 151, 177], ["SMN", "PROTEIN", 201, 204], ["the disease mechanism", "PROBLEM", 58, 79], ["the primary disease pathology", "PROBLEM", 105, 134], ["central", "OBSERVATION_MODIFIER", 9, 16], ["SMA", "ANATOMY", 26, 29], ["disease", "OBSERVATION", 62, 69], ["spinal", "ANATOMY", 151, 157], ["lower", "ANATOMY_MODIFIER", 158, 163], ["SMN function", "OBSERVATION", 201, 213]]], ["LIX1 expression is largely restricted to the central nervous system (CNS), primarily in spinal motor neurons, thus offering an explanation of the tissue restriction of pathology in feline SMA.", [["central nervous system", "ANATOMY", 45, 67], ["CNS", "ANATOMY", 69, 72], ["spinal motor neurons", "ANATOMY", 88, 108], ["tissue", "ANATOMY", 146, 152], ["feline SMA", "DISEASE", 181, 191], ["LIX1", "GENE_OR_GENE_PRODUCT", 0, 4], ["central nervous system", "ANATOMICAL_SYSTEM", 45, 67], ["CNS", "ANATOMICAL_SYSTEM", 69, 72], ["spinal motor neurons", "CELL", 88, 108], ["tissue", "TISSUE", 146, 152], ["feline", "ORGANISM", 181, 187], ["SMA", "GENE_OR_GENE_PRODUCT", 188, 191], ["LIX1", "PROTEIN", 0, 4], ["spinal motor neurons", "CELL_TYPE", 88, 108], ["central", "ANATOMY_MODIFIER", 45, 52], ["nervous system", "ANATOMY", 53, 67], ["spinal motor", "ANATOMY", 88, 100], ["SMA", "ANATOMY", 188, 191]]], ["Determination of LIX1 function may well provide fresh insight into the mechanisms of human SMA pathology, impetus for more targeted therapeutics, and answers to fundamental questions of motor neuron development, maintenance, and/or function. through the cat genome browser, GARFIELD.", [["motor neuron", "ANATOMY", 186, 198], ["LIX1", "GENE_OR_GENE_PRODUCT", 17, 21], ["human", "ORGANISM", 85, 90], ["SMA", "GENE_OR_GENE_PRODUCT", 91, 94], ["motor neuron", "MULTI-TISSUE_STRUCTURE", 186, 198], ["LIX1", "PROTEIN", 17, 21], ["cat genome browser", "DNA", 254, 272], ["GARFIELD", "DNA", 274, 282], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["LIX1 function", "PROBLEM", 17, 30], ["SMA", "ANATOMY", 91, 94]]], ["17 A recent report of the mapping and characterization of a novel gene causative of feline spinal muscular atrophy 34 marked the first identification of a disease gene purely from positional reasoning.", [["spinal muscular", "ANATOMY", 91, 106], ["spinal muscular atrophy", "DISEASE", 91, 114], ["feline", "ORGANISM", 84, 90], ["disease gene", "DNA", 155, 167], ["feline", "SPECIES", 84, 90], ["the mapping", "TEST", 22, 33], ["feline spinal muscular atrophy", "PROBLEM", 84, 114], ["a disease gene purely", "PROBLEM", 153, 174], ["spinal muscular", "ANATOMY", 91, 106], ["atrophy", "OBSERVATION", 107, 114], ["disease", "OBSERVATION", 155, 162]]], ["Human spinal muscular atrophies (SMAs) are a genetically heterogeneous group of neuropathies that varies in clinical severity, from lethal in infancy to onset of mild weakness in adulthood, but all are characterized by neurogenic muscle atrophy due to degeneration of lower motor neurons of the spinal cord.", [["spinal muscular atrophies", "ANATOMY", 6, 31], ["SMAs", "ANATOMY", 33, 37], ["muscle", "ANATOMY", 230, 236], ["lower motor neurons", "ANATOMY", 268, 287], ["spinal cord", "ANATOMY", 295, 306], ["spinal muscular atrophies", "DISEASE", 6, 31], ["SMAs", "DISEASE", 33, 37], ["neuropathies", "DISEASE", 80, 92], ["weakness", "DISEASE", 167, 175], ["muscle atrophy", "DISEASE", 230, 244], ["Human", "ORGANISM", 0, 5], ["spinal muscular atrophies", "CANCER", 6, 31], ["SMAs", "CANCER", 33, 37], ["muscle", "ORGAN", 230, 236], ["motor neurons", "MULTI-TISSUE_STRUCTURE", 274, 287], ["spinal cord", "ORGAN", 295, 306], ["lower motor neurons", "CELL_TYPE", 268, 287], ["Human", "SPECIES", 0, 5], ["Human spinal muscular atrophies", "PROBLEM", 0, 31], ["neuropathies", "PROBLEM", 80, 92], ["mild weakness in adulthood", "PROBLEM", 162, 188], ["neurogenic muscle atrophy", "PROBLEM", 219, 244], ["degeneration of lower motor neurons of the spinal cord", "PROBLEM", 252, 306], ["spinal muscular", "ANATOMY", 6, 21], ["atrophies", "OBSERVATION", 22, 31], ["SMAs", "ANATOMY", 33, 37], ["heterogeneous", "OBSERVATION_MODIFIER", 57, 70], ["neuropathies", "OBSERVATION", 80, 92], ["mild", "OBSERVATION_MODIFIER", 162, 166], ["weakness", "OBSERVATION", 167, 175], ["neurogenic", "OBSERVATION", 219, 229], ["muscle", "ANATOMY", 230, 236], ["atrophy", "OBSERVATION", 237, 244], ["degeneration", "OBSERVATION", 252, 264], ["lower", "ANATOMY_MODIFIER", 268, 273], ["motor neurons", "ANATOMY_MODIFIER", 274, 287], ["spinal cord", "ANATOMY", 295, 306]]], ["58 For approximately 97% of people affected with SMA, disease pathology is attributable to a mutation in the SMN1 gene, on human chromosome 5q13, which is subject to a high frequency of deletions and gene conversion events with the divergent and only partially functional centromeric copy/copies of the duplicated SMN2 locus.", [["chromosome 5q13", "ANATOMY", 129, 144], ["centromeric", "ANATOMY", 272, 283], ["SMA", "DISEASE", 49, 52], ["people", "ORGANISM", 28, 34], ["SMA", "GENE_OR_GENE_PRODUCT", 49, 52], ["SMN1", "GENE_OR_GENE_PRODUCT", 109, 113], ["human", "ORGANISM", 123, 128], ["chromosome 5q13", "CELLULAR_COMPONENT", 129, 144], ["centromeric", "CELLULAR_COMPONENT", 272, 283], ["SMN2", "GENE_OR_GENE_PRODUCT", 314, 318], ["SMN1 gene", "DNA", 109, 118], ["human chromosome 5q13", "DNA", 123, 144], ["SMN2 locus", "DNA", 314, 324], ["people", "SPECIES", 28, 34], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["SMA, disease pathology", "PROBLEM", 49, 71], ["a mutation in the SMN1 gene", "PROBLEM", 91, 118], ["human chromosome", "TREATMENT", 123, 139], ["a high frequency of deletions", "PROBLEM", 166, 195], ["gene conversion events", "PROBLEM", 200, 222], ["the duplicated SMN2 locus", "PROBLEM", 299, 324], ["SMA", "ANATOMY", 49, 52], ["disease", "OBSERVATION", 54, 61], ["SMN2 locus", "OBSERVATION", 314, 324]]], ["59, 60 A domestic cat model of SMA has been described that is a model of autosomal recessive juvenile-onset SMA.", [["SMA", "DISEASE", 31, 34], ["autosomal recessive juvenile-onset SMA", "DISEASE", 73, 111], ["cat", "ORGANISM", 18, 21], ["SMA", "GENE_OR_GENE_PRODUCT", 31, 34], ["SMA", "CANCER", 108, 111], ["SMA", "PROTEIN", 31, 34], ["autosomal recessive juvenile-onset SMA", "PROBLEM", 73, 111], ["domestic cat", "OBSERVATION", 9, 21], ["SMA", "ANATOMY", 31, 34], ["autosomal", "OBSERVATION_MODIFIER", 73, 82], ["recessive", "OBSERVATION_MODIFIER", 83, 92], ["juvenile", "OBSERVATION", 93, 101], ["onset", "OBSERVATION_MODIFIER", 102, 107], ["SMA", "ANATOMY", 108, 111]]], ["61 With the feline SMN gene excluded as the disease locus, 61 a full genome linkage scan was conducted in a pedigree segregating for SMA.", [["feline", "ORGANISM", 12, 18], ["SMN", "GENE_OR_GENE_PRODUCT", 19, 22], ["feline SMN gene", "DNA", 12, 27], ["disease locus", "DNA", 44, 57], ["SMA", "PROTEIN", 133, 136], ["feline", "SPECIES", 12, 18], ["the disease locus", "PROBLEM", 40, 57], ["a full genome linkage scan", "TEST", 62, 88], ["SMA", "ANATOMY", 133, 136]]], ["61 The disease phenotype was linked to chromosome A1q, 34 in a region of conserved synteny to human chromosome 5q15.", [["chromosome A1q", "ANATOMY", 39, 53], ["chromosome 5q15", "ANATOMY", 100, 115], ["chromosome A1q", "CELLULAR_COMPONENT", 39, 53], ["human", "ORGANISM", 94, 99], ["chromosome 5q15", "CELLULAR_COMPONENT", 100, 115], ["chromosome A1q", "DNA", 39, 53], ["human chromosome 5q15", "DNA", 94, 115], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["The disease phenotype", "PROBLEM", 3, 24], ["disease", "OBSERVATION", 7, 14]]], ["Fine mapping was accomplished with development of new STRs andTHE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEThe world's veterinary schools produce thousands of practitioners each year, most of whom carefully document genetic and chronic diseases of our pets.", [["Fine mapping", "TEST", 0, 12], ["new STRs", "TEST", 50, 58], ["HUMAN HEREDITARY DISEASE", "PROBLEM", 90, 114], ["genetic and chronic diseases of our pets", "PROBLEM", 223, 263], ["new", "OBSERVATION_MODIFIER", 50, 53], ["HEREDITARY DISEASE", "OBSERVATION", 96, 114], ["chronic", "OBSERVATION_MODIFIER", 235, 242], ["diseases", "OBSERVATION", 243, 251]]], ["The result is a comprehensive veterinary literature that has described over 200 feline hereditary pathologies 17 (http://www.angis.org.au/).", [["hereditary pathologies", "DISEASE", 87, 109], ["hereditary pathologies", "PROBLEM", 87, 109]]], ["The clinical and physiological study of these feline hereditary diseases provides a strong comparative medicine opportunity for prevention, diagnostics, and treatment studies in a laboratory setting.", [["hereditary diseases", "DISEASE", 53, 72], ["feline", "ORGANISM", 46, 52], ["physiological study", "TEST", 17, 36], ["these feline hereditary diseases", "PROBLEM", 40, 72], ["diagnostics", "TEST", 140, 151], ["treatment studies", "TEST", 157, 174]]], ["Additionally, large animal homologues are similar to humans in natural genetic diversity and offer the possibility of evaluating long-term effects of treatment.", [["humans", "ORGANISM", 53, 59], ["humans", "SPECIES", 53, 59], ["humans", "SPECIES", 53, 59], ["large animal homologues", "PROBLEM", 14, 37], ["treatment", "TREATMENT", 150, 159], ["large", "OBSERVATION_MODIFIER", 14, 19], ["animal homologues", "OBSERVATION", 20, 37]]], ["64 To date, causal mutations have been characterized in 19 felid genes that cause hereditary disease (Table 25 -1).", [["hereditary disease", "DISEASE", 82, 100], ["felid genes", "DNA", 59, 70], ["causal mutations", "PROBLEM", 12, 28], ["hereditary disease", "PROBLEM", 82, 100]]], ["The largest representation comes from lysosomal storage enzyme disorders that arise from defects in genes playing a role in degradation of macromolecules targeted to the lysosomes.", [["lysosomal", "ANATOMY", 38, 47], ["lysosomes", "ANATOMY", 170, 179], ["lysosomes", "CELLULAR_COMPONENT", 170, 179], ["lysosomal storage enzyme", "PROTEIN", 38, 62], ["lysosomal storage enzyme disorders", "PROBLEM", 38, 72], ["defects in genes", "PROBLEM", 89, 105], ["macromolecules", "TREATMENT", 139, 153], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["lysosomal storage", "OBSERVATION", 38, 55], ["enzyme disorders", "OBSERVATION", 56, 72], ["defects", "OBSERVATION", 89, 96]]], ["Many of the genes that cause these pathologies have been mapped in the cat.", [["cat", "ORGANISM", 71, 74], ["these pathologies", "PROBLEM", 29, 46], ["pathologies", "OBSERVATION", 35, 46]]], ["65 Corrective therapeutic strategies have been proposed and examined in the cat, including enzyme replacement, heterologous bone marrow transplantation, and substrate reduction therapy.", [["bone marrow", "ANATOMY", 124, 135], ["cat", "ORGANISM", 76, 79], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 124, 135], ["Corrective therapeutic strategies", "TREATMENT", 3, 36], ["enzyme replacement", "TREATMENT", 91, 109], ["heterologous bone marrow transplantation", "TREATMENT", 111, 151], ["substrate reduction therapy", "TREATMENT", 157, 184], ["bone marrow transplantation", "OBSERVATION", 124, 151]]], ["64, 66 Limitations to these treatment strategies include high morbidity and mortality, limited positive outcomes, incomplete response to therapy, cost, and in some cases requirements for continuous lifelong therapy.", [["these treatment strategies", "TREATMENT", 22, 48], ["high morbidity", "PROBLEM", 57, 71], ["limited positive outcomes", "PROBLEM", 87, 112], ["therapy", "TREATMENT", 137, 144], ["cost", "TREATMENT", 146, 150], ["continuous lifelong therapy", "TREATMENT", 187, 214]]], ["66 Gene therapy poses the most recent of intervention strategies.", [["Gene therapy", "TREATMENT", 3, 15], ["intervention strategies", "TREATMENT", 41, 64]]], ["Feline models have been important in elucidating molecular pathogenesis and are now playing a critical role in evaluating and optimizing the range of therapeutic strategies prior to clinical trials in humans.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEThe mucopolysaccharidoses are disorders that result from the defi ciency of lysosomal enzymes involved in the degradation of mucopolysaccharides.", [["lysosomal", "ANATOMY", 336, 345], ["mucopolysaccharidoses", "DISEASE", 264, 285], ["Feline", "ORGANISM", 0, 6], ["humans", "ORGANISM", 201, 207], ["mucopolysaccharidoses", "SIMPLE_CHEMICAL", 264, 285], ["mucopolysaccharides", "SIMPLE_CHEMICAL", 385, 404], ["lysosomal enzymes", "PROTEIN", 336, 353], ["humans", "SPECIES", 201, 207], ["humans", "SPECIES", 201, 207], ["therapeutic strategies", "TREATMENT", 150, 172], ["HUMAN HEREDITARY DISEASE", "PROBLEM", 236, 260], ["The mucopolysaccharidoses", "PROBLEM", 260, 285], ["disorders", "PROBLEM", 290, 299], ["lysosomal enzymes", "TEST", 336, 353], ["the degradation of mucopolysaccharides", "PROBLEM", 366, 404], ["HEREDITARY DISEASE", "OBSERVATION", 242, 260], ["mucopolysaccharidoses", "OBSERVATION", 264, 285]]], ["The cat offers homologous models for mucopolysaccharidosis Types I, VI, and VII.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEMucopolysaccharidosis Type I (MPS I), which results from a genetic deficient activity of the enzyme \u03b1-l-iduronidase (IDUA), can lead to mental retardation, growth abnormalities, and shortened life span in humans.", [["mucopolysaccharidosis", "DISEASE", 37, 58], ["DISEASEMucopolysaccharidosis Type I", "DISEASE", 125, 160], ["MPS", "DISEASE", 162, 165], ["mental retardation", "DISEASE", 268, 286], ["growth abnormalities", "DISEASE", 288, 308], ["cat", "ORGANISM", 4, 7], ["mucopolysaccharidosis Types I", "GENE_OR_GENE_PRODUCT", 37, 66], ["VII", "GENE_OR_GENE_PRODUCT", 76, 79], ["DISEASEMucopolysaccharidosis Type I", "GENE_OR_GENE_PRODUCT", 125, 160], ["MPS I", "GENE_OR_GENE_PRODUCT", 162, 167], ["\u03b1-l-iduronidase", "GENE_OR_GENE_PRODUCT", 232, 247], ["IDUA", "GENE_OR_GENE_PRODUCT", 249, 253], ["humans", "ORGANISM", 337, 343], ["mucopolysaccharidosis Types I, VI, and VII", "PROTEIN", 37, 79], ["enzyme \u03b1-l-iduronidase", "PROTEIN", 225, 247], ["IDUA", "PROTEIN", 249, 253], ["humans", "SPECIES", 337, 343], ["humans", "SPECIES", 337, 343], ["mucopolysaccharidosis", "PROBLEM", 37, 58], ["mental retardation", "PROBLEM", 268, 286], ["growth abnormalities", "PROBLEM", 288, 308], ["shortened life span in humans", "PROBLEM", 314, 343]]], ["67 Naturally occurring models have been characterized in the cat 68,69 and dog.", [["cat", "ORGANISM", 61, 64], ["dog", "ORGANISM", 75, 78], ["dog", "SPECIES", 75, 78]]], ["70 Immune responses can nullify the effect of gene corrective therapy.", [["gene corrective therapy", "TREATMENT", 46, 69]]], ["It has been demonstrated that cats, but not dogs, mount a potent CTL response to canine IDUA after neonatal gene therapy, which can be prevented with transient CTLA4-Ig.", [["IDUA", "CHEMICAL", 88, 92], ["cats", "ORGANISM", 30, 34], ["dogs", "ORGANISM", 44, 48], ["CTL", "CANCER", 65, 68], ["canine", "ORGANISM", 81, 87], ["IDUA", "CANCER", 88, 92], ["CTLA4", "GENE_OR_GENE_PRODUCT", 160, 165], ["CTLA4", "PROTEIN", 160, 165], ["cats", "SPECIES", 30, 34], ["dogs", "SPECIES", 44, 48], ["canine", "SPECIES", 81, 87], ["canine IDUA", "TREATMENT", 81, 92], ["neonatal gene therapy", "TREATMENT", 99, 120], ["transient CTLA4", "TREATMENT", 150, 165]]], ["71 The efficacy of neonatal retroviral therapy has also been explored in the cat.", [["retroviral", "ORGANISM", 28, 38], ["cat", "ORGANISM", 77, 80], ["neonatal retroviral therapy", "TREATMENT", 19, 46], ["retroviral therapy", "OBSERVATION", 28, 46]]], ["66 The cat model, additionally, provides an ideal system to study mechanisms of brain neurodegeneration and neural-directed strategies, especially given a large body of preexisting literature on cat neurology.", [["brain", "ANATOMY", 80, 85], ["neural", "ANATOMY", 108, 114], ["brain neurodegeneration", "DISEASE", 80, 103], ["cat", "ORGANISM", 7, 10], ["brain", "ORGAN", 80, 85], ["cat", "ORGANISM", 195, 198], ["brain neurodegeneration", "PROBLEM", 80, 103], ["brain", "ANATOMY", 80, 85], ["neurodegeneration", "OBSERVATION", 86, 103]]], ["MPS VI or Marteaux-Lamy disease, deficient activity of arylsulfatase B (ARSB), is characterized in humans and cats with growth retardation, coarse facial features, corneal opacity, and skeletal deformities.", [["facial", "ANATOMY", 147, 153], ["corneal", "ANATOMY", 164, 171], ["skeletal", "ANATOMY", 185, 193], ["MPS", "DISEASE", 0, 3], ["Lamy disease", "DISEASE", 19, 31], ["growth retardation", "DISEASE", 120, 138], ["corneal opacity", "DISEASE", 164, 179], ["skeletal deformities", "DISEASE", 185, 205], ["MPS VI", "GENE_OR_GENE_PRODUCT", 0, 6], ["arylsulfatase B", "GENE_OR_GENE_PRODUCT", 55, 70], ["ARSB", "GENE_OR_GENE_PRODUCT", 72, 76], ["humans", "ORGANISM", 99, 105], ["cats", "ORGANISM", 110, 114], ["corneal", "TISSUE", 164, 171], ["skeletal", "ORGAN", 185, 193], ["arylsulfatase B", "PROTEIN", 55, 70], ["ARSB", "PROTEIN", 72, 76], ["humans", "SPECIES", 99, 105], ["cats", "SPECIES", 110, 114], ["humans", "SPECIES", 99, 105], ["Marteaux", "TEST", 10, 18], ["Lamy disease", "PROBLEM", 19, 31], ["deficient activity of arylsulfatase B (ARSB)", "PROBLEM", 33, 77], ["growth retardation", "PROBLEM", 120, 138], ["coarse facial features", "PROBLEM", 140, 162], ["corneal opacity", "PROBLEM", 164, 179], ["skeletal deformities", "PROBLEM", 185, 205], ["Lamy disease", "OBSERVATION", 19, 31], ["activity", "OBSERVATION_MODIFIER", 43, 51], ["coarse", "OBSERVATION_MODIFIER", 140, 146], ["facial", "ANATOMY", 147, 153], ["corneal", "ANATOMY", 164, 171], ["opacity", "OBSERVATION", 172, 179], ["skeletal", "ANATOMY", 185, 193], ["deformities", "OBSERVATION", 194, 205]]], ["[72] [73] [74] [75] The feline model also exhibits abnormal lysosomal storage in occasional neurons and glia distributed throughout the cerebral cortex.", [["lysosomal", "ANATOMY", 60, 69], ["neurons", "ANATOMY", 92, 99], ["glia", "ANATOMY", 104, 108], ["cerebral cortex", "ANATOMY", 136, 151], ["[72] [73] [74] [75", "SIMPLE_CHEMICAL", 0, 18], ["feline", "ORGANISM", 24, 30], ["lysosomal", "CELLULAR_COMPONENT", 60, 69], ["neurons", "CELL", 92, 99], ["glia", "CELL", 104, 108], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 136, 151], ["occasional neurons", "CELL_TYPE", 81, 99], ["glia", "CELL_TYPE", 104, 108], ["The feline model", "TEST", 20, 36], ["abnormal lysosomal storage in occasional neurons", "PROBLEM", 51, 99], ["abnormal", "OBSERVATION_MODIFIER", 51, 59], ["lysosomal storage", "OBSERVATION", 60, 77], ["occasional neurons", "OBSERVATION", 81, 99], ["glia", "ANATOMY_MODIFIER", 104, 108], ["cerebral cortex", "ANATOMY", 136, 151]]], ["76 Fibroblast-mediated in vitro gene therapy has been examined in this cat model.", [["Fibroblast", "CELL", 3, 13], ["cat", "ORGANISM", 71, 74], ["Fibroblast", "TREATMENT", 3, 13], ["vitro gene therapy", "TREATMENT", 26, 44]]], ["77 Recently, an adeno-associated vector containing feline ARSB has demonstrated gene therapy-based correction of corneal clouding in the MPS VI cat.", [["corneal", "ANATOMY", 113, 120], ["corneal clouding", "DISEASE", 113, 129], ["MPS", "DISEASE", 137, 140], ["feline", "ORGANISM", 51, 57], ["ARSB", "CANCER", 58, 62], ["corneal", "TISSUE", 113, 120], ["feline ARSB", "DNA", 51, 62], ["feline", "SPECIES", 51, 57], ["MPS VI cat", "SPECIES", 137, 147], ["an adeno-associated vector", "TREATMENT", 13, 39], ["gene therapy", "TREATMENT", 80, 92], ["corneal clouding", "PROBLEM", 113, 129], ["gene therapy", "OBSERVATION", 80, 92], ["corneal", "ANATOMY", 113, 120], ["clouding", "OBSERVATION", 121, 129]]], ["78 MPS VII results from deficiency of \u03b2-glucuronidase (GUSB), which in humans manifests as cartilaginous and bony malformations, growth and mental retardation, abdominal organ enlargement, and corneal clouding.", [["cartilaginous", "ANATOMY", 91, 104], ["bony", "ANATOMY", 109, 113], ["abdominal organ", "ANATOMY", 160, 175], ["corneal", "ANATOMY", 193, 200], ["MPS VII", "DISEASE", 3, 10], ["bony malformations", "DISEASE", 109, 127], ["growth and mental retardation", "DISEASE", 129, 158], ["abdominal organ enlargement", "DISEASE", 160, 187], ["corneal clouding", "DISEASE", 193, 209], ["MPS VII", "GENE_OR_GENE_PRODUCT", 3, 10], ["\u03b2-glucuronidase", "GENE_OR_GENE_PRODUCT", 38, 53], ["GUSB", "GENE_OR_GENE_PRODUCT", 55, 59], ["humans", "ORGANISM", 71, 77], ["cartilaginous", "TISSUE", 91, 104], ["bony malformations", "PATHOLOGICAL_FORMATION", 109, 127], ["organ", "ORGAN", 170, 175], ["corneal", "TISSUE", 193, 200], ["MPS VII", "PROTEIN", 3, 10], ["\u03b2-glucuronidase", "PROTEIN", 38, 53], ["GUSB", "PROTEIN", 55, 59], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["MPS VII results", "TEST", 3, 18], ["deficiency of \u03b2-glucuronidase (GUSB)", "PROBLEM", 24, 60], ["cartilaginous and bony malformations", "PROBLEM", 91, 127], ["mental retardation", "PROBLEM", 140, 158], ["abdominal organ enlargement", "PROBLEM", 160, 187], ["corneal clouding", "PROBLEM", 193, 209], ["bony", "ANATOMY", 109, 113], ["malformations", "OBSERVATION", 114, 127], ["abdominal organ", "ANATOMY", 160, 175], ["enlargement", "OBSERVATION", 176, 187], ["corneal", "ANATOMY", 193, 200], ["clouding", "OBSERVATION", 201, 209]]], ["79 Naturally occurring animal models have been described in mice, 80 dogs, 81 and the cat.", [["mice", "ORGANISM", 60, 64], ["dogs", "ORGANISM", 69, 73], ["cat", "ORGANISM", 86, 89], ["mice", "SPECIES", 60, 64], ["dogs", "SPECIES", 69, 73], ["cat", "SPECIES", 86, 89], ["mice", "SPECIES", 60, 64]]], ["82 Enzymatic activity has been restored in fibroblasts and restored by retroviral gene transfer of rat GUSB cDNA.", [["fibroblasts", "ANATOMY", 43, 54], ["fibroblasts", "CELL", 43, 54], ["retroviral", "ORGANISM", 71, 81], ["rat", "ORGANISM", 99, 102], ["GUSB", "GENE_OR_GENE_PRODUCT", 103, 107], ["fibroblasts", "CELL_TYPE", 43, 54], ["rat GUSB cDNA", "DNA", 99, 112], ["rat", "SPECIES", 99, 102], ["rat", "SPECIES", 99, 102]]], ["As GUSB is an essential housekeeping enzyme, this feline model is important for examination of exogenous genes and gene product delivery to a variety of tissue types, and could prove especially valuable due to extensive research conducted on the anatomy and physiology of the cat central nervous and visual systems.", [["tissue", "ANATOMY", 153, 159], ["central nervous", "ANATOMY", 280, 295], ["GUSB", "GENE_OR_GENE_PRODUCT", 3, 7], ["feline", "ORGANISM", 50, 56], ["tissue", "TISSUE", 153, 159], ["cat", "ORGANISM", 276, 279], ["central nervous", "ANATOMICAL_SYSTEM", 280, 295], ["GUSB", "PROTEIN", 3, 7], ["housekeeping enzyme", "PROTEIN", 24, 43], ["exogenous genes", "DNA", 95, 110], ["examination", "TEST", 80, 91], ["exogenous genes", "PROBLEM", 95, 110], ["gene product delivery", "TREATMENT", 115, 136], ["central", "ANATOMY_MODIFIER", 280, 287], ["nervous", "ANATOMY", 288, 295]]], ["Three different serotypes of adeno-associated viral constructs of GUSB demonstrated the efficacy of this vector to achieve gene transfer in the normal cat brain, as a model for the efficacy of this construct in a large mammalian brain.", [["brain", "ANATOMY", 155, 160], ["brain", "ANATOMY", 229, 234], ["cat", "ORGANISM", 151, 154], ["brain", "ORGAN", 155, 160], ["brain", "ORGAN", 229, 234], ["adeno-associated viral constructs", "DNA", 29, 62], ["adeno-associated viral constructs of GUSB", "PROBLEM", 29, 70], ["this vector", "TREATMENT", 100, 111], ["a large mammalian brain", "PROBLEM", 211, 234], ["serotypes", "OBSERVATION_MODIFIER", 16, 25], ["adeno-associated", "OBSERVATION_MODIFIER", 29, 45], ["viral constructs", "OBSERVATION", 46, 62], ["normal", "OBSERVATION", 144, 150], ["brain", "ANATOMY", 155, 160], ["large", "OBSERVATION", 213, 218], ["brain", "ANATOMY", 229, 234]]], ["83 Defi ciency of lysosomal \u03b1-mannosidase leads to an accumulation of mannose-rich oligosaccharides, 84 which leads to mental retardation, recurrent infections, skeletal changes and hearing impairment.", [["lysosomal", "ANATOMY", 18, 27], ["skeletal", "ANATOMY", 161, 169], ["mental retardation", "DISEASE", 119, 137], ["infections", "DISEASE", 149, 159], ["hearing impairment", "DISEASE", 182, 200], ["mannose", "CHEMICAL", 70, 77], ["lysosomal \u03b1-mannosidase", "GENE_OR_GENE_PRODUCT", 18, 41], ["mannose-rich oligosaccharides", "SIMPLE_CHEMICAL", 70, 99], ["skeletal", "ORGAN", 161, 169], ["lysosomal \u03b1-mannosidase", "PROTEIN", 18, 41], ["lysosomal \u03b1-mannosidase", "TREATMENT", 18, 41], ["mental retardation", "PROBLEM", 119, 137], ["recurrent infections", "PROBLEM", 139, 159], ["skeletal changes", "PROBLEM", 161, 177], ["hearing impairment", "PROBLEM", 182, 200], ["lysosomal \u03b1-mannosidase", "OBSERVATION", 18, 41], ["accumulation", "OBSERVATION_MODIFIER", 54, 66], ["mental retardation", "OBSERVATION", 119, 137], ["recurrent", "OBSERVATION_MODIFIER", 139, 148], ["infections", "OBSERVATION", 149, 159], ["skeletal", "ANATOMY", 161, 169], ["hearing impairment", "OBSERVATION", 182, 200]]], ["85 This feline model was initially important in achieving bone marrow transplantation as corrective strategy for neuronal storage diseases of the CNS.", [["bone marrow", "ANATOMY", 58, 69], ["neuronal", "ANATOMY", 113, 121], ["CNS", "ANATOMY", 146, 149], ["neuronal storage diseases of the CNS", "DISEASE", 113, 149], ["feline", "ORGANISM", 8, 14], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 58, 69], ["neuronal", "CELL", 113, 121], ["CNS", "ANATOMICAL_SYSTEM", 146, 149], ["bone marrow transplantation", "TREATMENT", 58, 85], ["corrective strategy", "TREATMENT", 89, 108], ["neuronal storage diseases of the CNS", "PROBLEM", 113, 149], ["CNS", "ANATOMY", 146, 149]]], ["86, 87 Recently, adeno-associated viral (AAV) constructs of feline \u03b1-mannosidase were used to demonstrate the efficacy of CNS gene therapy.", [["CNS", "ANATOMY", 122, 125], ["adeno-associated viral", "ORGANISM", 17, 39], ["AAV", "ORGANISM", 41, 44], ["feline", "ORGANISM", 60, 66], ["\u03b1-mannosidase", "GENE_OR_GENE_PRODUCT", 67, 80], ["CNS", "ANATOMICAL_SYSTEM", 122, 125], ["adeno-associated viral (AAV) constructs", "DNA", 17, 56], ["feline \u03b1-mannosidase", "PROTEIN", 60, 80], ["feline", "SPECIES", 60, 66], ["AAV", "SPECIES", 41, 44], ["adeno-associated viral (AAV) constructs of feline \u03b1-mannosidase", "TREATMENT", 17, 80], ["CNS gene therapy", "TREATMENT", 122, 138]]], ["Treated cats exhibited widespread improvement of neuropathology, showing the effi cacy of this treatment in a large mammalian brain for CNS correction of human lysosomal enzyme defi ciencies.", [["brain", "ANATOMY", 126, 131], ["CNS", "ANATOMY", 136, 139], ["lysosomal", "ANATOMY", 160, 169], ["neuropathology", "DISEASE", 49, 63], ["cats", "ORGANISM", 8, 12], ["brain", "ORGAN", 126, 131], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["human", "ORGANISM", 154, 159], ["human lysosomal enzyme", "PROTEIN", 154, 176], ["cats", "SPECIES", 8, 12], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["neuropathology", "PROBLEM", 49, 63], ["this treatment", "TREATMENT", 90, 104], ["a large mammalian brain", "PROBLEM", 108, 131], ["CNS correction", "TREATMENT", 136, 150], ["human lysosomal enzyme defi ciencies", "PROBLEM", 154, 190], ["widespread", "OBSERVATION_MODIFIER", 23, 33], ["improvement", "OBSERVATION_MODIFIER", 34, 45], ["brain", "ANATOMY", 126, 131]]], ["88 Lipoprotein lipase (LPL) is a crucial enzyme involved in the regulation of lipoprotein and lipid metabolism ability to thrive.", [["Lipoprotein lipase", "GENE_OR_GENE_PRODUCT", 3, 21], ["LPL", "GENE_OR_GENE_PRODUCT", 23, 26], ["lipoprotein", "SIMPLE_CHEMICAL", 78, 89], ["lipid", "SIMPLE_CHEMICAL", 94, 99], ["Lipoprotein lipase", "PROTEIN", 3, 21], ["LPL", "PROTEIN", 23, 26], ["Lipoprotein lipase", "TEST", 3, 21], ["LPL", "TEST", 23, 26], ["a crucial enzyme", "TEST", 31, 47], ["lipid metabolism ability to thrive", "PROBLEM", 94, 128]]], ["89 Cats with LPL deficiency display a remarkably similar phenotype to humans, including severe pancreatitis, chylomicronemia, and failure to thrive.", [["LPL deficiency", "DISEASE", 13, 27], ["pancreatitis", "DISEASE", 95, 107], ["chylomicronemia", "DISEASE", 109, 124], ["LPL", "GENE_OR_GENE_PRODUCT", 13, 16], ["humans", "ORGANISM", 70, 76], ["LPL", "PROTEIN", 13, 16], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76], ["LPL deficiency", "PROBLEM", 13, 27], ["severe pancreatitis", "PROBLEM", 88, 107], ["chylomicronemia", "PROBLEM", 109, 124], ["failure to thrive", "PROBLEM", 130, 147], ["similar phenotype", "OBSERVATION", 49, 66], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["pancreatitis", "OBSERVATION", 95, 107], ["chylomicronemia", "OBSERVATION", 109, 124], ["failure", "OBSERVATION", 130, 137]]], ["46 There is currently no adequate treatment for this pathology in humans.", [["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["adequate treatment", "TREATMENT", 25, 43], ["this pathology in humans", "PROBLEM", 48, 72], ["no", "UNCERTAINTY", 22, 24], ["adequate", "OBSERVATION_MODIFIER", 25, 33], ["treatment", "OBSERVATION", 34, 43], ["pathology", "OBSERVATION", 53, 62]]], ["Cats could prove to be the most valuable animal model of LPL deficiency, as of numerous animal model systems examined including the mouse, the cat most closely resembles the lipoprotein pattern and lipid transport system of humans.", [["LPL deficiency", "DISEASE", 57, 71], ["Cats", "ORGANISM", 0, 4], ["LPL", "GENE_OR_GENE_PRODUCT", 57, 60], ["mouse", "ORGANISM", 132, 137], ["cat", "ORGANISM", 143, 146], ["lipid", "SIMPLE_CHEMICAL", 198, 203], ["humans", "ORGANISM", 224, 230], ["LPL", "PROTEIN", 57, 60], ["mouse", "SPECIES", 132, 137], ["humans", "SPECIES", 224, 230], ["mouse", "SPECIES", 132, 137], ["humans", "SPECIES", 224, 230], ["LPL deficiency", "PROBLEM", 57, 71], ["LPL deficiency", "OBSERVATION", 57, 71]]], ["Recently, AAV-mediated transfer of a human LPL S447X variant into feline muscle cells demonstrated correction of the hypertriglyceridemia associated with feline pathology; this offers much promise for treatment of human LPL defi ciency.", [["muscle cells", "ANATOMY", 73, 85], ["hypertriglyceridemia", "DISEASE", 117, 137], ["AAV", "ORGANISM", 10, 13], ["human", "ORGANISM", 37, 42], ["LPL", "GENE_OR_GENE_PRODUCT", 43, 46], ["S447X", "GENE_OR_GENE_PRODUCT", 47, 52], ["feline", "ORGANISM", 66, 72], ["muscle cells", "CELL", 73, 85], ["feline", "ORGANISM", 154, 160], ["human", "ORGANISM", 214, 219], ["LPL", "GENE_OR_GENE_PRODUCT", 220, 223], ["human LPL S447X variant", "PROTEIN", 37, 60], ["feline muscle cells", "CELL_TYPE", 66, 85], ["LPL", "PROTEIN", 220, 223], ["human", "SPECIES", 37, 42], ["feline", "SPECIES", 66, 72], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 214, 219], ["a human LPL", "TREATMENT", 35, 46], ["the hypertriglyceridemia", "PROBLEM", 113, 137], ["feline pathology", "PROBLEM", 154, 170], ["human LPL defi ciency", "TREATMENT", 214, 235], ["hypertriglyceridemia", "OBSERVATION", 117, 137], ["LPL", "ANATOMY", 220, 223]]], ["90 A separate class of lysosomal storage disorder characterized in the cat is the gangliosidoses, G M1 and G M2 , which are heritable neurodegenerative diseases.", [["lysosomal", "ANATOMY", 23, 32], ["gangliosidoses", "ANATOMY", 82, 96], ["lysosomal storage disorder", "DISEASE", 23, 49], ["neurodegenerative diseases", "DISEASE", 134, 160], ["cat", "ORGANISM", 71, 74], ["G M1", "GENE_OR_GENE_PRODUCT", 98, 102], ["G M2", "GENE_OR_GENE_PRODUCT", 107, 111], ["lysosomal storage disorder", "PROBLEM", 23, 49], ["heritable neurodegenerative diseases", "PROBLEM", 124, 160], ["lysosomal storage disorder", "OBSERVATION", 23, 49], ["cat", "ANATOMY_MODIFIER", 71, 74], ["gangliosidoses", "ANATOMY", 82, 96], ["M1", "ANATOMY_MODIFIER", 100, 102], ["G M2", "ANATOMY_MODIFIER", 107, 111], ["heritable", "OBSERVATION_MODIFIER", 124, 133], ["neurodegenerative", "OBSERVATION_MODIFIER", 134, 151], ["diseases", "OBSERVATION", 152, 160]]], ["A deficiency of lysosomal \u03b2-galactosidase results in the neuronal accumulation of the G M1 ganglioside, while the degradation of the G M2 ganglioside is initiated by coordinated action of at least three gene products, the \u03b1 and \u03b2 submits of \u03b2-N-acetylhexosaminidase and the G M2 activator (GM2A) protein.", [["lysosomal", "ANATOMY", 16, 25], ["neuronal", "ANATOMY", 57, 65], ["ganglioside", "CHEMICAL", 91, 102], ["ganglioside", "CHEMICAL", 138, 149], ["lysosomal \u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 16, 41], ["neuronal", "CELL", 57, 65], ["G M1 ganglioside", "GENE_OR_GENE_PRODUCT", 86, 102], ["G M2 ganglioside", "GENE_OR_GENE_PRODUCT", 133, 149], ["\u03b1", "GENE_OR_GENE_PRODUCT", 222, 223], ["\u03b2-N-acetylhexosaminidase", "GENE_OR_GENE_PRODUCT", 241, 265], ["G M2 activator", "GENE_OR_GENE_PRODUCT", 274, 288], ["GM2A", "GENE_OR_GENE_PRODUCT", 290, 294], ["lysosomal \u03b2-galactosidase", "PROTEIN", 16, 41], ["G M2 ganglioside", "PROTEIN", 133, 149], ["\u03b1", "PROTEIN", 222, 223], ["\u03b2", "PROTEIN", 228, 229], ["\u03b2-N-acetylhexosaminidase", "PROTEIN", 241, 265], ["G M2 activator (GM2A) protein", "PROTEIN", 274, 303], ["A deficiency of lysosomal \u03b2-galactosidase", "PROBLEM", 0, 41], ["the G M1 ganglioside", "TREATMENT", 82, 102], ["the G M2 ganglioside", "TREATMENT", 129, 149], ["\u03b2-N-acetylhexosaminidase", "TREATMENT", 241, 265], ["the G M2 activator", "TREATMENT", 270, 288], ["deficiency", "OBSERVATION", 2, 12], ["lysosomal \u03b2-galactosidase", "OBSERVATION", 16, 41], ["neuronal accumulation", "OBSERVATION", 57, 78]]], ["42, 91 Mutations in any of these enzymes result in an accumulation of gangliosides G M1 and G M2 in the lysosomes of affected neurons, resulting in progressive deterioration of the CNS.", [["lysosomes", "ANATOMY", 104, 113], ["neurons", "ANATOMY", 126, 133], ["CNS", "ANATOMY", 181, 184], ["deterioration of the CNS", "DISEASE", 160, 184], ["gangliosides G M1", "GENE_OR_GENE_PRODUCT", 70, 87], ["G M2", "GENE_OR_GENE_PRODUCT", 92, 96], ["lysosomes", "CELLULAR_COMPONENT", 104, 113], ["neurons", "CELL", 126, 133], ["CNS", "ANATOMICAL_SYSTEM", 181, 184], ["G M2", "PROTEIN", 92, 96], ["affected neurons", "CELL_TYPE", 117, 133], ["these enzymes", "TEST", 27, 40], ["an accumulation of gangliosides", "PROBLEM", 51, 82], ["affected neurons", "PROBLEM", 117, 133], ["progressive deterioration of the CNS", "PROBLEM", 148, 184], ["gangliosides G M1", "OBSERVATION_MODIFIER", 70, 87], ["affected neurons", "ANATOMY", 117, 133], ["progressive", "OBSERVATION_MODIFIER", 148, 159], ["deterioration", "OBSERVATION", 160, 173], ["CNS", "ANATOMY", 181, 184]]], ["Feline models have been especially important in characterizing the pathobiology and molecular biology of these diseases.", [["Feline", "ORGANISM", 0, 6], ["these diseases", "PROBLEM", 105, 119], ["diseases", "OBSERVATION", 111, 119]]], ["G M2 -gangliosidosis has been characterized in cat models defi cient in the G M2 activator protein and HexB, 40, 42, 92, 93 exhibiting remarkably similar pathology to human Sandhoff's disease.", [["gangliosidosis", "DISEASE", 6, 20], ["Sandhoff's disease", "DISEASE", 173, 191], ["G M2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cat", "ORGANISM", 47, 50], ["G M2 activator", "GENE_OR_GENE_PRODUCT", 76, 90], ["HexB", "GENE_OR_GENE_PRODUCT", 103, 107], ["human", "ORGANISM", 167, 172], ["G M2", "PROTEIN", 0, 4], ["G M2 activator protein", "PROTEIN", 76, 98], ["HexB", "PROTEIN", 103, 107], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["gangliosidosis", "PROBLEM", 6, 20], ["HexB", "TEST", 103, 107], ["human Sandhoff's disease", "PROBLEM", 167, 191], ["M2", "ANATOMY", 2, 4], ["gangliosidosis", "OBSERVATION", 6, 20], ["human Sandhoff", "OBSERVATION", 167, 181]]], ["91 Limited reduction in G M2 neuronal storage has been reported following bone marrow therapy.", [["neuronal", "ANATOMY", 29, 37], ["bone marrow", "ANATOMY", 74, 85], ["G M2", "GENE_OR_GENE_PRODUCT", 24, 28], ["neuronal", "CELL", 29, 37], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 74, 85], ["Limited reduction in G M2 neuronal storage", "PROBLEM", 3, 45], ["bone marrow therapy", "TREATMENT", 74, 93], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["G M2", "OBSERVATION_MODIFIER", 24, 28], ["bone", "ANATOMY", 74, 78], ["marrow therapy", "OBSERVATION", 79, 93]]], ["86 Feline models will be important in the development of therapeutic strategies for these disorders.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEMucolipidosis II (I-cell disease) is caused by deficient activity of the enzyme N-acetylglucosamine-1-phosphotransferase, which leads to a failure to internalize enzymes into lysosomes.", [["cell", "ANATOMY", 172, 176], ["lysosomes", "ANATOMY", 327, 336], ["I-cell disease", "DISEASE", 170, 184], ["N-acetylglucosamine-1-phosphotransferase", "CHEMICAL", 232, 272], ["N-acetylglucosamine", "CHEMICAL", 232, 251], ["Feline", "ORGANISM", 3, 9], ["HEREDITARY DISEASEMucolipidosis II", "CANCER", 134, 168], ["I-cell", "CELL", 170, 176], ["N-acetylglucosamine-1-phosphotransferase", "GENE_OR_GENE_PRODUCT", 232, 272], ["lysosomes", "CELLULAR_COMPONENT", 327, 336], ["enzyme N-acetylglucosamine-1-phosphotransferase", "PROTEIN", 225, 272], ["enzymes", "PROTEIN", 314, 321], ["therapeutic strategies", "TREATMENT", 57, 79], ["these disorders", "PROBLEM", 84, 99], ["HUMAN HEREDITARY DISEASEMucolipidosis II (I-cell disease", "PROBLEM", 128, 184], ["the enzyme N-acetylglucosamine", "TEST", 221, 251], ["a failure to internalize enzymes into lysosomes", "PROBLEM", 289, 336], ["failure", "OBSERVATION", 291, 298]]], ["The cat is the only known animal model for this pathology.", [["cat", "ORGANISM", 4, 7], ["this pathology", "PROBLEM", 43, 57]]], ["94 Congenital diseases of feline muscle and neuromuscular junction have been reviewed by Gashen et al. 95 Some pathologies have been observed in isolated breeds, including hypokalemic myopathy of Burmese cats, 96 glycogen storage disease type IV in Norwegian Forest cats, 44 and myopathy observed in the Devon Rex.", [["muscle", "ANATOMY", 33, 39], ["neuromuscular junction", "ANATOMY", 44, 66], ["Congenital diseases of feline muscle", "DISEASE", 3, 39], ["hypokalemic myopathy", "DISEASE", 172, 192], ["glycogen", "CHEMICAL", 213, 221], ["myopathy", "DISEASE", 279, 287], ["feline", "ORGANISM", 26, 32], ["muscle", "ORGAN", 33, 39], ["neuromuscular junction", "MULTI-TISSUE_STRUCTURE", 44, 66], ["cats", "ORGANISM", 204, 208], ["glycogen", "SIMPLE_CHEMICAL", 213, 221], ["feline", "SPECIES", 26, 32], ["cats", "SPECIES", 204, 208], ["cats", "SPECIES", 266, 270], ["Congenital diseases of feline muscle and neuromuscular junction", "PROBLEM", 3, 66], ["Some pathologies", "PROBLEM", 106, 122], ["hypokalemic myopathy", "PROBLEM", 172, 192], ["Burmese cats", "PROBLEM", 196, 208], ["glycogen storage disease type IV", "PROBLEM", 213, 245], ["Norwegian Forest cats", "TEST", 249, 270], ["myopathy", "PROBLEM", 279, 287], ["Congenital", "OBSERVATION_MODIFIER", 3, 13], ["diseases", "OBSERVATION", 14, 22], ["feline muscle", "ANATOMY", 26, 39], ["neuromuscular junction", "ANATOMY", 44, 66], ["hypokalemic myopathy", "OBSERVATION", 172, 192], ["myopathy", "OBSERVATION", 279, 287], ["Devon Rex", "OBSERVATION", 304, 313]]], ["97 The cat is the only reported animal model for type IV glycogen storage disease.", [["type IV glycogen storage disease", "DISEASE", 49, 81], ["cat", "ORGANISM", 7, 10], ["glycogen", "SIMPLE_CHEMICAL", 57, 65], ["type IV glycogen storage disease", "PROBLEM", 49, 81], ["glycogen storage disease", "OBSERVATION", 57, 81]]], ["Myotonia congenital, 95,98 muscular dystrophy (dystrophin defi cient), 52 and laminin \u03b1 2 defi ciency 52, 99 have also been reported in the cat.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEX-linked muscular dystrophy in humans is characterized by progressive degeneration of skeletal and cardiac muscle.", [["muscular", "ANATOMY", 27, 35], ["muscular", "ANATOMY", 205, 213], ["skeletal", "ANATOMY", 282, 290], ["cardiac muscle", "ANATOMY", 295, 309], ["Myotonia congenital", "DISEASE", 0, 19], ["muscular dystrophy", "DISEASE", 27, 45], ["muscular dystrophy", "DISEASE", 205, 223], ["degeneration of skeletal and cardiac muscle", "DISEASE", 266, 309], ["muscular", "ORGAN", 27, 35], ["dystrophin", "GENE_OR_GENE_PRODUCT", 47, 57], ["laminin \u03b1 2", "GENE_OR_GENE_PRODUCT", 78, 89], ["cat", "ORGANISM", 140, 143], ["muscular", "ORGAN", 205, 213], ["humans", "ORGANISM", 227, 233], ["skeletal", "TISSUE", 282, 290], ["cardiac muscle", "TISSUE", 295, 309], ["cat", "SPECIES", 140, 143], ["humans", "SPECIES", 227, 233], ["humans", "SPECIES", 227, 233], ["Myotonia congenital", "PROBLEM", 0, 19], ["muscular dystrophy", "PROBLEM", 27, 45], ["muscular dystrophy", "PROBLEM", 205, 223], ["progressive degeneration of skeletal and cardiac muscle", "PROBLEM", 254, 309], ["muscular dystrophy", "OBSERVATION", 27, 45], ["muscular dystrophy", "OBSERVATION", 205, 223], ["progressive", "OBSERVATION_MODIFIER", 254, 265], ["degeneration", "OBSERVATION", 266, 278], ["skeletal", "ANATOMY", 282, 290], ["cardiac muscle", "ANATOMY", 295, 309]]], ["Mutations in humans lead to either an absence of or abnormality in the protein product dystrophin.", [["humans", "ORGANISM", 13, 19], ["dystrophin", "GENE_OR_GENE_PRODUCT", 87, 97], ["protein product", "PROTEIN", 71, 86], ["dystrophin", "PROTEIN", 87, 97], ["humans", "SPECIES", 13, 19], ["humans", "SPECIES", 13, 19], ["Mutations in humans", "PROBLEM", 0, 19], ["abnormality in the protein product dystrophin", "PROBLEM", 52, 97]]], ["100, 101 A deletion in the dystrophin muscle promoter characterized in the cat eliminates expression of muscle and Purkinje neuronal dystrophin isoforms.", [["muscle", "ANATOMY", 38, 44], ["muscle", "ANATOMY", 104, 110], ["Purkinje neuronal", "ANATOMY", 115, 132], ["dystrophin", "GENE_OR_GENE_PRODUCT", 27, 37], ["muscle", "ORGAN", 38, 44], ["cat", "ORGANISM", 75, 78], ["muscle", "ORGAN", 104, 110], ["Purkinje neuronal dystrophin", "GENE_OR_GENE_PRODUCT", 115, 143], ["dystrophin muscle promoter", "DNA", 27, 53], ["muscle and Purkinje neuronal dystrophin isoforms", "PROTEIN", 104, 152], ["A deletion in the dystrophin muscle promoter", "PROBLEM", 9, 53], ["muscle and Purkinje neuronal dystrophin isoforms", "PROBLEM", 104, 152], ["deletion", "OBSERVATION", 11, 19], ["dystrophin muscle", "ANATOMY", 27, 44], ["muscle", "ANATOMY", 104, 110], ["Purkinje neuronal", "OBSERVATION", 115, 132], ["dystrophin isoforms", "OBSERVATION", 133, 152]]], ["52 Marked clinical heterogeneity is observed in these models, from severe disability exhibited in human and dog, to minor muscle fi brosis and an actual regenerative process leading to muscle hypertrophy in mouse and cat.", [["muscle", "ANATOMY", 122, 128], ["muscle", "ANATOMY", 185, 191], ["disability", "DISEASE", 74, 84], ["muscle hypertrophy", "DISEASE", 185, 203], ["human", "ORGANISM", 98, 103], ["dog", "ORGANISM_SUBDIVISION", 108, 111], ["muscle", "ORGAN", 122, 128], ["muscle", "ORGAN", 185, 191], ["mouse", "ORGANISM", 207, 212], ["cat", "ORGANISM", 217, 220], ["human", "SPECIES", 98, 103], ["dog", "SPECIES", 108, 111], ["mouse", "SPECIES", 207, 212], ["cat", "SPECIES", 217, 220], ["human", "SPECIES", 98, 103], ["mouse", "SPECIES", 207, 212], ["Marked clinical heterogeneity", "PROBLEM", 3, 32], ["severe disability", "PROBLEM", 67, 84], ["minor muscle fi brosis", "PROBLEM", 116, 138], ["an actual regenerative process", "PROBLEM", 143, 173], ["muscle hypertrophy in mouse and cat", "PROBLEM", 185, 220], ["Marked", "OBSERVATION_MODIFIER", 3, 9], ["heterogeneity", "OBSERVATION", 19, 32], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["disability", "OBSERVATION", 74, 84], ["muscle fi", "ANATOMY", 122, 131], ["brosis", "OBSERVATION", 132, 138], ["regenerative process", "OBSERVATION", 153, 173], ["muscle", "ANATOMY", 185, 191], ["hypertrophy", "OBSERVATION", 192, 203]]], ["[102] [103] [104] These different sequellae could be important in characterizing immediate and secondary consequences of the lack of dystrophin 105 and points out the importance of multiple animal models.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEHypertrophic cardiomyopathy is a clinically heterogeneous myocardial disease contributing to one of the most common causes of sudden cardiac death in young adults.", [["myocardial", "ANATOMY", 314, 324], ["cardiac", "ANATOMY", 389, 396], ["DISEASEHypertrophic cardiomyopathy", "DISEASE", 249, 283], ["myocardial disease", "DISEASE", 314, 332], ["sudden cardiac death", "DISEASE", 382, 402], ["dystrophin 105", "GENE_OR_GENE_PRODUCT", 133, 147], ["myocardial", "MULTI-TISSUE_STRUCTURE", 314, 324], ["cardiac", "ORGAN", 389, 396], ["dystrophin 105", "PROTEIN", 133, 147], ["These different sequellae", "PROBLEM", 18, 43], ["dystrophin 105", "PROBLEM", 133, 147], ["HUMAN HEREDITARY DISEASEHypertrophic cardiomyopathy", "PROBLEM", 232, 283], ["a clinically heterogeneous myocardial disease", "PROBLEM", 287, 332], ["sudden cardiac death", "PROBLEM", 382, 402], ["cardiomyopathy", "OBSERVATION", 269, 283], ["heterogeneous", "OBSERVATION_MODIFIER", 300, 313], ["myocardial", "ANATOMY", 314, 324], ["disease", "OBSERVATION", 325, 332], ["cardiac", "ANATOMY", 389, 396], ["death", "OBSERVATION", 397, 402]]], ["106 The cat represent the first spontaneous large animal model for this familial disease 47 and will prove to be valuable for examining pathophysiological processes and therapeutic interventions.THE POTENTIAL FOR KNOCKOUT CATSThere is a continued demand for alternative mammalian models for studying human diseases.", [["familial disease", "DISEASE", 72, 88], ["cat", "ORGANISM", 8, 11], ["human", "ORGANISM", 300, 305], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 300, 305], ["this familial disease", "PROBLEM", 67, 88], ["therapeutic interventions", "TREATMENT", 169, 194], ["KNOCKOUT CATSThere", "TREATMENT", 213, 231], ["alternative mammalian models", "TREATMENT", 258, 286], ["studying human diseases", "PROBLEM", 291, 314]]], ["Compared to traditional murine models, the cat's more similar physiology, increased size, and longevity have made it ideal for testing the safety and efficacy of some therapeutic modalities in naturally occurring feline disease models.", [["feline disease", "DISEASE", 213, 227], ["murine", "ORGANISM", 24, 30], ["cat", "ORGANISM", 43, 46], ["feline", "ORGANISM", 213, 219], ["murine", "SPECIES", 24, 30], ["testing", "TEST", 127, 134], ["some therapeutic modalities", "TREATMENT", 162, 189], ["feline disease models", "PROBLEM", 213, 234], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["size", "OBSERVATION_MODIFIER", 84, 88]]], ["[107] [108] [109] [110] Additionally, cats have a genetically heterogeneous background, similar to humans.", [["cats", "ORGANISM", 38, 42], ["humans", "ORGANISM", 99, 105], ["cats", "SPECIES", 38, 42], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105], ["a genetically heterogeneous background", "PROBLEM", 48, 86], ["heterogeneous", "OBSERVATION_MODIFIER", 62, 75]]], ["A good example of a human disease in need of a better mammalian model is cystic fibrosis, as mice targeted with the most common human mutation (\u2206F508) in the cystic fibrosis transmembrane receptor (CFTR) fail to spontaneously develop the same opportunistic lung infections that plague human patients with cystic fi brosis.", [["cystic", "ANATOMY", 73, 79], ["lung", "ANATOMY", 257, 261], ["fibrosis", "DISEASE", 80, 88], ["fibrosis", "DISEASE", 165, 173], ["opportunistic lung infections", "DISEASE", 243, 272], ["cystic fi brosis", "DISEASE", 305, 321], ["human", "ORGANISM", 20, 25], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 73, 88], ["mice", "ORGANISM", 93, 97], ["human", "ORGANISM", 128, 133], ["\u2206F508", "ORGANISM", 144, 149], ["cystic fibrosis transmembrane receptor", "GENE_OR_GENE_PRODUCT", 158, 196], ["CFTR", "GENE_OR_GENE_PRODUCT", 198, 202], ["lung", "ORGAN", 257, 261], ["human", "ORGANISM", 285, 290], ["patients", "ORGANISM", 291, 299], ["cystic fibrosis transmembrane receptor", "PROTEIN", 158, 196], ["CFTR", "PROTEIN", 198, 202], ["human", "SPECIES", 20, 25], ["mice", "SPECIES", 93, 97], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 285, 290], ["patients", "SPECIES", 291, 299], ["human", "SPECIES", 20, 25], ["mice", "SPECIES", 93, 97], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 285, 290], ["a human disease", "PROBLEM", 18, 33], ["cystic fibrosis", "PROBLEM", 73, 88], ["the cystic fibrosis transmembrane receptor (CFTR)", "PROBLEM", 154, 203], ["the same opportunistic lung infections", "PROBLEM", 234, 272], ["cystic fi brosis", "PROBLEM", 305, 321], ["good", "OBSERVATION_MODIFIER", 2, 6], ["disease", "OBSERVATION", 26, 33], ["cystic", "OBSERVATION_MODIFIER", 73, 79], ["fibrosis", "OBSERVATION", 80, 88], ["cystic", "OBSERVATION_MODIFIER", 158, 164], ["fibrosis", "OBSERVATION", 165, 173], ["opportunistic", "OBSERVATION_MODIFIER", 243, 256], ["lung", "ANATOMY", 257, 261], ["infections", "OBSERVATION", 262, 272]]], ["111, 112 One group has been working to produce a ferret cystic fibrosis model through gene targeting of somatic cells for nuclear transfer.", [["cystic", "ANATOMY", 56, 62], ["somatic cells", "ANATOMY", 104, 117], ["nuclear", "ANATOMY", 122, 129], ["fibrosis", "DISEASE", 63, 71], ["ferret", "ORGANISM", 49, 55], ["cystic", "ORGAN", 56, 62], ["somatic cells", "CELL", 104, 117], ["nuclear", "CELLULAR_COMPONENT", 122, 129], ["somatic cells", "CELL_TYPE", 104, 117], ["a ferret cystic fibrosis model", "PROBLEM", 47, 77], ["somatic cells", "PROBLEM", 104, 117], ["cystic", "OBSERVATION_MODIFIER", 56, 62], ["fibrosis", "OBSERVATION", 63, 71]]], ["113, 114 While reproductive cloning has a consistently low success rate (1-4%) across mammalian species, 115 targeting genetic loci through homologous recombination in somatic cells is currently the only viable method for producing knockout models in all mammalian species other than the mouse, for which targeted embryonic stem cells are routinely used.", [["somatic cells", "ANATOMY", 168, 181], ["embryonic stem cells", "ANATOMY", 314, 334], ["somatic cells", "CELL", 168, 181], ["mouse", "ORGANISM", 288, 293], ["embryonic stem cells", "CELL", 314, 334], ["somatic cells", "CELL_TYPE", 168, 181], ["targeted embryonic stem cells", "CELL_TYPE", 305, 334], ["mouse", "SPECIES", 288, 293], ["mouse", "SPECIES", 288, 293], ["across mammalian species", "PROBLEM", 79, 103], ["genetic loci through homologous recombination in somatic cells", "PROBLEM", 119, 181], ["knockout models", "PROBLEM", 232, 247], ["all mammalian species", "PROBLEM", 251, 272], ["targeted embryonic stem cells", "TREATMENT", 305, 334], ["somatic cells", "OBSERVATION", 168, 181], ["embryonic stem cells", "OBSERVATION", 314, 334]]], ["Nuclear transfer of targeted fibroblasts has been successfully used to produce viable \u03b1-1,3-galactosyltransferase knockout pig and cow models for xenotransplantation studies.", [["Nuclear", "ANATOMY", 0, 7], ["fibroblasts", "ANATOMY", 29, 40], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["fibroblasts", "CELL", 29, 40], ["\u03b1-1,3-galactosyltransferase", "GENE_OR_GENE_PRODUCT", 86, 113], ["pig", "ORGANISM", 123, 126], ["cow", "ORGANISM", 131, 134], ["targeted fibroblasts", "CELL_TYPE", 20, 40], ["\u03b1-1,3-galactosyltransferase", "PROTEIN", 86, 113], ["pig", "SPECIES", 123, 126], ["pig", "SPECIES", 123, 126], ["cow", "SPECIES", 131, 134], ["targeted fibroblasts", "PROBLEM", 20, 40], ["xenotransplantation studies", "TEST", 146, 173]]], ["116, 117 With the successful reproductive cloning of cats by several groups, 118-120 the development of gene-targeted cat models through nuclear transfer is now feasible.", [["nuclear", "ANATOMY", 137, 144], ["cats", "ORGANISM", 53, 57], ["cat", "ORGANISM", 118, 121], ["nuclear", "CELLULAR_COMPONENT", 137, 144]]], ["121 The imminent release of the annotated feline genome project, 17 integration of recombination and radiation hybrid maps, [5] [6] [7] [8] [9] [10] 122 and availability of multiple PAC, BAC, 123 flow-sorted autosome, and Y-chromosome libraries 124, 125 (J. Pecon-Slattery et al., unpublished observations) at the Laboratory of Genomic Diversity will facilitate efforts by researchers to develop new cat models of specific human genetic diseases.COAT COLOR GENES IN THE DOMESTIC CATThe coat color loci influence the development, maturation, and migration of melanocytes as well as the synthesis of melanin and the formation, transport, and transfer of melanosomes.", [["melanocytes", "ANATOMY", 558, 569], ["melanosomes", "ANATOMY", 652, 663], ["[5] [6] [7] [8] [9] [10] 122", "CHEMICAL", 124, 152], ["PAC", "CHEMICAL", 182, 185], ["genetic diseases", "DISEASE", 429, 445], ["feline", "ORGANISM", 42, 48], ["[5] [6] [7] [8] [9] [10] 122", "SIMPLE_CHEMICAL", 124, 152], ["autosome", "CELLULAR_COMPONENT", 208, 216], ["cat", "ORGANISM", 400, 403], ["human", "ORGANISM", 423, 428], ["melanocytes", "CELL", 558, 569], ["melanin", "SIMPLE_CHEMICAL", 598, 605], ["melanosomes", "CELLULAR_COMPONENT", 652, 663], ["multiple PAC, BAC, 123 flow-sorted autosome", "DNA", 173, 216], ["CAT", "PROTEIN", 479, 482], ["coat color loci", "DNA", 486, 501], ["melanocytes", "CELL_TYPE", 558, 569], ["human", "SPECIES", 423, 428], ["human", "SPECIES", 423, 428], ["the annotated feline genome project", "TREATMENT", 28, 63], ["radiation hybrid maps", "TREATMENT", 101, 122], ["multiple PAC", "TEST", 173, 185], ["BAC", "TEST", 187, 190], ["flow", "TEST", 196, 200], ["Y-chromosome libraries", "TEST", 222, 244], ["specific human genetic diseases", "PROBLEM", 414, 445], ["The coat color loci", "PROBLEM", 482, 501], ["melanocytes", "PROBLEM", 558, 569], ["the synthesis of melanin", "PROBLEM", 581, 605], ["COLOR GENES", "OBSERVATION", 451, 462], ["coat", "OBSERVATION_MODIFIER", 486, 490], ["color loci", "OBSERVATION", 491, 501], ["maturation", "OBSERVATION_MODIFIER", 529, 539]]], ["Genes involved in these processes often have pleiotropic effects, which impact other important biochemical pathways.", [["pleiotropic effects", "PROBLEM", 45, 64]]], ["Coat color loci in the mouse have been known to be part of diverse cellular, developmental, and physiological processes and in some cases to be implicated in pathologies such as anemia, sterility, and neurological disorders.", [["cellular", "ANATOMY", 67, 75], ["neurological", "ANATOMY", 201, 213], ["anemia", "DISEASE", 178, 184], ["sterility", "DISEASE", 186, 195], ["neurological disorders", "DISEASE", 201, 223], ["mouse", "ORGANISM", 23, 28], ["cellular", "CELL", 67, 75], ["Coat color loci", "DNA", 0, 15], ["mouse", "SPECIES", 23, 28], ["mouse", "SPECIES", 23, 28], ["Coat color loci", "PROBLEM", 0, 15], ["diverse cellular, developmental, and physiological processes", "PROBLEM", 59, 119], ["pathologies", "PROBLEM", 158, 169], ["anemia", "PROBLEM", 178, 184], ["sterility", "PROBLEM", 186, 195], ["neurological disorders", "PROBLEM", 201, 223], ["color loci", "OBSERVATION", 5, 15], ["known to be", "UNCERTAINTY", 39, 50], ["diverse", "OBSERVATION_MODIFIER", 59, 66], ["cellular", "OBSERVATION", 67, 75], ["anemia", "OBSERVATION", 178, 184]]], ["[126] [127] [128] The cat is an excellent model system with which to study coat color phenotypes.", [["cat", "ORGANISM", 22, 25]]], ["At least nine different coat color loci have been identified in the cat, 129 and several are now characterized on a molecular genetic level including, a (nonagouti) responsible for melanism, 18 b (Brown), which changes black pigmentation to brown or variants of brown, 32 c (color), causing the darker pigmentation at extremities (i.e., ears, tail), observed in Siamese and Burmese cats 32,37 and albinism, 36 and d (dilute), which causes dilution of expected color (i.e., black pigmentation appears gray).", [["extremities", "ANATOMY", 318, 329], ["ears", "ANATOMY", 337, 341], ["tail", "ANATOMY", 343, 347], ["melanism", "DISEASE", 181, 189], ["albinism", "DISEASE", 397, 405], ["cat", "ORGANISM", 68, 71], ["extremities", "ORGANISM_SUBDIVISION", 318, 329], ["ears", "ORGAN", 337, 341], ["tail", "ORGANISM_SUBDIVISION", 343, 347], ["cats", "ORGANISM", 382, 386], ["coat color loci", "DNA", 24, 39], ["cats", "SPECIES", 382, 386], ["Burmese cats 32,37", "SPECIES", 374, 392], ["nine different coat color loci", "PROBLEM", 9, 39], ["melanism", "PROBLEM", 181, 189], ["black pigmentation to brown or variants of brown, 32 c (color)", "PROBLEM", 219, 281], ["the darker pigmentation at extremities", "PROBLEM", 291, 329], ["Burmese cats", "TEST", 374, 386], ["albinism", "TEST", 397, 405], ["least", "OBSERVATION_MODIFIER", 3, 8], ["nine", "OBSERVATION_MODIFIER", 9, 13], ["different", "OBSERVATION_MODIFIER", 14, 23], ["coat", "OBSERVATION_MODIFIER", 24, 28], ["color loci", "OBSERVATION", 29, 39], ["black", "OBSERVATION_MODIFIER", 219, 224], ["pigmentation", "OBSERVATION_MODIFIER", 225, 237], ["brown", "OBSERVATION_MODIFIER", 241, 246], ["brown", "OBSERVATION_MODIFIER", 262, 267], ["32 c", "OBSERVATION_MODIFIER", 269, 273], ["darker pigmentation", "OBSERVATION", 295, 314], ["extremities", "ANATOMY", 318, 329], ["ears", "ANATOMY", 337, 341], ["tail", "ANATOMY", 343, 347]]], ["35 The cat is also unique in mammalian species in exhibiting a variation in coat pattern, demonstrating agouti (A) (nonpatterned coat) and variants of the T (tabby) locus, which affect striping and spotting patterns.VIRAL PATHOGENS OF THE DOMESTIC CATThe cat has provided several useful models for infectious disease.", [["infectious disease", "DISEASE", 298, 316], ["cat", "ORGANISM", 7, 10], ["agouti (A)", "GENE_OR_GENE_PRODUCT", 104, 114], ["T (tabby)", "GENE_OR_GENE_PRODUCT", 155, 164], ["cat", "ORGANISM", 255, 258], ["T (tabby) locus", "DNA", 155, 170], ["a variation in coat pattern", "PROBLEM", 61, 88], ["agouti (A) (nonpatterned coat)", "PROBLEM", 104, 134], ["infectious disease", "PROBLEM", 298, 316], ["mammalian species", "OBSERVATION", 29, 46], ["variation", "OBSERVATION_MODIFIER", 63, 72], ["coat pattern", "OBSERVATION", 76, 88], ["infectious", "OBSERVATION", 298, 308]]], ["These include feline leukemia and feline sarcoma virus, feline coronavirus, and Type C retroviruses that interact with cellular oncogenes to induce leukemia, lymphoma, and sarcoma.", [["feline leukemia", "ANATOMY", 14, 29], ["cellular", "ANATOMY", 119, 127], ["leukemia", "ANATOMY", 148, 156], ["lymphoma", "ANATOMY", 158, 166], ["sarcoma", "ANATOMY", 172, 179], ["feline leukemia", "DISEASE", 14, 29], ["feline sarcoma", "DISEASE", 34, 48], ["feline coronavirus", "DISEASE", 56, 74], ["leukemia, lymphoma", "DISEASE", 148, 166], ["sarcoma", "DISEASE", 172, 179], ["feline", "ORGANISM", 14, 20], ["leukemia", "CANCER", 21, 29], ["feline sarcoma virus", "ORGANISM", 34, 54], ["feline coronavirus", "ORGANISM", 56, 74], ["Type C retroviruses", "ORGANISM", 80, 99], ["cellular", "CELL", 119, 127], ["leukemia", "CANCER", 148, 156], ["lymphoma", "CANCER", 158, 166], ["sarcoma", "CANCER", 172, 179], ["cellular oncogenes", "DNA", 119, 137], ["feline", "SPECIES", 14, 20], ["feline sarcoma virus", "SPECIES", 34, 54], ["feline coronavirus", "SPECIES", 56, 74], ["feline sarcoma virus", "SPECIES", 34, 54], ["feline coronavirus", "SPECIES", 56, 74], ["Type C retroviruses", "SPECIES", 80, 99], ["feline leukemia", "PROBLEM", 14, 29], ["feline sarcoma virus", "PROBLEM", 34, 54], ["feline coronavirus", "PROBLEM", 56, 74], ["Type C retroviruses", "PROBLEM", 80, 99], ["cellular oncogenes", "TREATMENT", 119, 137], ["leukemia", "PROBLEM", 148, 156], ["lymphoma", "PROBLEM", 158, 166], ["sarcoma", "PROBLEM", 172, 179], ["feline leukemia", "OBSERVATION", 14, 29], ["feline sarcoma virus", "OBSERVATION", 34, 54], ["feline coronavirus", "OBSERVATION", 56, 74], ["retroviruses", "OBSERVATION", 87, 99], ["leukemia", "OBSERVATION", 148, 156], ["lymphoma", "OBSERVATION", 158, 166], ["sarcoma", "OBSERVATION", 172, 179]]], ["[130] [131] [132] Historically, many of the human oncogenes that defi ne signal transduction pathways were originally discovered in the context of feline leukemia virus interaction in cat models.", [["leukemia", "ANATOMY", 154, 162], ["feline leukemia", "DISEASE", 147, 162], ["human", "ORGANISM", 44, 49], ["feline leukemia virus", "ORGANISM", 147, 168], ["cat", "ORGANISM", 184, 187], ["human oncogenes", "DNA", 44, 59], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["feline leukemia virus", "SPECIES", 147, 168], ["feline leukemia virus interaction in cat models", "PROBLEM", 147, 194], ["feline leukemia virus", "OBSERVATION", 147, 168]]], ["The cat provides the only naturally occurring model for human AIDS pathogenesis, in its endemic fatal transmissible feline immunodefi ciency virus (FIV).", [["AIDS", "DISEASE", 62, 66], ["feline immunodefi ciency", "DISEASE", 116, 140], ["cat", "ORGANISM", 4, 7], ["human", "ORGANISM", 56, 61], ["feline", "ORGANISM", 116, 122], ["immunodefi ciency virus", "ORGANISM", 123, 146], ["FIV", "ORGANISM", 148, 151], ["human", "SPECIES", 56, 61], ["feline immunodefi ciency virus", "SPECIES", 116, 146], ["human", "SPECIES", 56, 61], ["feline immunodefi ciency virus", "SPECIES", 116, 146], ["FIV", "SPECIES", 148, 151], ["human AIDS pathogenesis", "PROBLEM", 56, 79]]], ["133, 134 Similar to its close phylogenetic relative HIV, FIV induces CD4-T lymphocyte depletion in affected cats, an immune system collapse, and susceptibility to adventitious microbial agents as a prelude to wasting disease and death.", [["CD4-T lymphocyte", "ANATOMY", 69, 85], ["immune system", "ANATOMY", 117, 130], ["wasting disease", "DISEASE", 209, 224], ["death", "DISEASE", 229, 234], ["HIV", "ORGANISM", 52, 55], ["FIV", "ORGANISM", 57, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["T lymphocyte", "CELL", 73, 85], ["cats", "ORGANISM", 108, 112], ["CD4", "PROTEIN", 69, 72], ["cats", "SPECIES", 108, 112], ["HIV", "SPECIES", 52, 55], ["FIV", "SPECIES", 57, 60], ["CD4", "TEST", 69, 72], ["T lymphocyte depletion", "PROBLEM", 73, 95], ["affected cats", "PROBLEM", 99, 112], ["an immune system collapse", "PROBLEM", 114, 139], ["adventitious microbial agents", "TREATMENT", 163, 192], ["wasting disease", "PROBLEM", 209, 224], ["death", "PROBLEM", 229, 234], ["lymphocyte depletion", "OBSERVATION", 75, 95], ["immune system", "OBSERVATION", 117, 130], ["collapse", "OBSERVATION", 131, 139]]], ["133, 135 Interestingly, over 10 wildcat species (including lions, leopards, cheetahs, ocelots, pumas and other big cats) are endemic with their own species-specific strain of FIV [136] [137] [138] [139] [140] [141] ; however, unlike strains in domestic cats, the wildcat FIV strains do not appear to cause acute immunodeficiency in the wildcat species, perhaps a consequence of historic natural selection of host genetic resistance to the fatal virus.", [["ocelots", "ANATOMY", 86, 93], ["pumas", "ANATOMY", 95, 100], ["FIV [136] [137] [138] [139] [140] [141", "CHEMICAL", 175, 213], ["immunodeficiency", "DISEASE", 312, 328], ["cats", "ORGANISM", 115, 119], ["FIV", "ORGANISM", 175, 178], ["domestic cats", "ORGANISM", 244, 257], ["wildcat FIV", "ORGANISM", 263, 274], ["cats", "SPECIES", 115, 119], ["cats", "SPECIES", 253, 257], ["FIV", "SPECIES", 175, 178], ["ocelots", "TREATMENT", 86, 93], ["pumas", "TREATMENT", 95, 100], ["strains in domestic cats", "PROBLEM", 233, 257], ["the wildcat FIV strains", "PROBLEM", 259, 282], ["acute immunodeficiency in the wildcat species", "PROBLEM", 306, 351], ["the fatal virus", "PROBLEM", 435, 450], ["acute", "OBSERVATION_MODIFIER", 306, 311], ["immunodeficiency", "OBSERVATION", 312, 328], ["host genetic resistance", "OBSERVATION", 408, 431], ["fatal virus", "OBSERVATION", 439, 450]]], ["139, 142 Lion and puma-specific FIV strains have recently been demonstrated to utilize novel, more promiscuous mechanisms for cell entry than FIV, suggesting a divergent tropism and biological properties of these viruses.", [["cell", "ANATOMY", 126, 130], ["puma-specific FIV", "ORGANISM", 18, 35], ["cell", "CELL", 126, 130], ["FIV", "ORGANISM", 142, 145], ["FIV", "SPECIES", 142, 145], ["Lion", "TEST", 9, 13], ["puma-specific FIV strains", "TEST", 18, 43], ["cell entry than FIV", "PROBLEM", 126, 145], ["a divergent tropism", "PROBLEM", 158, 177], ["these viruses", "PROBLEM", 207, 220], ["divergent tropism", "OBSERVATION", 160, 177], ["viruses", "OBSERVATION", 213, 220]]], ["143 The World Health Organization reported a new human respiratory illness outbreak (severe acute respiratory syndrome, SARS) that emerged in Guangdong Province, China in 2003.", [["respiratory illness", "DISEASE", 55, 74], ["acute respiratory syndrome", "DISEASE", 92, 118], ["SARS", "DISEASE", 120, 124], ["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["a new human respiratory illness outbreak", "PROBLEM", 43, 83], ["severe acute respiratory syndrome", "PROBLEM", 85, 118], ["SARS", "PROBLEM", 120, 124], ["new", "OBSERVATION_MODIFIER", 45, 48], ["respiratory illness", "OBSERVATION", 55, 74], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118]]], ["144, 145 Sequence analysis demonstrated that the infectious agent was a previously unrecognized coronavirus.", [["coronavirus", "DISEASE", 96, 107], ["coronavirus", "ORGANISM", 96, 107], ["Sequence analysis", "TEST", 9, 26], ["the infectious agent", "PROBLEM", 45, 65], ["a previously unrecognized coronavirus", "PROBLEM", 70, 107], ["infectious", "OBSERVATION", 49, 59], ["coronavirus", "OBSERVATION", 96, 107]]], ["146, 147 An animal model demonstrating clinical symptoms and pathology of SARS-infected patients has not been reported.", [["SARS-infected", "DISEASE", 74, 87], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["clinical symptoms", "PROBLEM", 39, 56], ["SARS", "PROBLEM", 74, 78]]], ["148 Of interest, the recent report of a highly virulent feline coronavirus epidemic in captive African cheetahs, a disease model for human SARS, illustrates the critical role of ancestral population genetic variation.", [["feline coronavirus", "DISEASE", 56, 74], ["SARS", "DISEASE", 139, 143], ["feline coronavirus", "ORGANISM", 56, 74], ["human", "ORGANISM", 133, 138], ["feline coronavirus", "SPECIES", 56, 74], ["human", "SPECIES", 133, 138], ["feline coronavirus", "SPECIES", 56, 74], ["African cheetahs", "SPECIES", 95, 111], ["human", "SPECIES", 133, 138], ["a highly virulent feline coronavirus", "PROBLEM", 38, 74], ["human SARS", "PROBLEM", 133, 143]]], ["132 In addition, cats injected with the SARS virus developed clinical symptoms, an important insight in implicating the virus in the SARS epidemic.", [["SARS", "DISEASE", 40, 44], ["SARS", "DISEASE", 133, 137], ["cats", "ORGANISM", 17, 21], ["cats", "SPECIES", 17, 21], ["SARS virus", "SPECIES", 40, 50], ["cats", "TREATMENT", 17, 21], ["the SARS virus", "PROBLEM", 36, 50], ["clinical symptoms", "PROBLEM", 61, 78], ["the virus", "PROBLEM", 116, 125]]], ["[149] [150] [151] [152] The feline panleukopenia (feline distemper) virus has revealed a natural history parable in its abrupt transformation of the cat virus to an epidemic, fatal canine parvovirus, that emerged in the world's puppy population in 1978.", [["feline panleukopenia", "DISEASE", 28, 48], ["feline distemper) virus", "DISEASE", 50, 73], ["canine parvovirus", "DISEASE", 181, 198], ["feline", "ORGANISM", 28, 34], ["panleukopenia", "ORGANISM", 35, 48], ["feline distemper", "ORGANISM", 50, 66], ["cat virus", "ORGANISM", 149, 158], ["canine parvovirus", "ORGANISM", 181, 198], ["feline distemper", "SPECIES", 50, 66], ["cat", "SPECIES", 149, 152], ["canine parvovirus", "SPECIES", 181, 198], ["feline panleukopenia (feline distemper) virus", "SPECIES", 28, 73], ["cat virus", "SPECIES", 149, 158], ["canine parvovirus", "SPECIES", 181, 198], ["The feline panleukopenia", "TEST", 24, 48], ["feline distemper) virus", "PROBLEM", 50, 73], ["the cat virus", "PROBLEM", 145, 158], ["fatal canine parvovirus", "PROBLEM", 175, 198], ["abrupt", "OBSERVATION_MODIFIER", 120, 126]]], ["153 In contrast, the canine distemper virus, which is normally restricted to canid species, precipitously adapted to and decimated East African lions in 1994, killing one-third of the lions in the Serengeti ecosystem within a 9-month outbreak.", [["canine distemper virus", "ORGANISM", 21, 43], ["canine distemper virus", "SPECIES", 21, 43], ["canine distemper virus", "SPECIES", 21, 43], ["the canine distemper virus", "PROBLEM", 17, 43], ["distemper virus", "OBSERVATION", 28, 43], ["lions", "OBSERVATION", 184, 189]]], ["154 A clear involvement of host defense mecha- nisms in these and other infectious disease episodes renders the cats and their pathogens an excellent candidate species for characterizing the interaction of microbial adaptation and host disease gene defenses.", [["infectious disease", "DISEASE", 72, 90], ["mecha- nisms", "GENE_OR_GENE_PRODUCT", 40, 52], ["cats", "ORGANISM", 112, 116], ["cats", "SPECIES", 112, 116], ["host defense mecha", "PROBLEM", 27, 45], ["nisms", "PROBLEM", 47, 52], ["other infectious disease episodes", "PROBLEM", 66, 99], ["host disease gene defenses", "PROBLEM", 231, 257], ["clear", "OBSERVATION", 6, 11], ["host", "OBSERVATION_MODIFIER", 27, 31], ["defense", "OBSERVATION_MODIFIER", 32, 39], ["mecha", "OBSERVATION_MODIFIER", 40, 45], ["infectious", "OBSERVATION_MODIFIER", 72, 82]]], ["Given the critical importance of infectious disease in scores of chronic and acute human disease, there are powerful research opportunities in the cat family.", [["infectious disease", "DISEASE", 33, 51], ["acute human disease", "DISEASE", 77, 96], ["human", "ORGANISM", 83, 88], ["cat", "ORGANISM", 147, 150], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["chronic and acute human disease", "PROBLEM", 65, 96], ["infectious", "OBSERVATION", 33, 43], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["human disease", "OBSERVATION", 83, 96]]], ["142, 155 Finally, recent concern over the emergence of avian flu H5N1 has shown a strong susceptibility of cats, both domestic and large cats, again raising possibilities for pathogenesis and therapy development.", [["flu H5N1", "DISEASE", 61, 69], ["avian flu H5N1", "ORGANISM", 55, 69], ["cats", "ORGANISM", 107, 111], ["cats", "ORGANISM", 137, 141], ["avian flu H5N1", "SPECIES", 55, 69], ["cats", "SPECIES", 107, 111], ["cats", "SPECIES", 137, 141], ["avian flu H5N1", "SPECIES", 55, 69], ["avian flu H5N1", "PROBLEM", 55, 69], ["pathogenesis", "PROBLEM", 175, 187], ["therapy development", "TREATMENT", 192, 211], ["large", "OBSERVATION_MODIFIER", 131, 136], ["cats", "OBSERVATION", 137, 141], ["raising possibilities for", "UNCERTAINTY", 149, 174]]], ["156, 157 With the development of genomic resources in the cat (Table 25 -2) and the application of complementary comparative tools developed in other species, the domestic cat is emerging as a promising resource of phenotypically defined genetic variation of biomedical significance.", [["cat", "ORGANISM", 58, 61], ["cat", "ORGANISM", 172, 175]]], ["Exploration of similar resources in other species, particularly the dog and mouse, has provided important insight into otherwise unexplained biomedical disorders.", [["dog", "ORGANISM", 68, 71], ["mouse", "ORGANISM", 76, 81], ["dog", "SPECIES", 68, 71], ["mouse", "SPECIES", 76, 81], ["mouse", "SPECIES", 76, 81], ["Exploration", "TREATMENT", 0, 11], ["otherwise unexplained biomedical disorders", "PROBLEM", 119, 161]]]], "PMC7455096": [["BackgroundCopper, a largely available trace element in the human body, is a cofactor in many enzymatic reactions that are vital for the functioning of the hematologic, vascular, skeletal, antioxidant, and neurologic systems [1, 2].", [["body", "ANATOMY", 65, 69], ["hematologic", "ANATOMY", 155, 166], ["vascular", "ANATOMY", 168, 176], ["skeletal", "ANATOMY", 178, 186], ["neurologic", "ANATOMY", 205, 215], ["BackgroundCopper", "CHEMICAL", 0, 16], ["BackgroundCopper", "SIMPLE_CHEMICAL", 0, 16], ["human", "ORGANISM", 59, 64], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["hematologic", "CANCER", 155, 166], ["vascular", "MULTI-TISSUE_STRUCTURE", 168, 176], ["skeletal", "TISSUE", 178, 186], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["a largely available trace element in the human body", "PROBLEM", 18, 69], ["a cofactor in many enzymatic reactions", "PROBLEM", 74, 112], ["trace element", "OBSERVATION", 38, 51], ["human body", "ANATOMY", 59, 69], ["enzymatic reactions", "OBSERVATION", 93, 112], ["vascular", "ANATOMY", 168, 176], ["skeletal", "ANATOMY", 178, 186]]], ["It is absorbed mainly in the stomach and proximal duodenum [3].", [["stomach", "ANATOMY", 29, 36], ["proximal duodenum", "ANATOMY", 41, 58], ["stomach", "ORGAN", 29, 36], ["duodenum", "ORGAN", 50, 58], ["stomach", "ANATOMY", 29, 36], ["proximal", "ANATOMY_MODIFIER", 41, 49], ["duodenum", "ANATOMY", 50, 58]]], ["Copper deficiency is extremely unusual in healthy individuals [4].BackgroundBariatric surgical procedures cause anatomical changes of the gastrointestinal tract that could lead to hypocupremia and/or predispose patients to a range of nutritional deficiencies that can lead to anemia, osteoporosis, and protein malnutrition [5].", [["gastrointestinal tract", "ANATOMY", 138, 160], ["Copper", "CHEMICAL", 0, 6], ["anatomical changes of the gastrointestinal tract", "DISEASE", 112, 160], ["hypocupremia", "DISEASE", 180, 192], ["nutritional deficiencies", "DISEASE", 234, 258], ["anemia", "DISEASE", 276, 282], ["osteoporosis", "DISEASE", 284, 296], ["malnutrition", "DISEASE", 310, 322], ["Copper", "CHEMICAL", 0, 6], ["Copper", "SIMPLE_CHEMICAL", 0, 6], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 138, 160], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["Copper deficiency", "PROBLEM", 0, 17], ["BackgroundBariatric surgical procedures", "TREATMENT", 66, 105], ["anatomical changes of the gastrointestinal tract", "PROBLEM", 112, 160], ["hypocupremia", "PROBLEM", 180, 192], ["nutritional deficiencies", "PROBLEM", 234, 258], ["anemia", "PROBLEM", 276, 282], ["osteoporosis", "PROBLEM", 284, 296], ["protein malnutrition", "PROBLEM", 302, 322], ["deficiency", "OBSERVATION", 7, 17], ["gastrointestinal tract", "ANATOMY", 138, 160], ["osteoporosis", "OBSERVATION", 284, 296]]], ["Thus, without appropriate supplementation of a range of micro- and macronutrients post-bariatric procedures, patients might develop such deficiencies.BackgroundSingle anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) is a relatively recent bariatric surgical procedure in which sleeve gastrectomy is followed by end-to-side duodeno-ileal diversion [6].", [["ileal", "ANATOMY", 187, 192], ["ileal", "ANATOMY", 348, 353], ["SADI-S", "CHEMICAL", 225, 231], ["patients", "ORGANISM", 109, 117], ["ileal", "MULTI-TISSUE_STRUCTURE", 187, 192], ["ileal", "MULTI-TISSUE_STRUCTURE", 348, 353], ["patients", "SPECIES", 109, 117], ["macronutrients post-bariatric procedures", "TREATMENT", 67, 107], ["such deficiencies", "PROBLEM", 132, 149], ["BackgroundSingle anastomosis duodeno", "TREATMENT", 150, 186], ["ileal bypass", "TREATMENT", 187, 199], ["sleeve gastrectomy", "TREATMENT", 205, 223], ["a relatively recent bariatric surgical procedure", "TREATMENT", 236, 284], ["sleeve gastrectomy", "TREATMENT", 294, 312], ["end-to-side duodeno-ileal diversion", "TREATMENT", 328, 363], ["anastomosis", "OBSERVATION", 167, 178], ["ileal", "ANATOMY", 187, 192], ["bypass", "OBSERVATION", 193, 199], ["sleeve gastrectomy", "OBSERVATION", 205, 223], ["bariatric surgical", "OBSERVATION", 256, 274], ["sleeve gastrectomy", "OBSERVATION", 294, 312], ["ileal", "ANATOMY", 348, 353], ["diversion", "OBSERVATION", 354, 363]]], ["The elimination of one anastomosis results in decreased surgery time and possibly less surgery-related complications [7].", [["one anastomosis", "TREATMENT", 19, 34], ["decreased surgery", "TREATMENT", 46, 63], ["less surgery", "TREATMENT", 82, 94], ["complications", "PROBLEM", 103, 116], ["one", "OBSERVATION_MODIFIER", 19, 22], ["anastomosis", "OBSERVATION", 23, 34], ["decreased", "OBSERVATION_MODIFIER", 46, 55], ["surgery", "OBSERVATION", 56, 63]]], ["Whilst SADI-S has significant weight loss and positive metabolic outcomes, malabsorptive effects might occur, e.g., albumin, zinc, folate, vitamins A, D, and E, zinc, and copper [6, 7].", [["SADI-S", "CHEMICAL", 7, 13], ["weight loss", "DISEASE", 30, 41], ["zinc", "CHEMICAL", 125, 129], ["folate", "CHEMICAL", 131, 137], ["vitamins A, D, and E, zinc", "CHEMICAL", 139, 165], ["copper", "CHEMICAL", 171, 177], ["zinc", "CHEMICAL", 125, 129], ["folate", "CHEMICAL", 131, 137], ["vitamins A, D, and E", "CHEMICAL", 139, 159], ["zinc", "CHEMICAL", 161, 165], ["copper", "CHEMICAL", 171, 177], ["SADI-S", "GENE_OR_GENE_PRODUCT", 7, 13], ["albumin", "GENE_OR_GENE_PRODUCT", 116, 123], ["zinc", "SIMPLE_CHEMICAL", 125, 129], ["folate", "SIMPLE_CHEMICAL", 131, 137], ["vitamins A", "SIMPLE_CHEMICAL", 139, 149], ["D", "SIMPLE_CHEMICAL", 151, 152], ["E", "SIMPLE_CHEMICAL", 158, 159], ["zinc", "SIMPLE_CHEMICAL", 161, 165], ["copper [6, 7]", "SIMPLE_CHEMICAL", 171, 184], ["SADI", "TEST", 7, 11], ["significant weight loss", "PROBLEM", 18, 41], ["positive metabolic outcomes", "PROBLEM", 46, 73], ["malabsorptive effects", "PROBLEM", 75, 96], ["albumin", "TEST", 116, 123], ["zinc", "TREATMENT", 125, 129], ["folate", "TREATMENT", 131, 137], ["vitamins", "TREATMENT", 139, 147], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["weight loss", "OBSERVATION", 30, 41], ["positive", "OBSERVATION_MODIFIER", 46, 54], ["metabolic outcomes", "OBSERVATION", 55, 73]]], ["The diagnosis of hypocupremia could be challenging due to its rarity and its similar clinical presentation as vitamin B12 deficiency [8].BackgroundPublished reports of the malnutrition outcomes after SADI-S are extremely rare [9].", [["hypocupremia", "DISEASE", 17, 29], ["vitamin B12", "CHEMICAL", 110, 121], ["malnutrition", "DISEASE", 172, 184], ["vitamin B12", "CHEMICAL", 110, 121], ["vitamin B12", "SIMPLE_CHEMICAL", 110, 121], ["hypocupremia", "PROBLEM", 17, 29], ["vitamin B12 deficiency", "PROBLEM", 110, 132], ["the malnutrition outcomes", "PROBLEM", 168, 193], ["SADI", "TEST", 200, 204]]], ["An exception is a study of 97 SADI-S patients, where 12% developed copper deficiency at 1 year and 11% at 3 years post-op [10].", [["copper", "CHEMICAL", 67, 73], ["copper", "CHEMICAL", 67, 73], ["patients", "ORGANISM", 37, 45], ["copper", "SIMPLE_CHEMICAL", 67, 73], ["patients", "SPECIES", 37, 45], ["a study", "TEST", 16, 23], ["copper deficiency", "PROBLEM", 67, 84]]], ["We report a case of severe copper deficiency after revisional SADI-S leading to severe pancytopenia with cellular atypia.", [["cellular", "ANATOMY", 105, 113], ["copper deficiency", "DISEASE", 27, 44], ["SADI-S", "CHEMICAL", 62, 68], ["pancytopenia", "DISEASE", 87, 99], ["copper", "CHEMICAL", 27, 33], ["copper", "SIMPLE_CHEMICAL", 27, 33], ["cellular", "CELL", 105, 113], ["severe copper deficiency", "PROBLEM", 20, 44], ["revisional SADI-S", "PROBLEM", 51, 68], ["severe pancytopenia", "PROBLEM", 80, 99], ["cellular atypia", "PROBLEM", 105, 120], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["pancytopenia", "OBSERVATION", 87, 99], ["cellular atypia", "OBSERVATION", 105, 120]]], ["To the best of our knowledge, this could be the first case report of severe copper deficiency leading to profound hematological abnormalities post-SADI-S.Case ReportFigure 1 depicts the sequence of events over 7 years.Case ReportA 37-year-old Qatari female presented to our outpatient bariatric clinic (Hamad General Hospital, largest tertiary care institution in Qatar) with a 4-month complaint of generalized fatigability and progressive bilateral lower limbs swelling with occasional numbness of the distal aspects of the lower limbs but no weakness.", [["hematological", "ANATOMY", 114, 127], ["lower limbs", "ANATOMY", 450, 461], ["lower limbs", "ANATOMY", 525, 536], ["copper deficiency", "DISEASE", 76, 93], ["hematological abnormalities", "DISEASE", 114, 141], ["fatigability", "DISEASE", 411, 423], ["swelling", "DISEASE", 462, 470], ["numbness", "DISEASE", 487, 495], ["copper", "CHEMICAL", 76, 82], ["copper", "SIMPLE_CHEMICAL", 76, 82], ["Qatari", "ORGANISM", 243, 249], ["female", "ORGANISM", 250, 256], ["lower limbs", "ORGANISM_SUBDIVISION", 450, 461], ["lower limbs", "ORGANISM_SUBDIVISION", 525, 536], ["severe copper deficiency", "PROBLEM", 69, 93], ["profound hematological abnormalities", "PROBLEM", 105, 141], ["generalized fatigability", "PROBLEM", 399, 423], ["progressive bilateral lower limbs swelling", "PROBLEM", 428, 470], ["occasional numbness of the distal aspects of the lower limbs", "PROBLEM", 476, 536], ["weakness", "PROBLEM", 544, 552], ["profound", "OBSERVATION_MODIFIER", 105, 113], ["progressive", "OBSERVATION_MODIFIER", 428, 439], ["bilateral", "ANATOMY_MODIFIER", 440, 449], ["lower", "ANATOMY_MODIFIER", 450, 455], ["limbs", "ANATOMY", 456, 461], ["swelling", "OBSERVATION", 462, 470], ["occasional", "OBSERVATION_MODIFIER", 476, 486], ["numbness", "OBSERVATION", 487, 495], ["distal", "ANATOMY_MODIFIER", 503, 509], ["lower limbs", "ANATOMY", 525, 536], ["no", "UNCERTAINTY", 541, 543], ["weakness", "OBSERVATION", 544, 552]]], ["Her complaints had worsened over time, and were affecting her quality of life and ability to work.", [["Her complaints", "PROBLEM", 0, 14], ["worsened", "OBSERVATION_MODIFIER", 19, 27]]], ["She also had frequent episodes of palpitations, exertional shortness of breath, but no chest pain.", [["chest", "ANATOMY", 87, 92], ["palpitations", "DISEASE", 34, 46], ["exertional shortness of breath", "DISEASE", 48, 78], ["chest pain", "DISEASE", 87, 97], ["chest", "ORGANISM_SUBDIVISION", 87, 92], ["palpitations", "PROBLEM", 34, 46], ["exertional shortness of breath", "PROBLEM", 48, 78], ["chest pain", "PROBLEM", 87, 97], ["frequent", "OBSERVATION_MODIFIER", 13, 21], ["palpitations", "OBSERVATION", 34, 46], ["no", "UNCERTAINTY", 84, 86], ["chest", "ANATOMY", 87, 92], ["pain", "OBSERVATION", 93, 97]]], ["There was no nausea or vomiting, but she indicated that there was an increase in her bowel motions which had become more greasy.", [["bowel", "ANATOMY", 85, 90], ["nausea", "DISEASE", 13, 19], ["vomiting", "DISEASE", 23, 31], ["bowel", "ORGAN", 85, 90], ["nausea", "PROBLEM", 13, 19], ["vomiting", "PROBLEM", 23, 31], ["an increase in her bowel motions", "PROBLEM", 66, 98], ["no", "UNCERTAINTY", 10, 12], ["nausea", "OBSERVATION", 13, 19], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["bowel", "ANATOMY", 85, 90]]], ["She denied bloody stools abdominal pain, change in appetite, fever, joint pain, or skin changes.", [["abdominal", "ANATOMY", 25, 34], ["joint", "ANATOMY", 68, 73], ["skin", "ANATOMY", 83, 87], ["abdominal pain", "DISEASE", 25, 39], ["fever", "DISEASE", 61, 66], ["joint pain", "DISEASE", 68, 78], ["abdominal", "ORGANISM_SUBDIVISION", 25, 34], ["joint", "ORGANISM_SUBDIVISION", 68, 73], ["skin", "ORGAN", 83, 87], ["bloody stools", "PROBLEM", 11, 24], ["abdominal pain", "PROBLEM", 25, 39], ["change in appetite", "PROBLEM", 41, 59], ["fever", "PROBLEM", 61, 66], ["joint pain", "PROBLEM", 68, 78], ["skin changes", "PROBLEM", 83, 95], ["abdominal", "ANATOMY", 25, 34], ["pain", "OBSERVATION", 35, 39], ["joint", "ANATOMY", 68, 73], ["pain", "OBSERVATION", 74, 78], ["skin", "ANATOMY", 83, 87]]], ["She also complained of occasional headaches but no visual changes.", [["headaches", "DISEASE", 34, 43], ["occasional headaches", "PROBLEM", 23, 43], ["visual changes", "PROBLEM", 51, 65], ["occasional", "OBSERVATION_MODIFIER", 23, 33], ["headaches", "OBSERVATION", 34, 43], ["no", "UNCERTAINTY", 48, 50], ["visual changes", "OBSERVATION", 51, 65]]], ["Past medical history was remarkable for T2DM controlled with oral hypoglycemic agents (sitagliptin 50 mg and metformin 1000) and basal insulin, hypertension controlled by antihypertensives (valsartan 160 mg and hydrochlorothiazide 12.5 mg), bronchial asthma with recurrent exacerbations, primary infertility, and severe obesity.Case ReportThe patient had undertaken laparoscopic sleeve gastrectomy (LSG) on April 2013 (Fig. 1A) as her weight then was 162 kg (BMI 57 kg/m2).", [["oral", "ANATOMY", 61, 65], ["bronchial", "ANATOMY", 241, 250], ["T2DM", "DISEASE", 40, 44], ["sitagliptin", "CHEMICAL", 87, 98], ["metformin 1000", "CHEMICAL", 109, 123], ["hypertension", "DISEASE", 144, 156], ["valsartan", "CHEMICAL", 190, 199], ["hydrochlorothiazide", "CHEMICAL", 211, 230], ["bronchial asthma", "DISEASE", 241, 257], ["primary infertility", "DISEASE", 288, 307], ["obesity", "DISEASE", 320, 327], ["sitagliptin", "CHEMICAL", 87, 98], ["metformin", "CHEMICAL", 109, 118], ["valsartan", "CHEMICAL", 190, 199], ["hydrochlorothiazide", "CHEMICAL", 211, 230], ["oral", "ORGANISM_SUBDIVISION", 61, 65], ["sitagliptin", "SIMPLE_CHEMICAL", 87, 98], ["metformin", "SIMPLE_CHEMICAL", 109, 118], ["insulin", "GENE_OR_GENE_PRODUCT", 135, 142], ["valsartan", "SIMPLE_CHEMICAL", 190, 199], ["hydrochlorothiazide", "SIMPLE_CHEMICAL", 211, 230], ["patient", "ORGANISM", 343, 350], ["patient", "SPECIES", 343, 350], ["T2DM", "PROBLEM", 40, 44], ["oral hypoglycemic agents", "TREATMENT", 61, 85], ["sitagliptin", "TREATMENT", 87, 98], ["metformin", "TREATMENT", 109, 118], ["basal insulin", "TREATMENT", 129, 142], ["hypertension", "PROBLEM", 144, 156], ["antihypertensives", "TREATMENT", 171, 188], ["valsartan", "TREATMENT", 190, 199], ["hydrochlorothiazide", "TREATMENT", 211, 230], ["bronchial asthma", "PROBLEM", 241, 257], ["recurrent exacerbations", "PROBLEM", 263, 286], ["primary infertility", "PROBLEM", 288, 307], ["severe obesity", "PROBLEM", 313, 327], ["undertaken laparoscopic sleeve gastrectomy", "TREATMENT", 355, 397], ["her weight", "TEST", 431, 441], ["hypertension", "OBSERVATION", 144, 156], ["bronchial", "ANATOMY", 241, 250], ["asthma", "OBSERVATION", 251, 257], ["recurrent", "OBSERVATION_MODIFIER", 263, 272], ["exacerbations", "OBSERVATION", 273, 286], ["severe", "OBSERVATION_MODIFIER", 313, 319], ["obesity", "OBSERVATION", 320, 327], ["sleeve gastrectomy", "OBSERVATION", 379, 397]]], ["After the LSG, her minimum post-operative weight was 90 kg, the T2DM and hypertension resolved within the first year post-operatively and she was off medications for both conditions.", [["T2DM", "DISEASE", 64, 68], ["hypertension", "DISEASE", 73, 85], ["the LSG", "TREATMENT", 6, 13], ["her minimum post-operative weight", "TEST", 15, 48], ["the T2DM", "PROBLEM", 60, 68], ["hypertension", "PROBLEM", 73, 85], ["medications", "TREATMENT", 150, 161], ["LSG", "OBSERVATION", 10, 13], ["T2DM", "OBSERVATION", 64, 68], ["hypertension", "OBSERVATION", 73, 85]]], ["Moreover, her asthma exacerbations became minimal.", [["asthma", "DISEASE", 14, 20], ["her asthma exacerbations", "PROBLEM", 10, 34], ["asthma", "OBSERVATION", 14, 20], ["minimal", "OBSERVATION_MODIFIER", 42, 49]]], ["Weight regain started on the second year post-LSG until she reached 118 kg (BMI 42 kg/m2).", [["Weight", "TEST", 0, 6], ["LSG", "TREATMENT", 46, 49]]], ["Hence, 3 years after her initial LSG, in December 2016, she underwent revisional laparoscopic SADI-S.", [["her initial LSG", "TREATMENT", 21, 36], ["revisional laparoscopic SADI", "TREATMENT", 70, 98]]], ["Eleven months after the SADI-S (November 2017), she presented to our bariatric surgery clinic with the abovementioned complaints, claimed to be adherent to the multivitamin with minerals daily tablets and iron supplements, and denied smoking or alcohol consumption.Case ReportUpon examination, she appeared vitally stable, weighed 93.6 kg (BMI 35.6 kg/m2), with normal cardiovascular, chest, and abdominal examinations, and no neurological deficits.", [["cardiovascular", "ANATOMY", 369, 383], ["chest", "ANATOMY", 385, 390], ["abdominal", "ANATOMY", 396, 405], ["neurological", "ANATOMY", 427, 439], ["multivitamin", "CHEMICAL", 160, 172], ["iron", "CHEMICAL", 205, 209], ["smoking", "CHEMICAL", 234, 241], ["alcohol", "CHEMICAL", 245, 252], ["neurological deficits", "DISEASE", 427, 448], ["iron", "CHEMICAL", 205, 209], ["alcohol", "CHEMICAL", 245, 252], ["multivitamin", "SIMPLE_CHEMICAL", 160, 172], ["minerals", "SIMPLE_CHEMICAL", 178, 186], ["iron", "SIMPLE_CHEMICAL", 205, 209], ["alcohol", "SIMPLE_CHEMICAL", 245, 252], ["chest", "ORGANISM_SUBDIVISION", 385, 390], ["abdominal", "ORGANISM_SUBDIVISION", 396, 405], ["the multivitamin with minerals daily tablets", "TREATMENT", 156, 200], ["iron supplements", "TREATMENT", 205, 221], ["examination", "TEST", 281, 292], ["BMI", "TEST", 340, 343], ["abdominal examinations", "TEST", 396, 418], ["neurological deficits", "PROBLEM", 427, 448], ["stable", "OBSERVATION_MODIFIER", 315, 321], ["normal", "OBSERVATION", 362, 368], ["cardiovascular", "ANATOMY", 369, 383], ["chest", "ANATOMY", 385, 390], ["abdominal", "ANATOMY", 396, 405], ["no", "UNCERTAINTY", 424, 426], ["neurological", "OBSERVATION_MODIFIER", 427, 439], ["deficits", "OBSERVATION", 440, 448]]], ["She appeared pale and had significant bilateral lower limb edema (Grade 3), and was admitted for inpatient assessment and further management.Case ReportLaboratory results upon admission showed microcytic hypochromic anemia, leucopenia, thrombocytopenia, hypoalbuminemia, and high level of vitamin B12 (Fig. 1C).", [["lower limb edema", "ANATOMY", 48, 64], ["lower limb edema", "DISEASE", 48, 64], ["microcytic hypochromic anemia", "DISEASE", 193, 222], ["leucopenia", "DISEASE", 224, 234], ["thrombocytopenia", "DISEASE", 236, 252], ["hypoalbuminemia", "DISEASE", 254, 269], ["vitamin B12", "CHEMICAL", 289, 300], ["vitamin B12", "CHEMICAL", 289, 300], ["lower limb", "ORGANISM_SUBDIVISION", 48, 58], ["edema", "PATHOLOGICAL_FORMATION", 59, 64], ["vitamin B12", "SIMPLE_CHEMICAL", 289, 300], ["pale", "PROBLEM", 13, 17], ["significant bilateral lower limb edema", "PROBLEM", 26, 64], ["inpatient assessment", "TEST", 97, 117], ["further management", "TREATMENT", 122, 140], ["microcytic hypochromic anemia", "PROBLEM", 193, 222], ["leucopenia", "PROBLEM", 224, 234], ["thrombocytopenia", "PROBLEM", 236, 252], ["hypoalbuminemia", "PROBLEM", 254, 269], ["vitamin B12 (Fig", "TREATMENT", 289, 305], ["pale", "OBSERVATION", 13, 17], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["bilateral", "ANATOMY_MODIFIER", 38, 47], ["lower limb", "ANATOMY", 48, 58], ["edema", "OBSERVATION", 59, 64], ["microcytic", "OBSERVATION_MODIFIER", 193, 203], ["hypochromic anemia", "OBSERVATION", 204, 222], ["leucopenia", "OBSERVATION", 224, 234], ["thrombocytopenia", "OBSERVATION", 236, 252], ["hypoalbuminemia", "OBSERVATION", 254, 269]]], ["She was started on IV multivitamins and trace elements, thiamine IV, and high-protein diet, and eventually required total parental nutrition until laboratory results became available.", [["multivitamins", "CHEMICAL", 22, 35], ["thiamine IV", "CHEMICAL", 56, 67], ["multivitamins", "CHEMICAL", 22, 35], ["thiamine IV", "CHEMICAL", 56, 67], ["multivitamins", "SIMPLE_CHEMICAL", 22, 35], ["thiamine IV", "SIMPLE_CHEMICAL", 56, 67], ["IV multivitamins", "TREATMENT", 19, 35], ["trace elements", "TREATMENT", 40, 54], ["thiamine IV", "TREATMENT", 56, 67], ["high-protein diet", "TREATMENT", 73, 90], ["total parental nutrition", "TREATMENT", 116, 140]]], ["Peripheral blood smear confirmed pancytopenia with cellular atypia (Fig. 1C).", [["Peripheral blood", "ANATOMY", 0, 16], ["cellular", "ANATOMY", 51, 59], ["pancytopenia", "DISEASE", 33, 45], ["Peripheral blood", "ORGANISM_SUBSTANCE", 0, 16], ["cellular", "CELL", 51, 59], ["Peripheral blood smear", "TEST", 0, 22], ["pancytopenia", "PROBLEM", 33, 45], ["cellular atypia", "PROBLEM", 51, 66], ["blood", "ANATOMY", 11, 16], ["pancytopenia", "OBSERVATION", 33, 45], ["cellular atypia", "OBSERVATION", 51, 66]]], ["Further investigations revealed low ceruloplasmin, and severe deficiencies of copper, zinc, selenium, vitamin D, and folate but normal cholesterol and lipid profile (Fig. 1C).", [["copper", "CHEMICAL", 78, 84], ["zinc", "CHEMICAL", 86, 90], ["selenium", "CHEMICAL", 92, 100], ["vitamin D", "CHEMICAL", 102, 111], ["folate", "CHEMICAL", 117, 123], ["cholesterol", "CHEMICAL", 135, 146], ["copper", "CHEMICAL", 78, 84], ["zinc", "CHEMICAL", 86, 90], ["selenium", "CHEMICAL", 92, 100], ["vitamin D", "CHEMICAL", 102, 111], ["folate", "CHEMICAL", 117, 123], ["cholesterol", "CHEMICAL", 135, 146], ["ceruloplasmin", "GENE_OR_GENE_PRODUCT", 36, 49], ["copper", "SIMPLE_CHEMICAL", 78, 84], ["zinc", "SIMPLE_CHEMICAL", 86, 90], ["selenium", "SIMPLE_CHEMICAL", 92, 100], ["vitamin D", "SIMPLE_CHEMICAL", 102, 111], ["folate", "SIMPLE_CHEMICAL", 117, 123], ["cholesterol", "SIMPLE_CHEMICAL", 135, 146], ["lipid", "SIMPLE_CHEMICAL", 151, 156], ["ceruloplasmin", "PROTEIN", 36, 49], ["Further investigations", "TEST", 0, 22], ["low ceruloplasmin", "PROBLEM", 32, 49], ["severe deficiencies of copper", "PROBLEM", 55, 84], ["zinc", "TEST", 86, 90], ["selenium", "TEST", 92, 100], ["vitamin D", "TREATMENT", 102, 111], ["folate", "TREATMENT", 117, 123], ["lipid profile", "TEST", 151, 164], ["low ceruloplasmin", "OBSERVATION_MODIFIER", 32, 49], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["deficiencies", "OBSERVATION", 62, 74]]], ["Hemoglobin electrophoresis showed normal hemoglobin pattern.Case ReportFor the severe microcytic hypochromic anemia, she received a transfusion of two units of packed red blood cells (Fig. 1D) that resulted in a transient rise in hematocrit count and hemoglobin level (Fig. 1E), followed by a gradual drop of both levels over the following days (Fig. 1F).", [["red blood cells", "ANATOMY", 167, 182], ["microcytic hypochromic anemia", "DISEASE", 86, 115], ["Hemoglobin", "GENE_OR_GENE_PRODUCT", 0, 10], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 41, 51], ["red blood cells", "CELL", 167, 182], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 251, 261], ["hemoglobin", "PROTEIN", 41, 51], ["packed red blood cells", "CELL_TYPE", 160, 182], ["hemoglobin", "PROTEIN", 251, 261], ["Hemoglobin electrophoresis", "TEST", 0, 26], ["the severe microcytic hypochromic anemia", "PROBLEM", 75, 115], ["packed red blood cells", "TREATMENT", 160, 182], ["a transient rise", "PROBLEM", 210, 226], ["hematocrit count", "TEST", 230, 246], ["hemoglobin level", "TEST", 251, 267], ["a gradual drop of both levels", "PROBLEM", 291, 320], ["normal", "OBSERVATION", 34, 40], ["hemoglobin pattern", "OBSERVATION", 41, 59], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["microcytic", "OBSERVATION_MODIFIER", 86, 96], ["hypochromic anemia", "OBSERVATION", 97, 115], ["transient", "OBSERVATION_MODIFIER", 212, 221], ["rise", "OBSERVATION_MODIFIER", 222, 226], ["hematocrit count", "OBSERVATION", 230, 246], ["gradual", "OBSERVATION_MODIFIER", 293, 300], ["drop", "OBSERVATION", 301, 305]]], ["The pancytopenia progressively improved following the initiation of an additional 0.5 mg of copper chloride IV daily dose after diagnosis of copper deficiency.Case ReportScreening for celiac disease was negative and esophagogastroduodenoscopy was normal.", [["celiac", "ANATOMY", 184, 190], ["pancytopenia", "DISEASE", 4, 16], ["copper chloride", "CHEMICAL", 92, 107], ["copper", "CHEMICAL", 141, 147], ["celiac disease", "DISEASE", 184, 198], ["copper chloride IV", "CHEMICAL", 92, 110], ["copper", "CHEMICAL", 141, 147], ["copper chloride IV", "SIMPLE_CHEMICAL", 92, 110], ["copper", "SIMPLE_CHEMICAL", 141, 147], ["celiac", "ORGAN", 184, 190], ["The pancytopenia", "PROBLEM", 0, 16], ["copper chloride IV", "TREATMENT", 92, 110], ["copper deficiency", "PROBLEM", 141, 158], ["celiac disease", "PROBLEM", 184, 198], ["esophagogastroduodenoscopy", "TEST", 216, 242], ["pancytopenia", "OBSERVATION", 4, 16], ["progressively", "OBSERVATION_MODIFIER", 17, 30], ["improved", "OBSERVATION_MODIFIER", 31, 39], ["copper deficiency", "OBSERVATION", 141, 158], ["celiac", "ANATOMY", 184, 190], ["normal", "OBSERVATION", 247, 253]]], ["At discharge, her blood picture was improving (Fig. 1G).", [["blood", "ANATOMY", 18, 23], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["her blood picture", "TEST", 14, 31]]], ["She was prescribed multivitamin and minerals daily tablet, copper gluconate 2 mg daily, selenium 200 mcg bid, vitamin D, calcium and iron supplements, cyanocobalamin 1 mg daily, pancreatic enzymes for suspected pancreatic insufficiency, and high-protein supplement.", [["pancreatic", "ANATOMY", 178, 188], ["pancreatic", "ANATOMY", 211, 221], ["multivitamin", "CHEMICAL", 19, 31], ["copper gluconate", "CHEMICAL", 59, 75], ["selenium", "CHEMICAL", 88, 96], ["vitamin D", "CHEMICAL", 110, 119], ["calcium", "CHEMICAL", 121, 128], ["iron", "CHEMICAL", 133, 137], ["cyanocobalamin", "CHEMICAL", 151, 165], ["pancreatic insufficiency", "DISEASE", 211, 235], ["multivitamin", "CHEMICAL", 19, 31], ["copper gluconate", "CHEMICAL", 59, 75], ["selenium", "CHEMICAL", 88, 96], ["vitamin D", "CHEMICAL", 110, 119], ["calcium", "CHEMICAL", 121, 128], ["iron", "CHEMICAL", 133, 137], ["cyanocobalamin", "CHEMICAL", 151, 165], ["multivitamin", "SIMPLE_CHEMICAL", 19, 31], ["minerals", "SIMPLE_CHEMICAL", 36, 44], ["copper gluconate", "SIMPLE_CHEMICAL", 59, 75], ["selenium", "SIMPLE_CHEMICAL", 88, 96], ["vitamin D", "SIMPLE_CHEMICAL", 110, 119], ["calcium", "SIMPLE_CHEMICAL", 121, 128], ["iron", "SIMPLE_CHEMICAL", 133, 137], ["cyanocobalamin", "SIMPLE_CHEMICAL", 151, 165], ["pancreatic", "ORGAN", 178, 188], ["pancreatic", "ORGAN", 211, 221], ["pancreatic enzymes", "PROTEIN", 178, 196], ["multivitamin and minerals", "TREATMENT", 19, 44], ["copper gluconate", "TREATMENT", 59, 75], ["selenium", "TREATMENT", 88, 96], ["vitamin D", "TREATMENT", 110, 119], ["calcium", "TREATMENT", 121, 128], ["iron supplements", "TREATMENT", 133, 149], ["cyanocobalamin", "TREATMENT", 151, 165], ["pancreatic enzymes", "TEST", 178, 196], ["pancreatic insufficiency", "PROBLEM", 211, 235], ["high-protein supplement", "TREATMENT", 241, 264], ["pancreatic", "ANATOMY", 178, 188], ["pancreatic", "ANATOMY", 211, 221], ["insufficiency", "OBSERVATION", 222, 235]]], ["At follow-up, 2 weeks after discharge, her laboratory results showed a normal level of serum copper, resolution of the leukopenia, neutropenia, and thrombocytopenia, and improvement of microcytic hypochromic anemia (Fig. 1H).", [["serum", "ANATOMY", 87, 92], ["copper", "CHEMICAL", 93, 99], ["leukopenia", "DISEASE", 119, 129], ["neutropenia", "DISEASE", 131, 142], ["thrombocytopenia", "DISEASE", 148, 164], ["microcytic hypochromic anemia", "DISEASE", 185, 214], ["copper", "CHEMICAL", 93, 99], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["copper", "SIMPLE_CHEMICAL", 93, 99], ["serum copper", "PROBLEM", 87, 99], ["the leukopenia", "PROBLEM", 115, 129], ["neutropenia", "PROBLEM", 131, 142], ["thrombocytopenia", "PROBLEM", 148, 164], ["microcytic hypochromic anemia", "PROBLEM", 185, 214], ["leukopenia", "OBSERVATION", 119, 129], ["neutropenia", "OBSERVATION", 131, 142], ["thrombocytopenia", "OBSERVATION", 148, 164], ["improvement", "OBSERVATION_MODIFIER", 170, 181], ["microcytic", "OBSERVATION_MODIFIER", 185, 195], ["hypochromic anemia", "OBSERVATION", 196, 214]]], ["She reported significant improvements in her symptoms and better quality of life.DiscussionWe report a case report of severe copper deficiency leading to hematological abnormalities post-SADI-S.", [["hematological", "ANATOMY", 154, 167], ["copper deficiency", "DISEASE", 125, 142], ["hematological abnormalities", "DISEASE", 154, 181], ["copper", "CHEMICAL", 125, 131], ["copper", "SIMPLE_CHEMICAL", 125, 131], ["her symptoms", "PROBLEM", 41, 53], ["severe copper deficiency", "PROBLEM", 118, 142], ["hematological abnormalities", "PROBLEM", 154, 181], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["improvements", "OBSERVATION_MODIFIER", 25, 37]]], ["The mechanism/s by which copper deficiency causes anemia are multifactorial.", [["copper", "CHEMICAL", 25, 31], ["anemia", "DISEASE", 50, 56], ["copper", "CHEMICAL", 25, 31], ["copper", "SIMPLE_CHEMICAL", 25, 31], ["The mechanism/s", "PROBLEM", 0, 15], ["copper deficiency", "PROBLEM", 25, 42], ["anemia", "PROBLEM", 50, 56], ["anemia", "OBSERVATION", 50, 56]]], ["Copper and iron interact through ceruloplasmin, a copper-dependent oxidase that helps to transport iron into the plasma along with transferrin [11].", [["plasma", "ANATOMY", 113, 119], ["Copper", "CHEMICAL", 0, 6], ["iron", "CHEMICAL", 11, 15], ["copper", "CHEMICAL", 50, 56], ["iron", "CHEMICAL", 99, 103], ["Copper", "CHEMICAL", 0, 6], ["iron", "CHEMICAL", 11, 15], ["copper", "CHEMICAL", 50, 56], ["iron", "CHEMICAL", 99, 103], ["Copper", "SIMPLE_CHEMICAL", 0, 6], ["iron", "SIMPLE_CHEMICAL", 11, 15], ["ceruloplasmin", "GENE_OR_GENE_PRODUCT", 33, 46], ["copper", "SIMPLE_CHEMICAL", 50, 56], ["oxidase", "GENE_OR_GENE_PRODUCT", 67, 74], ["iron", "SIMPLE_CHEMICAL", 99, 103], ["plasma", "ORGANISM_SUBSTANCE", 113, 119], ["transferrin", "GENE_OR_GENE_PRODUCT", 131, 142], ["ceruloplasmin", "PROTEIN", 33, 46], ["copper-dependent oxidase", "PROTEIN", 50, 74], ["iron", "TREATMENT", 11, 15], ["ceruloplasmin", "TREATMENT", 33, 46], ["a copper-dependent oxidase", "TREATMENT", 48, 74]]], ["In addition, hephaestin, a trans-membrane copper containing ferroxidase, helps to export iron from enterocytes into the blood circulation, and as copper is essential to mobilize iron from the liver to the bone marrow where it is consumed, thus copper significantly affects erythropoiesis [11].", [["membrane", "ANATOMY", 33, 41], ["enterocytes", "ANATOMY", 99, 110], ["blood", "ANATOMY", 120, 125], ["liver", "ANATOMY", 192, 197], ["bone marrow", "ANATOMY", 205, 216], ["hephaestin", "CHEMICAL", 13, 23], ["copper", "CHEMICAL", 42, 48], ["iron", "CHEMICAL", 89, 93], ["copper", "CHEMICAL", 146, 152], ["iron", "CHEMICAL", 178, 182], ["copper", "CHEMICAL", 244, 250], ["hephaestin", "CHEMICAL", 13, 23], ["copper", "CHEMICAL", 42, 48], ["iron", "CHEMICAL", 89, 93], ["copper", "CHEMICAL", 146, 152], ["iron", "CHEMICAL", 178, 182], ["copper", "CHEMICAL", 244, 250], ["hephaestin", "SIMPLE_CHEMICAL", 13, 23], ["ferroxidase", "GENE_OR_GENE_PRODUCT", 60, 71], ["iron", "SIMPLE_CHEMICAL", 89, 93], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 99, 110], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["copper", "SIMPLE_CHEMICAL", 146, 152], ["iron", "SIMPLE_CHEMICAL", 178, 182], ["liver", "ORGAN", 192, 197], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 205, 216], ["copper", "SIMPLE_CHEMICAL", 244, 250], ["ferroxidase", "PROTEIN", 60, 71], ["enterocytes", "CELL_TYPE", 99, 110], ["hephaestin", "TREATMENT", 13, 23], ["a trans-membrane copper containing ferroxidase", "TREATMENT", 25, 71], ["iron", "TREATMENT", 178, 182], ["copper significantly affects erythropoiesis", "PROBLEM", 244, 287], ["blood circulation", "ANATOMY", 120, 137], ["liver", "ANATOMY", 192, 197], ["bone marrow", "ANATOMY", 205, 216]]], ["These mechanisms and interactions explain how the laboratory findings of copper deficiency and myelodysplastic syndromes mimic each other [11, 12].", [["copper", "CHEMICAL", 73, 79], ["myelodysplastic syndromes", "DISEASE", 95, 120], ["copper", "CHEMICAL", 73, 79], ["copper", "SIMPLE_CHEMICAL", 73, 79], ["copper deficiency", "PROBLEM", 73, 90], ["myelodysplastic syndromes", "PROBLEM", 95, 120], ["myelodysplastic syndromes", "OBSERVATION", 95, 120]]], ["Our patient had anemia and leucopenia (mainly neutropenia), in agreement with myelodysplastic syndrome [11, 12].", [["anemia", "DISEASE", 16, 22], ["leucopenia", "DISEASE", 27, 37], ["neutropenia", "DISEASE", 46, 57], ["myelodysplastic syndrome", "DISEASE", 78, 102], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["anemia", "PROBLEM", 16, 22], ["leucopenia", "PROBLEM", 27, 37], ["neutropenia", "PROBLEM", 46, 57], ["myelodysplastic syndrome", "PROBLEM", 78, 102], ["anemia", "OBSERVATION", 16, 22], ["leucopenia", "OBSERVATION", 27, 37], ["myelodysplastic syndrome", "OBSERVATION", 78, 102]]], ["In addition, she had moderate thrombocytopenia which is less frequently reported in copper deficiency [4].DiscussionThe patient underwent LSG as a primary weight loss surgery followed by SADI-S as revisional surgery.", [["thrombocytopenia", "DISEASE", 30, 46], ["copper", "CHEMICAL", 84, 90], ["weight loss", "DISEASE", 155, 166], ["SADI-S", "CHEMICAL", 187, 193], ["copper", "CHEMICAL", 84, 90], ["copper", "SIMPLE_CHEMICAL", 84, 90], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["moderate thrombocytopenia", "PROBLEM", 21, 46], ["copper deficiency", "PROBLEM", 84, 101], ["LSG", "TREATMENT", 138, 141], ["a primary weight loss surgery", "TREATMENT", 145, 174], ["revisional surgery", "TREATMENT", 197, 215], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["thrombocytopenia", "OBSERVATION", 30, 46], ["less frequently", "OBSERVATION_MODIFIER", 56, 71]]], ["Weight loss surgery that is characterized by combined restrictive and malabsorptive effects alters copper absorption in the stomach, duodenum, and ilium [13].", [["stomach", "ANATOMY", 124, 131], ["duodenum", "ANATOMY", 133, 141], ["ilium", "ANATOMY", 147, 152], ["Weight loss", "DISEASE", 0, 11], ["copper", "CHEMICAL", 99, 105], ["copper", "CHEMICAL", 99, 105], ["copper", "SIMPLE_CHEMICAL", 99, 105], ["stomach", "ORGAN", 124, 131], ["duodenum", "ORGAN", 133, 141], ["ilium", "ORGAN", 147, 152], ["Weight loss surgery", "TREATMENT", 0, 19], ["combined restrictive and malabsorptive effects", "PROBLEM", 45, 91], ["copper absorption in the stomach, duodenum, and ilium", "PROBLEM", 99, 152], ["restrictive", "OBSERVATION", 54, 65], ["malabsorptive effects", "OBSERVATION", 70, 91], ["stomach", "ANATOMY", 124, 131], ["duodenum", "ANATOMY", 133, 141], ["ilium", "ANATOMY", 147, 152]]], ["In addition, other factors e.g. pre-operative deficiencies, post-surgery food intolerance, changes in taste and eating patterns, and non-adherence to dietary and supplement recommendations could collectively lead to copper deficiency.", [["food intolerance", "DISEASE", 73, 89], ["copper", "CHEMICAL", 216, 222], ["copper", "CHEMICAL", 216, 222], ["copper", "SIMPLE_CHEMICAL", 216, 222], ["pre-operative deficiencies", "PROBLEM", 32, 58], ["food intolerance", "PROBLEM", 73, 89], ["changes in taste", "PROBLEM", 91, 107], ["dietary and supplement recommendations", "TREATMENT", 150, 188], ["copper deficiency", "PROBLEM", 216, 233]]], ["The literature completely lacks case reports outlining the types and levels of the range of micro- and macronutrient deficiencies after SADI-S.", [["micro", "TEST", 92, 97], ["macronutrient deficiencies", "PROBLEM", 103, 129], ["SADI", "TEST", 136, 140]]], ["However, copper deficiency has been reported following mainly malabsorptive procedures, e.g., gastric bypass surgery [14, 15], and less frequently after sleeve gastrectomy and duodenal switch [16, 17].DiscussionWhile the neurological examination of our patient was normal, she mentioned a history of occasional episodes of lower limb numbness that might be attributed to the copper deficiency, given that her laboratory results showed normal thiamine and vitamin B12 blood levels.", [["gastric", "ANATOMY", 94, 101], ["duodenal", "ANATOMY", 176, 184], ["neurological", "ANATOMY", 221, 233], ["lower limb", "ANATOMY", 323, 333], ["blood", "ANATOMY", 467, 472], ["copper", "CHEMICAL", 9, 15], ["lower limb numbness", "DISEASE", 323, 342], ["copper", "CHEMICAL", 375, 381], ["thiamine", "CHEMICAL", 442, 450], ["vitamin B12", "CHEMICAL", 455, 466], ["copper", "CHEMICAL", 9, 15], ["copper", "CHEMICAL", 375, 381], ["thiamine", "CHEMICAL", 442, 450], ["vitamin B12", "CHEMICAL", 455, 466], ["copper", "SIMPLE_CHEMICAL", 9, 15], ["gastric", "ORGAN", 94, 101], ["duodenal", "ORGAN", 176, 184], ["patient", "ORGANISM", 253, 260], ["lower limb", "ORGANISM_SUBDIVISION", 323, 333], ["copper", "SIMPLE_CHEMICAL", 375, 381], ["thiamine", "SIMPLE_CHEMICAL", 442, 450], ["vitamin B12", "SIMPLE_CHEMICAL", 455, 466], ["blood", "ORGANISM_SUBSTANCE", 467, 472], ["patient", "SPECIES", 253, 260], ["copper deficiency", "PROBLEM", 9, 26], ["malabsorptive procedures", "TREATMENT", 62, 86], ["gastric bypass surgery", "TREATMENT", 94, 116], ["sleeve gastrectomy", "TREATMENT", 153, 171], ["duodenal switch", "TREATMENT", 176, 191], ["the neurological examination", "TEST", 217, 245], ["lower limb numbness", "PROBLEM", 323, 342], ["the copper deficiency", "PROBLEM", 371, 392], ["vitamin B12 blood levels", "TEST", 455, 479], ["gastric", "ANATOMY", 94, 101], ["bypass", "OBSERVATION", 102, 108], ["sleeve gastrectomy", "OBSERVATION", 153, 171], ["duodenal", "ANATOMY", 176, 184], ["lower", "ANATOMY_MODIFIER", 323, 328], ["limb", "ANATOMY", 329, 333], ["numbness", "OBSERVATION", 334, 342]]], ["Various myelopathies and peripheral neuropathies have been reported with copper deficiency, some of which were severe and irreversible [3, 4, 18, 19].", [["myelopathies", "ANATOMY", 8, 20], ["myelopathies", "DISEASE", 8, 20], ["peripheral neuropathies", "DISEASE", 25, 48], ["copper", "CHEMICAL", 73, 79], ["copper", "CHEMICAL", 73, 79], ["myelopathies", "CANCER", 8, 20], ["copper", "SIMPLE_CHEMICAL", 73, 79], ["Various myelopathies", "PROBLEM", 0, 20], ["peripheral neuropathies", "PROBLEM", 25, 48], ["copper deficiency", "PROBLEM", 73, 90], ["myelopathies", "OBSERVATION", 8, 20], ["peripheral", "ANATOMY_MODIFIER", 25, 35], ["neuropathies", "OBSERVATION", 36, 48], ["copper deficiency", "OBSERVATION", 73, 90], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["irreversible", "OBSERVATION_MODIFIER", 122, 134]]], ["In addition, although copper deficiency has been observed as a possible cause of ischemic heart disease by significantly promoting major risk factors such as hypercholesterolemia, chronic inflammation, oxidative stress, and glucose intolerance [20], our patient had normal cholesterol and lipid profiles.DiscussionRefractory iron deficiency anemia with copper deficiency has been described post-duodenal switch surgery [21].", [["heart", "ANATOMY", 90, 95], ["post-duodenal", "ANATOMY", 390, 403], ["copper", "CHEMICAL", 22, 28], ["ischemic heart disease", "DISEASE", 81, 103], ["hypercholesterolemia", "DISEASE", 158, 178], ["inflammation", "DISEASE", 188, 200], ["glucose intolerance", "DISEASE", 224, 243], ["cholesterol", "CHEMICAL", 273, 284], ["iron", "CHEMICAL", 325, 329], ["anemia", "DISEASE", 341, 347], ["copper", "CHEMICAL", 353, 359], ["copper", "CHEMICAL", 22, 28], ["glucose", "CHEMICAL", 224, 231], ["cholesterol", "CHEMICAL", 273, 284], ["iron", "CHEMICAL", 325, 329], ["copper", "CHEMICAL", 353, 359], ["copper", "SIMPLE_CHEMICAL", 22, 28], ["heart", "ORGAN", 90, 95], ["glucose", "SIMPLE_CHEMICAL", 224, 231], ["patient", "ORGANISM", 254, 261], ["cholesterol", "SIMPLE_CHEMICAL", 273, 284], ["lipid", "SIMPLE_CHEMICAL", 289, 294], ["iron", "SIMPLE_CHEMICAL", 325, 329], ["copper", "SIMPLE_CHEMICAL", 353, 359], ["patient", "SPECIES", 254, 261], ["copper deficiency", "PROBLEM", 22, 39], ["ischemic heart disease", "PROBLEM", 81, 103], ["hypercholesterolemia", "PROBLEM", 158, 178], ["chronic inflammation", "PROBLEM", 180, 200], ["oxidative stress", "PROBLEM", 202, 218], ["glucose intolerance", "PROBLEM", 224, 243], ["iron deficiency anemia", "PROBLEM", 325, 347], ["copper deficiency", "PROBLEM", 353, 370], ["post-duodenal switch surgery", "TREATMENT", 390, 418], ["possible cause of", "UNCERTAINTY", 63, 80], ["ischemic", "OBSERVATION_MODIFIER", 81, 89], ["heart", "ANATOMY", 90, 95], ["disease", "OBSERVATION", 96, 103], ["hypercholesterolemia", "OBSERVATION", 158, 178], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["inflammation", "OBSERVATION", 188, 200], ["iron deficiency", "OBSERVATION", 325, 340], ["copper deficiency", "OBSERVATION", 353, 370]]], ["In our case, the two units of packed red blood cells transfusion resulted in a transient rise in hematocrit count and hemoglobin level (Fig. 1E), followed by a gradual dropping of both, highlighting that among anemic patients, copper deficiency could cause a refractory response to blood transfusion and iron replacement.", [["red blood cells", "ANATOMY", 37, 52], ["blood", "ANATOMY", 282, 287], ["anemic", "DISEASE", 210, 216], ["copper", "CHEMICAL", 227, 233], ["iron", "CHEMICAL", 304, 308], ["copper", "CHEMICAL", 227, 233], ["iron", "CHEMICAL", 304, 308], ["red blood cells", "CELL", 37, 52], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 118, 128], ["patients", "ORGANISM", 217, 225], ["copper", "SIMPLE_CHEMICAL", 227, 233], ["blood", "ORGANISM_SUBSTANCE", 282, 287], ["iron", "SIMPLE_CHEMICAL", 304, 308], ["packed red blood cells", "CELL_TYPE", 30, 52], ["hemoglobin", "PROTEIN", 118, 128], ["patients", "SPECIES", 217, 225], ["packed red blood cells transfusion", "TREATMENT", 30, 64], ["a transient rise", "PROBLEM", 77, 93], ["hematocrit count", "TEST", 97, 113], ["hemoglobin level", "TEST", 118, 134], ["copper deficiency", "PROBLEM", 227, 244], ["a refractory response", "PROBLEM", 257, 278], ["blood transfusion", "TREATMENT", 282, 299], ["iron replacement", "TREATMENT", 304, 320], ["transient", "OBSERVATION_MODIFIER", 79, 88], ["rise", "OBSERVATION_MODIFIER", 89, 93], ["hematocrit count", "OBSERVATION", 97, 113], ["refractory", "OBSERVATION_MODIFIER", 259, 269]]], ["Hence, prompt diagnosis and treatment of copper deficiency could help to prevent serious complications such as severe pancytopenia with its consequences and neuropathy.", [["copper", "CHEMICAL", 41, 47], ["pancytopenia", "DISEASE", 118, 130], ["neuropathy", "DISEASE", 157, 167], ["copper", "CHEMICAL", 41, 47], ["copper", "SIMPLE_CHEMICAL", 41, 47], ["copper deficiency", "PROBLEM", 41, 58], ["serious complications", "PROBLEM", 81, 102], ["severe pancytopenia", "PROBLEM", 111, 130], ["neuropathy", "PROBLEM", 157, 167], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["pancytopenia", "OBSERVATION", 118, 130], ["neuropathy", "OBSERVATION", 157, 167]]], ["Finally, although the patient also had concomitant folate deficiency, however, her peripheral smear showed hypochromic microcytic anemia (as opposed to the macrocytic anemia observed with folate deficiency), suggesting that among post-bariatric surgery patients with concomitant hypocuperimia, that the effects of the copper deficiency on erythropoiesis could be more pronounced than that of the folate.ConclusionAlthough rare, the current case emphasizes that the bariatric team should be aware that after bariatric procedures such as SADI-S, micronutrient deficiencies could be encountered.", [["peripheral smear", "ANATOMY", 83, 99], ["folate", "CHEMICAL", 51, 57], ["hypochromic microcytic anemia", "DISEASE", 107, 136], ["macrocytic anemia", "DISEASE", 156, 173], ["folate", "CHEMICAL", 188, 194], ["hypocuperimia", "DISEASE", 279, 292], ["copper", "CHEMICAL", 318, 324], ["folate", "CHEMICAL", 396, 402], ["SADI-S", "CHEMICAL", 536, 542], ["micronutrient deficiencies", "DISEASE", 544, 570], ["folate", "CHEMICAL", 51, 57], ["folate", "CHEMICAL", 188, 194], ["copper", "CHEMICAL", 318, 324], ["folate", "CHEMICAL", 396, 402], ["patient", "ORGANISM", 22, 29], ["folate", "SIMPLE_CHEMICAL", 51, 57], ["folate", "SIMPLE_CHEMICAL", 188, 194], ["patients", "ORGANISM", 253, 261], ["copper", "SIMPLE_CHEMICAL", 318, 324], ["folate", "SIMPLE_CHEMICAL", 396, 402], ["patient", "SPECIES", 22, 29], ["patients", "SPECIES", 253, 261], ["concomitant folate deficiency", "PROBLEM", 39, 68], ["her peripheral smear", "TEST", 79, 99], ["hypochromic microcytic anemia", "PROBLEM", 107, 136], ["the macrocytic anemia", "PROBLEM", 152, 173], ["folate deficiency", "PROBLEM", 188, 205], ["post-bariatric surgery", "TREATMENT", 230, 252], ["concomitant hypocuperimia", "PROBLEM", 267, 292], ["the copper deficiency on erythropoiesis", "PROBLEM", 314, 353], ["the folate", "TEST", 392, 402], ["bariatric procedures", "TREATMENT", 507, 527], ["micronutrient deficiencies", "PROBLEM", 544, 570], ["folate deficiency", "OBSERVATION", 51, 68], ["hypochromic", "OBSERVATION_MODIFIER", 107, 118], ["microcytic anemia", "OBSERVATION", 119, 136], ["macrocytic anemia", "OBSERVATION", 156, 173], ["folate deficiency", "OBSERVATION", 188, 205], ["more pronounced", "OBSERVATION_MODIFIER", 363, 378]]], ["In order to avoid complications, early diagnosis, and prompt treatment of copper and other micronutrient deficiencies are critical.", [["copper", "CHEMICAL", 74, 80], ["copper", "CHEMICAL", 74, 80], ["copper", "SIMPLE_CHEMICAL", 74, 80], ["complications", "PROBLEM", 18, 31], ["copper and other micronutrient deficiencies", "PROBLEM", 74, 117]]], ["Mild neurological symptoms among post-bariatric surgery patients should alert the bariatric team to possible micronutrient/copper deficiency.", [["neurological", "ANATOMY", 5, 17], ["neurological symptoms", "DISEASE", 5, 26], ["copper", "CHEMICAL", 123, 129], ["copper", "CHEMICAL", 123, 129], ["patients", "ORGANISM", 56, 64], ["micronutrient", "SIMPLE_CHEMICAL", 109, 122], ["copper", "SIMPLE_CHEMICAL", 123, 129], ["patients", "SPECIES", 56, 64], ["Mild neurological symptoms", "PROBLEM", 0, 26], ["post-bariatric surgery", "TREATMENT", 33, 55], ["micronutrient/copper deficiency", "PROBLEM", 109, 140]]], ["Findings of anemia, pancytopenia, and cellular atypia warrant extensive assessment and replacement of micronutrients.", [["cellular", "ANATOMY", 38, 46], ["anemia", "DISEASE", 12, 18], ["pancytopenia", "DISEASE", 20, 32], ["cellular", "CELL", 38, 46], ["anemia", "PROBLEM", 12, 18], ["pancytopenia", "PROBLEM", 20, 32], ["cellular atypia", "PROBLEM", 38, 53], ["extensive assessment", "TEST", 62, 82], ["replacement of micronutrients", "TREATMENT", 87, 116], ["anemia", "OBSERVATION", 12, 18], ["pancytopenia", "OBSERVATION", 20, 32], ["cellular", "OBSERVATION_MODIFIER", 38, 46], ["atypia", "OBSERVATION", 47, 53]]]], "58d40237863eda4fbd1a36a35716bbb14ad997e9": [["IntroductionCoronavirus disease COVID-19 outbreak began in late December 2019 in Wuhan, the capital of Hubei Province, China .", [["Coronavirus disease", "DISEASE", 12, 31], ["IntroductionCoronavirus disease COVID", "PROBLEM", 0, 37], ["Coronavirus disease", "OBSERVATION", 12, 31]]], ["Scientists from all over the world are attempting to investigate this novel virus, known as 2019-nCoV, which is highly contagious, and to discover effective interventions to control and prevent the disease (Heymann, 2020; Huang et al., 2020) .", [["this novel virus", "PROBLEM", 65, 81], ["effective interventions", "TREATMENT", 147, 170], ["the disease", "PROBLEM", 194, 205], ["contagious", "OBSERVATION_MODIFIER", 119, 129]]], ["Coronaviruses are positive-sense single-stranded RNA viruses (ssRNA \u00fe ) belonging to the Coronaviridae family.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 89, 102], ["Coronaviridae family", "PROTEIN", 89, 109], ["Coronaviruses", "PROBLEM", 0, 13], ["positive", "OBSERVATION", 18, 26]]], ["Human Coronaviruses HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 are observed in almost one-third of the common cold (Lim et al., 2016) .", [["Human", "ORGANISM", 0, 5], ["Coronaviruses HCoV-229E", "ORGANISM", 6, 29], ["HCoV-NL63", "ORGANISM", 31, 40], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 42, 51], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 57, 66], ["Human Coronaviruses HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1", "DNA", 0, 66], ["Human", "SPECIES", 0, 5], ["Human Coronaviruses HCoV-229E", "SPECIES", 0, 29], ["Human Coronaviruses HCoV", "TEST", 0, 24], ["HCoV", "TEST", 31, 35], ["HCoV", "TEST", 42, 46], ["OC43", "TEST", 47, 51], ["HCoV", "TEST", 57, 61], ["common cold", "ANATOMY", 107, 118]]], ["However, recently some cases of human coronavirus infections have led to fatal endemics, including SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome) and COVID-19 that are common diseases between humans and animals whose belong to the genus Betacoronavirus of the Coronaviridae family (Al-Tawfiq et al., 2014) .", [["coronavirus infections", "DISEASE", 38, 60], ["SARS", "DISEASE", 99, 103], ["Acute Respiratory Syndrome", "DISEASE", 112, 138], ["Middle East Respiratory Syndrome", "DISEASE", 147, 179], ["human", "ORGANISM", 32, 37], ["coronavirus", "ORGANISM", 38, 49], ["humans", "ORGANISM", 227, 233], ["human", "SPECIES", 32, 37], ["humans", "SPECIES", 227, 233], ["human coronavirus", "SPECIES", 32, 49], ["humans", "SPECIES", 227, 233], ["human coronavirus infections", "PROBLEM", 32, 60], ["fatal endemics", "PROBLEM", 73, 87], ["SARS (Severe Acute Respiratory Syndrome", "PROBLEM", 99, 138], ["MERS (Middle East Respiratory Syndrome", "PROBLEM", 141, 179], ["COVID", "TEST", 185, 190], ["common diseases", "PROBLEM", 203, 218], ["coronavirus infections", "OBSERVATION", 38, 60], ["Severe", "OBSERVATION_MODIFIER", 105, 111], ["Acute", "OBSERVATION_MODIFIER", 112, 117], ["Respiratory Syndrome", "OBSERVATION", 118, 138], ["Middle", "ANATOMY_MODIFIER", 147, 153], ["Respiratory Syndrome", "OBSERVATION", 159, 179]]], ["So far, the novel COVID-19 has caused more than 700,000 illnesses and more than 33,000 deaths worldwide (W.H.O., 2020) .", [["COVID-19", "CHEMICAL", 18, 26], ["deaths", "DISEASE", 87, 93]]], ["The genome size of this virus is about 30 kb and encodes structural and non-structural proteins like other coronaviruses.", [["non-structural proteins", "PROTEIN", 72, 95], ["this virus", "PROBLEM", 19, 29], ["encodes structural and non-structural proteins like other coronaviruses", "PROBLEM", 49, 120], ["size", "OBSERVATION_MODIFIER", 11, 15], ["virus", "OBSERVATION", 24, 29], ["non-structural proteins", "OBSERVATION", 72, 95], ["coronaviruses", "OBSERVATION", 107, 120]]], ["Structural proteins include S protein (Spike), E protein (Envelope), M protein (Membrane), and N protein (Nucleocapsid) (Ahmed et al., 2020) .", [["S protein", "GENE_OR_GENE_PRODUCT", 28, 37], ["Spike", "GENE_OR_GENE_PRODUCT", 39, 44], ["E protein", "GENE_OR_GENE_PRODUCT", 47, 56], ["Envelope", "GENE_OR_GENE_PRODUCT", 58, 66], ["M protein", "GENE_OR_GENE_PRODUCT", 69, 78], ["Membrane", "GENE_OR_GENE_PRODUCT", 80, 88], ["N protein", "GENE_OR_GENE_PRODUCT", 95, 104], ["S protein", "PROTEIN", 28, 37], ["Spike", "PROTEIN", 39, 44], ["E protein", "PROTEIN", 47, 56], ["Envelope", "PROTEIN", 58, 66], ["M protein", "PROTEIN", 69, 78], ["Membrane", "PROTEIN", 80, 88], ["N protein", "PROTEIN", 95, 104], ["Nucleocapsid", "PROTEIN", 106, 118], ["Structural proteins", "TEST", 0, 19], ["S protein", "TEST", 28, 37], ["Spike", "TEST", 39, 44], ["E protein", "TEST", 47, 56], ["M protein", "TEST", 69, 78]]], ["The increasing rate of COVID-19 disease and the high morbidity necessitate the development of a specific and safe vaccine candidate as soon as possible.", [["COVID-19 disease", "PROBLEM", 23, 39], ["the high morbidity", "PROBLEM", 44, 62], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["rate", "OBSERVATION_MODIFIER", 15, 19]]], ["There is very little known actually about the pathogenesis of the virus; therefore, an immunoinformatics-based approach to investigate the immunogenic epitopes and vaccine design using data from proteins sequencing of the COVID-19 is required.IntroductionN protein is the only structural protein that associates with replicase-transcriptase complexes and binds with genomic RNA in coronaviruses (Cong et al., 2017) .", [["replicase-transcriptase", "GENE_OR_GENE_PRODUCT", 317, 340], ["coronaviruses", "ORGANISM", 381, 394], ["COVID-19", "DNA", 222, 230], ["structural protein", "PROTEIN", 277, 295], ["replicase-transcriptase complexes", "PROTEIN", 317, 350], ["genomic RNA", "RNA", 366, 377], ["the virus", "PROBLEM", 62, 71], ["an immunoinformatics-based approach", "TREATMENT", 84, 119], ["the immunogenic epitopes", "TREATMENT", 135, 159], ["the COVID", "TEST", 218, 227], ["IntroductionN protein", "TREATMENT", 243, 264], ["replicase-transcriptase complexes", "TREATMENT", 317, 350], ["genomic RNA in coronaviruses", "PROBLEM", 366, 394], ["very", "OBSERVATION_MODIFIER", 9, 13], ["little", "OBSERVATION_MODIFIER", 14, 20], ["virus", "OBSERVATION", 66, 71]]], ["This protein is multifunctional and one of the most crucial structural components of coronaviruses.", [["coronaviruses", "ORGANISM", 85, 98], ["coronaviruses", "PROBLEM", 85, 98], ["multifunctional", "OBSERVATION_MODIFIER", 16, 31], ["most crucial", "OBSERVATION_MODIFIER", 47, 59], ["structural", "OBSERVATION_MODIFIER", 60, 70], ["components", "OBSERVATION_MODIFIER", 71, 81], ["coronaviruses", "OBSERVATION", 85, 98]]], ["N protein is a structural and antigenic protein that is involved in packaging, transcription, and replication coronaviruses (4).", [["N protein", "PROTEIN", 0, 9], ["structural and antigenic protein", "PROTEIN", 15, 47], ["a structural and antigenic protein", "PROBLEM", 13, 47]]], ["This data showed that N protein is a suitable candidate for targeting drug and vaccine design because this protein is conserved, antigenic and multifunctional (6).", [["N protein", "PROTEIN", 22, 31], ["This data", "TEST", 0, 9], ["targeting drug and vaccine", "TREATMENT", 60, 86], ["this protein", "TEST", 102, 114]]], ["Leung and et al. concluded that N protein can be a suitable vaccine candidate against SARS-Cov because induce strong antibody and this process may trigger cytokine production (Leung et al., 2004) .", [["SARS", "DISEASE", 86, 90], ["N protein", "PROTEIN", 32, 41], ["strong antibody", "PROTEIN", 110, 125], ["cytokine", "PROTEIN", 155, 163], ["N protein", "PROBLEM", 32, 41], ["a suitable vaccine", "TREATMENT", 49, 67], ["SARS", "PROBLEM", 86, 90], ["Cov", "PROBLEM", 91, 94], ["strong antibody", "PROBLEM", 110, 125], ["this process", "PROBLEM", 130, 142], ["cytokine production", "PROBLEM", 155, 174], ["et al", "OBSERVATION", 10, 15]]], ["Coronaviruses M protein also has a key role in the assembly of virions.", [["virions", "ANATOMY", 63, 70], ["Coronaviruses M protein", "GENE_OR_GENE_PRODUCT", 0, 23], ["virions", "CELLULAR_COMPONENT", 63, 70], ["Coronaviruses M protein", "PROTEIN", 0, 23], ["Coronaviruses M protein", "TEST", 0, 23], ["virions", "OBSERVATION", 63, 70]]], ["The SARS-CoV M protein can interact with N protein and make a network of interactions with the genomic RNA (He et al., 2004) .", [["SARS", "DISEASE", 4, 8], ["M protein", "PROTEIN", 13, 22], ["N protein", "PROTEIN", 41, 50], ["genomic RNA", "RNA", 95, 106], ["SARS-CoV", "SPECIES", 4, 12], ["N protein", "TREATMENT", 41, 50]]], ["Ong and et al. the COVID-19 antigens such as S, N and M proteins introduced as a vaccine candidate (6).", [["COVID-19 antigens", "PROTEIN", 19, 36], ["S, N and M proteins", "PROTEIN", 45, 64], ["the COVID", "TEST", 15, 24], ["M proteins", "TREATMENT", 54, 64]]], ["This protein has also been studied as an epitope vaccine candidate against SARS-CoV (7).IntroductionOpen reading frame 3a (ORF3a) is required for viral replication and virulence of SARS CoV.", [["SARS", "DISEASE", 75, 79], ["SARS", "DISEASE", 181, 185], ["SARS-CoV", "ORGANISM", 75, 83], ["IntroductionOpen reading frame 3", "GENE_OR_GENE_PRODUCT", 88, 120], ["ORF3a", "GENE_OR_GENE_PRODUCT", 123, 128], ["IntroductionOpen reading frame 3", "DNA", 88, 120], ["ORF3a", "DNA", 123, 128], ["SARS-CoV", "SPECIES", 75, 83], ["SARS CoV.", "SPECIES", 181, 190], ["an epitope vaccine", "TREATMENT", 38, 56], ["IntroductionOpen", "TREATMENT", 88, 104], ["viral replication", "TREATMENT", 146, 163]]], ["Severe induction of proinflammatory cytokine is a sign of SARS-CoV and MERS-CoV infections.", [["infections", "DISEASE", 80, 90], ["SARS-CoV", "ORGANISM", 58, 66], ["MERS-CoV", "ORGANISM", 71, 79], ["proinflammatory cytokine", "PROTEIN", 20, 44], ["SARS-CoV", "SPECIES", 58, 66], ["MERS-CoV", "SPECIES", 71, 79], ["Severe induction of proinflammatory cytokine", "PROBLEM", 0, 44], ["SARS", "PROBLEM", 58, 62], ["CoV", "PROBLEM", 63, 66], ["MERS", "PROBLEM", 71, 75], ["CoV infections", "PROBLEM", 76, 90], ["proinflammatory cytokine", "OBSERVATION", 20, 44], ["CoV infections", "OBSERVATION", 76, 90]]], ["ORF3a activates both pro-IL-1b gene expression and IL-1b secretion and leads to severe lung injury.", [["lung", "ANATOMY", 87, 91], ["lung injury", "DISEASE", 87, 98], ["ORF3a", "GENE_OR_GENE_PRODUCT", 0, 5], ["pro-IL-1b", "GENE_OR_GENE_PRODUCT", 21, 30], ["IL-1b", "GENE_OR_GENE_PRODUCT", 51, 56], ["lung", "ORGAN", 87, 91], ["ORF3a", "PROTEIN", 0, 5], ["pro-IL-1b gene", "DNA", 21, 35], ["pro-IL", "TEST", 21, 27], ["severe lung injury", "PROBLEM", 80, 98], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["lung", "ANATOMY", 87, 91], ["injury", "OBSERVATION", 92, 98]]], ["Also, ORF3a has an important role in SARS-CoV assembly or budding with the participation of M and E proteins (McBride & Fielding, 2012) .", [["ORF3a", "CHEMICAL", 6, 11], ["ORF3a", "GENE_OR_GENE_PRODUCT", 6, 11], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 37, 45], ["ORF3a", "PROTEIN", 6, 11], ["M and E proteins", "PROTEIN", 92, 108], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41]]], ["These proteins are not only involved in the pathogenesis of the COVID-19 virus but also have high antigenicity (Chan et al., 2020; Siu et al., 2019; Xu et al., 2020) .", [["COVID-19 virus", "ORGANISM", 64, 78], ["COVID-19 virus", "SPECIES", 64, 78], ["the COVID", "TEST", 60, 69], ["not only", "UNCERTAINTY", 19, 27], ["high antigenicity", "OBSERVATION_MODIFIER", 93, 110]]], ["In this study E, M, N, ORF10, ORF8, ORF3a and M proteins were evaluated by available bioinformatics tools for designing an efficient multi-epitope vaccine for the stimulation of immune responses against COVID-19 infection.IntroductionSince the COVID-19 has been recently discovered, little immunological information is available.", [["COVID-19", "CHEMICAL", 203, 211], ["infection", "DISEASE", 212, 221], ["COVID-19", "CHEMICAL", 244, 252], ["ORF10", "GENE_OR_GENE_PRODUCT", 23, 28], ["ORF8", "GENE_OR_GENE_PRODUCT", 30, 34], ["ORF3a", "GENE_OR_GENE_PRODUCT", 36, 41], ["M proteins", "GENE_OR_GENE_PRODUCT", 46, 56], ["COVID-19", "ORGANISM", 203, 211], ["E, M, N, ORF10, ORF8, ORF3a and M proteins", "PROTEIN", 14, 56], ["COVID-19", "DNA", 244, 252], ["COVID-19", "SPECIES", 203, 211], ["M proteins", "PROBLEM", 46, 56], ["bioinformatics tools", "TEST", 85, 105], ["an efficient multi-epitope vaccine", "TREATMENT", 120, 154], ["immune responses", "PROBLEM", 178, 194], ["COVID-19 infection", "PROBLEM", 203, 221], ["infection", "OBSERVATION", 212, 221]]], ["Preliminary studies based on phylogenetic analyses of the COVID-19 whole genome have suggested that this virus is very similar to the SARS-CoV (79.7% Identify) (9, 14) .", [["SARS", "DISEASE", 134, 138], ["SARS-CoV", "ORGANISM", 134, 142], ["COVID-19 whole genome", "DNA", 58, 79], ["SARS-CoV", "SPECIES", 134, 142], ["Preliminary studies", "TEST", 0, 19], ["phylogenetic analyses", "TEST", 29, 50], ["the COVID", "TEST", 54, 63], ["this virus", "PROBLEM", 100, 110], ["the SARS", "TEST", 130, 138], ["CoV", "TEST", 139, 142]]], ["Given the apparent similarity between the two viruses, it could be concluded that previous studies on the protective immune responses against SARS-CoV may be useful for developing a vaccine for COVID-19.", [["SARS", "DISEASE", 142, 146], ["SARS-CoV", "ORGANISM", 142, 150], ["SARS-CoV", "SPECIES", 142, 150], ["the two viruses", "PROBLEM", 38, 53], ["previous studies", "TEST", 82, 98], ["SARS", "PROBLEM", 142, 146], ["a vaccine", "TREATMENT", 180, 189], ["COVID", "TEST", 194, 199], ["viruses", "OBSERVATION", 46, 53]]], ["Previous studies have suggested that both humoral and cellular immunity play important roles in protective responses against this virus (Deming et al., 2007; Yang et al., 2004) .", [["cellular", "ANATOMY", 54, 62], ["cellular", "CELL", 54, 62], ["Previous studies", "TEST", 0, 16], ["this virus", "PROBLEM", 125, 135]]], ["Studies revealed that the formation of antibodies against the N protein of SARS-CoV, an immunogenic protein that is highly expressed during infection, is relatively common in patients infected with this virus (Liu et al., 2004; Lin et al., 2003) .", [["SARS", "DISEASE", 75, 79], ["infection", "DISEASE", 140, 149], ["SARS-CoV", "ORGANISM", 75, 83], ["patients", "ORGANISM", 175, 183], ["antibodies", "PROTEIN", 39, 49], ["N protein", "PROTEIN", 62, 71], ["SARS-CoV", "PROTEIN", 75, 83], ["immunogenic protein", "PROTEIN", 88, 107], ["patients", "SPECIES", 175, 183], ["SARS-CoV", "SPECIES", 75, 83], ["Studies", "TEST", 0, 7], ["antibodies", "TEST", 39, 49], ["the N protein", "TEST", 58, 71], ["SARS", "PROBLEM", 75, 79], ["CoV", "PROBLEM", 80, 83], ["an immunogenic protein", "PROBLEM", 85, 107], ["infection", "PROBLEM", 140, 149], ["infection", "OBSERVATION", 140, 149]]], ["Although these antibodies are effective, they have a shorter lifespan in recovering the patients.", [["patients", "ORGANISM", 88, 96], ["antibodies", "PROTEIN", 15, 25], ["patients", "SPECIES", 88, 96], ["a shorter lifespan", "TREATMENT", 51, 69]]], ["In addition to the specific humoral immunity, it has been shown that the CD 4\u00fe and CD 8\u00fe responses provide long-lasting protection against COVID-19.", [["CD 4", "GENE_OR_GENE_PRODUCT", 73, 77], ["CD 8", "GENE_OR_GENE_PRODUCT", 83, 87], ["COVID-19", "DNA", 139, 147], ["the CD", "TEST", 69, 75], ["CD", "TEST", 83, 85], ["COVID", "TEST", 139, 144]]], ["These studies showed that besides antibody-mediated immune response, cellular immunity is critical to induce protectivity in these infections (Liu et al., 2017) .", [["cellular", "ANATOMY", 69, 77], ["infections", "DISEASE", 131, 141], ["cellular", "CELL", 69, 77], ["These studies", "TEST", 0, 13], ["antibody", "TEST", 34, 42], ["infections", "OBSERVATION", 131, 141]]], ["The concept of a multi-epitope vaccine is to efficiently identify and assemble B and T-cell epitopes that are more capable of stimulating the immune system and therefore can induce more potent and effective both arms of immune responses.", [["T-cell", "ANATOMY", 85, 91], ["immune system", "ANATOMY", 142, 155], ["B", "CELL", 79, 80], ["T-cell", "CELL", 85, 91], ["B and T-cell epitopes", "PROTEIN", 79, 100], ["a multi-epitope vaccine", "TREATMENT", 15, 38], ["assemble B and T-cell epitopes", "PROBLEM", 70, 100]]], ["Peptides and epitopes have shown to be desirable candidates for vaccine development due to their relatively easy production, chemical stability, and lack of infectious potential (Patronov & Doytchinova, 2013) .", [["epitopes", "PROTEIN", 13, 21], ["vaccine", "TREATMENT", 64, 71], ["infectious", "OBSERVATION_MODIFIER", 157, 167]]], ["The experimental design and production of multi-epitope vaccines have improved dramatically in recent years.", [["multi-epitope vaccines", "TREATMENT", 42, 64], ["improved", "OBSERVATION_MODIFIER", 70, 78], ["dramatically", "OBSERVATION_MODIFIER", 79, 91]]], ["These vaccines are mainly made up of B-cell, CD 8\u00fe cytolytic T-cell (CTLs) and CD 4\u00fe helper T-cells (HTLs) epitopes (Chiarella et al., 2009) .", [["B-cell", "ANATOMY", 37, 43], ["T-cell", "ANATOMY", 61, 67], ["CTLs", "ANATOMY", 69, 73], ["CD 4\u00fe helper T-cells", "ANATOMY", 79, 99], ["HTLs", "ANATOMY", 101, 105], ["B-cell", "CELL", 37, 43], ["CD 8", "CELL", 45, 49], ["T-cell", "CELL", 61, 67], ["CTLs", "CELL", 69, 73], ["B-cell", "CELL_TYPE", 37, 43], ["cytolytic T-cell", "CELL_TYPE", 51, 67], ["CTLs", "CELL_TYPE", 69, 73], ["CD 4\u00fe helper T-cells", "CELL_TYPE", 79, 99], ["HTLs", "CELL_TYPE", 101, 105], ["These vaccines", "TREATMENT", 0, 14], ["CD", "TEST", 45, 47], ["cytolytic T", "TEST", 51, 62], ["CTLs", "TEST", 69, 73], ["CD", "TEST", 79, 81]]], ["Since the antigenic epitopes of a protein could be predicted and detected, therefore the whole protein is not suitable to stimulate an immune response (Testa & Philip, 2012; Zheng et al., 2017) .", [["antigenic epitopes", "PROTEIN", 10, 28], ["a protein", "TEST", 32, 41], ["the whole protein", "TEST", 85, 102]]], ["During the development of a vaccine candidate against COVID-19, complex pathogenic mechanisms and numerous pathogenic factors should be considered in vaccine formulation.IntroductionIn the present study, we aimed to design a novel multiepitope fusion protein (Nucleocapsid, ORF3a, and Membrane protein or NOM) containing more efficient antigenic epitopes-rich domains.", [["COVID-19", "ORGANISM", 54, 62], ["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 260, 272], ["ORF3a", "GENE_OR_GENE_PRODUCT", 274, 279], ["Membrane protein", "GENE_OR_GENE_PRODUCT", 285, 301], ["multiepitope fusion protein", "PROTEIN", 231, 258], ["Nucleocapsid", "PROTEIN", 260, 272], ["ORF3a", "PROTEIN", 274, 279], ["Membrane protein", "PROTEIN", 285, 301], ["NOM", "PROTEIN", 305, 308], ["antigenic epitopes", "PROTEIN", 336, 354], ["rich domains", "PROTEIN", 355, 367], ["a vaccine", "TREATMENT", 26, 35], ["COVID", "TEST", 54, 59], ["complex pathogenic mechanisms", "PROBLEM", 64, 93], ["numerous pathogenic factors", "PROBLEM", 98, 125], ["vaccine formulation", "TREATMENT", 150, 169], ["the present study", "TEST", 185, 202], ["a novel multiepitope fusion protein", "TREATMENT", 223, 258], ["Membrane protein or NOM", "TREATMENT", 285, 308], ["numerous", "OBSERVATION_MODIFIER", 98, 106], ["pathogenic", "OBSERVATION", 107, 117]]], ["The biological activity of the engineered fusion protein was assessed by bioinformatics tools using the interaction between the vaccine candidate and the innate immune system receptor (TLR4) and cellular immune system receptor (HLA-A \u00c3 11:01).", [["cellular", "ANATOMY", 195, 203], ["innate immune system receptor", "GENE_OR_GENE_PRODUCT", 154, 183], ["TLR4", "GENE_OR_GENE_PRODUCT", 185, 189], ["cellular immune system receptor", "GENE_OR_GENE_PRODUCT", 195, 226], ["engineered fusion protein", "PROTEIN", 31, 56], ["innate immune system receptor", "PROTEIN", 154, 183], ["TLR4", "PROTEIN", 185, 189], ["cellular immune system receptor", "PROTEIN", 195, 226], ["HLA", "PROTEIN", 228, 231], ["11:01", "PROTEIN", 236, 241], ["the engineered fusion protein", "TREATMENT", 27, 56], ["bioinformatics tools", "TEST", 73, 93], ["the vaccine candidate", "TREATMENT", 124, 145], ["activity", "OBSERVATION_MODIFIER", 15, 23]]], ["We strongly believe that the outcome of the present report will provide a potential vaccine candidate against 2019-nCoV.Materials and methodsIn this study, we designed a suitable vaccine candidate against COVID-19, by exploiting the programs of reverse vaccinology ( Figure 1)Retrieval of protein sequencesAt first, the amino acid sequences of proteins were retrieved from the National Centre for Biotechnology Information (NCBI) at www.ncbi.nlm.nih.gov in FASTA format and performed for subsequent analysis (Table 1 ).Selection of antigenic proteinsWe selected six proteins of COVID-19 virus ( Table 1) that have an essential role in virulence and replication of the virus, and previous studies have highlighted the necessity of these proteins in coronaviruses function.", [["amino acid", "CHEMICAL", 320, 330], ["amino acid", "CHEMICAL", 320, 330], ["COVID-19", "CELL", 205, 213], ["amino acid", "AMINO_ACID", 320, 330], ["COVID-19 virus", "ORGANISM", 578, 592], ["Table 1", "GENE_OR_GENE_PRODUCT", 595, 602], ["coronaviruses", "ORGANISM", 748, 761], ["COVID-19", "DNA", 205, 213], ["protein sequences", "PROTEIN", 289, 306], ["amino acid sequences", "PROTEIN", 320, 340], ["antigenic proteins", "PROTEIN", 532, 550], ["COVID", "PROTEIN", 578, 583], ["COVID-19 virus", "SPECIES", 578, 592], ["this study", "TEST", 144, 154], ["COVID", "TEST", 205, 210], ["reverse vaccinology", "TREATMENT", 245, 264], ["protein sequences", "TEST", 289, 306], ["the amino acid sequences", "TEST", 316, 340], ["subsequent analysis", "TEST", 488, 507], ["antigenic proteins", "PROBLEM", 532, 550], ["COVID", "TEST", 578, 583], ["the virus", "PROBLEM", 664, 673], ["previous studies", "TEST", 679, 695], ["these proteins in coronaviruses function", "PROBLEM", 730, 770], ["antigenic proteins", "OBSERVATION", 532, 550]]], ["After the antigenic analysis of these proteins, three proteins of N, ORF3a, and M were selected for final analysis.Prediction of T-cell (HLA class I and II) epitopes1d sequence-based screening server RANKPEP was used to identify T-cell epitopes (Reche & Reinherz, 2007) .", [["T-cell", "ANATOMY", 129, 135], ["T-cell", "ANATOMY", 229, 235], ["ORF3a", "GENE_OR_GENE_PRODUCT", 69, 74], ["T-cell", "CELL", 129, 135], ["HLA class I", "GENE_OR_GENE_PRODUCT", 137, 148], ["T-cell", "CELL", 229, 235], ["N", "PROTEIN", 66, 67], ["ORF3a", "PROTEIN", 69, 74], ["HLA class I and II) epitopes1d sequence", "DNA", 137, 176], ["RANKPEP", "PROTEIN", 200, 207], ["T-cell epitopes", "PROTEIN", 229, 244], ["the antigenic analysis", "TEST", 6, 28], ["these proteins", "TEST", 32, 46], ["ORF3a", "TEST", 69, 74], ["final analysis", "TEST", 100, 114], ["epitopes1d sequence", "TEST", 157, 176], ["T-", "ANATOMY", 129, 131], ["cell", "OBSERVATION", 131, 135]]], ["This server predicts peptide binders to MHC molecules from protein sequences using the position-specific scoring matrix (PSSM).", [["MHC molecules", "PROTEIN", 40, 53], ["This server predicts peptide binders", "TREATMENT", 0, 36], ["protein sequences", "TEST", 59, 76]]], ["We have selected all HLA class I alleles from the selection panel of RANKPEP server for prediction of epitopes of HLA class I. To prediction of epitopes of HLA class II, we considered DRB1 \u00c3 0101, DRB1 \u00c3 0301, DRB1 \u00c3 0401, DRB1 \u00c3 0701, DRB1 \u00c3 0801, DRB1 \u00c3 1101, DRB1 \u00c3 1301, and DRB1 \u00c3 1501 that cover HLA variability of over 95% of the human population worldwide (Kruiswijk et al., 2020) .B-cell epitopes (linear) identificationFor the prediction of B-cell epitopes, the amino acid sequence was analyzed using BepiPred and Kolaskar & Tongaonkar Antigenicity (http://www.iedb.org/) servers (Vita et al., 2019) .", [["B-cell", "ANATOMY", 390, 396], ["B-cell", "ANATOMY", 451, 457], ["amino acid", "CHEMICAL", 472, 482], ["amino acid", "CHEMICAL", 472, 482], ["HLA class II", "GENE_OR_GENE_PRODUCT", 156, 168], ["human", "ORGANISM", 337, 342], ["B-cell", "CELL", 390, 396], ["B-cell", "CELL", 451, 457], ["amino acid", "AMINO_ACID", 472, 482], ["HLA class I alleles", "DNA", 21, 40], ["RANKPEP", "PROTEIN", 69, 76], ["epitopes", "PROTEIN", 102, 110], ["epitopes", "PROTEIN", 144, 152], ["HLA class II", "PROTEIN", 156, 168], ["DRB1 \u00c3 1301", "DNA", 262, 273], ["DRB1 \u00c3 1501", "DNA", 279, 290], ["B-cell epitopes", "PROTEIN", 390, 405], ["B-cell epitopes", "PROTEIN", 451, 466], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 337, 342], ["DRB1", "TEST", 184, 188], ["DRB1", "TEST", 197, 201], ["DRB1", "TEST", 210, 214], ["DRB1", "TEST", 223, 227], ["DRB1", "TEST", 236, 240], ["DRB1", "TEST", 249, 253], ["DRB1", "TEST", 262, 266], ["DRB1", "TEST", 279, 283], ["HLA variability", "TEST", 302, 317], ["B-cell epitopes", "TREATMENT", 451, 466], ["the amino acid sequence", "TEST", 468, 491], ["BepiPred", "TREATMENT", 511, 519], ["Kolaskar", "TREATMENT", 524, 532], ["cell epitopes", "OBSERVATION", 392, 405], ["cell epitopes", "OBSERVATION", 453, 466]]], ["Bepipred for linear epitope prediction uses both hidden Markov model and amino acid propensity scales methods.", [["amino acid", "CHEMICAL", 73, 83], ["amino acid", "CHEMICAL", 73, 83], ["linear epitope prediction", "TREATMENT", 13, 38], ["hidden Markov model", "TREATMENT", 49, 68], ["amino acid propensity scales methods", "TREATMENT", 73, 109]]], ["Kolaskar and Tongaonkar evaluate the protein for B cell epitopes using the physicochemical properties of the amino acids and their frequencies of occurrence in recognized B cell epitopes (Kolaskar & Tongaonkar, 1990; Mirza et al., 2016) .Selection of epitope-rich domains and the final sequenceAccording to the prediction results of the servers used, B cell epitopes and HLA class I and II epitopes that have had high scores were extracted and combined to generate multi-Antigenicity and allergenicity evaluationAntigenicity of designed recombinant protein predicted using the VaxiJen v2.0 server.", [["B cell", "ANATOMY", 49, 55], ["B cell", "ANATOMY", 171, 177], ["B cell", "ANATOMY", 351, 357], ["amino acids", "CHEMICAL", 109, 120], ["amino acids", "CHEMICAL", 109, 120], ["B cell", "CELL", 49, 55], ["amino acids", "AMINO_ACID", 109, 120], ["B cell", "CELL", 171, 177], ["B cell", "CELL", 351, 357], ["HLA class I", "GENE_OR_GENE_PRODUCT", 371, 382], ["B cell epitopes", "PROTEIN", 49, 64], ["B cell epitopes", "PROTEIN", 171, 186], ["epitope-rich domains", "PROTEIN", 251, 271], ["B cell epitopes", "PROTEIN", 351, 366], ["HLA class I and II epitopes", "PROTEIN", 371, 398], ["recombinant protein", "PROTEIN", 537, 556], ["VaxiJen", "PROTEIN", 577, 584], ["Kolaskar", "TREATMENT", 0, 8], ["Tongaonkar", "TREATMENT", 13, 23], ["B cell epitopes", "TREATMENT", 49, 64], ["the amino acids", "TREATMENT", 105, 120], ["B cell epitopes", "TREATMENT", 351, 366], ["II epitopes", "PROBLEM", 387, 398], ["high scores", "PROBLEM", 413, 424], ["allergenicity evaluation", "TEST", 488, 512], ["B cell epitopes", "OBSERVATION", 171, 186]]], ["The VaxiJen classified antigens based on auto cross-covariance (ACC) transformation of protein sequences into uniform vectors of principal amino acid properties which is a novel alignment-independent method and overcome the limitations of alignment-dependent sequence methods (Doytchinova & Flower, 2007) .", [["amino acid", "CHEMICAL", 139, 149], ["amino acid", "CHEMICAL", 139, 149], ["amino acid", "AMINO_ACID", 139, 149], ["VaxiJen classified antigens", "PROTEIN", 4, 31], ["auto cross-covariance (ACC)", "TREATMENT", 41, 68], ["protein sequences", "TEST", 87, 104], ["principal amino acid properties", "PROBLEM", 129, 160], ["principal", "OBSERVATION_MODIFIER", 129, 138], ["amino acid", "OBSERVATION", 139, 149]]], ["The prediction of vaccine candidate allergenicity is essential.", [["vaccine candidate allergenicity", "TREATMENT", 18, 49]]], ["The allergenicity of the designed protein was computed by AllerTOP (http://www.ddg-pharmfac.net/AllerTOP/).", [["AllerTOP", "SIMPLE_CHEMICAL", 58, 66]]], ["AllerTOP method predicts recombinant protein allergenicity on auto crosscovariance ACC that describe residue hydrophobicity, size, abundance, helix-and b-strand forming propensities (Dimitrov et al., 2013) .", [["recombinant protein", "PROTEIN", 25, 44], ["AllerTOP method", "TREATMENT", 0, 15], ["recombinant protein allergenicity", "PROBLEM", 25, 58], ["auto crosscovariance ACC", "TREATMENT", 62, 86], ["residue hydrophobicity", "PROBLEM", 101, 123], ["helix", "TEST", 142, 147], ["residue hydrophobicity", "OBSERVATION", 101, 123], ["size", "OBSERVATION_MODIFIER", 125, 129]]], ["AllerTOP v.2 has the highest accuracy (88.7%) compared to several servers for allergen prediction (Dimitrov et al., 2013) .The physicochemical parametersThe analyzed parameters consisted of the molecular weight, theoretical pI, amino acid composition, atomic composition, extinction coefficient, estimated half-life, instability index, aliphatic index and grand average of hydropathicity that were evaluated by ProtParam online server (http://us.expasy.org/ tools/ protparam.html) (Gasteiger et al., 2005) .Secondary and tertiary structure predictionGOR was used for the designed protein secondary structure prediction (https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat. pl?page=/NPSA/npsa_gor4.html) (Kloczkowski et al., 2002) .", [["AllerTOP", "CHEMICAL", 0, 8], ["amino acid", "CHEMICAL", 228, 238], ["amino acid", "CHEMICAL", 228, 238], ["amino acid", "AMINO_ACID", 228, 238], ["AllerTOP", "TREATMENT", 0, 8], ["The physicochemical parameters", "TEST", 123, 153], ["the molecular weight", "TEST", 190, 210], ["amino acid composition", "TEST", 228, 250], ["instability index", "PROBLEM", 317, 334], ["aliphatic index", "PROBLEM", 336, 351], ["hydropathicity", "PROBLEM", 373, 387], ["Secondary and tertiary structure predictionGOR", "PROBLEM", 507, 553], ["the designed protein secondary structure prediction", "PROBLEM", 567, 618], ["aliphatic index", "OBSERVATION", 336, 351], ["tertiary structure", "OBSERVATION", 521, 539]]], ["GOR4 predict protein secondary structure using information theory.Secondary and tertiary structure predictionThe tertiary structure was built using the Galaxy web.", [["GOR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["GOR4", "PROTEIN", 0, 4], ["Secondary and tertiary structure prediction", "PROBLEM", 66, 109], ["secondary structure", "OBSERVATION", 21, 40], ["tertiary structure", "OBSERVATION", 80, 98], ["tertiary structure", "OBSERVATION", 113, 131]]], ["GalaxyWEB server (http://galaxy.seoklab.org/ tbm) is based on the TBM method.", [["GalaxyWEB", "SIMPLE_CHEMICAL", 0, 9], ["GalaxyWEB server", "TEST", 0, 16], ["http://galaxy.seoklab.org/ tbm)", "TREATMENT", 18, 49], ["the TBM method", "TREATMENT", 62, 76]]], ["This server detects similar proteins and alignment with the target sequence, then make the model and finally perform model refinement (Shin et al., 2014 ).Tertiary structure refinement and validationThe best-modeled structure was refined using the Galaxy Refine server at (http://galaxy.seoklab.org/cgi-bin/submit.cgi?-type=REFINE).", [["the target sequence", "TEST", 56, 75], ["Tertiary structure refinement", "TREATMENT", 155, 184], ["validation", "TEST", 189, 199]]], ["This method showed one of the best performances in improving protein structure quality.", [["This method", "TEST", 0, 11], ["protein structure", "OBSERVATION", 61, 78]]], ["Analysis of the final 3 D model was made using MolProbity, ProSA and Ramachandran plot.", [["MolProbity", "TREATMENT", 47, 57]]], ["Ramachandran plot obtained from RAMPAGE calculates torsional angles residue-by-residue in protein and indicates that residues are in allowed, favored or outlier regions (Oberholser, 2010) .", [["Ramachandran plot", "TEST", 0, 17], ["torsional angles residue", "PROBLEM", 51, 75], ["torsional angles", "OBSERVATION", 51, 67]]], ["ProSA web used to recognize the errors in the generated 3 D models using atomic coordinates of the model.", [["ProSA", "PROTEIN", 0, 5]]], ["ProSA web was created Z-score (overall model quality) and a plot of residue energies of proteins (Wiederstein & Sippl, 2007) .", [["ProSA", "PROTEIN", 0, 5]]], ["Clash analysis is very important for the validation of proteins.", [["Clash analysis", "TEST", 0, 14]]], ["MolProbity is a structure-validation web service that calculates the clash score, Protein-geometry score, Poor rotamers, Ramachandran plot, and MolProbity score.Defining discontinuous B-cell epitopes of designed proteinThe interaction between antigen epitopes and antibodies is very essential to eliminate the infection.", [["B-cell", "ANATOMY", 184, 190], ["infection", "DISEASE", 310, 319], ["B-cell", "CELL", 184, 190], ["antigen epitopes", "GENE_OR_GENE_PRODUCT", 243, 259], ["discontinuous B-cell epitopes", "PROTEIN", 170, 199], ["antigen epitopes", "PROTEIN", 243, 259], ["antibodies", "PROTEIN", 264, 274], ["the clash score", "TEST", 65, 80], ["Protein", "TEST", 82, 89], ["Ramachandran plot", "TEST", 121, 138], ["discontinuous B-cell epitopes", "TREATMENT", 170, 199], ["antigen epitopes", "TEST", 243, 259], ["antibodies", "TEST", 264, 274], ["the infection", "PROBLEM", 306, 319], ["B-cell epitopes", "OBSERVATION", 184, 199], ["infection", "OBSERVATION", 310, 319]]], ["Conformational epitopes are the most important and the most prevalent epitopes that are recognized by antibodies.", [["epitopes", "PROTEIN", 70, 78], ["antibodies", "PROTEIN", 102, 112], ["Conformational epitopes", "PROBLEM", 0, 23]]], ["All conformational epitope prediction methods require the 3 D structures of proteins.", [["All conformational epitope prediction methods", "TREATMENT", 0, 45]]], ["Discontinuous epitopes of recombinant protein predicted using the ElliPro server.", [["Discontinuous epitopes", "PROTEIN", 0, 22], ["recombinant protein", "PROTEIN", 26, 45], ["Discontinuous epitopes of recombinant protein", "PROBLEM", 0, 45]]], ["This web-based predicts discontinuous epitopes based on protein-antibody interactions.", [["discontinuous epitopes", "PROBLEM", 24, 46], ["protein", "TEST", 56, 63]]], ["ElliPro server predicts conformational and linear B cell epitopes using Thornton's method and by MODELLER program or BLAST search of PDB predict and visualize of antibody epitopes (Ponomarenko et al., 2008) .Obtaining and preparing the structures of immune receptors and NOM recombinant proteinThe crystallographic structures of TLR4 (PDB ID: 2Z62 (Kim et al., 2007) ) and HLA-A \u00c3 11:01 (PDB ID: 5WJL (Culshaw et al., 2017) ) were obtained from the PDB database (Berman et al., 2000) .", [["B cell", "ANATOMY", 50, 56], ["B cell", "CELL", 50, 56], ["TLR4", "GENE_OR_GENE_PRODUCT", 329, 333], ["antibody epitopes", "PROTEIN", 162, 179], ["immune receptors", "PROTEIN", 250, 266], ["NOM recombinant protein", "PROTEIN", 271, 294], ["TLR4", "PROTEIN", 329, 333], ["linear B cell epitopes", "TREATMENT", 43, 65], ["Thornton's method", "TREATMENT", 72, 89], ["PDB predict", "TEST", 133, 144], ["antibody epitopes", "PROBLEM", 162, 179], ["immune receptors", "TREATMENT", 250, 266], ["HLA", "TEST", 373, 376], ["TLR4", "ANATOMY", 329, 333], ["PDB", "ANATOMY", 449, 452]]], ["The structures were cleaned and crystallographic waters and co-crystallized molecules were deleted and only the monomer forms of each receptor were kept.", [["crystallographic waters and co-crystallized molecules", "TREATMENT", 32, 85], ["each receptor", "TREATMENT", 129, 142]]], ["Then, the structures of the two receptors and the NOM protein were prepared by the Dock prep tool in UCSF Chimera software (Pettersen et al., 2004) where hydrogen atoms and charge were added to the structures to make them ready for the next step.", [["hydrogen", "CHEMICAL", 154, 162], ["hydrogen", "CHEMICAL", 154, 162], ["hydrogen atoms", "SIMPLE_CHEMICAL", 154, 168], ["NOM protein", "PROTEIN", 50, 61], ["hydrogen atoms and charge", "TREATMENT", 154, 179]]], ["In the next step, to stabilize and relax the structures in an aqueous physiological environment, each of the monomer form of the receptors and the NOM protein were simulated for 100 ns.", [["NOM protein", "PROTEIN", 147, 158], ["the NOM protein", "TEST", 143, 158]]], ["The details of the MD simulation will be explained later.Protein-Protein molecular docking and refinementAfter the MD simulation of each receptor and the NOM recombinant protein, the last frame of the trajectory of each simulation was extracted and used as the input structures for protein-protein molecular docking.", [["NOM recombinant protein", "PROTEIN", 154, 177], ["Protein", "TEST", 57, 64], ["the NOM recombinant protein", "TREATMENT", 150, 177], ["protein-protein molecular docking", "TREATMENT", 282, 315]]], ["The PatchDock webserver (Schneidman-Duhovny et al., 2005) with default parameters was used to predict the best positions and orientations where the two proteins can have the highest number of favorable interactions.", [["default parameters", "TEST", 63, 81]]], ["Afterward, the top 10 solutions were subjected to Firedock webserver (Andrusier et al., 2007; Mashiach et al., 2008) to refine the interaction of protein-protein complexes resulted from molecular docking.", [["protein-protein complexes", "PROTEIN", 146, 171], ["protein-protein complexes", "TREATMENT", 146, 171]]], ["The top two complexes from Coronavirus NOM protein-TLR4 and NOM recombinant protein-HLA-A \u00c3 11:01 complexes were chosen based on global energies.", [["TLR4", "GENE_OR_GENE_PRODUCT", 51, 55], ["Coronavirus NOM protein", "PROTEIN", 27, 50], ["TLR4", "PROTEIN", 51, 55], ["NOM recombinant protein", "PROTEIN", 60, 83], ["HLA-A \u00c3 11:01 complexes", "PROTEIN", 84, 107], ["Coronavirus NOM protein", "TEST", 27, 50], ["NOM recombinant protein", "TEST", 60, 83], ["HLA", "TEST", 84, 87]]], ["These four complexes were then taken to the next step, MD simulation.Molecular dynamics simulationAfter performing the protein-protein molecular docking and finding the best orientations of the vaccine candidate and the receptor proteins to interact with one another, the two best-scored complexes were subjected to MD simulation.", [["receptor proteins", "PROTEIN", 220, 237], ["the protein-protein molecular docking", "TREATMENT", 115, 152], ["the vaccine", "TREATMENT", 190, 201]]], ["The monomer form of each protein and also the docked complexes were placed in the center of a triclinic box with a distance of 1 nm from all edges and solvated with TIP3P water model (Jorgensen et al., 1983) .", [["TIP3P", "CHEMICAL", 165, 170], ["docked complexes", "PROTEIN", 46, 62], ["triclinic box", "PROTEIN", 94, 107], ["a triclinic box", "TREATMENT", 92, 107], ["TIP3P water model", "TREATMENT", 165, 182], ["docked complexes", "OBSERVATION", 46, 62], ["triclinic box", "OBSERVATION", 94, 107], ["edges", "OBSERVATION_MODIFIER", 141, 146]]], ["Then, sodium and chloride ions were added to produce a neutral physiological salt concentration of 150 mM.", [["sodium", "CHEMICAL", 6, 12], ["chloride", "CHEMICAL", 17, 25], ["sodium", "CHEMICAL", 6, 12], ["chloride", "CHEMICAL", 17, 25], ["sodium", "SIMPLE_CHEMICAL", 6, 12], ["chloride ions", "SIMPLE_CHEMICAL", 17, 30], ["salt", "SIMPLE_CHEMICAL", 77, 81], ["sodium and chloride ions", "TREATMENT", 6, 30], ["150 mM", "OBSERVATION_MODIFIER", 99, 105]]], ["Each system was energy minimized, using the steepest descent algorithm, until the Fmax was found to be smaller than 10 kJ.mol \u00c01 nm \u00c01 .", [["the steepest descent algorithm", "TREATMENT", 40, 70], ["the Fmax", "TEST", 78, 86]]], ["All of the covalent bonds were constrained using the Linear Constraint Solver (LINCS) algorithm (Hess et al., 1997) to maintain constant bond lengths.", [["the Linear Constraint Solver (LINCS) algorithm", "TREATMENT", 49, 95], ["covalent bonds", "OBSERVATION", 11, 25]]], ["The longrange electrostatic interactions were treated using the Particle Mesh Ewald (PME) method (Darden et al., 1993; Essmann et al., 1995) and the cut off radii for Coulomb and Van der Waals short-range interactions were set to 0.9 nm.", [["The longrange electrostatic interactions", "PROBLEM", 0, 40], ["the Particle Mesh", "TREATMENT", 60, 77]]], ["Then 100 ps NVT (constant number of particles (N), volume (V), and temperature (T)) and 300 ps NPT (constant number of particles (N), pressure (P), and temperature (T)) equilibrations were performed for each system.", [["volume (V", "TEST", 51, 60], ["ps NPT", "TEST", 92, 98], ["pressure (P)", "TEST", 134, 146], ["equilibrations", "TEST", 169, 183]]], ["After the necessary equilibrations, 100 ns of production run were performed for each of the four complexes.", [["100 ns of production run", "TREATMENT", 36, 60]]], ["Finally, simulations were carried out under the periodic boundary conditions (PBC), set at XYZ coordinates to ensure that the atoms had stayed inside the simulation box, and the subsequent analyses were then performed using GROMACS utilities, VMD (Humphrey et al., 1996) and USCF Chimera, and also the plots and the figures were created using Daniel's XL Toolbox (v 7.3.2) add-in (Kraus, 2014)Mmpbsa binding free energyThe binding free energies of the protein-protein complexes were calculated by Molecular Mechanics-Poisson-Boltzmann Solvent-Accessible surface area, MMPBSA method (Kollman et al., 2000) using g_mmpbsa package (Kumari et al., 2014) .", [["protein-protein complexes", "PROTEIN", 452, 477], ["the subsequent analyses", "TEST", 174, 197], ["the protein-protein complexes", "TEST", 448, 477], ["Boltzmann Solvent", "TREATMENT", 525, 542], ["Accessible surface area", "TREATMENT", 543, 566]]], ["In our case, the NOM recombinant protein is defined as the ligand and the immune receptors are defined as the receptors.", [["NOM recombinant protein", "PROTEIN", 17, 40], ["immune receptors", "PROTEIN", 74, 90]]], ["The MMPBSA calculation was done for every ns of each simulation trajectories.Defining T-cell epitopesThe results of several studies have shown that strong virusspecific T-cell response is required for the elimination of respiratory virus infections such as SARS-CoV and influenza A and para-influenza.", [["T-cell", "ANATOMY", 86, 92], ["T-cell", "ANATOMY", 169, 175], ["respiratory virus infections", "DISEASE", 220, 248], ["SARS-CoV", "DISEASE", 257, 265], ["influenza A", "DISEASE", 270, 281], ["para-influenza", "DISEASE", 286, 300], ["T-cell", "CELL", 86, 92], ["T-cell", "CELL", 169, 175], ["respiratory virus", "ORGANISM", 220, 237], ["SARS-CoV", "ORGANISM", 257, 265], ["influenza A", "ORGANISM", 270, 281], ["para-influenza", "CANCER", 286, 300], ["MMPBSA", "DNA", 4, 10], ["T-cell epitopes", "PROTEIN", 86, 101], ["respiratory virus", "SPECIES", 220, 237], ["SARS-CoV", "SPECIES", 257, 265], ["The MMPBSA calculation", "TEST", 0, 22], ["several studies", "TEST", 116, 131], ["respiratory virus infections", "PROBLEM", 220, 248], ["SARS", "PROBLEM", 257, 261], ["CoV", "PROBLEM", 262, 265], ["influenza A", "PROBLEM", 270, 281], ["para-influenza", "PROBLEM", 286, 300], ["cell epitopes", "OBSERVATION", 88, 101], ["respiratory virus", "OBSERVATION", 220, 237]]], ["These studies conclude that future vaccine interventions should also consider strategies to enhance T cell response to provide robust long-term memory (Channappanavar et al., 2014; Janice Oh et al., 2012) .", [["T cell", "ANATOMY", 100, 106], ["T cell", "CELL", 100, 106], ["These studies", "TEST", 0, 13], ["future vaccine interventions", "TREATMENT", 28, 56]]], ["Studies have shown that high levels of T cell responses against N protein were found 2 years after the patient's recovery (Peng et al., 2006) .", [["T cell", "ANATOMY", 39, 45], ["T cell", "CELL", 39, 45], ["N protein", "GENE_OR_GENE_PRODUCT", 64, 73], ["patient", "ORGANISM", 103, 110], ["N protein", "PROTEIN", 64, 73], ["patient", "SPECIES", 103, 110], ["Studies", "TEST", 0, 7], ["high levels of T cell responses", "PROBLEM", 24, 55], ["N protein", "PROBLEM", 64, 73], ["high", "OBSERVATION_MODIFIER", 24, 28]]], ["Antibodies are essential to combat SARS-CoV infection, and the body needs SARS-CoV specific CD4 \u00fe T helper cells to produce these specific antibodies.", [["body", "ANATOMY", 63, 67], ["CD4 \u00fe T helper cells", "ANATOMY", 92, 112], ["SARS-CoV infection", "DISEASE", 35, 53], ["SARS-CoV", "ORGANISM", 35, 43], ["body", "ORGANISM_SUBDIVISION", 63, 67], ["CoV", "ORGANISM", 79, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD4 \u00fe T helper cells", "CELL_TYPE", 92, 112], ["specific antibodies", "PROTEIN", 130, 149], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 74, 82], ["Antibodies", "TEST", 0, 10], ["SARS", "PROBLEM", 35, 39], ["CoV infection", "PROBLEM", 40, 53], ["SARS", "TEST", 74, 78], ["CoV specific CD4", "TEST", 79, 95], ["infection", "OBSERVATION", 44, 53]]], ["Also, CD8 \u00fe cytotoxic T cells are important for recognizing and killing infected cells, especially in the lungs of infected individuals.", [["CD8 \u00fe cytotoxic T cells", "ANATOMY", 6, 29], ["cells", "ANATOMY", 81, 86], ["lungs", "ANATOMY", 106, 111], ["CD8", "GENE_OR_GENE_PRODUCT", 6, 9], ["cells", "CELL", 81, 86], ["lungs", "ORGAN", 106, 111], ["CD8", "PROTEIN", 6, 9], ["cytotoxic T cells", "CELL_TYPE", 12, 29], ["infected cells", "CELL_TYPE", 72, 86], ["CD8 \u00fe cytotoxic T cells", "PROBLEM", 6, 29], ["killing infected cells", "PROBLEM", 64, 86], ["infected individuals", "PROBLEM", 115, 135], ["cytotoxic T cells", "OBSERVATION", 12, 29], ["infected cells", "OBSERVATION", 72, 86], ["lungs", "ANATOMY", 106, 111], ["infected", "OBSERVATION", 115, 123]]], ["We used the Rankpep server which covers almost all HLA supertypes to predicted different epitops from N, ORF3a and M proteins sequence according to HLA I and HLA II alleles.", [["ORF3a", "GENE_OR_GENE_PRODUCT", 105, 110], ["HLA I", "GENE_OR_GENE_PRODUCT", 148, 153], ["HLA II", "GENE_OR_GENE_PRODUCT", 158, 164], ["HLA supertypes", "PROTEIN", 51, 65], ["N, ORF3a and M proteins", "PROTEIN", 102, 125], ["HLA I and HLA II alleles", "DNA", 148, 172], ["the Rankpep server", "TREATMENT", 8, 26]]], ["Antigenic epitopes with high binding affinity score were predicted that are summarized in table 2a-b.Defining linear B-cell epitopesSuccessful vaccination against viruses such as measles and rubella reflects the importance of protective antibodies.", [["B-cell", "ANATOMY", 117, 123], ["measles and rubella", "DISEASE", 179, 198], ["B-cell", "CELL", 117, 123], ["measles", "ORGANISM", 179, 186], ["Antigenic epitopes", "PROTEIN", 0, 18], ["protective antibodies", "PROTEIN", 226, 247], ["Antigenic epitopes", "PROBLEM", 0, 18], ["high binding affinity score", "PROBLEM", 24, 51], ["linear B-cell epitopes", "TREATMENT", 110, 132], ["Successful vaccination", "TREATMENT", 132, 154], ["viruses", "PROBLEM", 163, 170], ["measles", "PROBLEM", 179, 186], ["rubella", "PROBLEM", 191, 198], ["protective antibodies", "TREATMENT", 226, 247], ["linear", "OBSERVATION_MODIFIER", 110, 116], ["-cell", "OBSERVATION_MODIFIER", 118, 123]]], ["Protection against virus infection such as Coronaviruses depends on the simulation of neutralizing antibodies in addition to the T cell-mediated immunity.", [["T cell", "ANATOMY", 129, 135], ["infection", "DISEASE", 25, 34], ["T cell", "CELL", 129, 135], ["neutralizing antibodies", "PROTEIN", 86, 109], ["Protection", "TREATMENT", 0, 10], ["virus infection", "PROBLEM", 19, 34], ["Coronaviruses", "PROBLEM", 43, 56], ["neutralizing antibodies", "TREATMENT", 86, 109]]], ["While cytotoxic lymphocytes can kill infected cells, antibodies have the potential to eliminate infected cells and prevent the infectious virus from infecting a cell (neutralization).", [["lymphocytes", "ANATOMY", 16, 27], ["cells", "ANATOMY", 46, 51], ["cells", "ANATOMY", 105, 110], ["cell", "ANATOMY", 161, 165], ["cytotoxic lymphocytes", "CELL", 6, 27], ["cells", "CELL", 46, 51], ["cells", "CELL", 105, 110], ["cell", "CELL", 161, 165], ["cytotoxic lymphocytes", "CELL_TYPE", 6, 27], ["infected cells", "CELL_TYPE", 37, 51], ["antibodies", "PROTEIN", 53, 63], ["infected cells", "CELL_TYPE", 96, 110], ["cytotoxic lymphocytes", "PROBLEM", 6, 27], ["infected cells", "PROBLEM", 37, 51], ["antibodies", "TREATMENT", 53, 63], ["infected cells", "PROBLEM", 96, 110], ["the infectious virus", "PROBLEM", 123, 143], ["cytotoxic lymphocytes", "OBSERVATION", 6, 27], ["infectious", "OBSERVATION_MODIFIER", 127, 137], ["cell", "OBSERVATION", 161, 165]]], ["SARS-CoV-specific Neutralizing antibodies block viral entry (D\u20ac orner & Radbruch, 2007; Hsueh et al., 2004) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-specific Neutralizing antibodies", "PROTEIN", 0, 41], ["SARS", "PROBLEM", 0, 4]]], ["In this study, for the linear epitope prediction, the Bepipred server was employed.", [["this study", "TEST", 3, 13], ["the linear epitope prediction", "TREATMENT", 19, 48]]], ["Bepipred analysis revealed several continuous predicted epitopes of N, ORF3a and M proteins.", [["ORF3a", "GENE_OR_GENE_PRODUCT", 71, 76], ["M proteins", "GENE_OR_GENE_PRODUCT", 81, 91], ["epitopes", "PROTEIN", 56, 64], ["N, ORF3a and M proteins", "PROTEIN", 68, 91], ["Bepipred analysis", "TEST", 0, 17], ["several continuous predicted epitopes of N", "PROBLEM", 27, 69]]], ["For cross-checking the predicted epitopes, the sequence of all three proteins was also predicted by Kolaskar & Tongaonkar Antigenicity.", [["epitopes", "PROTEIN", 33, 41]]], ["The linear Bcell epitopes are represented in (Table 3 ).", [["linear Bcell epitopes", "PROTEIN", 4, 25], ["The linear Bcell epitopes", "PROBLEM", 0, 25], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["Bcell", "OBSERVATION_MODIFIER", 11, 16], ["epitopes", "OBSERVATION", 17, 25]]], ["Given that both cellular and humoral immune responses are essential against coronaviruses infection (Janice Oh et al., 2012) , finally, epitopes that were shared between B cell and T-cell were selected.Selected targets for designing the final vaccineThe main strategy in the present study was to design and construct a novel multi-epitope protein from COVID-19 based on in silico methods to elicit humoral and cellular immune responses.", [["cellular", "ANATOMY", 16, 24], ["B cell", "ANATOMY", 170, 176], ["T-cell", "ANATOMY", 181, 187], ["cellular", "ANATOMY", 410, 418], ["coronaviruses infection", "DISEASE", 76, 99], ["cellular", "CELL", 16, 24], ["coronaviruses", "ORGANISM", 76, 89], ["B cell", "CELL", 170, 176], ["T-cell", "CELL", 181, 187], ["cellular", "CELL", 410, 418], ["epitopes", "PROTEIN", 136, 144], ["B cell and T-cell", "CELL_TYPE", 170, 187], ["multi-epitope protein", "PROTEIN", 325, 346], ["coronaviruses infection", "PROBLEM", 76, 99], ["B cell and T-cell", "TREATMENT", 170, 187], ["the final vaccine", "TREATMENT", 233, 250], ["a novel multi-epitope protein", "TREATMENT", 317, 346], ["COVID", "TEST", 352, 357], ["silico methods", "TEST", 373, 387], ["main", "OBSERVATION_MODIFIER", 254, 258], ["cellular immune", "OBSERVATION", 410, 425]]], ["Due to the low immunogenicity of the epitope, we chose epitope-rich domains to generate a more diverse and robust response (Wieser et al., 2010) .", [["epitope", "PROTEIN", 37, 44], ["epitope-rich domains", "PROTEIN", 55, 75], ["the low immunogenicity of the epitope", "PROBLEM", 7, 44], ["epitope-rich domains", "TREATMENT", 55, 75], ["low immunogenicity", "OBSERVATION_MODIFIER", 11, 29]]], ["Based on in silico analysis, five epitope-rich domains including highly scored and shared epitopes between T and B-cell epitopes were selected and joined to each other with a three AAA linker (Table 4 ).", [["B-cell", "ANATOMY", 113, 119], ["T", "CELL", 107, 108], ["B-cell", "CELL", 113, 119], ["epitope-rich domains", "PROTEIN", 34, 54], ["epitopes", "PROTEIN", 90, 98], ["T and B-cell epitopes", "PROTEIN", 107, 128], ["AAA linker", "PROTEIN", 181, 191], ["silico analysis", "TEST", 12, 27], ["five epitope-rich domains", "PROBLEM", 29, 54], ["T and B-cell epitopes", "TREATMENT", 107, 128], ["a three AAA linker", "TREATMENT", 173, 191]]], ["The schematic diagram of designed vaccine domains with linker's sites has been shown in Figure 2 .Assessment of antigenicity and allergenicityPrediction of the vaccine candidate antigenicity represents a numerical criterion for the capability of the vaccine to bind to the B-and T-cell receptors and increase the immune response in the host cell.", [["T-cell", "ANATOMY", 279, 285], ["cell", "ANATOMY", 341, 345], ["B", "GENE_OR_GENE_PRODUCT", 273, 274], ["T-cell", "CELL", 279, 285], ["host cell", "CELL", 336, 345], ["B-and T-cell receptors", "PROTEIN", 273, 295], ["host cell", "CELL_TYPE", 336, 345], ["designed vaccine domains", "TREATMENT", 25, 49], ["linker's sites", "TREATMENT", 55, 69], ["allergenicity", "PROBLEM", 129, 142], ["the vaccine", "TREATMENT", 246, 257], ["immune response", "OBSERVATION", 313, 328], ["host cell", "OBSERVATION", 336, 345]]], ["VaxiJen v2.0 was used to predict the antigenicity of the designed protein.", [["VaxiJen v2.0", "TREATMENT", 0, 12]]], ["VaxiJen analysis of NOM protein showed potent antigenicity 0.5999 with a 0.4% threshold.", [["NOM protein", "PROTEIN", 20, 31], ["VaxiJen analysis", "TEST", 0, 16], ["NOM protein", "TEST", 20, 31], ["potent antigenicity", "TEST", 39, 58]]], ["The results indicate that the designed protein sequences without adjuvant are antigenic.", [["the designed protein sequences", "TEST", 26, 56], ["adjuvant", "TREATMENT", 65, 73], ["antigenic", "PROBLEM", 78, 87]]], ["Allergen proteins induce an IgE antibody response (Dimitrov et al., 2013) .", [["IgE", "GENE_OR_GENE_PRODUCT", 28, 31], ["Allergen proteins", "PROTEIN", 0, 17], ["IgE antibody", "PROTEIN", 28, 40], ["Allergen proteins", "TEST", 0, 17], ["an IgE antibody response", "TEST", 25, 49]]], ["The designed vaccine candidate must not show an allergic reaction to the body.", [["body", "ANATOMY", 73, 77], ["allergic reaction", "DISEASE", 48, 65], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["The designed vaccine", "TREATMENT", 0, 20], ["an allergic reaction", "PROBLEM", 45, 65], ["allergic", "OBSERVATION", 48, 56], ["body", "ANATOMY", 73, 77]]], ["Based on prediction approaches in Allertop, this protein was not recognized as an allergen.The physicochemical parameters and protein secondary structure predictionPrimary structure analysis NOM designed protein (337 aa) has a molecular weight of 37513.57 D. The total number of positively charged residues (Arg \u00fe Lys) and negatively charged residues (Asp \u00fe Glu) were 19 and 32 respectively.", [["Arg", "CHEMICAL", 308, 311], ["Lys", "CHEMICAL", 314, 317], ["Asp", "CHEMICAL", 352, 355], ["Glu", "CHEMICAL", 358, 361], ["Arg \u00fe Lys", "AMINO_ACID", 308, 317], ["Asp \u00fe Glu", "AMINO_ACID", 352, 361], ["The physicochemical parameters", "TEST", 91, 121], ["Primary structure analysis", "TEST", 164, 190], ["a molecular weight", "TEST", 225, 243], ["Arg \u00fe Lys", "TEST", 308, 317], ["Asp \u00fe Glu", "TEST", 352, 361]]], ["The instability index (< 40) indicates that the designed protein has high stability for the initiation of an immunogenic reaction.", [["The instability index", "TEST", 0, 21], ["the designed protein", "PROBLEM", 44, 64], ["an immunogenic reaction", "PROBLEM", 106, 129], ["instability", "OBSERVATION_MODIFIER", 4, 15], ["index", "OBSERVATION_MODIFIER", 16, 21], ["high stability", "OBSERVATION_MODIFIER", 69, 83]]], ["The instability index (II) was 35.75 which classifies the protein as stable.", [["The instability index", "TEST", 0, 21], ["the protein", "TEST", 54, 65], ["instability", "OBSERVATION_MODIFIER", 4, 15], ["index", "OBSERVATION_MODIFIER", 16, 21], ["stable", "OBSERVATION_MODIFIER", 69, 75]]], ["The aliphatic index of NOM recombinant protein was calculated 97.92 and indicates this protein has stability in several temperatures.", [["NOM recombinant protein", "PROTEIN", 23, 46], ["The aliphatic index", "TEST", 0, 19], ["NOM recombinant protein", "TEST", 23, 46], ["this protein", "PROBLEM", 82, 94], ["aliphatic", "OBSERVATION_MODIFIER", 4, 13], ["index", "OBSERVATION_MODIFIER", 14, 19], ["stability", "OBSERVATION_MODIFIER", 99, 108], ["several temperatures", "OBSERVATION_MODIFIER", 112, 132]]], ["Natively unfolded protein regions and alpha-helix are important forms of structural antigens that can be arranged in their native structure and thus identified by antibodies that are produced in response to infection.", [["infection", "DISEASE", 207, 216], ["Natively unfolded protein regions", "PROTEIN", 0, 33], ["alpha-helix", "PROTEIN", 38, 49], ["structural antigens", "PROTEIN", 73, 92], ["antibodies", "PROTEIN", 163, 173], ["Natively unfolded protein regions", "PROBLEM", 0, 33], ["alpha-helix", "PROBLEM", 38, 49], ["structural antigens", "PROBLEM", 73, 92], ["infection", "PROBLEM", 207, 216], ["unfolded", "OBSERVATION_MODIFIER", 9, 17], ["protein", "OBSERVATION", 18, 25], ["alpha-helix", "OBSERVATION_MODIFIER", 38, 49], ["infection", "OBSERVATION", 207, 216]]], ["The composition of the predicted secondary structure of the NOM multi-epitope vaccine candidate was 43.92% (alpha helix), 16.02% (extended strand), and 40.06% (random coil).", [["NOM", "CHEMICAL", 60, 63], ["NOM", "SIMPLE_CHEMICAL", 60, 63], ["alpha helix", "PROTEIN", 108, 119], ["the NOM multi-epitope vaccine", "TREATMENT", 56, 85], ["alpha helix", "TEST", 108, 119]]], ["All this information indicates the designed protein is suitable as a vaccine candidate.Tertiary structure prediction and validationThree-dimensional structure was modeled by GalaxyWEB for our designed protein (Figure 3a) .", [["GalaxyWEB", "SIMPLE_CHEMICAL", 174, 183], ["GalaxyWEB", "PROTEIN", 174, 183], ["Tertiary structure prediction", "TEST", 87, 116]]], ["This model was used for evaluation and refinement.", [["evaluation", "TEST", 24, 34]]], ["For validation of the model, ProSA-web, Ramachandran plot and MolProbity were used that compare and analyze the protein structure.", [["ProSA", "PROTEIN", 29, 34], ["Ramachandran plot", "TEST", 40, 57], ["MolProbity", "TREATMENT", 62, 72]]], ["The ProSA Web determined Z-score for the best predicted 3 D model (Figure 3b ).", [["ProSA", "PROTEIN", 4, 9], ["Z", "PROTEIN", 25, 26]]], ["The Z-score of the NOM predicted model was -4.42, which is within the range of scores typically found for native proteins of similar size.Tertiary structure prediction and validationThe Ramachandran plot indicates that most of the residues are found in the favored and allowed regions (99.7%) and only 0.3% in the outlier region, this shows that the quality of the designed model is satisfactory.", [["native proteins", "PROTEIN", 106, 121], ["The Z-score", "TEST", 0, 11], ["Tertiary structure prediction", "TEST", 138, 167], ["The Ramachandran plot", "TEST", 182, 203], ["the residues", "PROBLEM", 227, 239], ["proteins", "OBSERVATION", 113, 121], ["similar", "OBSERVATION_MODIFIER", 125, 132], ["size", "OBSERVATION_MODIFIER", 133, 137], ["satisfactory", "OBSERVATION_MODIFIER", 383, 395]]], ["Phe 282, Asn311, Tyr228, Lys194, Asp223, Ser229, Ser4, His197, Tyr68 residues were observed in the allowed and outlier regions of Ramachandran plot (Figure 3c ).", [["Phe", "CHEMICAL", 0, 3], ["Phe", "CHEMICAL", 0, 3], ["Asn311", "CHEMICAL", 9, 15], ["Tyr228", "CHEMICAL", 17, 23], ["Lys194", "CHEMICAL", 25, 31], ["Asp223", "CHEMICAL", 33, 39], ["Ser229", "CHEMICAL", 41, 47], ["Ser4", "CHEMICAL", 49, 53], ["His", "CHEMICAL", 55, 58], ["Tyr68", "CHEMICAL", 63, 68], ["Phe 282", "AMINO_ACID", 0, 7], ["Asn311", "GENE_OR_GENE_PRODUCT", 9, 15], ["Tyr228", "GENE_OR_GENE_PRODUCT", 17, 23], ["Lys194", "GENE_OR_GENE_PRODUCT", 25, 31], ["Asp223", "GENE_OR_GENE_PRODUCT", 33, 39], ["Ser229", "GENE_OR_GENE_PRODUCT", 41, 47], ["Ser4", "GENE_OR_GENE_PRODUCT", 49, 53], ["His197", "AMINO_ACID", 55, 61], ["Tyr68", "GENE_OR_GENE_PRODUCT", 63, 68], ["Phe", "TEST", 0, 3], ["Tyr228", "TEST", 17, 23], ["Asp223", "TEST", 33, 39], ["Ser4", "TEST", 49, 53], ["Tyr68 residues", "PROBLEM", 63, 77], ["Ramachandran plot", "TEST", 130, 147]]], ["In MolProbity analysis, the all-atom clash score was 9.37, the MolProbity score was 2.21.", [["MolProbity analysis", "TEST", 3, 22], ["the all-atom clash score", "TEST", 24, 48], ["the MolProbity score", "TEST", 59, 79]]], ["All structural images were created using PyMol (The PyMOL Molecular Graphics System, Version 1.1, Schr\u20ac odinger, LLC).Defining discontinuous B-cell epitopesEllipro Server was used for predicting conformational B-cell epitopes from the 3 D structure of NOM recombinant protein.", [["B-cell", "ANATOMY", 141, 147], ["B-cell", "ANATOMY", 210, 216], ["B-cell", "CELL", 141, 147], ["discontinuous B-cell epitopes", "PROTEIN", 127, 156], ["conformational B-cell epitopes", "PROTEIN", 195, 225], ["NOM recombinant protein", "PROTEIN", 252, 275], ["All structural images", "TEST", 0, 21], ["Version", "TEST", 85, 92], ["discontinuous B-cell epitopes", "TREATMENT", 127, 156], ["predicting conformational B-cell epitopes", "PROBLEM", 184, 225], ["NOM recombinant protein", "PROBLEM", 252, 275], ["LLC", "ANATOMY", 113, 116]]], ["Discontinuous B-cell epitopes were predicted with scores ranging from0.679 to 0.945.", [["B-cell", "ANATOMY", 14, 20], ["B-cell", "CELL", 14, 20], ["Discontinuous B-cell epitopes", "PROTEIN", 0, 29], ["Discontinuous B-cell epitopes", "TREATMENT", 0, 29], ["scores", "TEST", 50, 56], ["cell epitopes", "OBSERVATION", 16, 29]]], ["Amino acid residues, the number of residues, sequence location as well as their scores have been listed in Tables 5.", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["Amino acid residues", "TREATMENT", 0, 19], ["acid residues", "OBSERVATION", 6, 19]]], ["The graphical representation of the discontinuous epitopes has been displayed in Figure 4 .Establishing the stability of the initial structuresA vaccine can interact with different receptors of the immune system.", [["immune system", "ANATOMY", 198, 211], ["immune system", "ANATOMICAL_SYSTEM", 198, 211], ["discontinuous epitopes", "PROTEIN", 36, 58], ["the discontinuous epitopes", "PROBLEM", 32, 58], ["A vaccine", "TREATMENT", 143, 152], ["stability", "OBSERVATION_MODIFIER", 108, 117]]], ["We have docked designed final constructs (NOM) with TLR4 and HLA-A \u00c3 11:01 receptors.", [["TLR4", "GENE_OR_GENE_PRODUCT", 52, 56], ["HLA-A \u00c3 11:01 receptors", "GENE_OR_GENE_PRODUCT", 61, 84], ["TLR4", "PROTEIN", 52, 56], ["HLA-A \u00c3 11:01 receptors", "PROTEIN", 61, 84]]], ["The interaction between these receptors and NOM recombinant protein induce different immune responses.", [["NOM recombinant", "GENE_OR_GENE_PRODUCT", 44, 59], ["NOM recombinant protein", "PROTEIN", 44, 67], ["these receptors", "TREATMENT", 24, 39]]], ["To achieve a stable and relaxed state of the NOM recombinant protein and the immune receptors, a MD simulation of 100 ns was performed for each structure.", [["NOM recombinant protein", "PROTEIN", 45, 68], ["immune receptors", "PROTEIN", 77, 93], ["stable", "OBSERVATION_MODIFIER", 13, 19]]], ["These simulations ensure that the structures are stable enough to be used for protein-protein molecular docking.", [["protein-protein molecular docking", "TREATMENT", 78, 111], ["stable", "OBSERVATION", 49, 55]]], ["After 100 ns of the production run, as it is shown in Figure 5 , the RMSD (Root Mean Square Distance) values of the monomers show that the backbone structure of TLR4 (PDB ID: 2Z62) is very rigid and stable.", [["TLR4", "GENE_OR_GENE_PRODUCT", 161, 165], ["TLR4", "PROTEIN", 161, 165], ["PDB ID: 2Z62", "PROTEIN", 167, 179], ["very rigid", "PROBLEM", 184, 194], ["TLR4", "ANATOMY", 161, 165], ["rigid", "OBSERVATION", 189, 194], ["stable", "OBSERVATION_MODIFIER", 199, 205]]], ["The structure of the NOM recombinant protein also reached stability after about 25 ns after a considerable structural change.", [["NOM recombinant protein", "PROTEIN", 21, 44], ["a considerable structural change", "PROBLEM", 92, 124], ["stability", "OBSERVATION_MODIFIER", 58, 67]]], ["The backbone structure of the HLA-A \u00c3 11:01 (PDB ID: 5WJL), however, showed big spikes in the RMSD values but all three structures were visually inspected and were considered stable enough for the next step of the project.Protein-protein molecular dockingTo find the best orientation for optimal interaction of the NOM protein with the immune receptors we decided to use protein-protein molecular docking.", [["HLA", "PROTEIN", 30, 33], ["5WJL", "PROTEIN", 53, 57], ["NOM protein", "PROTEIN", 315, 326], ["immune receptors", "PROTEIN", 336, 352], ["big spikes in the RMSD values", "PROBLEM", 76, 105], ["Protein", "TEST", 222, 229], ["the immune receptors", "TREATMENT", 332, 352], ["protein-protein molecular docking", "TREATMENT", 371, 404], ["backbone", "ANATOMY_MODIFIER", 4, 12], ["HLA", "ANATOMY", 30, 33], ["big spikes", "OBSERVATION", 76, 86], ["stable", "OBSERVATION_MODIFIER", 175, 181]]], ["We used PatchDock webserver which concentrates on recognizing and matching patterns of the surfaces of the proteins to put them in the best possible positions.", [["PatchDock webserver", "TREATMENT", 8, 27]]], ["The FireDock algorithms refine the docked complexes by side-chain rearrangement and soft rigid-body optimization.", [["docked complexes", "PROTEIN", 35, 51], ["The FireDock algorithms", "TREATMENT", 0, 23], ["side-chain rearrangement", "TREATMENT", 55, 79], ["soft rigid-body optimization", "TREATMENT", 84, 112], ["soft rigid", "OBSERVATION", 84, 94]]], ["The ranking of the docked complexes is based on short-range, long-range, attractive and repulsive interaction energies between the residues of the two proteins, which are all summed up in the global energy or the binding energy of the complexes.", [["docked complexes", "PROTEIN", 19, 35], ["attractive and repulsive interaction energies", "PROBLEM", 73, 118], ["docked complexes", "OBSERVATION", 19, 35], ["repulsive", "OBSERVATION_MODIFIER", 88, 97], ["interaction energies", "OBSERVATION", 98, 118]]], ["We considered global energy as the main criterion for choosing the best complexes and chose the two top-scored solutions with the best global energy.", [["global energy", "PROBLEM", 14, 27], ["global energy", "OBSERVATION", 14, 27]]], ["As it is shown in Table 6 , the solution numbers 5 and 6 from the NOM-TLR4 complex and the solution numbers 2 and 3, from NOM-HLA-A \u00c3 11:01 complex, were chosen for further calculations.", [["TLR4", "GENE_OR_GENE_PRODUCT", 70, 74], ["NOM", "PROTEIN", 66, 69], ["TLR4 complex", "PROTEIN", 70, 82], ["NOM", "PROTEIN", 122, 125], ["HLA", "PROTEIN", 126, 129], ["11:01 complex", "PROTEIN", 134, 147], ["the solution numbers", "TEST", 28, 48], ["the solution numbers", "TEST", 87, 107], ["further calculations", "TEST", 165, 185]]], ["The results showed a strong interaction between designed protein amino acids and receptors.", [["amino acids", "CHEMICAL", 65, 76], ["amino acids", "CHEMICAL", 65, 76], ["amino acids", "AMINO_ACID", 65, 76], ["protein amino acids and receptors", "PROTEIN", 57, 90], ["protein amino acids", "TREATMENT", 57, 76]]], ["The interactions between the binding receptors and the docked NOM protein were visualized using the UCSF Chimera program.", [["NOM", "GENE_OR_GENE_PRODUCT", 62, 65], ["binding receptors", "PROTEIN", 29, 46], ["NOM protein", "PROTEIN", 62, 73], ["the binding receptors", "TREATMENT", 25, 46]]], ["Residues of HLA-A \u00c3 1101(GLU 53 , ASN 174 , GLY 56 , ASN 174 , GLU 53 , PRO 57 ) participated in the After the protein-protein molecular docking, 4 solutions were chosen for MD simulation, solution numbers 2 and 3 from NOM protein-HLA-A \u00c3 11:01 complex and solution numbers 5 and 6 from NOM protein-TLR4 complex.", [["TLR4", "GENE_OR_GENE_PRODUCT", 299, 303], ["NOM protein", "PROTEIN", 219, 230], ["HLA-A \u00c3 11:01 complex", "PROTEIN", 231, 252], ["solution numbers 5 and 6", "PROTEIN", 257, 281], ["NOM protein", "PROTEIN", 287, 298], ["TLR4 complex", "PROTEIN", 299, 311], ["HLA", "TEST", 12, 15], ["GLU", "TEST", 25, 28], ["ASN", "TEST", 34, 37], ["GLY", "TEST", 44, 47], ["ASN", "TEST", 53, 56], ["GLU", "TEST", 63, 66], ["PRO", "TEST", 72, 75], ["the protein", "TEST", 107, 118], ["NOM protein", "TEST", 219, 230], ["HLA", "TEST", 231, 234], ["solution numbers", "TEST", 257, 273], ["NOM protein", "TEST", 287, 298], ["TLR4 complex", "OBSERVATION_MODIFIER", 299, 311]]], ["To examine their stability throughout the simulations period, the RMSD values of each protein was analyzed.", [["the RMSD values", "TEST", 62, 77]]], ["As it is shown in Figure 7 , each protein has different RMSD values and in some of them, the backbone atoms have considerable movements during the simulations.", [["considerable", "OBSERVATION_MODIFIER", 113, 125], ["movements", "OBSERVATION", 126, 135]]], ["The RMSD values of TLR4 in NOM protein-TLR4 complexes and the values of HLA-A \u00c3 11:01 in NOM protein-HLA-A \u00c3 11:01 complexes are very stable and the average values do not reach very high values.", [["TLR4", "GENE_OR_GENE_PRODUCT", 19, 23], ["TLR4", "GENE_OR_GENE_PRODUCT", 39, 43], ["TLR4", "PROTEIN", 19, 23], ["NOM protein", "PROTEIN", 27, 38], ["TLR4 complexes", "PROTEIN", 39, 53], ["NOM protein", "PROTEIN", 89, 100], ["HLA", "PROTEIN", 101, 104], ["The RMSD values", "TEST", 0, 15], ["TLR4", "TEST", 19, 23], ["NOM protein", "TEST", 27, 38], ["the values", "TEST", 58, 68], ["HLA", "TEST", 72, 75], ["NOM protein", "TEST", 89, 100], ["HLA", "TEST", 101, 104], ["the average values", "TEST", 145, 163], ["RMSD", "OBSERVATION_MODIFIER", 4, 8], ["TLR4", "OBSERVATION_MODIFIER", 19, 23], ["very", "OBSERVATION_MODIFIER", 129, 133], ["stable", "OBSERVATION_MODIFIER", 134, 140]]], ["However, the RMSD values of the NOM protein in every complex reach high values which means that the structure of the vaccine has more movements to refine the interactions with the immune receptors.", [["NOM protein", "GENE_OR_GENE_PRODUCT", 32, 43], ["NOM protein", "PROTEIN", 32, 43], ["immune receptors", "PROTEIN", 180, 196], ["the RMSD values", "TEST", 9, 24], ["the NOM protein", "TEST", 28, 43], ["the vaccine", "TREATMENT", 113, 124], ["the immune receptors", "TREATMENT", 176, 196], ["NOM protein", "OBSERVATION", 32, 43]]], ["However, the interactions between the NOM recombinant protein and the immune receptors are quite strong and MMPBSA binding energy calculations exhibit great binding energies.", [["MMPBSA", "SIMPLE_CHEMICAL", 108, 114], ["NOM recombinant protein", "PROTEIN", 38, 61], ["immune receptors", "PROTEIN", 70, 86], ["the NOM recombinant protein", "TREATMENT", 34, 61], ["the immune receptors", "TEST", 66, 86], ["MMPBSA binding energy calculations", "TEST", 108, 142], ["great binding energies", "PROBLEM", 151, 173], ["binding energies", "OBSERVATION", 157, 173]]], ["As it is shown in Table 7 , the Van der Waals and electrostatic energies of the complexes are strong enough to keep the two proteins in contact with each other.", [["the Van der Waals and electrostatic energies of the complexes", "TREATMENT", 28, 89]]], ["Moreover, the deviation of each value is very small which means that the interactions are very stable and consistent throughout the simulations.", [["deviation", "OBSERVATION", 14, 23], ["very", "OBSERVATION_MODIFIER", 41, 45], ["small", "OBSERVATION_MODIFIER", 46, 51], ["very", "OBSERVATION_MODIFIER", 90, 94], ["stable", "OBSERVATION_MODIFIER", 95, 101]]], ["In another word, the higher scale of RMSD values with consistent binding energies only show that the structure of the NOM protein is well optimized for interacting with the immune receptors.Protein-protein molecular dockingIn addition to the analysis described above, to analyze the fluctuations of the backbone atoms of structures of the proteins, we decided to perform RMSF (Root Mean Square Fluctuation) analysis.", [["NOM", "GENE_OR_GENE_PRODUCT", 118, 121], ["NOM protein", "PROTEIN", 118, 129], ["immune receptors", "PROTEIN", 173, 189], ["RMSD values", "TEST", 37, 48], ["consistent binding energies", "PROBLEM", 54, 81], ["the immune receptors", "TREATMENT", 169, 189], ["Protein", "TEST", 190, 197], ["the analysis", "TEST", 238, 250], ["RMSF", "TEST", 371, 375], ["analysis", "TEST", 407, 415]]], ["In this analysis, the average value of fluctuation of each residue during the simulation is plotted, Figure 8 .", [["this analysis", "TEST", 3, 16], ["each residue", "PROBLEM", 54, 66], ["the simulation", "TEST", 74, 88]]], ["As it is shown in Figure 8a , the RMSF values of NOM recombinant protein in five simulations indicate that the fluctuation of the monomer form of the vaccine in many regions is considerably more than the complex forms.", [["NOM recombinant protein", "PROTEIN", 49, 72], ["the RMSF values", "TEST", 30, 45], ["NOM recombinant protein", "PROBLEM", 49, 72], ["the vaccine", "TREATMENT", 146, 157]]], ["This is a direct indication that the NOM recombinant protein is much more stable when it is in complex with the two immune receptors.", [["NOM recombinant protein", "PROTEIN", 37, 60], ["immune receptors", "PROTEIN", 116, 132], ["the NOM recombinant protein", "PROBLEM", 33, 60]]], ["Furthermore, the RMSF values of the NOM recombinant protein in complex with HLA-A \u00c3 11:01 are lower compared with that of NOM recombinant protein in complex with TLR4.", [["TLR4", "GENE_OR_GENE_PRODUCT", 162, 166], ["NOM recombinant protein", "PROTEIN", 36, 59], ["HLA", "PROTEIN", 76, 79], ["NOM recombinant protein", "PROTEIN", 122, 145], ["TLR4", "PROTEIN", 162, 166], ["the RMSF values", "TEST", 13, 28], ["HLA", "TEST", 76, 79], ["RMSF", "OBSERVATION", 17, 21]]], ["Also, with the evidence that the binding energies are also lower, we can conclude that NOM recombinant protein can bind to the HLA-A \u00c3 11:01 better than the other immune receptor.Protein-protein molecular dockingIn Figure 8b and Figure 8c , the RMSF values of the monomer forms of the immune receptors show lower values compared to the complex forms.", [["immune receptor", "GENE_OR_GENE_PRODUCT", 163, 178], ["NOM recombinant protein", "PROTEIN", 87, 110], ["immune receptor", "PROTEIN", 163, 178], ["Protein-protein molecular dockingIn Figure 8b", "PROTEIN", 179, 224], ["immune receptors", "PROTEIN", 285, 301], ["the binding energies", "PROBLEM", 29, 49], ["NOM recombinant protein", "PROBLEM", 87, 110], ["Protein", "TEST", 179, 186], ["Figure", "TEST", 215, 221], ["Figure", "TEST", 229, 235], ["the RMSF values", "TEST", 241, 256], ["the immune receptors", "TEST", 281, 301], ["lower values", "OBSERVATION_MODIFIER", 307, 319]]], ["This behavior is exactly the opposite of the NOM designed protein.", [["NOM designed protein", "PROTEIN", 45, 65]]], ["This can be an indication that the structures are very stable in their natural function and their structures considerably change when they get into contact with the designed NOM protein.", [["NOM", "GENE_OR_GENE_PRODUCT", 174, 177], ["NOM protein", "PROTEIN", 174, 185], ["very", "OBSERVATION_MODIFIER", 50, 54], ["stable", "OBSERVATION_MODIFIER", 55, 61]]], ["Furthermore, the structural illustration of the monomer forms and also the complex forms of the vaccine and the immune receptors, Figure 9 , shows that the vaccine can fill the cavities and bind tightly to them, as it was proved by the binding energies.ConclusionCOVID-19 pandemic is much more than a health crisis.", [["immune receptors", "PROTEIN", 112, 128], ["Figure 9", "PROTEIN", 130, 138], ["the vaccine", "TREATMENT", 92, 103], ["the immune receptors", "TEST", 108, 128], ["the vaccine", "TREATMENT", 152, 163], ["ConclusionCOVID", "TEST", 253, 268], ["pandemic", "PROBLEM", 272, 280]]], ["The development of a safe and effective vaccine could reduce the rate of this infection.", [["infection", "DISEASE", 78, 87], ["a safe and effective vaccine", "TREATMENT", 19, 47], ["this infection", "PROBLEM", 73, 87], ["infection", "OBSERVATION", 78, 87]]], ["Immunoinformatics methods are valuable in reducing time and cost in vaccine design and other fields of life sciences.", [["Immunoinformatics methods", "TREATMENT", 0, 25], ["cost in vaccine design", "TREATMENT", 60, 82]]], ["We have predicted and validated NOM recombinant protein against HLA-A \u00c3 11:01 and TLR4 receptors.", [["HLA-A \u00c3 11:01", "GENE_OR_GENE_PRODUCT", 64, 77], ["TLR4 receptors", "GENE_OR_GENE_PRODUCT", 82, 96], ["NOM recombinant protein", "PROTEIN", 32, 55], ["HLA-A \u00c3 11:01 and TLR4 receptors", "PROTEIN", 64, 96], ["HLA", "TEST", 64, 67], ["TLR4 receptors", "TREATMENT", 82, 96]]], ["Our evaluation was based on vaccine candidate structural analysis and molecular docking and MD simulations study.", [["Our evaluation", "TEST", 0, 14], ["vaccine", "TREATMENT", 28, 35], ["structural analysis", "TEST", 46, 65], ["MD simulations study", "TEST", 92, 112]]], ["The NOM-TLR4 and NOM-HLA-A \u00c3 11:01 complexes were very stable in their natural function with strong molecular interactions in around 100 ns.", [["TLR4", "GENE_OR_GENE_PRODUCT", 8, 12], ["NOM", "PROTEIN", 4, 7], ["TLR4", "PROTEIN", 8, 12], ["NOM", "PROTEIN", 17, 20], ["HLA", "PROTEIN", 21, 24], ["11:01 complexes", "PROTEIN", 29, 44], ["The NOM", "TEST", 0, 7], ["TLR4", "ANATOMY", 8, 12], ["stable", "OBSERVATION_MODIFIER", 55, 61]]], ["Higher binding energy even after the MD simulation of 100 ns confirmed the stability and specificity NOM-TLR4 and NOM-HLA-A \u00c3 11:01 interaction.", [["TLR4", "GENE_OR_GENE_PRODUCT", 105, 109], ["NOM", "SIMPLE_CHEMICAL", 114, 117], ["TLR4", "PROTEIN", 105, 109], ["NOM", "PROTEIN", 114, 117], ["Higher binding energy", "PROBLEM", 0, 21]]], ["Our vaccine candidate can stimulate both cellular and humoral immunity, given that B and T-cell epitopes have been selected in the final construct.", [["cellular", "ANATOMY", 41, 49], ["T-cell", "ANATOMY", 89, 95], ["cellular", "CELL", 41, 49], ["B", "CELL", 83, 84], ["T-cell", "CELL", 89, 95], ["B and T-cell epitopes", "PROTEIN", 83, 104], ["Our vaccine", "TREATMENT", 0, 11], ["B and T-cell epitopes", "TREATMENT", 83, 104]]], ["Taken all together, according to physicochemical evaluations as well as structural and immunological analyses, NOM recombinant protein could be considered as a possible vaccine candidate against COVID-19.", [["COVID-19", "CELL", 195, 203], ["NOM recombinant protein", "PROTEIN", 111, 134], ["COVID-19", "DNA", 195, 203], ["physicochemical evaluations", "TEST", 33, 60], ["structural and immunological analyses", "TEST", 72, 109], ["NOM recombinant protein", "PROBLEM", 111, 134], ["COVID", "TEST", 195, 200]]]], "a99c4b9e539ac13e666430236b3483c72b79154f": [["Abstract Purpose: Despite their controversial role, corticosteroids (CS) are frequently administered to patients with H1N1 virus infection with severe respiratory failure secondary to viral pneumonia.", [["respiratory", "ANATOMY", 151, 162], ["CS", "CHEMICAL", 69, 71], ["H1N1 virus infection", "DISEASE", 118, 138], ["respiratory failure", "DISEASE", 151, 170], ["viral pneumonia", "DISEASE", 184, 199], ["corticosteroids", "CHEMICAL", 52, 67], ["corticosteroids", "SIMPLE_CHEMICAL", 52, 67], ["CS", "SIMPLE_CHEMICAL", 69, 71], ["patients", "ORGANISM", 104, 112], ["H1N1 virus", "ORGANISM", 118, 128], ["patients", "SPECIES", 104, 112], ["H1N1 virus", "SPECIES", 118, 128], ["H1N1 virus", "SPECIES", 118, 128], ["corticosteroids (CS)", "TREATMENT", 52, 72], ["H1N1 virus infection", "PROBLEM", 118, 138], ["severe respiratory failure", "PROBLEM", 144, 170], ["viral pneumonia", "PROBLEM", 184, 199], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["respiratory failure", "OBSERVATION", 151, 170], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["pneumonia", "OBSERVATION", 190, 199]]], ["We hypothesized that invasive pulmonary aspergillosis (IPA) is a frequent complication in critically ill patients with H1N1 virus infection and that CS may contribute to this complication.", [["invasive pulmonary aspergillosis", "ANATOMY", 21, 53], ["invasive pulmonary aspergillosis", "DISEASE", 21, 53], ["IPA", "DISEASE", 55, 58], ["critically ill", "DISEASE", 90, 104], ["H1N1 virus infection", "DISEASE", 119, 139], ["pulmonary", "ORGAN", 30, 39], ["aspergillosis", "PATHOLOGICAL_FORMATION", 40, 53], ["patients", "ORGANISM", 105, 113], ["H1N1 virus", "ORGANISM", 119, 129], ["patients", "SPECIES", 105, 113], ["H1N1 virus", "SPECIES", 119, 129], ["H1N1 virus", "SPECIES", 119, 129], ["invasive pulmonary aspergillosis", "PROBLEM", 21, 53], ["a frequent complication", "PROBLEM", 63, 86], ["H1N1 virus infection", "PROBLEM", 119, 139], ["this complication", "PROBLEM", 170, 187], ["invasive", "OBSERVATION_MODIFIER", 21, 29], ["pulmonary", "ANATOMY", 30, 39], ["aspergillosis", "OBSERVATION", 40, 53]]], ["Methods: We retrospectively selected all adult patients with confirmed H1N1 virus infection admitted to the intensive care unit (ICU) of two tertiary care hospitals from September 2009 to March 2011.", [["H1N1 virus infection", "DISEASE", 71, 91], ["patients", "ORGANISM", 47, 55], ["H1N1 virus", "ORGANISM", 71, 81], ["patients", "SPECIES", 47, 55], ["H1N1 virus", "SPECIES", 71, 81], ["H1N1 virus", "SPECIES", 71, 81], ["H1N1 virus infection", "PROBLEM", 71, 91]]], ["Differences in baseline factors, risk factors, and outcome parameters were studied between patients with and without IPA.", [["IPA", "CHEMICAL", 117, 120], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["risk factors", "PROBLEM", 33, 45], ["outcome parameters", "TEST", 51, 69]]], ["Results: Of 40 critically ill patients with confirmed H1N1, 9 (23 %) developed IPA 3 days after ICU admission.", [["critically ill", "DISEASE", 15, 29], ["H1N1", "DISEASE", 54, 58], ["IPA", "DISEASE", 79, 82], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["H1N1", "PROBLEM", 54, 58]]], ["Five patients had proven and four had probable IPA.", [["IPA", "DISEASE", 47, 50], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["probable", "UNCERTAINTY", 38, 46], ["IPA", "OBSERVATION", 47, 50]]], ["Significantly more IPA patients received CS within 7 days before ICU admission (78 versus 23 %, p = 0.002).", [["IPA", "CHEMICAL", 19, 22], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["IPA patients also received significantly higher doses of CS before ICU admission [hydrocortisone equivalent 800 (360-2,635) versus 0 (0-0) mg, p = 0.005].", [["hydrocortisone", "CHEMICAL", 82, 96], ["hydrocortisone", "CHEMICAL", 82, 96], ["patients", "ORGANISM", 4, 12], ["hydrocortisone", "SIMPLE_CHEMICAL", 82, 96], ["patients", "SPECIES", 4, 12], ["hydrocortisone equivalent", "TREATMENT", 82, 107]]], ["On multivariate analysis, use of CS before ICU admission was independently associated with IPA [odds ratio (OR) 14.4 (2.0-101.6), p = 0.007].", [["multivariate analysis", "TEST", 3, 24]]], ["Conclusions: IPA was diagnosed in 23 % of critically ill patients with H1N1 virus infection after a median of 3 days after ICU admission.", [["critically ill", "DISEASE", 42, 56], ["H1N1 virus infection", "DISEASE", 71, 91], ["patients", "ORGANISM", 57, 65], ["H1N1 virus", "ORGANISM", 71, 81], ["patients", "SPECIES", 57, 65], ["H1N1 virus", "SPECIES", 71, 81], ["H1N1 virus", "SPECIES", 71, 81], ["IPA", "TEST", 13, 16], ["H1N1 virus infection", "PROBLEM", 71, 91]]], ["Our data suggest that use of CS 7 days before ICU admission is an independent risk factor for fungal superinfection.", [["fungal superinfection", "DISEASE", 94, 115], ["fungal superinfection", "PROBLEM", 94, 115], ["fungal", "OBSERVATION_MODIFIER", 94, 100], ["superinfection", "OBSERVATION", 101, 115]]], ["These findings may have consequences for clinical practice as they point out the need for increased awareness of IPA, especially in those critically ill H1N1 patients already receiving CS.IntroductionSince June 2009, infection with influenza A (H1N1) virus has reached pandemic proportions.", [["IPA", "CHEMICAL", 113, 116], ["H1N1", "DISEASE", 153, 157], ["infection", "DISEASE", 217, 226], ["influenza A (H1N1) virus", "DISEASE", 232, 256], ["patients", "ORGANISM", 158, 166], ["influenza A (H1N1) virus", "ORGANISM", 232, 256], ["patients", "SPECIES", 158, 166], ["influenza A (H1N1) virus", "SPECIES", 232, 256], ["influenza A (H1N1) virus", "SPECIES", 232, 256], ["increased awareness of IPA", "PROBLEM", 90, 116], ["infection", "PROBLEM", 217, 226], ["influenza A (H1N1) virus", "PROBLEM", 232, 256], ["infection", "OBSERVATION", 217, 226]]], ["A minority of patients with H1N1 virus infection (0.3-13 %) needed hospitalization, and 10-30 % of these developed rapidly progressive pneumonia.", [["H1N1 virus infection", "DISEASE", 28, 48], ["pneumonia", "DISEASE", 135, 144], ["patients", "ORGANISM", 14, 22], ["H1N1 virus", "ORGANISM", 28, 38], ["patients", "SPECIES", 14, 22], ["H1N1 virus", "SPECIES", 28, 38], ["H1N1 virus", "SPECIES", 28, 38], ["H1N1 virus infection", "PROBLEM", 28, 48], ["rapidly progressive pneumonia", "PROBLEM", 115, 144], ["H1N1 virus", "OBSERVATION", 28, 38], ["rapidly", "OBSERVATION_MODIFIER", 115, 122], ["progressive", "OBSERVATION_MODIFIER", 123, 134], ["pneumonia", "OBSERVATION", 135, 144]]], ["The ensuing profound inflammatory response caused the most severe form of acute lung injury, called acute respiratory distress syndrome (ARDS), either isolated or as part of a multiple organ dysfunction syndrome (MODS) [1] .", [["lung", "ANATOMY", 80, 84], ["respiratory", "ANATOMY", 106, 117], ["organ", "ANATOMY", 185, 190], ["acute lung injury", "DISEASE", 74, 91], ["acute respiratory distress syndrome", "DISEASE", 100, 135], ["ARDS", "DISEASE", 137, 141], ["multiple organ dysfunction syndrome", "DISEASE", 176, 211], ["MODS", "DISEASE", 213, 217], ["lung", "ORGAN", 80, 84], ["organ", "ORGAN", 185, 190], ["The ensuing profound inflammatory response", "PROBLEM", 0, 42], ["acute lung injury", "PROBLEM", 74, 91], ["acute respiratory distress syndrome", "PROBLEM", 100, 135], ["ARDS", "PROBLEM", 137, 141], ["a multiple organ dysfunction syndrome", "PROBLEM", 174, 211], ["profound", "OBSERVATION_MODIFIER", 12, 20], ["inflammatory response", "OBSERVATION", 21, 42], ["most severe", "OBSERVATION_MODIFIER", 54, 65], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["lung", "ANATOMY", 80, 84], ["injury", "OBSERVATION", 85, 91], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory distress syndrome", "OBSERVATION", 106, 135], ["multiple", "OBSERVATION_MODIFIER", 176, 184], ["organ", "ANATOMY", 185, 190], ["dysfunction", "OBSERVATION", 191, 202]]], ["ARDS due to this infection was associated with a high mortality rate (14-41 %) [1, 2] .", [["ARDS", "DISEASE", 0, 4], ["infection", "DISEASE", 17, 26], ["ARDS", "PROBLEM", 0, 4], ["this infection", "PROBLEM", 12, 26], ["a high mortality rate", "PROBLEM", 47, 68], ["infection", "OBSERVATION", 17, 26]]], ["Controversy exists regarding use of anti-inflammatory agents such as corticosteroids (CS) for ARDS.", [["ARDS", "DISEASE", 94, 98], ["corticosteroids", "CHEMICAL", 69, 84], ["corticosteroids", "SIMPLE_CHEMICAL", 69, 84], ["anti-inflammatory agents", "TREATMENT", 36, 60], ["corticosteroids (CS)", "TREATMENT", 69, 89], ["ARDS", "PROBLEM", 94, 98], ["ARDS", "OBSERVATION", 94, 98]]], ["While an initial meta-analysis concluded that a definitive role of CS in ARDS was not established, a more recent one reported improved mortality as well as length of stay and less organ dysfunction with early, low-to moderate-dose CS in some subgroups of ARDS patients [3, 4] .IntroductionDespite their controversial role, CS have been administered to 18-69 % of patients with ARDS secondary to H1N1 virus infection [5] [6] [7] .", [["organ", "ANATOMY", 180, 185], ["ARDS", "DISEASE", 73, 77], ["organ dysfunction", "DISEASE", 180, 197], ["ARDS", "DISEASE", 255, 259], ["ARDS", "DISEASE", 377, 381], ["H1N1 virus infection", "DISEASE", 395, 415], ["organ", "ORGAN", 180, 185], ["patients", "ORGANISM", 260, 268], ["patients", "ORGANISM", 363, 371], ["H1N1 virus", "ORGANISM", 395, 405], ["patients", "SPECIES", 260, 268], ["patients", "SPECIES", 363, 371], ["H1N1 virus", "SPECIES", 395, 405], ["ARDS", "PROBLEM", 73, 77], ["less organ dysfunction", "PROBLEM", 175, 197], ["ARDS", "PROBLEM", 255, 259], ["ARDS", "PROBLEM", 377, 381], ["H1N1 virus infection", "PROBLEM", 395, 415], ["ARDS", "OBSERVATION", 73, 77], ["ARDS", "OBSERVATION", 255, 259]]], ["However, several recent studies reported possible harmful effects of CS in severe pneumonia due to H1N1 virus infection.", [["CS", "CHEMICAL", 69, 71], ["pneumonia", "DISEASE", 82, 91], ["H1N1 virus infection", "DISEASE", 99, 119], ["H1N1 virus", "ORGANISM", 99, 109], ["H1N1 virus", "SPECIES", 99, 109], ["H1N1 virus", "SPECIES", 99, 109], ["several recent studies", "TEST", 9, 31], ["CS in severe pneumonia", "PROBLEM", 69, 91], ["H1N1 virus infection", "PROBLEM", 99, 119], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["pneumonia", "OBSERVATION", 82, 91], ["H1N1 virus", "OBSERVATION", 99, 109]]], ["Two groups of investigators found that CS administration (very early) in the course of H1N1-related ARDS was associated with significantly higher ICU and hospital mortality [8, 9] .", [["H1N1", "DISEASE", 87, 91], ["ARDS", "DISEASE", 100, 104], ["CS administration", "TREATMENT", 39, 56], ["H1N1", "PROBLEM", 87, 91], ["ARDS", "PROBLEM", 100, 104], ["ARDS", "OBSERVATION", 100, 104]]], ["Martin-Loeches et al. [10] also reported in a worldwide population that early use of CS did not result in better outcome and was associated with increased risk for superinfection.IntroductionRemarkably, use of CS is associated with increased incidence of invasive aspergillosis in chronic obstructive pulmonary disease (COPD) patients with severe respiratory insufficiency [11] .", [["invasive aspergillosis", "ANATOMY", 255, 277], ["pulmonary", "ANATOMY", 301, 310], ["respiratory", "ANATOMY", 347, 358], ["superinfection", "DISEASE", 164, 178], ["aspergillosis", "DISEASE", 264, 277], ["chronic obstructive pulmonary disease", "DISEASE", 281, 318], ["COPD", "DISEASE", 320, 324], ["respiratory insufficiency", "DISEASE", 347, 372], ["pulmonary", "ORGAN", 301, 310], ["patients", "ORGANISM", 326, 334], ["patients", "SPECIES", 326, 334], ["superinfection", "PROBLEM", 164, 178], ["invasive aspergillosis", "PROBLEM", 255, 277], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 281, 325], ["severe respiratory insufficiency", "PROBLEM", 340, 372], ["superinfection", "OBSERVATION", 164, 178], ["invasive", "OBSERVATION_MODIFIER", 255, 263], ["aspergillosis", "OBSERVATION", 264, 277], ["chronic", "OBSERVATION_MODIFIER", 281, 288], ["obstructive", "OBSERVATION_MODIFIER", 289, 300], ["pulmonary", "ANATOMY", 301, 310], ["disease", "OBSERVATION", 311, 318], ["COPD", "OBSERVATION", 320, 324], ["severe", "OBSERVATION_MODIFIER", 340, 346], ["respiratory insufficiency", "OBSERVATION", 347, 372]]], ["Invasive aspergillosis is also described as a dreaded complication with high mortality in critically ill patients without malignancy or neutropenia [11, 12] .", [["Invasive aspergillosis", "DISEASE", 0, 22], ["critically ill", "DISEASE", 90, 104], ["malignancy", "DISEASE", 122, 132], ["neutropenia", "DISEASE", 136, 147], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["Invasive aspergillosis", "PROBLEM", 0, 22], ["a dreaded complication", "PROBLEM", 44, 66], ["malignancy", "PROBLEM", 122, 132], ["neutropenia", "PROBLEM", 136, 147], ["aspergillosis", "OBSERVATION", 9, 22], ["neutropenia", "OBSERVATION", 136, 147]]], ["Recent clinical reports suggest that CS therapy may be associated with increased ICU-acquired pneumonia and possibly favor fungal superinfection in patients with H1N1 virus infection [8, 13] .", [["CS", "CHEMICAL", 37, 39], ["pneumonia", "DISEASE", 94, 103], ["fungal superinfection", "DISEASE", 123, 144], ["H1N1 virus infection", "DISEASE", 162, 182], ["CS", "SIMPLE_CHEMICAL", 37, 39], ["patients", "ORGANISM", 148, 156], ["H1N1 virus", "ORGANISM", 162, 172], ["patients", "SPECIES", 148, 156], ["H1N1 virus", "SPECIES", 162, 172], ["H1N1 virus", "SPECIES", 162, 172], ["CS therapy", "TREATMENT", 37, 47], ["increased ICU-acquired pneumonia", "PROBLEM", 71, 103], ["fungal superinfection", "PROBLEM", 123, 144], ["H1N1 virus infection", "PROBLEM", 162, 182], ["pneumonia", "OBSERVATION", 94, 103], ["possibly favor", "UNCERTAINTY", 108, 122], ["fungal", "OBSERVATION_MODIFIER", 123, 129], ["superinfection", "OBSERVATION", 130, 144]]], ["However, in these studies, including 465 patients, only 2 % of critically ill patients with H1N1 virus infection were found to develop invasive pulmonary aspergillosis (IPA).", [["invasive pulmonary aspergillosis", "ANATOMY", 135, 167], ["critically ill", "DISEASE", 63, 77], ["H1N1 virus infection", "DISEASE", 92, 112], ["invasive pulmonary aspergillosis", "DISEASE", 135, 167], ["IPA", "DISEASE", 169, 172], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 78, 86], ["H1N1 virus", "ORGANISM", 92, 102], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 144, 167], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 78, 86], ["H1N1 virus", "SPECIES", 92, 102], ["H1N1 virus", "SPECIES", 92, 102], ["these studies", "TEST", 12, 25], ["H1N1 virus infection", "PROBLEM", 92, 112], ["invasive pulmonary aspergillosis", "PROBLEM", 135, 167], ["invasive", "OBSERVATION_MODIFIER", 135, 143], ["pulmonary", "ANATOMY", 144, 153], ["aspergillosis", "OBSERVATION", 154, 167]]], ["In addition, case reports of IPA as a fungal superinfection in critically patients with H1N1 virus infection have been described recently [13] [14] [15] [16] [17] [18] .IntroductionIn the present observational study, we hypothesize that IPA is a much more frequent complication in critically ill H1N1 patients and that use of CS may contribute to this superinfection.Study populationWe retrospectively reviewed the medical records of all patients who were admitted to the adult intensive care units of two tertiary hospitals [University Hospitals Leuven (UZL), Leuven, Belgium and Antwerp University Hospital (UZA), Edegem, Belgium] from September 2009 to March 2011 in whom H1N1 virus infection was diagnosed during or 1 week prior to ICU stay.", [["IPA", "CHEMICAL", 29, 32], ["fungal superinfection", "DISEASE", 38, 59], ["H1N1 virus infection", "DISEASE", 88, 108], ["IPA", "CHEMICAL", 237, 240], ["critically ill", "DISEASE", 281, 295], ["H1N1", "DISEASE", 296, 300], ["CS", "CHEMICAL", 326, 328], ["superinfection", "DISEASE", 352, 366], ["H1N1 virus infection", "DISEASE", 675, 695], ["patients", "ORGANISM", 74, 82], ["H1N1 virus", "ORGANISM", 88, 98], ["[13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 138, 167], ["patients", "ORGANISM", 301, 309], ["patients", "ORGANISM", 438, 446], ["patients", "SPECIES", 74, 82], ["H1N1 virus", "SPECIES", 88, 98], ["patients", "SPECIES", 301, 309], ["patients", "SPECIES", 438, 446], ["H1N1 virus", "SPECIES", 88, 98], ["H1N1 virus", "SPECIES", 675, 685], ["IPA", "PROBLEM", 29, 32], ["a fungal superinfection", "PROBLEM", 36, 59], ["H1N1 virus infection", "PROBLEM", 88, 108], ["observational study", "TEST", 196, 215], ["CS", "TREATMENT", 326, 328], ["this superinfection", "PROBLEM", 347, 366], ["H1N1 virus infection", "PROBLEM", 675, 695], ["fungal", "OBSERVATION_MODIFIER", 38, 44], ["superinfection", "OBSERVATION", 45, 59], ["superinfection", "OBSERVATION", 352, 366]]], ["The medical ICU of UZL has 17 beds, whereas the mixed ICU of UZA has 45 beds.", [["UZA", "CHEMICAL", 61, 64]]], ["Patients 8 years old were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Diagnosis of H1N1 virus infection was based on a positive result from a probe-based reverse-transcriptase polymerase chain reaction (RT-PCR) test for H1N1 from a nasopharyngeal swab or bronchoalveolar lavage (BAL).", [["nasopharyngeal swab", "ANATOMY", 162, 181], ["bronchoalveolar lavage", "ANATOMY", 185, 207], ["BAL", "ANATOMY", 209, 212], ["H1N1 virus infection", "DISEASE", 13, 33], ["H1N1 virus", "ORGANISM", 13, 23], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 162, 181], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 185, 207], ["BAL", "MULTI-TISSUE_STRUCTURE", 209, 212], ["H1N1 virus", "SPECIES", 13, 23], ["H1N1 virus", "SPECIES", 13, 23], ["H1N1 virus infection", "PROBLEM", 13, 33], ["a probe", "TEST", 70, 77], ["transcriptase polymerase chain reaction", "PROBLEM", 92, 131], ["RT-PCR) test", "TEST", 133, 145], ["H1N1", "PROBLEM", 150, 154], ["a nasopharyngeal swab", "TEST", 160, 181], ["bronchoalveolar lavage", "TEST", 185, 207], ["H1N1", "OBSERVATION", 13, 17], ["nasopharyngeal", "ANATOMY", 162, 176], ["bronchoalveolar lavage", "OBSERVATION", 185, 207]]], ["This observational retrospective study without any specific intervention was reviewed and approved by both hospitals' Institutional Review Boards, and all data were processed anonymously.", [["This observational retrospective study", "TEST", 0, 38]]], ["Informed consent was waived by both ethics committees.DefinitionsFor the remainder of the manuscript, we abbreviate ''patients with H1N1 virus infection'' as ''H1N1 patients'' for the sake of simplicity.", [["H1N1 virus infection", "DISEASE", 132, 152], ["H1N1", "DISEASE", 160, 164], ["patients", "ORGANISM", 118, 126], ["H1N1 virus", "ORGANISM", 132, 142], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 118, 126], ["H1N1 virus", "SPECIES", 132, 142], ["patients", "SPECIES", 165, 173], ["H1N1 virus", "SPECIES", 132, 142], ["H1N1 virus infection", "PROBLEM", 132, 152]]], ["Invasive pulmonary aspergillosis was diagnosed based on the revised EORTC/MSG consensus group (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group) guidelines [19] .", [["pulmonary", "ANATOMY", 9, 18], ["Invasive pulmonary aspergillosis", "DISEASE", 0, 32], ["Cancer", "DISEASE", 147, 153], ["Invasive Fungal Infections", "DISEASE", 154, 180], ["Infectious Diseases Mycoses", "DISEASE", 241, 268], ["pulmonary", "ORGAN", 9, 18], ["Invasive pulmonary aspergillosis", "PROBLEM", 0, 32], ["Cancer", "PROBLEM", 147, 153], ["Invasive Fungal Infections", "PROBLEM", 154, 180], ["pulmonary", "ANATOMY", 9, 18], ["aspergillosis", "OBSERVATION", 19, 32]]], ["Patients had proven IPA if there was microscopic evidence of dichotomous branching hyphae with positive culture for Aspergillus spp. from endobronchial biopsy (not BAL), irrespective of host factors or clinical features.", [["hyphae", "ANATOMY", 83, 89], ["endobronchial biopsy", "ANATOMY", 138, 158], ["BAL", "ANATOMY", 164, 167], ["Aspergillus spp", "DISEASE", 116, 131], ["Patients", "ORGANISM", 0, 8], ["Aspergillus spp", "ORGANISM", 116, 131], ["endobronchial biopsy", "MULTI-TISSUE_STRUCTURE", 138, 158], ["Patients", "SPECIES", 0, 8], ["dichotomous branching hyphae", "PROBLEM", 61, 89], ["positive culture", "PROBLEM", 95, 111], ["Aspergillus spp", "PROBLEM", 116, 131], ["endobronchial biopsy", "TEST", 138, 158], ["host factors", "PROBLEM", 186, 198], ["clinical features", "PROBLEM", 202, 219], ["evidence of", "UNCERTAINTY", 49, 60], ["dichotomous", "OBSERVATION_MODIFIER", 61, 72], ["branching hyphae", "OBSERVATION", 73, 89], ["endobronchial", "ANATOMY", 138, 151], ["biopsy", "OBSERVATION", 152, 158]]], ["Probable IPA required a host factor, clinical features, and mycological evidence of aspergillosis.", [["IPA", "CHEMICAL", 9, 12], ["aspergillosis", "DISEASE", 84, 97], ["aspergillosis", "CANCER", 84, 97], ["a host factor", "PROBLEM", 22, 35], ["aspergillosis", "PROBLEM", 84, 97], ["aspergillosis", "OBSERVATION", 84, 97]]], ["Since host factors in the revised EORTC definitions are basically intended for immunocompromised hematological patients, we defined broader risk factors, based on ''modified EORTC criteria,'' according to our previous prospective study on the value of BAL for diagnosis of Aspergillus in ICU patients [20] .", [["Aspergillus", "DISEASE", 273, 284], ["patients", "ORGANISM", 111, 119], ["BAL", "ORGANISM_SUBSTANCE", 252, 255], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 292, 300], ["immunocompromised hematological patients", "PROBLEM", 79, 119], ["our previous prospective study", "TEST", 205, 235], ["Aspergillus", "PROBLEM", 273, 284]]], ["Mycological evidence was based on microscopy or culture of Aspergillus spp. cultured from a BAL specimen or a galactomannan (GM) optical index [0.5 from a BAL or serum sample.", [["BAL specimen", "ANATOMY", 92, 104], ["BAL", "ANATOMY", 155, 158], ["serum sample", "ANATOMY", 162, 174], ["GM", "CHEMICAL", 125, 127], ["Aspergillus spp", "ORGANISM", 59, 74], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["Aspergillus spp", "SPECIES", 59, 74], ["microscopy", "TEST", 34, 44], ["culture", "TEST", 48, 55], ["Aspergillus spp", "PROBLEM", 59, 74], ["a BAL specimen", "TEST", 90, 104], ["a galactomannan", "TEST", 108, 123], ["optical index", "TEST", 129, 142], ["a BAL", "TEST", 153, 158], ["serum sample", "TEST", 162, 174], ["Aspergillus spp", "OBSERVATION", 59, 74]]], ["Sandwich enzymelinked immunosorbent assay (ELISA) for GM detection (Platelia Aspergillus; Bio-Rad Laboratories, Marnes-la-Coquette, France) was performed according to the instructions of the manufacturer [20, 21] .", [["GM", "CHEMICAL", 54, 56], ["Sandwich enzymelinked immunosorbent assay", "TEST", 0, 41], ["ELISA", "TEST", 43, 48], ["GM detection", "TEST", 54, 66], ["Platelia", "TEST", 68, 76], ["Aspergillus", "TEST", 77, 88], ["Bio-Rad Laboratories", "TEST", 90, 110], ["Marnes", "TEST", 112, 118]]], ["Lower tract respiratory samples were inoculated onto a Sabouraud agar (2 days at 37\u00b0C and another 19 days at 30\u00b0C) for fungal isolation.", [["Lower tract respiratory samples", "ANATOMY", 0, 31], ["Lower tract respiratory samples", "PROBLEM", 0, 31], ["fungal isolation", "TREATMENT", 119, 135], ["tract", "ANATOMY_MODIFIER", 6, 11], ["respiratory", "ANATOMY", 12, 23], ["fungal isolation", "OBSERVATION", 119, 135]]], ["Aspergillus species were identified by their culture characteristics and morphologies.", [["Aspergillus species", "ORGANISM", 0, 19], ["Aspergillus species", "PROBLEM", 0, 19], ["their culture characteristics", "TEST", 39, 68]]], ["During the study period, routine baseline monitoring was performed in the ICU and in all high-risk wards taking care of oncology, hematology, and transplant patients.", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["the study", "TEST", 7, 16], ["routine baseline monitoring", "TEST", 25, 52]]], ["This monitoring was performed at least once a year [22] .", [["This monitoring", "TEST", 0, 15]]], ["Severity of illness was assessed based on the Acute Physiology and Chronic Evaluation Score (APACHE) II score and the Sequential Organ Failure Assessment (SOFA) score 24 h after admission.", [["illness", "DISEASE", 12, 19], ["illness", "PROBLEM", 12, 19], ["the Acute Physiology", "PROBLEM", 42, 62], ["Chronic Evaluation Score", "TEST", 67, 91], ["II score", "TEST", 101, 109], ["the Sequential Organ Failure", "PROBLEM", 114, 142], ["illness", "OBSERVATION", 12, 19], ["Organ", "ANATOMY", 129, 134], ["Failure", "OBSERVATION", 135, 142]]], ["Patients were considered immunosuppressed at baseline in case of underlying malignant hematological disease, solid-organ transplant recipient, or any other illness necessitating immunosuppressive therapy.", [["malignant hematological", "ANATOMY", 76, 99], ["organ", "ANATOMY", 115, 120], ["malignant hematological disease", "DISEASE", 76, 107], ["illness", "DISEASE", 156, 163], ["Patients", "ORGANISM", 0, 8], ["malignant hematological", "CANCER", 76, 99], ["organ", "ORGAN", 115, 120], ["Patients", "SPECIES", 0, 8], ["immunosuppressed", "PROBLEM", 25, 41], ["underlying malignant hematological disease", "PROBLEM", 65, 107], ["organ transplant recipient", "TREATMENT", 115, 141], ["any other illness", "PROBLEM", 146, 163], ["immunosuppressive therapy", "TREATMENT", 178, 203], ["immunosuppressed", "OBSERVATION", 25, 41], ["malignant", "OBSERVATION_MODIFIER", 76, 85]]], ["Neutropenia was defined as neutrophils 00/mm 3 for [10 days.", [["neutrophils", "ANATOMY", 27, 38], ["Neutropenia", "DISEASE", 0, 11], ["neutrophils", "CELL", 27, 38], ["neutrophils", "CELL_TYPE", 27, 38], ["Neutropenia", "PROBLEM", 0, 11], ["neutrophils", "TEST", 27, 38]]], ["In both centers, the doses and frequency of all drugs administered in the month before and during admission to the ICU were recorded in the medical records and the patient data management system (PDMS, Metavision; iMDsoft, Boston, USA).", [["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["all drugs", "TREATMENT", 44, 53]]], ["All CS doses are expressed in mg hydrocortisone equivalent.", [["hydrocortisone", "CHEMICAL", 33, 47], ["hydrocortisone", "CHEMICAL", 33, 47], ["hydrocortisone", "SIMPLE_CHEMICAL", 33, 47], ["All CS doses", "TREATMENT", 0, 12], ["mg hydrocortisone equivalent", "TREATMENT", 30, 58]]], ["Outcome measures included ICU or hospital survival and length of stay, days of organ support [mechanical ventilation, inhaled nitric oxide (NO) or high-frequency rescue ventilation, extracorporeal membrane oxygenation (ECMO), vasopressor, renal replacement therapy], and ICU complications (bacteremia, ventilator-associated pneumonia).", [["organ", "ANATOMY", 79, 84], ["extracorporeal membrane", "ANATOMY", 182, 205], ["renal", "ANATOMY", 239, 244], ["nitric oxide", "CHEMICAL", 126, 138], ["NO", "CHEMICAL", 140, 142], ["bacteremia", "DISEASE", 290, 300], ["pneumonia", "DISEASE", 324, 333], ["nitric oxide", "CHEMICAL", 126, 138], ["NO", "CHEMICAL", 140, 142], ["organ", "ORGAN", 79, 84], ["nitric oxide", "SIMPLE_CHEMICAL", 126, 138], ["NO", "SIMPLE_CHEMICAL", 140, 142], ["renal", "ORGAN", 239, 244], ["organ support", "TREATMENT", 79, 92], ["mechanical ventilation", "TREATMENT", 94, 116], ["inhaled nitric oxide", "TREATMENT", 118, 138], ["high-frequency rescue ventilation", "TREATMENT", 147, 180], ["extracorporeal membrane oxygenation", "TREATMENT", 182, 217], ["ECMO", "TREATMENT", 219, 223], ["vasopressor", "TREATMENT", 226, 237], ["renal replacement therapy", "TREATMENT", 239, 264], ["ICU complications", "PROBLEM", 271, 288], ["bacteremia", "PROBLEM", 290, 300], ["pneumonia", "PROBLEM", 324, 333], ["renal", "ANATOMY", 239, 244], ["replacement", "OBSERVATION", 245, 256], ["bacteremia", "OBSERVATION", 290, 300], ["pneumonia", "OBSERVATION", 324, 333]]], ["In both centers, CS were started on ICU in patients with refractory shock and/or late ARDS, according to the treating physician's judgement.Statistical analysisData were analyzed with SPSS (SPSS Inc., Chicago, USA).", [["shock", "DISEASE", 68, 73], ["ARDS", "DISEASE", 86, 90], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["refractory shock", "PROBLEM", 57, 73], ["late ARDS", "PROBLEM", 81, 90], ["Statistical analysisData", "TEST", 140, 164], ["SPSS", "TEST", 184, 188], ["shock", "OBSERVATION", 68, 73], ["ARDS", "OBSERVATION", 86, 90]]], ["Data are reported as percentage for categorical variables and as mean \u00b1 standard deviation (SD) or median with interquartile range (IQR), as appropriate, for continuous variables.", [["categorical variables", "TEST", 36, 57]]], ["In univariate analysis, categorical variables were compared by Fisher's exact test and continuous variables were compared by t test or Mann-Whitney U test as appropriate.", [["univariate analysis", "TEST", 3, 22], ["categorical variables", "TEST", 24, 45], ["Fisher's exact test", "TEST", 63, 82], ["Whitney U test", "TEST", 140, 154]]], ["Multivariate analysis was done by backward and forward stepwise logistic regression including known risk factors for IPA and baseline factors significantly different between IPA and non-IPA patients.", [["IPA", "CHEMICAL", 174, 177], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["Multivariate analysis", "TEST", 0, 21], ["forward stepwise logistic regression", "PROBLEM", 47, 83], ["known risk factors", "PROBLEM", 94, 112], ["IPA", "PROBLEM", 117, 120], ["baseline factors", "PROBLEM", 125, 141], ["IPA and non-IPA patients", "TREATMENT", 174, 198]]], ["All tests of significance were two-tailed, and p value of 0.05 was considered significant.Patient characteristicsBetween September 2009 and March 2011, we included 40 adult critically ill patients with confirmed H1N1 infection: 24/40 (60 %) in UZL and 16/40 (40 %) in UZA ( Table 1 ).", [["critically ill", "DISEASE", 173, 187], ["H1N1 infection", "DISEASE", 212, 226], ["patients", "ORGANISM", 188, 196], ["UZL", "CANCER", 244, 247], ["Patient", "SPECIES", 90, 97], ["patients", "SPECIES", 188, 196], ["All tests", "TEST", 0, 9], ["p value", "TEST", 47, 54], ["H1N1 infection", "PROBLEM", 212, 226], ["UZL", "TEST", 244, 247], ["infection", "OBSERVATION", 217, 226]]], ["The total number of admissions during the study period was 5,260.", [["the study", "TEST", 38, 47], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Eighteen of 40 (45 %) patients had H1N1 in the 2009 season, while 22/40 (55 %) had H1N1 in the 2010 season.", [["H1N1", "DISEASE", 35, 39], ["H1N1", "DISEASE", 83, 87], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["H1N1", "PROBLEM", 35, 39], ["H1N1", "PROBLEM", 83, 87]]], ["H1N1 infection was diagnosed during ICU stay in 31/40 (78 %) patients, while H1N1 was diagnosed shortly before ICU admission in 9/40 (22 %) patients.", [["H1N1 infection", "DISEASE", 0, 14], ["H1N1", "DISEASE", 77, 81], ["H1N1", "ORGANISM", 0, 4], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 140, 148], ["H1N1 infection", "PROBLEM", 0, 14], ["H1N1", "PROBLEM", 77, 81], ["infection", "OBSERVATION", 5, 14]]], ["The patients had mean age of 49 \u00b1 14 years, and 23/40 (58 %) were men.", [["patients", "ORGANISM", 4, 12], ["men", "ORGANISM", 66, 69], ["patients", "SPECIES", 4, 12], ["men", "SPECIES", 66, 69]]], ["On admission, the mean APACHE II score was 23 \u00b1 8 and the median SOFA score was 11 (5) (6) (7) (8) (9) (10) (11) (12) (13) , reflecting a high severity of illness and a high incidence of MODS.", [["illness", "DISEASE", 155, 162], ["MODS", "DISEASE", 187, 191], ["the mean APACHE II score", "TEST", 14, 38], ["the median SOFA score", "TEST", 54, 75], ["a high severity of illness", "PROBLEM", 136, 162], ["MODS", "PROBLEM", 187, 191], ["high severity", "OBSERVATION_MODIFIER", 138, 151], ["MODS", "OBSERVATION", 187, 191]]], ["Thirtyfive patients (88 %) were mechanically ventilated for median duration of 11 (5-13) days.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["Seven patients (18 %) received CS during ICU stay as rescue therapy for ''late ARDS.''", [["ARDS", "DISEASE", 79, 83], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["rescue therapy", "TREATMENT", 53, 67], ["''late ARDS", "PROBLEM", 72, 83], ["ARDS", "OBSERVATION", 79, 83]]], ["Twenty-one (52 %) patients needed rescue therapy with NO ventilation for refractory hypoxemia, and 11 (28 %) of these patients received ECMO.", [["NO", "CHEMICAL", 54, 56], ["hypoxemia", "DISEASE", 84, 93], ["NO", "CHEMICAL", 54, 56], ["patients", "ORGANISM", 18, 26], ["NO", "SIMPLE_CHEMICAL", 54, 56], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 118, 126], ["rescue therapy", "TREATMENT", 34, 48], ["ventilation", "TREATMENT", 57, 68], ["refractory hypoxemia", "PROBLEM", 73, 93], ["ECMO", "TREATMENT", 136, 140], ["hypoxemia", "OBSERVATION", 84, 93]]], ["Other baseline factors are described in Table 1 .Invasive pulmonary aspergillosis (IPA)Twenty-three percent (9/40) of these critically ill H1N1 patients developed IPA as early as 3 days after ICU admission, being 2 days after H1N1 diagnosis (Table 2 ).", [["pulmonary", "ANATOMY", 58, 67], ["Invasive pulmonary aspergillosis", "DISEASE", 49, 81], ["IPA", "DISEASE", 83, 86], ["critically ill", "DISEASE", 124, 138], ["H1N1", "DISEASE", 139, 143], ["IPA", "CHEMICAL", 163, 166], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 58, 81], ["H1N1", "ORGANISM", 139, 143], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["Other baseline factors", "PROBLEM", 0, 22], ["Invasive pulmonary aspergillosis", "PROBLEM", 49, 81], ["pulmonary", "ANATOMY", 58, 67], ["aspergillosis", "OBSERVATION", 68, 81]]], ["Figure 1 reflects the distribution of H1N1 cases in ICU over time and the proportion of those patients who were diagnosed with IPA.", [["H1N1", "DISEASE", 38, 42], ["IPA", "CHEMICAL", 127, 130], ["H1N1", "ORGANISM", 38, 42], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["H1N1 cases", "PROBLEM", 38, 48], ["IPA", "PROBLEM", 127, 130], ["H1N1", "OBSERVATION", 38, 42]]], ["In all 40 included H1N1 patients, at least one lower tract respiratory sample was inoculated onto a Sabouraud agar for fungal isolation.", [["lower tract respiratory sample", "ANATOMY", 47, 77], ["H1N1", "DISEASE", 19, 23], ["H1N1", "ORGANISM", 19, 23], ["patients", "ORGANISM", 24, 32], ["lower tract", "ORGANISM_SUBDIVISION", 47, 58], ["patients", "SPECIES", 24, 32], ["one lower tract respiratory sample", "PROBLEM", 43, 77], ["a Sabouraud agar", "TREATMENT", 98, 114], ["fungal isolation", "TREATMENT", 119, 135], ["lower tract", "ANATOMY", 47, 58], ["fungal isolation", "OBSERVATION", 119, 135]]], ["Aspergillus fumigatus was isolated in lower respiratory tract sample cultures of 8/9 cases of IPA.", [["lower respiratory tract sample cultures", "ANATOMY", 38, 77], ["IPA", "CHEMICAL", 94, 97], ["Aspergillus fumigatus", "ORGANISM", 0, 21], ["Aspergillus fumigatus", "SPECIES", 0, 21], ["Aspergillus fumigatus", "SPECIES", 0, 21], ["Aspergillus fumigatus", "PROBLEM", 0, 21], ["sample cultures", "TEST", 62, 77], ["IPA", "PROBLEM", 94, 97], ["fumigatus", "OBSERVATION", 12, 21], ["lower", "ANATOMY_MODIFIER", 38, 43], ["respiratory tract", "ANATOMY", 44, 61]]], ["In one IPA patient, microbiological data were limited to GM detection in BAL and serum, in combination with new bilateral infiltrates on chest X-ray and macroscopic white pseudomembranous lesions on bronchoscopy.", [["BAL", "ANATOMY", 73, 76], ["serum", "ANATOMY", 81, 86], ["white pseudomembranous lesions", "ANATOMY", 165, 195], ["GM", "CHEMICAL", 57, 59], ["pseudomembranous lesions", "DISEASE", 171, 195], ["patient", "ORGANISM", 11, 18], ["BAL", "ORGANISM_SUBSTANCE", 73, 76], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["pseudomembranous lesions", "PATHOLOGICAL_FORMATION", 171, 195], ["patient", "SPECIES", 11, 18], ["microbiological data", "TEST", 20, 40], ["GM detection", "TEST", 57, 69], ["BAL", "TEST", 73, 76], ["serum", "TEST", 81, 86], ["new bilateral infiltrates", "PROBLEM", 108, 133], ["chest X-ray", "TEST", 137, 148], ["macroscopic white pseudomembranous lesions", "PROBLEM", 153, 195], ["bronchoscopy", "TEST", 199, 211], ["new", "OBSERVATION_MODIFIER", 108, 111], ["bilateral", "ANATOMY_MODIFIER", 112, 121], ["infiltrates", "OBSERVATION", 122, 133], ["chest", "ANATOMY", 137, 142], ["macroscopic", "OBSERVATION_MODIFIER", 153, 164], ["white", "OBSERVATION_MODIFIER", 165, 170], ["pseudomembranous", "OBSERVATION_MODIFIER", 171, 187], ["lesions", "OBSERVATION", 188, 195]]], ["Unfortunately, the biopsy specimens of these bronchial lesions were lost for microscopic or microbiological processing.", [["biopsy specimens", "ANATOMY", 19, 35], ["bronchial lesions", "ANATOMY", 45, 62], ["biopsy specimens", "CANCER", 19, 35], ["bronchial lesions", "CANCER", 45, 62], ["the biopsy specimens", "TEST", 15, 35], ["these bronchial lesions", "PROBLEM", 39, 62], ["microscopic or microbiological processing", "TEST", 77, 118], ["bronchial", "ANATOMY", 45, 54], ["lesions", "OBSERVATION", 55, 62]]], ["Five patients had ''proven'' disease.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["''proven'' disease", "PROBLEM", 18, 36], ["disease", "OBSERVATION", 29, 36]]], ["''Probable'' infection was diagnosed in the other 4/9 patients.", [["infection", "DISEASE", 13, 22], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["'' infection", "PROBLEM", 10, 22], ["Probable", "UNCERTAINTY", 2, 10], ["infection", "OBSERVATION", 13, 22]]], ["All but one of the latter four patients had positive Aspergillus BAL cultures, and all four patients had a positive BAL GM ( Table 2 ).", [["GM", "CHEMICAL", 120, 122], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 92, 100], ["positive Aspergillus BAL cultures", "PROBLEM", 44, 77], ["Aspergillus BAL", "OBSERVATION", 53, 68]]], ["All patients who received amoxicillin-clavulanate or piperacillin-tazobactam in the 5 days before a positive GM detection had multiple confirmatory positive GM samples clearly separated in time (C4 days later) from the latest administration of these antibiotics (n = 3) or had ''proven'' fungal infection (n = 1).", [["samples", "ANATOMY", 160, 167], ["amoxicillin-clavulanate", "CHEMICAL", 26, 49], ["piperacillin-tazobactam", "CHEMICAL", 53, 76], ["GM", "CHEMICAL", 109, 111], ["GM", "CHEMICAL", 157, 159], ["fungal infection", "DISEASE", 288, 304], ["amoxicillin-clavulanate", "CHEMICAL", 26, 49], ["piperacillin-tazobactam", "CHEMICAL", 53, 76], ["patients", "ORGANISM", 4, 12], ["amoxicillin-clavulanate", "SIMPLE_CHEMICAL", 26, 49], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 53, 76], ["patients", "SPECIES", 4, 12], ["amoxicillin", "TREATMENT", 26, 37], ["clavulanate", "TREATMENT", 38, 49], ["piperacillin", "TREATMENT", 53, 65], ["tazobactam", "TREATMENT", 66, 76], ["a positive GM detection", "PROBLEM", 98, 121], ["multiple confirmatory positive GM samples", "PROBLEM", 126, 167], ["these antibiotics", "TREATMENT", 244, 261], ["fungal infection", "PROBLEM", 288, 304], ["fungal", "OBSERVATION_MODIFIER", 288, 294], ["infection", "OBSERVATION", 295, 304]]], ["All IPA patients received voriconazole for 43 \u00b1 19 days.", [["IPA", "CHEMICAL", 4, 7], ["voriconazole", "CHEMICAL", 26, 38], ["voriconazole", "CHEMICAL", 26, 38], ["patients", "ORGANISM", 8, 16], ["voriconazole", "SIMPLE_CHEMICAL", 26, 38], ["patients", "SPECIES", 8, 16], ["voriconazole", "TREATMENT", 26, 38]]], ["At the time of the ICU admissions, there were no works in progress in either of the two hospitals in the vicinity of the patients' wards.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129]]], ["In both centers, extensive environmental fungal sampling is performed regularly in the ICU and the hospital wards.", [["extensive environmental fungal sampling", "TEST", 17, 56], ["extensive", "OBSERVATION_MODIFIER", 17, 26], ["environmental", "OBSERVATION_MODIFIER", 27, 40], ["fungal sampling", "OBSERVATION", 41, 56]]], ["During both H1N1 seasons only very few environmental fungal isolates could be detected, and there was no increase compared with previous years.", [["very few environmental fungal isolates", "PROBLEM", 30, 68], ["no", "UNCERTAINTY", 102, 104], ["increase", "OBSERVATION_MODIFIER", 105, 113]]], ["Four of nine IPA patients were transferred from a referral hospital, and no data regarding environmental fungal sampling in these referral hospitals were available.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["environmental fungal sampling", "TEST", 91, 120]]], ["Table 1 presents the differences in baseline characteristics, risk factors, and outcome parameters between IPA and non-IPA patients.", [["IPA", "CHEMICAL", 107, 110], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["outcome parameters", "TEST", 80, 98], ["IPA and non-IPA patients", "TREATMENT", 107, 131]]], ["IPA patients were mostly men.", [["patients", "ORGANISM", 4, 12], ["men", "ORGANISM", 25, 28], ["patients", "SPECIES", 4, 12], ["men", "SPECIES", 25, 28]]], ["No patients were known with liver cirrhosis or had neutropenia during their ICU stay.", [["liver", "ANATOMY", 28, 33], ["liver cirrhosis", "DISEASE", 28, 43], ["neutropenia", "DISEASE", 51, 62], ["patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 28, 33], ["patients", "SPECIES", 3, 11], ["liver cirrhosis", "PROBLEM", 28, 43], ["neutropenia", "PROBLEM", 51, 62], ["liver", "ANATOMY", 28, 33], ["cirrhosis", "OBSERVATION", 34, 43], ["neutropenia", "OBSERVATION", 51, 62]]], ["There was no difference in the number of IPA versus non-IPA patients developing ventilator-associated pneumonia, but IPA patients had more bacteremia during ICU admission.", [["IPA", "CHEMICAL", 41, 44], ["non-IPA", "DISEASE", 52, 59], ["ventilator-associated pneumonia", "DISEASE", 80, 111], ["IPA", "CHEMICAL", 117, 120], ["bacteremia", "DISEASE", 139, 149], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 121, 129], ["ventilator-associated pneumonia", "PROBLEM", 80, 111], ["more bacteremia", "PROBLEM", 134, 149], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["pneumonia", "OBSERVATION", 102, 111], ["bacteremia", "OBSERVATION", 139, 149]]], ["Importantly, ICU stay [26 (13-Corticosteroid useSignificantly more IPA patients received CS before ICU admission than non-IPA patients [7/9 (78 %) versus 7/31 (23 %), p = 0.002].", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 126, 134]]], ["The two IPA patients who did not receive CS before ICU admission received CS during ICU stay before IPA diagnosis, the first one from day 0 (the day of ICU admission) onwards for septic shock and the other one from day 2 onwards for late ARDS.", [["septic shock", "DISEASE", 179, 191], ["ARDS", "DISEASE", 238, 242], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["septic shock", "PROBLEM", 179, 191], ["late ARDS", "PROBLEM", 233, 242], ["septic shock", "OBSERVATION", 179, 191], ["ARDS", "OBSERVATION", 238, 242]]], ["The dosage of CS intake was also significantly higher in the IPA group [cumulative equivalent hydrocortisone dose of 800 (360-2,635) versus 0 (0-0) mg, p = 0.005].", [["IPA", "CHEMICAL", 61, 64], ["hydrocortisone", "CHEMICAL", 94, 108], ["hydrocortisone", "CHEMICAL", 94, 108], ["CS", "SIMPLE_CHEMICAL", 14, 16], ["hydrocortisone", "SIMPLE_CHEMICAL", 94, 108], ["CS intake", "TEST", 14, 23], ["cumulative equivalent hydrocortisone dose", "TREATMENT", 72, 113]]], ["Moreover, on multivariate analysis, including also sex and known risk factors for IPA, use of CS before ICU admission was independently associated with presence of IPA [OR 14.4 (2.0-101.6), p = 0.007].DiscussionThis retrospective study showed that 23 % of critically ill patients admitted to ICU with H1N1 viral infection developed invasive aspergillosis as early as 3 days after ICU admission, being 2 days after H1N1 diagnosis.", [["invasive aspergillosis", "ANATOMY", 332, 354], ["IPA", "CHEMICAL", 82, 85], ["IPA", "CHEMICAL", 164, 167], ["critically ill", "DISEASE", 256, 270], ["H1N1 viral infection", "DISEASE", 301, 321], ["aspergillosis", "DISEASE", 341, 354], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["multivariate analysis", "TEST", 13, 34], ["IPA", "TEST", 164, 167], ["This retrospective study", "TEST", 211, 235], ["H1N1 viral infection", "PROBLEM", 301, 321], ["invasive aspergillosis", "PROBLEM", 332, 354], ["infection", "OBSERVATION", 312, 321], ["invasive", "OBSERVATION_MODIFIER", 332, 340], ["aspergillosis", "OBSERVATION", 341, 354]]], ["Use of CS 7 days before ICU admission was an independent risk factor for this complication.DiscussionTo the best of our knowledge, this study is the first one to report such a high incidence of proven and probable IPA in critically ill H1N1 patients.", [["IPA", "CHEMICAL", 214, 217], ["critically ill H1N1", "DISEASE", 221, 240], ["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["this complication", "PROBLEM", 73, 90], ["this study", "TEST", 131, 141]]], ["Five of the nine IPA patients had proven IPA, based on microscopic evidence of Aspergillus in endobronchial biopsy.", [["IPA", "DISEASE", 41, 44], ["patients", "ORGANISM", 21, 29], ["endobronchial biopsy", "MULTI-TISSUE_STRUCTURE", 94, 114], ["patients", "SPECIES", 21, 29], ["Aspergillus", "PROBLEM", 79, 90], ["endobronchial biopsy", "TEST", 94, 114], ["evidence of", "UNCERTAINTY", 67, 78], ["Aspergillus", "OBSERVATION", 79, 90], ["endobronchial", "ANATOMY", 94, 107], ["biopsy", "OBSERVATION", 108, 114]]], ["Four IPA patients were diagnosed with probable IPA using the modified EORTC criteria for ICU patients as published previously [20] .", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 93, 101]]], ["Increasing evidence indeed shows that ICU patients frequently develop IPA even without the classical risk factors according to the revised EORTC criteria [12, 20, [23] [24] [25] [26] .", [["IPA", "DISEASE", 70, 73], ["patients", "ORGANISM", 42, 50], ["[23] [24] [25", "SIMPLE_CHEMICAL", 163, 176], ["patients", "SPECIES", 42, 50], ["IPA", "PROBLEM", 70, 73], ["the revised EORTC criteria", "TEST", 127, 153]]], ["This is an inherent limitation that applies to all reports on incidence of invasive aspergillosis in ICU patients.", [["invasive aspergillosis", "ANATOMY", 75, 97], ["aspergillosis", "DISEASE", 84, 97], ["aspergillosis", "CANCER", 84, 97], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["invasive aspergillosis", "PROBLEM", 75, 97], ["invasive", "OBSERVATION_MODIFIER", 75, 83], ["aspergillosis", "OBSERVATION", 84, 97]]], ["The modified diagnosis of probable IPA in our ICU population should be further examined in multicentric studies.", [["IPA", "CHEMICAL", 35, 38], ["IPA", "PROBLEM", 35, 38], ["multicentric studies", "TEST", 91, 111], ["probable", "UNCERTAINTY", 26, 34], ["IPA", "OBSERVATION_MODIFIER", 35, 38]]], ["Finally, the key message of this paper is to draw the attention of the ICU physician to the fact that new risk categories for developing IPA (such as H1N1 with steroid use) may be identified, indicating the need for a high level of clinical vigilance to detect such extremely dangerous but treatable co-infection.DiscussionIn a prospective study, Martin-Loeches et al. [10] reported fungal superinfections (IPA) in 1.8 % of 220 CStreated critically ill H1N1 patients.", [["IPA", "CHEMICAL", 137, 140], ["steroid", "CHEMICAL", 160, 167], ["co-infection", "DISEASE", 300, 312], ["fungal superinfections", "DISEASE", 383, 405], ["IPA", "CHEMICAL", 407, 410], ["critically ill", "DISEASE", 438, 452], ["H1N1", "DISEASE", 453, 457], ["steroid", "CHEMICAL", 160, 167], ["steroid", "SIMPLE_CHEMICAL", 160, 167], ["patients", "ORGANISM", 458, 466], ["patients", "SPECIES", 458, 466], ["developing IPA", "PROBLEM", 126, 140], ["H1N1", "PROBLEM", 150, 154], ["steroid use", "TREATMENT", 160, 171], ["treatable co-infection", "PROBLEM", 290, 312], ["a prospective study", "TEST", 326, 345], ["fungal superinfections", "PROBLEM", 383, 405], ["co-infection", "OBSERVATION", 300, 312], ["fungal", "OBSERVATION_MODIFIER", 383, 389], ["superinfections", "OBSERVATION", 390, 405]]], ["Kim et al. [9] found In comparison with these two studies, we noticed that our H1N1 patients were sicker and received more CS prior to ICU admission, which could explain the higher incidence of IPA in our study.", [["H1N1", "DISEASE", 79, 83], ["IPA", "CHEMICAL", 194, 197], ["H1N1", "ORGANISM", 79, 83], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["these two studies", "TEST", 40, 57], ["our study", "TEST", 201, 210]]], ["Moreover, our diagnostic approach included not only BAL cultures, but also implementation of GM detection in serum and BAL.", [["BAL cultures", "ANATOMY", 52, 64], ["serum", "ANATOMY", 109, 114], ["BAL", "ANATOMY", 119, 122], ["GM", "CHEMICAL", 93, 95], ["BAL cultures", "CELL", 52, 64], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["BAL", "ORGANISM_SUBSTANCE", 119, 122], ["BAL cultures", "CELL_LINE", 52, 64], ["BAL cultures", "TEST", 52, 64], ["GM detection in serum and BAL", "TEST", 93, 122]]], ["This latter test has been validated as a valuable diagnostic tool in a prospective study in our ICU [20] .", [["This latter test", "TEST", 0, 16], ["a prospective study", "TEST", 69, 88]]], ["Extensive environmental fungal sampling in the ICUs as well as in the hospital wards did not indicate an outbreak of IPA during the study period in both ICUs.", [["IPA", "CHEMICAL", 117, 120], ["Extensive environmental fungal sampling", "PROBLEM", 0, 39], ["the study", "TEST", 128, 137], ["environmental", "OBSERVATION_MODIFIER", 10, 23], ["fungal sampling", "OBSERVATION", 24, 39]]], ["A few years before the H1N1 flu seasons, Meersseman et al. [12] reported incidences of proven and probable IPA on the same ICU unit (UZL) where the current study was performed [12, 20] .", [["flu", "DISEASE", 28, 31], ["the current study", "TEST", 144, 161]]], ["In a retrospective study between January 2000 and 2003, 5.7 % (105/1,850) of ICU patients had proven or probable IPA [12] .", [["IPA", "DISEASE", 113, 116], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["In a prospective follow-up study between July 2005 and December 2006, the same authors found 3 % (34/1,109) of ICU patients to have proven or probable IPA [20] .", [["IPA", "DISEASE", 151, 154], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["Besides a high incidence of IPA and in line with others, we also found a worse outcome of IPA patients: ICU and hospital length of stay were significantly higher in IPA patients [27] .", [["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 169, 177], ["IPA", "PROBLEM", 28, 31]]], ["There are several reasons why critically ill patients with pneumonia due to H1N1 are at risk for developing aspergillosis.", [["critically ill", "DISEASE", 30, 44], ["pneumonia", "DISEASE", 59, 68], ["H1N1", "DISEASE", 76, 80], ["aspergillosis", "DISEASE", 108, 121], ["patients", "ORGANISM", 45, 53], ["aspergillosis", "CANCER", 108, 121], ["patients", "SPECIES", 45, 53], ["pneumonia", "PROBLEM", 59, 68], ["H1N1", "PROBLEM", 76, 80], ["developing aspergillosis", "PROBLEM", 97, 121], ["pneumonia", "OBSERVATION", 59, 68], ["H1N1", "OBSERVATION", 76, 80], ["aspergillosis", "OBSERVATION", 108, 121]]], ["First, influenza viruses have been reported to cause cell-mediated destruction of airway epithelium and disruption of normal mucociliary clearance, fostering colonization and invasion with Aspergillus spp.", [["cell", "ANATOMY", 53, 57], ["airway epithelium", "ANATOMY", 82, 99], ["mucociliary", "ANATOMY", 125, 136], ["influenza viruses", "DISEASE", 7, 24], ["Aspergillus spp", "DISEASE", 189, 204], ["influenza viruses", "ORGANISM", 7, 24], ["cell", "CELL", 53, 57], ["airway epithelium", "TISSUE", 82, 99], ["mucociliary", "ORGAN", 125, 136], ["Aspergillus spp", "ORGANISM", 189, 204], ["influenza viruses", "PROBLEM", 7, 24], ["cell-mediated destruction of airway epithelium", "PROBLEM", 53, 99], ["normal mucociliary clearance", "PROBLEM", 118, 146], ["fostering colonization", "PROBLEM", 148, 170], ["invasion", "PROBLEM", 175, 183], ["Aspergillus spp", "PROBLEM", 189, 204], ["influenza viruses", "OBSERVATION", 7, 24], ["destruction", "OBSERVATION", 67, 78], ["airway", "ANATOMY", 82, 88], ["epithelium", "ANATOMY_MODIFIER", 89, 99], ["normal", "OBSERVATION_MODIFIER", 118, 124], ["mucociliary clearance", "OBSERVATION", 125, 146], ["invasion", "OBSERVATION_MODIFIER", 175, 183], ["Aspergillus spp", "OBSERVATION", 189, 204]]], ["[28] [29] [30] .", [["[28] [29] [30]", "SIMPLE_CHEMICAL", 0, 14]]], ["Since 1952, 32 cases of Aspergillus superinfection associated with influenza have been reported [14, 15, 31] .", [["Aspergillus superinfection", "DISEASE", 24, 50], ["influenza", "DISEASE", 67, 76], ["Aspergillus superinfection", "PROBLEM", 24, 50], ["influenza", "PROBLEM", 67, 76], ["Aspergillus superinfection", "OBSERVATION", 24, 50]]], ["A recent study of lung pathology in fatal H1N1 cases suggested that viral overload leads to altered immune responses, as with fatal H5N1 cases [32] .", [["lung", "ANATOMY", 18, 22], ["viral overload", "DISEASE", 68, 82], ["H5N1", "DISEASE", 132, 136], ["lung", "ORGAN", 18, 22], ["A recent study", "TEST", 0, 14], ["lung pathology", "TEST", 18, 32], ["viral overload", "PROBLEM", 68, 82], ["altered immune responses", "PROBLEM", 92, 116], ["fatal H5N1 cases", "PROBLEM", 126, 142], ["lung", "ANATOMY", 18, 22], ["pathology", "OBSERVATION", 23, 32], ["viral overload", "OBSERVATION", 68, 82]]], ["H1N1 leads to a necrotic pneumonia, as shown by increased lactate dehydrogenase (LDH) levels, being an ideal breeding medium for fungal colonization and growth of hyphae.", [["hyphae", "ANATOMY", 163, 169], ["H1N1", "DISEASE", 0, 4], ["necrotic", "DISEASE", 16, 24], ["pneumonia", "DISEASE", 25, 34], ["lactate", "CHEMICAL", 58, 65], ["lactate", "CHEMICAL", 58, 65], ["H1N1", "ORGANISM", 0, 4], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 58, 79], ["LDH", "GENE_OR_GENE_PRODUCT", 81, 84], ["lactate dehydrogenase", "PROTEIN", 58, 79], ["LDH", "PROTEIN", 81, 84], ["H1N1", "PROBLEM", 0, 4], ["a necrotic pneumonia", "PROBLEM", 14, 34], ["increased lactate dehydrogenase (LDH) levels", "PROBLEM", 48, 92], ["fungal colonization", "PROBLEM", 129, 148], ["hyphae", "PROBLEM", 163, 169], ["necrotic", "OBSERVATION_MODIFIER", 16, 24], ["pneumonia", "OBSERVATION", 25, 34], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["lactate dehydrogenase", "OBSERVATION", 58, 79], ["fungal colonization", "OBSERVATION", 129, 148], ["growth", "OBSERVATION_MODIFIER", 153, 159], ["hyphae", "OBSERVATION", 163, 169]]], ["Secondly, CS is frequently administered in conjunction with antiviral agents in order to limit inflammation in lung parenchyma.", [["lung parenchyma", "ANATOMY", 111, 126], ["CS", "CHEMICAL", 10, 12], ["inflammation", "DISEASE", 95, 107], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 111, 126], ["antiviral agents", "TREATMENT", 60, 76], ["inflammation in lung parenchyma", "PROBLEM", 95, 126], ["inflammation", "OBSERVATION", 95, 107], ["lung", "ANATOMY", 111, 115], ["parenchyma", "ANATOMY_MODIFIER", 116, 126]]], ["CS diminish host defenses and are increasingly recognized as a risk factor for developing aspergillosis in ICU patients [12, 23] .", [["aspergillosis", "DISEASE", 90, 103], ["aspergillosis", "CANCER", 90, 103], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["developing aspergillosis", "PROBLEM", 79, 103], ["diminish", "OBSERVATION_MODIFIER", 3, 11], ["host", "OBSERVATION_MODIFIER", 12, 16], ["defenses", "OBSERVATION_MODIFIER", 17, 25], ["aspergillosis", "OBSERVATION", 90, 103]]], ["CS exert their immunosuppressive effects via transcriptional inhibition of nuclear factor-kappaB (NF-jB), leading to inhibition of cellular immunity [monocytes, T-lymphocytes, and polymorphonuclear leukocytes (PMNs)] which is essential for defense against IPA [23, 33] .", [["cellular", "ANATOMY", 131, 139], ["monocytes", "ANATOMY", 150, 159], ["T-lymphocytes", "ANATOMY", 161, 174], ["polymorphonuclear leukocytes", "ANATOMY", 180, 208], ["PMNs", "ANATOMY", 210, 214], ["CS", "CHEMICAL", 0, 2], ["IPA", "CHEMICAL", 256, 259], ["CS", "SIMPLE_CHEMICAL", 0, 2], ["nuclear factor-kappaB", "GENE_OR_GENE_PRODUCT", 75, 96], ["NF-jB", "GENE_OR_GENE_PRODUCT", 98, 103], ["cellular", "CELL", 131, 139], ["monocytes", "CELL", 150, 159], ["T-lymphocytes", "CELL", 161, 174], ["polymorphonuclear leukocytes", "CELL", 180, 208], ["PMNs", "CELL", 210, 214], ["nuclear factor-kappaB", "PROTEIN", 75, 96], ["NF-jB", "PROTEIN", 98, 103], ["monocytes", "CELL_TYPE", 150, 159], ["T-lymphocytes", "CELL_TYPE", 161, 174], ["polymorphonuclear leukocytes", "CELL_TYPE", 180, 208], ["PMNs", "CELL_TYPE", 210, 214], ["nuclear factor", "TEST", 75, 89], ["cellular immunity", "TEST", 131, 148], ["monocytes", "TEST", 150, 159], ["T", "TEST", 161, 162], ["lymphocytes", "TEST", 163, 174], ["polymorphonuclear leukocytes", "TEST", 180, 208], ["PMNs", "TEST", 210, 214], ["IPA", "TEST", 256, 259], ["immunosuppressive", "OBSERVATION", 15, 32], ["jB", "ANATOMY", 101, 103], ["lymphocytes", "ANATOMY", 163, 174], ["polymorphonuclear leukocytes", "ANATOMY", 180, 208]]], ["Moreover, in vitro experiments showed enhanced growth of Aspergillus spp. on CS exposure.", [["Aspergillus spp", "DISEASE", 57, 72], ["CS", "CHEMICAL", 77, 79], ["Aspergillus spp", "ORGANISM", 57, 72], ["Aspergillus spp", "SPECIES", 57, 72], ["Aspergillus spp", "PROBLEM", 57, 72], ["CS exposure", "TREATMENT", 77, 88], ["enhanced", "OBSERVATION_MODIFIER", 38, 46], ["growth", "OBSERVATION_MODIFIER", 47, 53], ["Aspergillus spp", "OBSERVATION", 57, 72]]], ["Finally, CS may also hinder the efficacy of antifungal therapy [33, 34] .", [["antifungal therapy", "TREATMENT", 44, 62]]], ["Administration of CS may be especially detrimental in severe influenza pneumonia, possibly by favoring persistent viral replication.", [["CS", "CHEMICAL", 18, 20], ["influenza pneumonia", "DISEASE", 61, 80], ["severe influenza pneumonia", "PROBLEM", 54, 80], ["persistent viral replication", "PROBLEM", 103, 131], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["influenza", "OBSERVATION_MODIFIER", 61, 70], ["pneumonia", "OBSERVATION", 71, 80], ["possibly by favoring", "UNCERTAINTY", 82, 102], ["persistent", "OBSERVATION_MODIFIER", 103, 113], ["viral replication", "OBSERVATION", 114, 131]]], ["As in H1N1, Li et al. [37] reported that CS administration resulted in increased rates of secondary infections in severe acute respiratory syndrome (SARS) patients.", [["Li", "CHEMICAL", 12, 14], ["CS", "CHEMICAL", 41, 43], ["infections", "DISEASE", 100, 110], ["acute respiratory syndrome", "DISEASE", 121, 147], ["SARS", "DISEASE", 149, 153], ["CS", "SIMPLE_CHEMICAL", 41, 43], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["H1N1", "PROBLEM", 6, 10], ["CS administration", "TREATMENT", 41, 58], ["secondary infections", "PROBLEM", 90, 110], ["severe acute respiratory syndrome", "PROBLEM", 114, 147], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["secondary", "OBSERVATION_MODIFIER", 90, 99], ["infections", "OBSERVATION", 100, 110], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["respiratory syndrome", "OBSERVATION", 127, 147]]], ["However, the retrospective design of our study does not allow conclusions about causal relationships between H1N1, CS, and IPA.", [["IPA", "CHEMICAL", 123, 126], ["our study", "TEST", 37, 46], ["H1N1", "PROBLEM", 109, 113]]], ["The limited number of patients in this study also limits the robustness of the multivariate analysis.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["this study", "TEST", 34, 44], ["the multivariate analysis", "TEST", 75, 100]]], ["In our study, early CS administration before ICU admission appeared to be relevant, since IPA was acquired early after ICU admission.DiscussionIn conclusion, we found that a significant amount of critically ill patients with H1N1 virus infection developed IPA soon after admission to the ICU.", [["IPA", "CHEMICAL", 90, 93], ["critically ill", "DISEASE", 196, 210], ["H1N1 virus infection", "DISEASE", 225, 245], ["IPA", "CHEMICAL", 256, 259], ["patients", "ORGANISM", 211, 219], ["H1N1 virus", "ORGANISM", 225, 235], ["patients", "SPECIES", 211, 219], ["H1N1 virus", "SPECIES", 225, 235], ["H1N1 virus", "SPECIES", 225, 235], ["our study", "TEST", 3, 12], ["H1N1 virus infection", "PROBLEM", 225, 245], ["significant", "OBSERVATION_MODIFIER", 174, 185], ["amount", "OBSERVATION_MODIFIER", 186, 192]]], ["The threshold to actively search for invasive aspergillosis in critically ill H1N1 patients (via BAL cultures and GM detection) should be low, and patients who are treated with CS warrant special attention.", [["invasive aspergillosis", "ANATOMY", 37, 59], ["BAL cultures", "ANATOMY", 97, 109], ["aspergillosis", "DISEASE", 46, 59], ["critically ill", "DISEASE", 63, 77], ["GM", "CHEMICAL", 114, 116], ["aspergillosis", "CANCER", 46, 59], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 147, 155], ["invasive aspergillosis", "PROBLEM", 37, 59], ["BAL cultures", "TEST", 97, 109], ["GM detection", "TEST", 114, 126], ["invasive", "OBSERVATION_MODIFIER", 37, 45], ["aspergillosis", "OBSERVATION", 46, 59]]], ["Moreover, one should be cautious about giving steroids to mechanically ventilated patients suffering from H1N1.", [["steroids", "CHEMICAL", 46, 54], ["H1N1", "DISEASE", 106, 110], ["steroids", "CHEMICAL", 46, 54], ["steroids", "SIMPLE_CHEMICAL", 46, 54], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["steroids", "TREATMENT", 46, 54], ["H1N1", "PROBLEM", 106, 110], ["H1N1", "OBSERVATION", 106, 110]]], ["These conclusions need further confirmation in larger studies.", [["further confirmation in larger studies", "TEST", 23, 61]]]], "1480a96aebe78b443dfb5d04a3cc84f543af13fe": [["IntroductionFlaviviruses are important human pathogens causing a variety of diseases ranging from mild febrile illness to severe encephalitis and haemorrhagic fever.", [["febrile illness", "DISEASE", 103, 118], ["encephalitis", "DISEASE", 129, 141], ["haemorrhagic fever", "DISEASE", 146, 164], ["Flaviviruses", "GENE_OR_GENE_PRODUCT", 12, 24], ["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["IntroductionFlaviviruses", "PROBLEM", 0, 24], ["human pathogens", "PROBLEM", 39, 54], ["a variety of diseases", "PROBLEM", 63, 84], ["mild febrile illness", "PROBLEM", 98, 118], ["severe encephalitis", "PROBLEM", 122, 141], ["haemorrhagic fever", "PROBLEM", 146, 164], ["Flaviviruses", "OBSERVATION", 12, 24], ["variety", "OBSERVATION_MODIFIER", 65, 72], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["febrile", "OBSERVATION_MODIFIER", 103, 110], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["encephalitis", "OBSERVATION", 129, 141], ["haemorrhagic", "OBSERVATION_MODIFIER", 146, 158], ["fever", "OBSERVATION", 159, 164]]], ["Among them, Japanese encephalitis virus (JEV) is a neuropathogenic virus commonly infecting children and is associated with acute encephalitis [1] .", [["Japanese encephalitis", "DISEASE", 12, 33], ["JEV", "DISEASE", 41, 44], ["encephalitis", "DISEASE", 130, 142], ["Japanese encephalitis virus", "ORGANISM", 12, 39], ["JEV", "ORGANISM", 41, 44], ["children", "ORGANISM", 92, 100], ["Japanese encephalitis virus", "SPECIES", 12, 39], ["children", "SPECIES", 92, 100], ["Japanese encephalitis virus", "SPECIES", 12, 39], ["JEV", "SPECIES", 41, 44], ["Japanese encephalitis virus (JEV", "PROBLEM", 12, 44], ["a neuropathogenic virus", "PROBLEM", 49, 72], ["acute encephalitis", "PROBLEM", 124, 142], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["encephalitis", "OBSERVATION", 130, 142]]], ["The disease burden of Japanese encephalitis (JE) is an increasing public health problem with an average of 50 000 cases per year in Asia [2, 3] .", [["Japanese encephalitis", "DISEASE", 22, 43], ["JE", "DISEASE", 45, 47], ["Japanese encephalitis (JE", "SPECIES", 22, 47], ["The disease burden", "PROBLEM", 0, 18], ["Japanese encephalitis", "PROBLEM", 22, 43], ["disease", "OBSERVATION", 4, 11], ["Japanese", "OBSERVATION_MODIFIER", 22, 30], ["encephalitis", "OBSERVATION", 31, 43], ["increasing", "OBSERVATION_MODIFIER", 55, 65]]], ["Despite this, the prospects for therapy of flavivirus infections are not encouraging, which has led to the unavailability of a specific and efficient antiviral agent against JEV [4] .", [["flavivirus infections", "DISEASE", 43, 64], ["JEV", "DISEASE", 174, 177], ["flavivirus", "ORGANISM", 43, 53], ["JEV", "ORGANISM", 174, 177], ["JEV", "SPECIES", 174, 177], ["therapy", "TREATMENT", 32, 39], ["flavivirus infections", "PROBLEM", 43, 64], ["efficient antiviral agent", "TREATMENT", 140, 165], ["JEV", "PROBLEM", 174, 177]]], ["This has rekindled the search for a drug that can inhibit JEV replication.IntroductionPentoxifylline is a methylxanthine derivative and has been used for treating human vascular diseases [5] .", [["vascular", "ANATOMY", 169, 177], ["Pentoxifylline", "CHEMICAL", 86, 100], ["methylxanthine", "CHEMICAL", 106, 120], ["vascular diseases", "DISEASE", 169, 186], ["Pentoxifylline", "CHEMICAL", 86, 100], ["methylxanthine", "CHEMICAL", 106, 120], ["JEV", "ORGANISM", 58, 61], ["Pentoxifylline", "SIMPLE_CHEMICAL", 86, 100], ["methylxanthine", "SIMPLE_CHEMICAL", 106, 120], ["human", "ORGANISM", 163, 168], ["vascular", "MULTI-TISSUE_STRUCTURE", 169, 177], ["human", "SPECIES", 163, 168], ["JEV", "SPECIES", 58, 61], ["human", "SPECIES", 163, 168], ["JEV replication", "TREATMENT", 58, 73], ["IntroductionPentoxifylline", "TREATMENT", 74, 100], ["a methylxanthine derivative", "TREATMENT", 104, 131], ["human vascular diseases", "PROBLEM", 163, 186], ["vascular", "ANATOMY", 169, 177], ["diseases", "OBSERVATION", 178, 186]]], ["Despite being a cardiovascular drug, pentoxifylline also demonstrated high antiviral activity against herpes simplex virus, vaccinia virus, rotavirus and tick-borne encephalitis virus, suggesting that this drug also has broad-spectrum virus inhibitory properties [6] .", [["cardiovascular", "ANATOMY", 16, 30], ["pentoxifylline", "CHEMICAL", 37, 51], ["herpes simplex virus", "DISEASE", 102, 122], ["encephalitis", "DISEASE", 165, 177], ["pentoxifylline", "CHEMICAL", 37, 51], ["pentoxifylline", "SIMPLE_CHEMICAL", 37, 51], ["herpes simplex virus", "ORGANISM", 102, 122], ["vaccinia virus", "ORGANISM", 124, 138], ["rotavirus", "ORGANISM", 140, 149], ["tick-borne encephalitis virus", "ORGANISM", 154, 183], ["herpes simplex virus", "SPECIES", 102, 122], ["vaccinia virus", "SPECIES", 124, 138], ["rotavirus", "SPECIES", 140, 149], ["tick-borne encephalitis virus", "SPECIES", 154, 183], ["herpes simplex virus", "SPECIES", 102, 122], ["vaccinia virus", "SPECIES", 124, 138], ["tick-borne encephalitis virus", "SPECIES", 154, 183], ["a cardiovascular drug", "TREATMENT", 14, 35], ["pentoxifylline", "TREATMENT", 37, 51], ["high antiviral activity", "PROBLEM", 70, 93], ["herpes simplex virus", "PROBLEM", 102, 122], ["vaccinia virus", "PROBLEM", 124, 138], ["rotavirus", "PROBLEM", 140, 149], ["tick-borne encephalitis virus", "PROBLEM", 154, 183], ["broad-spectrum virus inhibitory properties", "TREATMENT", 220, 262], ["high antiviral activity", "OBSERVATION", 70, 93]]], ["Furthermore, pentoxifylline also showed inhibition of human immunodeficiency virus (HIV) expression in acutely and chronically infected cells in vitro and in human peripheral blood mononuclear cells [7, 8] .", [["cells", "ANATOMY", 136, 141], ["peripheral blood mononuclear cells", "ANATOMY", 164, 198], ["pentoxifylline", "CHEMICAL", 13, 27], ["human immunodeficiency virus", "DISEASE", 54, 82], ["pentoxifylline", "CHEMICAL", 13, 27], ["pentoxifylline", "SIMPLE_CHEMICAL", 13, 27], ["human immunodeficiency virus", "ORGANISM", 54, 82], ["HIV", "ORGANISM", 84, 87], ["cells", "CELL", 136, 141], ["human", "ORGANISM", 158, 163], ["peripheral blood mononuclear cells", "CELL", 164, 198], ["acutely and chronically infected cells", "CELL_TYPE", 103, 141], ["human peripheral blood mononuclear cells", "CELL_TYPE", 158, 198], ["human immunodeficiency virus", "SPECIES", 54, 82], ["human", "SPECIES", 158, 163], ["human immunodeficiency virus", "SPECIES", 54, 82], ["HIV", "SPECIES", 84, 87], ["human", "SPECIES", 158, 163], ["pentoxifylline", "TREATMENT", 13, 27], ["human immunodeficiency virus", "PROBLEM", 54, 82], ["chronically infected cells", "PROBLEM", 115, 141], ["blood mononuclear cells", "TEST", 175, 198], ["human immunodeficiency virus", "OBSERVATION", 54, 82], ["chronically", "OBSERVATION_MODIFIER", 115, 126], ["infected cells", "OBSERVATION", 127, 141], ["peripheral", "ANATOMY_MODIFIER", 164, 174], ["blood", "ANATOMY", 175, 180], ["mononuclear cells", "OBSERVATION", 181, 198]]], ["However, the ability of pentoxifylline to inhibit JEV replication has notCytotoxicity of pentoxifylline and ribavirinThe cytotoxicity of pentoxifylline and ribavirin was evaluated using a trypan blue exclusion assay [9, 10] .", [["pentoxifylline", "CHEMICAL", 24, 38], ["JEV", "DISEASE", 50, 53], ["pentoxifylline", "CHEMICAL", 89, 103], ["ribavirin", "CHEMICAL", 108, 117], ["pentoxifylline", "CHEMICAL", 137, 151], ["ribavirin", "CHEMICAL", 156, 165], ["trypan blue", "CHEMICAL", 188, 199], ["pentoxifylline", "CHEMICAL", 24, 38], ["pentoxifylline", "CHEMICAL", 89, 103], ["ribavirin", "CHEMICAL", 108, 117], ["pentoxifylline", "CHEMICAL", 137, 151], ["ribavirin", "CHEMICAL", 156, 165], ["trypan blue", "CHEMICAL", 188, 199], ["pentoxifylline", "SIMPLE_CHEMICAL", 24, 38], ["JEV", "ORGANISM", 50, 53], ["pentoxifylline", "SIMPLE_CHEMICAL", 89, 103], ["ribavirin", "SIMPLE_CHEMICAL", 108, 117], ["pentoxifylline", "SIMPLE_CHEMICAL", 137, 151], ["ribavirin", "SIMPLE_CHEMICAL", 156, 165], ["JEV", "SPECIES", 50, 53], ["pentoxifylline", "TREATMENT", 24, 38], ["JEV replication", "TREATMENT", 50, 65], ["pentoxifylline", "TREATMENT", 89, 103], ["ribavirin", "TREATMENT", 108, 117], ["pentoxifylline", "TREATMENT", 137, 151], ["ribavirin", "TREATMENT", 156, 165], ["a trypan blue", "TREATMENT", 186, 199]]], ["Briefly, PS cells grown to semiconfluence were exposed to five different concentrations of the compounds for 4 days and viable cells were counted using 2.5% trypan blue dye and a haemocytometer [10] .", [["PS cells", "ANATOMY", 9, 17], ["cells", "ANATOMY", 127, 132], ["trypan blue", "CHEMICAL", 157, 168], ["trypan blue", "CHEMICAL", 157, 168], ["PS cells", "CELL", 9, 17], ["cells", "CELL", 127, 132], ["trypan blue dye", "SIMPLE_CHEMICAL", 157, 172], ["PS cells", "CELL_LINE", 9, 17], ["PS cells", "PROBLEM", 9, 17], ["viable cells", "PROBLEM", 120, 132], ["2.5% trypan blue dye", "TREATMENT", 152, 172]]], ["The concentration of compound that reduced cell growth by 50% was estimated as the 50% cytotoxic concentration (CC 50 ).", [["cell", "ANATOMY", 43, 47], ["CC", "CHEMICAL", 112, 114], ["cell", "CELL", 43, 47], ["reduced cell growth", "PROBLEM", 35, 54], ["reduced", "OBSERVATION_MODIFIER", 35, 42], ["cell", "OBSERVATION", 43, 47], ["growth", "OBSERVATION_MODIFIER", 48, 54]]], ["The effect of the compounds on cellular proliferation was also studied as described previously [10] .", [["cellular", "ANATOMY", 31, 39], ["cellular", "CELL", 31, 39], ["the compounds", "PROBLEM", 14, 27], ["cellular proliferation", "PROBLEM", 31, 53], ["compounds", "OBSERVATION_MODIFIER", 18, 27], ["cellular proliferation", "OBSERVATION", 31, 53]]], ["Ribavirin, a known inhibitor of flavivirus replication, was used in this study as a standard for comparing the results in all the experiments.Screening for inhibition of virus-induced cytopathic effect (CPE)The antiviral activity of pentoxifylline and ribavirin was initially determined using a CPE inhibition assay as described previously [10] .", [["Ribavirin", "CHEMICAL", 0, 9], ["pentoxifylline", "CHEMICAL", 233, 247], ["ribavirin", "CHEMICAL", 252, 261], ["Ribavirin", "CHEMICAL", 0, 9], ["pentoxifylline", "CHEMICAL", 233, 247], ["ribavirin", "CHEMICAL", 252, 261], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["pentoxifylline", "SIMPLE_CHEMICAL", 233, 247], ["ribavirin", "SIMPLE_CHEMICAL", 252, 261], ["Ribavirin", "TREATMENT", 0, 9], ["a known inhibitor", "TREATMENT", 11, 28], ["flavivirus replication", "TREATMENT", 32, 54], ["this study", "TEST", 68, 78], ["Screening", "TEST", 142, 151], ["virus", "PROBLEM", 170, 175], ["cytopathic effect", "PROBLEM", 184, 201], ["CPE", "PROBLEM", 203, 206], ["The antiviral activity of pentoxifylline", "TREATMENT", 207, 247], ["ribavirin", "TREATMENT", 252, 261], ["a CPE inhibition assay", "TREATMENT", 293, 315], ["cytopathic", "OBSERVATION_MODIFIER", 184, 194]]], ["Briefly, a PS cell monolayer was infected with 1 multiplicity of infection (MoI) of virus and incubated for 2 h at 37 \u2022 C. At the end of the incubation period, the monolayer was rinsed with sterile phosphate-buffered saline (PBS) and then doubling dilutions of ribavirin and pentoxifylline (beginning with the CC 50 ) were added and incubated for 3 days.", [["PS cell monolayer", "ANATOMY", 11, 28], ["monolayer", "ANATOMY", 164, 173], ["infection", "DISEASE", 65, 74], ["phosphate", "CHEMICAL", 198, 207], ["ribavirin", "CHEMICAL", 261, 270], ["pentoxifylline", "CHEMICAL", 275, 289], ["CC", "CHEMICAL", 310, 312], ["phosphate", "CHEMICAL", 198, 207], ["ribavirin", "CHEMICAL", 261, 270], ["pentoxifylline", "CHEMICAL", 275, 289], ["PS cell monolayer", "CELL", 11, 28], ["monolayer", "CELL", 164, 173], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 198, 223], ["ribavirin", "SIMPLE_CHEMICAL", 261, 270], ["pentoxifylline", "SIMPLE_CHEMICAL", 275, 289], ["PS cell monolayer", "CELL_LINE", 11, 28], ["a PS cell monolayer", "PROBLEM", 9, 28], ["infection", "PROBLEM", 65, 74], ["virus", "PROBLEM", 84, 89], ["the monolayer", "TREATMENT", 160, 173], ["sterile phosphate-buffered saline (PBS", "TREATMENT", 190, 228], ["ribavirin", "TREATMENT", 261, 270], ["pentoxifylline", "TREATMENT", 275, 289], ["the CC", "TREATMENT", 306, 312], ["infection", "OBSERVATION", 65, 74]]], ["The experiment was terminated when the virus control showed maximum CPE.", [["the virus control", "TREATMENT", 35, 52], ["maximum CPE", "PROBLEM", 60, 71], ["maximum", "OBSERVATION_MODIFIER", 60, 67], ["CPE", "OBSERVATION", 68, 71]]], ["The presence or absence of CPE was recorded microscopically every day and the plates were stained using crystal violet and compared with the virus control and drug control.", [["CPE", "PROBLEM", 27, 30], ["the plates", "TEST", 74, 84], ["crystal violet", "TEST", 104, 118], ["the virus control", "TREATMENT", 137, 154], ["drug control", "TREATMENT", 159, 171], ["CPE", "OBSERVATION", 27, 30]]], ["All the experiments were run in triplicate to ensure reproducibility.Confirmation of antiviral activity by the plaque reduction assayThe antiviral activity of pentoxifylline noted in the screening experiments was confirmed by the plaque reduction assay as described previously [10] .", [["plaque", "ANATOMY", 111, 117], ["plaque", "ANATOMY", 230, 236], ["pentoxifylline", "CHEMICAL", 159, 173], ["pentoxifylline", "CHEMICAL", 159, 173], ["plaque", "PATHOLOGICAL_FORMATION", 111, 117], ["pentoxifylline", "SIMPLE_CHEMICAL", 159, 173], ["antiviral activity", "TREATMENT", 85, 103], ["the plaque reduction assay", "TREATMENT", 107, 133], ["pentoxifylline", "TREATMENT", 159, 173], ["the plaque reduction assay", "PROBLEM", 226, 252], ["antiviral activity", "OBSERVATION", 85, 103], ["plaque", "OBSERVATION", 111, 117], ["antiviral activity", "OBSERVATION", 137, 155], ["plaque", "OBSERVATION", 230, 236]]], ["Briefly, PS cells grown to a confluent monolayer were infected with 1 MoI of JEV and adsorbed for 2 h at 37 \u2022 C. At the end of adsorption the monolayer was rinsed and 100 L of MEM containing varying concentrations of pentoxifylline (500, 250, 125, 62.5 and 31.25 g/mL) or ribavirin (50, 25, 12.5, 6.25 and 3.12 g/mL) was added.", [["PS cells", "ANATOMY", 9, 17], ["monolayer", "ANATOMY", 39, 48], ["monolayer", "ANATOMY", 142, 151], ["MEM", "CHEMICAL", 176, 179], ["pentoxifylline", "CHEMICAL", 217, 231], ["ribavirin", "CHEMICAL", 272, 281], ["pentoxifylline", "CHEMICAL", 217, 231], ["ribavirin", "CHEMICAL", 272, 281], ["PS cells", "CELL", 9, 17], ["monolayer", "CELL", 39, 48], ["JEV", "ORGANISM", 77, 80], ["monolayer", "CELL", 142, 151], ["pentoxifylline", "SIMPLE_CHEMICAL", 217, 231], ["ribavirin", "SIMPLE_CHEMICAL", 272, 281], ["PS cells", "CELL_LINE", 9, 17], ["JEV", "SPECIES", 77, 80], ["PS cells", "PROBLEM", 9, 17], ["a confluent monolayer", "PROBLEM", 27, 48], ["MEM", "TREATMENT", 176, 179], ["pentoxifylline", "TREATMENT", 217, 231], ["ribavirin", "TREATMENT", 272, 281], ["confluent", "OBSERVATION_MODIFIER", 29, 38], ["monolayer", "OBSERVATION_MODIFIER", 39, 48]]], ["The monolayer was then overlaid with maintenance medium containing 0.2% molten agarose (Sigma-Aldrich, St. Louis, MO).", [["monolayer", "ANATOMY", 4, 13], ["monolayer", "CELL", 4, 13], ["agarose", "SIMPLE_CHEMICAL", 79, 86], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 88, 101], ["St. Louis", "ORGANISM", 103, 112], ["MO", "ORGANISM", 114, 116], ["maintenance medium", "TREATMENT", 37, 55]]], ["Appropriate controls were included in each run of the assay.", [["the assay", "TEST", 50, 59]]], ["Incubation was carried out at 37 \u2022 C for 3 days .", [["Incubation", "TREATMENT", 0, 10]]], ["At the end of the incubation period, monolayers were fixed and stained using 1% crystal violet and plaques were counted using a hand lens.", [["monolayers", "ANATOMY", 37, 47], ["plaques", "ANATOMY", 99, 106], ["hand lens", "ANATOMY", 128, 137], ["monolayers", "CELL", 37, 47], ["crystal violet", "SIMPLE_CHEMICAL", 80, 94], ["plaques", "PATHOLOGICAL_FORMATION", 99, 106], ["1% crystal violet", "TREATMENT", 77, 94], ["plaques", "PROBLEM", 99, 106], ["plaques", "OBSERVATION", 99, 106], ["hand lens", "ANATOMY", 128, 137]]], ["Percentage inhibition of plaques was determined using the following formula: % inhibition = no. of plaques in virus control \u2212 no. of plaques in drug-treated no. of plaques in virus control \u00d7 100Confirmation of antiviral activity by the plaque reduction assayThe antiviral activity was expressed as 50% inhibitory concentration (IC 50 ), which is the concentration of compound required to inhibit viral plaques by 50% compared with the virus control.", [["plaques", "ANATOMY", 25, 32], ["plaques", "ANATOMY", 133, 140], ["plaques", "ANATOMY", 164, 171], ["plaque", "ANATOMY", 236, 242], ["plaques", "ANATOMY", 402, 409], ["plaques", "DISEASE", 133, 140], ["plaques", "DISEASE", 164, 171], ["viral plaques", "DISEASE", 396, 409], ["plaques", "PATHOLOGICAL_FORMATION", 25, 32], ["plaques", "PATHOLOGICAL_FORMATION", 164, 171], ["plaque", "PATHOLOGICAL_FORMATION", 236, 242], ["Percentage inhibition of plaques", "PROBLEM", 0, 32], ["plaques", "PROBLEM", 99, 106], ["plaques", "PROBLEM", 133, 140], ["plaques", "PROBLEM", 164, 171], ["virus control", "TREATMENT", 175, 188], ["antiviral activity", "TREATMENT", 210, 228], ["the plaque reduction assay", "TREATMENT", 232, 258], ["The antiviral activity", "TREATMENT", 258, 280], ["viral plaques", "PROBLEM", 396, 409], ["the virus control", "TREATMENT", 431, 448], ["plaques", "OBSERVATION", 25, 32], ["plaques", "OBSERVATION", 99, 106], ["virus", "OBSERVATION", 110, 115], ["plaques", "OBSERVATION", 133, 140], ["plaques", "OBSERVATION", 164, 171], ["virus", "OBSERVATION", 175, 180], ["antiviral activity", "OBSERVATION", 210, 228], ["plaque", "OBSERVATION", 236, 242], ["antiviral activity", "OBSERVATION", 262, 280], ["viral", "OBSERVATION_MODIFIER", 396, 401], ["plaques", "OBSERVATION", 402, 409]]], ["The therapeutic potential and the specificity of action of the compounds were calculated as the therapeutic index (TI), which is the ratio of CC 50 to IC 50.Determining the mechanism of action of pentoxifylline in relation to JEV replicationTo understand the possible mechanism of action of pentoxifylline in relation to the replicative cycle of JEV, various in vitro experiments detailed below were carried out.Determining the kinetics of JEV replication in PS cellsA 24-well plate containing sterile coverslips in each well was seeded with 4 \u00d7 10 4 cells/well and incubated to attain confluence.", [["coverslips", "ANATOMY", 502, 512], ["cells", "ANATOMY", 551, 556], ["CC", "CHEMICAL", 142, 144], ["pentoxifylline", "CHEMICAL", 196, 210], ["pentoxifylline", "CHEMICAL", 291, 305], ["pentoxifylline", "CHEMICAL", 196, 210], ["pentoxifylline", "CHEMICAL", 291, 305], ["pentoxifylline", "SIMPLE_CHEMICAL", 196, 210], ["JEV", "ORGANISM", 226, 229], ["pentoxifylline", "SIMPLE_CHEMICAL", 291, 305], ["JEV", "ORGANISM", 346, 349], ["JEV", "ORGANISM", 440, 443], ["cells", "CELL", 551, 556], ["JEV", "SPECIES", 226, 229], ["JEV", "SPECIES", 346, 349], ["JEV", "SPECIES", 440, 443], ["the compounds", "PROBLEM", 59, 72], ["pentoxifylline", "TREATMENT", 196, 210], ["JEV replication", "TREATMENT", 226, 241], ["pentoxifylline", "TREATMENT", 291, 305], ["JEV", "PROBLEM", 346, 349], ["JEV replication in PS cellsA", "TREATMENT", 440, 468], ["well plate containing sterile coverslips", "TREATMENT", 472, 512], ["therapeutic potential", "OBSERVATION_MODIFIER", 4, 25], ["JEV replication", "OBSERVATION", 226, 241]]], ["The monolayer was then infected with JEV (MoI = 1) for 1 h at 37 \u2022 C. Following incubation, the monolayer was rinsed and replenished with medium containing 1% FCS.", [["monolayer", "ANATOMY", 4, 13], ["monolayer", "ANATOMY", 96, 105], ["monolayer", "CELL", 4, 13], ["JEV", "ORGANISM", 37, 40], ["monolayer", "CELL", 96, 105], ["JEV", "SPECIES", 37, 40], ["JEV (MoI", "TREATMENT", 37, 45], ["the monolayer", "TREATMENT", 92, 105], ["1% FCS", "TREATMENT", 156, 162]]], ["This time point was considered as 0 h post infection.", [["infection", "DISEASE", 43, 52], ["infection", "PROBLEM", 43, 52], ["infection", "OBSERVATION", 43, 52]]], ["Subsequently at 2, 4, 6, 8, 10, 12, 14, 16 and 24 h post infection, the medium was harvested to determine the amount of extracellular virus released into the supernatant.", [["extracellular", "ANATOMY", 120, 133], ["supernatant", "ANATOMY", 158, 169], ["infection", "DISEASE", 57, 66], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 133], ["infection", "PROBLEM", 57, 66], ["extracellular virus", "PROBLEM", 120, 139], ["infection", "OBSERVATION", 57, 66], ["extracellular virus", "OBSERVATION", 120, 139]]], ["At each time point, the coverslip containing cells was also removed, fixed in chilled acetone and stained by immunofluorescence assay (IFA) using a monoclonal antibody against the envelope protein of JEV to detect the cell-bound antigen [11] .Understanding the kinetics of antiviral activity of pentoxifyllineA 24-well plate was seeded with PS cells and incubated at 37 \u2022 C overnight.", [["cells", "ANATOMY", 45, 50], ["cell", "ANATOMY", 218, 222], ["PS cells", "ANATOMY", 341, 349], ["pentoxifyllineA", "CHEMICAL", 295, 310], ["acetone", "CHEMICAL", 86, 93], ["pentoxifyllineA", "CHEMICAL", 295, 310], ["cells", "CELL", 45, 50], ["acetone", "SIMPLE_CHEMICAL", 86, 93], ["JEV", "ORGANISM", 200, 203], ["cell", "CELL", 218, 222], ["pentoxifyllineA", "SIMPLE_CHEMICAL", 295, 310], ["PS cells", "CELL", 341, 349], ["monoclonal antibody", "PROTEIN", 148, 167], ["envelope protein", "PROTEIN", 180, 196], ["PS cells", "CELL_LINE", 341, 349], ["JEV", "SPECIES", 200, 203], ["the coverslip containing cells", "TREATMENT", 20, 50], ["immunofluorescence assay", "TEST", 109, 133], ["IFA", "TEST", 135, 138], ["a monoclonal antibody", "TEST", 146, 167], ["the envelope protein", "TEST", 176, 196], ["JEV", "PROBLEM", 200, 203], ["the cell-bound antigen", "TEST", 214, 236], ["antiviral activity of pentoxifyllineA", "TREATMENT", 273, 310], ["PS cells", "TREATMENT", 341, 349]]], ["JEV was added to this monolayer and incubated for 2 h at 37 \u2022 C. At the end of virus adsorption, the monolayer was rinsed using sterile PBS and replenished with MEM containing 1% FCS.", [["monolayer", "ANATOMY", 22, 31], ["monolayer", "ANATOMY", 101, 110], ["JEV", "ORGANISM", 0, 3], ["monolayer", "CELL", 22, 31], ["monolayer", "CELL", 101, 110], ["JEV", "SPECIES", 0, 3], ["JEV", "PROBLEM", 0, 3], ["virus adsorption", "TREATMENT", 79, 95], ["the monolayer", "TREATMENT", 97, 110], ["sterile PBS", "TREATMENT", 128, 139], ["MEM", "TREATMENT", 161, 164], ["1% FCS", "TREATMENT", 176, 182]]], ["This time point was considered as 0 h post infection.", [["infection", "DISEASE", 43, 52], ["infection", "PROBLEM", 43, 52], ["infection", "OBSERVATION", 43, 52]]], ["Starting from the 0 h time point, 0.0017 M pentoxifylline was added at 0, 2, 4, 6, 8, 10, 12, 14, 16 and 24 h post infection and incubated at 37 \u2022 C. The supernatant fluid was harvested from the respective wells at 48 h post infection.", [["supernatant fluid", "ANATOMY", 154, 171], ["pentoxifylline", "CHEMICAL", 43, 57], ["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 225, 234], ["pentoxifylline", "CHEMICAL", 43, 57], ["pentoxifylline", "SIMPLE_CHEMICAL", 43, 57], ["pentoxifylline", "TREATMENT", 43, 57], ["infection", "PROBLEM", 115, 124], ["The supernatant fluid", "TREATMENT", 150, 171], ["infection", "PROBLEM", 225, 234], ["infection", "OBSERVATION", 115, 124], ["fluid", "OBSERVATION", 166, 171], ["infection", "OBSERVATION", 225, 234]]], ["The fluid was divided into two parts.", [["fluid", "ANATOMY", 4, 9], ["fluid", "ORGANISM_SUBSTANCE", 4, 9], ["The fluid", "TREATMENT", 0, 9], ["fluid", "OBSERVATION", 4, 9]]], ["One part was used to determine the virus yield (50% tissue culture infective dose (TCID 50 )/mL) and the second part was used to detect the presence of soluble JEV antigen by antigen capture enzyme-linked immunosorbent assay (ELISA) as described elsewhere [12] .", [["tissue culture", "ANATOMY", 52, 66], ["tissue", "TISSUE", 52, 58], ["JEV", "ORGANISM", 160, 163], ["JEV antigen", "PROTEIN", 160, 171], ["JEV", "SPECIES", 160, 163], ["the virus yield", "PROBLEM", 31, 46], ["soluble JEV antigen", "PROBLEM", 152, 171], ["antigen capture enzyme", "TEST", 175, 197], ["immunosorbent assay", "TEST", 205, 224]]], ["To detect cell-bound antigen, the coverslip cultures were fixed in chilled acetone for 30 min at 4 \u2022 C and stained using monoclonal antibody to JEV (clone F2C2) and anti-mouse IgG-fluorescein isothiocyanate (FITC) conjugate by indirect IFA.Confirmation of the mechanism of action of pentoxifyllineTo understand the mechanism of action of pentoxifylline, an in vitro translation experiment was carried out using commercially available Transcend TM Non-Radioactive Translation Detection System and Rabbit Reticulocyte Lysate (Promega, Madison, WI).", [["cell", "ANATOMY", 10, 14], ["cultures", "ANATOMY", 44, 52], ["acetone", "CHEMICAL", 75, 82], ["fluorescein isothiocyanate", "CHEMICAL", 180, 206], ["pentoxifylline", "CHEMICAL", 283, 297], ["pentoxifylline", "CHEMICAL", 338, 352], ["acetone", "CHEMICAL", 75, 82], ["fluorescein isothiocyanate", "CHEMICAL", 180, 206], ["FITC", "CHEMICAL", 208, 212], ["pentoxifylline", "CHEMICAL", 283, 297], ["pentoxifylline", "CHEMICAL", 338, 352], ["cell", "CELL", 10, 14], ["acetone", "SIMPLE_CHEMICAL", 75, 82], ["JEV", "ORGANISM", 144, 147], ["IgG-fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 176, 206], ["FITC) conjugate", "SIMPLE_CHEMICAL", 208, 223], ["pentoxifylline", "SIMPLE_CHEMICAL", 283, 297], ["pentoxifylline", "SIMPLE_CHEMICAL", 338, 352], ["cell-bound antigen", "PROTEIN", 10, 28], ["coverslip cultures", "CELL_LINE", 34, 52], ["monoclonal antibody", "PROTEIN", 121, 140], ["JEV (clone F2C2", "PROTEIN", 144, 159], ["anti-mouse IgG", "PROTEIN", 165, 179], ["fluorescein isothiocyanate (FITC) conjugate", "PROTEIN", 180, 223], ["anti-mouse", "SPECIES", 165, 175], ["Rabbit", "SPECIES", 496, 502], ["JEV", "SPECIES", 144, 147], ["Rabbit", "SPECIES", 496, 502], ["cell-bound antigen", "TEST", 10, 28], ["the coverslip cultures", "TEST", 30, 52], ["monoclonal antibody", "TEST", 121, 140], ["clone F2C2", "TEST", 149, 159], ["anti-mouse IgG", "TEST", 165, 179], ["fluorescein isothiocyanate (FITC) conjugate", "TREATMENT", 180, 223], ["pentoxifylline", "TREATMENT", 283, 297], ["pentoxifylline", "TREATMENT", 338, 352], ["Rabbit Reticulocyte Lysate", "TREATMENT", 496, 522]]], ["A PS cell monolayer was adsorbed with JEV (MoI = 1) for 1 h.", [["PS cell monolayer", "ANATOMY", 2, 19], ["PS cell monolayer", "CELL", 2, 19], ["JEV", "ORGANISM", 38, 41], ["PS cell monolayer", "CELL_LINE", 2, 19], ["JEV", "SPECIES", 38, 41], ["A PS cell monolayer", "TREATMENT", 0, 19], ["JEV (MoI", "TREATMENT", 38, 46], ["PS cell monolayer", "OBSERVATION", 2, 19]]], ["Following adsorption, monolayer was rinsed and 0.0017 M pentoxifylline was added to one set of JEV-infected cells and incubated for 4 h.", [["monolayer", "ANATOMY", 22, 31], ["cells", "ANATOMY", 108, 113], ["pentoxifylline", "CHEMICAL", 56, 70], ["pentoxifylline", "CHEMICAL", 56, 70], ["monolayer", "CELL", 22, 31], ["pentoxifylline", "SIMPLE_CHEMICAL", 56, 70], ["JEV", "ORGANISM", 95, 98], ["cells", "CELL", 108, 113], ["JEV-infected cells", "CELL_TYPE", 95, 113], ["JEV", "SPECIES", 95, 98], ["pentoxifylline", "TREATMENT", 56, 70], ["JEV-infected cells", "TREATMENT", 95, 113], ["infected cells", "OBSERVATION", 99, 113]]], ["Pentoxifylline at the same concentration was added to a second set of monolayer cultures at 10 h.", [["monolayer cultures", "ANATOMY", 70, 88], ["Pentoxifylline", "CHEMICAL", 0, 14], ["Pentoxifylline", "CHEMICAL", 0, 14], ["Pentoxifylline", "SIMPLE_CHEMICAL", 0, 14], ["monolayer cultures", "CELL", 70, 88], ["monolayer cultures", "CELL_LINE", 70, 88], ["Pentoxifylline", "TREATMENT", 0, 14], ["monolayer cultures", "TEST", 70, 88]]], ["The plates were further incubated for 48 h at 37 \u2022 C. Appropriate virus and cell controls were included.", [["cell", "ANATOMY", 76, 80], ["cell", "CELL", 76, 80], ["The plates", "TREATMENT", 0, 10], ["cell controls", "TREATMENT", 76, 89]]], ["At the end of incubation, the cells were treated with 750 L of TRIzol reagent (Gibco, Rockville, MD) and viral RNA was extracted as per the manufacturer's instruction.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["viral RNA", "RNA", 105, 114], ["TRIzol reagent", "TREATMENT", 63, 77], ["viral RNA", "PROBLEM", 105, 114], ["viral RNA", "OBSERVATION", 105, 114]]], ["The extracted RNA was subjected to real-time reverse transcriptase polymerase chain reaction (RT-PCR) using SYBR green I chemistry as described previously [13] with minor modifications [10] to ensure the presence of JEV RNA.", [["SYBR green", "CHEMICAL", 108, 118], ["JEV", "ORGANISM", 216, 219], ["reverse transcriptase", "PROTEIN", 45, 66], ["JEV RNA", "RNA", 216, 223], ["JEV", "SPECIES", 216, 219], ["The extracted RNA", "PROBLEM", 0, 17], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 45, 92], ["RT-PCR", "TEST", 94, 100], ["JEV RNA", "PROBLEM", 216, 223], ["JEV RNA", "OBSERVATION", 216, 223]]], ["The viral RNA obtained from JEV-infected cells, which encodes a 50-kDa protein, was subjected to in vitro translation using a commercial kit (Promega) as described previously [10] .", [["cells", "ANATOMY", 41, 46], ["JEV-infected", "DISEASE", 28, 40], ["JEV", "ORGANISM", 28, 31], ["cells", "CELL", 41, 46], ["viral RNA", "RNA", 4, 13], ["JEV-infected cells", "CELL_TYPE", 28, 46], ["50-kDa protein", "PROTEIN", 64, 78], ["JEV", "SPECIES", 28, 31], ["The viral RNA", "TEST", 0, 13], ["JEV", "PROBLEM", 28, 31], ["infected cells", "PROBLEM", 32, 46], ["a commercial kit (Promega)", "TREATMENT", 124, 150], ["viral RNA", "OBSERVATION", 4, 13], ["infected cells", "OBSERVATION", 32, 46]]], ["After completion of the translation reaction, 1 L of the product was subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).", [["sodium dodecyl sulphate", "CHEMICAL", 82, 105], ["sodium dodecyl sulphate polyacrylamide", "CHEMICAL", 82, 120], ["sodium dodecyl sulphate polyacrylamide", "SIMPLE_CHEMICAL", 82, 120], ["the translation reaction", "PROBLEM", 20, 44], ["the product", "TREATMENT", 53, 64], ["sodium dodecyl sulphate polyacrylamide gel electrophoresis", "TREATMENT", 82, 140]]], ["The gel was electroblotted onto a polyvinylidene fluoride (PVDF) membrane.", [["polyvinylidene fluoride", "CHEMICAL", 34, 57], ["polyvinylidene fluoride", "CHEMICAL", 34, 57], ["PVDF", "CHEMICAL", 59, 63], ["polyvinylidene fluoride", "SIMPLE_CHEMICAL", 34, 57], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["The gel", "TREATMENT", 0, 7], ["a polyvinylidene fluoride (PVDF) membrane", "TREATMENT", 32, 73]]], ["The membrane was reacted with specific monoclonal antibody to JEV and developed using diaminobenzidine and H 2 O 2 .In vivo evaluation of pentoxifyllineInitially, non-toxic concentrations of pentoxifylline were determined by administering intraperitoneally 50, 100, 200 and 300 mg/kg body weight of the compound to different groups (n = 4 per group) of 4-week-old Swiss albino mice.", [["membrane", "ANATOMY", 4, 12], ["body", "ANATOMY", 284, 288], ["pentoxifyllineInitially", "CHEMICAL", 138, 161], ["pentoxifylline", "CHEMICAL", 191, 205], ["diaminobenzidine", "CHEMICAL", 86, 102], ["H 2 O 2", "CHEMICAL", 107, 114], ["pentoxifyllineInitially", "CHEMICAL", 138, 161], ["pentoxifylline", "CHEMICAL", 191, 205], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["JEV", "ORGANISM", 62, 65], ["diaminobenzidine", "SIMPLE_CHEMICAL", 86, 102], ["H 2 O 2", "SIMPLE_CHEMICAL", 107, 114], ["pentoxifyllineInitially", "SIMPLE_CHEMICAL", 138, 161], ["pentoxifylline", "SIMPLE_CHEMICAL", 191, 205], ["body", "ORGANISM_SUBDIVISION", 284, 288], ["Swiss albino mice", "ORGANISM", 364, 381], ["monoclonal antibody", "PROTEIN", 39, 58], ["mice", "SPECIES", 377, 381], ["JEV", "SPECIES", 62, 65], ["Swiss albino mice", "SPECIES", 364, 381], ["specific monoclonal antibody to JEV", "PROBLEM", 30, 65], ["diaminobenzidine", "TREATMENT", 86, 102], ["vivo evaluation", "TEST", 119, 134], ["pentoxifyllineInitially", "TREATMENT", 138, 161], ["pentoxifylline", "TREATMENT", 191, 205]]], ["All mice were observed for a period of 45 days for loss or gain in weight and other evidence of toxicity compared with the untreated normal mice.", [["toxicity", "DISEASE", 96, 104], ["mice", "ORGANISM", 4, 8], ["mice", "ORGANISM", 140, 144], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 140, 144], ["loss or gain in weight", "PROBLEM", 51, 73], ["toxicity", "PROBLEM", 96, 104], ["toxicity", "OBSERVATION", 96, 104]]], ["The therapeutic potential of pentoxifylline was then evaluated using a peripheral challenge model as described previously [10] .", [["pentoxifylline", "CHEMICAL", 29, 43], ["pentoxifylline", "CHEMICAL", 29, 43], ["pentoxifylline", "SIMPLE_CHEMICAL", 29, 43], ["pentoxifylline", "TREATMENT", 29, 43], ["a peripheral challenge model", "TREATMENT", 69, 97]]], ["Briefly, 50 \u00d7 50% lethal dose (LD 50 ) of JEV was injected intraperitoneally into four groups of 4-week-old mice (n = 4) and the blood-brain barrier (BBB) was breached 2 h later using 1% sterile starch.", [["blood-brain barrier", "ANATOMY", 129, 148], ["BBB", "ANATOMY", 150, 153], ["JEV", "ORGANISM", 42, 45], ["mice", "ORGANISM", 108, 112], ["blood-", "MULTI-TISSUE_STRUCTURE", 129, 135], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 135, 148], ["BBB", "MULTI-TISSUE_STRUCTURE", 150, 153], ["starch", "SIMPLE_CHEMICAL", 195, 201], ["mice", "SPECIES", 108, 112], ["JEV", "SPECIES", 42, 45], ["mice", "SPECIES", 108, 112], ["JEV", "PROBLEM", 42, 45], ["the blood-brain barrier", "TREATMENT", 125, 148], ["1% sterile starch", "TREATMENT", 184, 201], ["brain", "ANATOMY", 135, 140]]], ["This was followed by intraperitoneal (i.p.) administration of pentoxifylline (50, 100 and 200 mg/kg body weight) twice daily into three groups of mice for 12 days.", [["intraperitoneal", "ANATOMY", 21, 36], ["body", "ANATOMY", 100, 104], ["pentoxifylline", "CHEMICAL", 62, 76], ["pentoxifylline", "CHEMICAL", 62, 76], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 21, 36], ["pentoxifylline", "SIMPLE_CHEMICAL", 62, 76], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["mice", "ORGANISM", 146, 150], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 146, 150], ["pentoxifylline", "TREATMENT", 62, 76]]], ["A fourth group of mice (n = 4) served as 'no drug controls'.", [["mice", "ORGANISM", 18, 22], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["A fourth group of mice (n = 4)", "TREATMENT", 0, 30]]], ["A fifth group of mice (n = 4) served as sham controls and received MEM intraperitoneally and starch intracerebrally.", [["MEM", "CHEMICAL", 67, 70], ["mice", "ORGANISM", 17, 21], ["starch", "SIMPLE_CHEMICAL", 93, 99], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["A fifth group of mice (n = 4)", "TREATMENT", 0, 29], ["MEM intraperitoneally", "TREATMENT", 67, 88]]], ["Mice were observed every day for 20 days post infection for the appearance of symptoms and death.", [["infection", "DISEASE", 46, 55], ["death", "DISEASE", 91, 96], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["infection", "PROBLEM", 46, 55], ["symptoms", "PROBLEM", 78, 86], ["death", "PROBLEM", 91, 96], ["infection", "OBSERVATION", 46, 55]]], ["At the end of the observation period the mice that survived the infection were sacrificed and their brains were harvested and subjected to JEV antigen detection by IFA, virus nucleic acid detection by real-time PCR and virus isolation as described previously [10] .Antiviral screening of pentoxifylline by in vitro CPE inhibition assayThe CC 50 was 500 g/mL for pentoxifylline and 50 g/mL for ribavirin.", [["brains", "ANATOMY", 100, 106], ["infection", "DISEASE", 64, 73], ["nucleic acid", "CHEMICAL", 175, 187], ["pentoxifylline", "CHEMICAL", 288, 302], ["CC", "CHEMICAL", 339, 341], ["pentoxifylline", "CHEMICAL", 362, 376], ["ribavirin", "CHEMICAL", 393, 402], ["pentoxifylline", "CHEMICAL", 288, 302], ["pentoxifylline", "CHEMICAL", 362, 376], ["ribavirin", "CHEMICAL", 393, 402], ["mice", "ORGANISM", 41, 45], ["brains", "ORGANISM", 100, 106], ["JEV", "ORGANISM", 139, 142], ["pentoxifylline", "SIMPLE_CHEMICAL", 288, 302], ["pentoxifylline", "SIMPLE_CHEMICAL", 362, 376], ["ribavirin", "SIMPLE_CHEMICAL", 393, 402], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["JEV", "SPECIES", 139, 142], ["the infection", "PROBLEM", 60, 73], ["JEV antigen detection", "TEST", 139, 160], ["IFA", "TEST", 164, 167], ["virus nucleic acid detection", "TEST", 169, 197], ["virus isolation", "TREATMENT", 219, 234], ["Antiviral screening", "TEST", 265, 284], ["pentoxifylline", "TREATMENT", 288, 302], ["vitro CPE inhibition", "TREATMENT", 309, 329], ["The CC", "TREATMENT", 335, 341], ["pentoxifylline", "TREATMENT", 362, 376], ["ribavirin", "TREATMENT", 393, 402], ["infection", "OBSERVATION", 64, 73]]], ["The antiviral activity of these two compounds was initially evaluated at a non-cytotoxic concentration (<CC 50 ) against JEV using a CPE inhibition assay and subsequently evaluated by the plaque reduction assay.", [["plaque", "ANATOMY", 188, 194], ["CC", "CHEMICAL", 105, 107], ["JEV", "ORGANISM", 121, 124], ["plaque", "PATHOLOGICAL_FORMATION", 188, 194], ["JEV", "SPECIES", 121, 124], ["a non-cytotoxic concentration (<CC", "TREATMENT", 73, 107], ["JEV", "PROBLEM", 121, 124], ["a CPE inhibition assay", "TEST", 131, 153], ["the plaque reduction assay", "TEST", 184, 210], ["antiviral activity", "OBSERVATION", 4, 22], ["plaque", "OBSERVATION", 188, 194]]], ["There was a dose-dependent reduction of viral plaques (Fig. 1) with an IC 50 of 50.3 g/mL (0.00018 M) for pentoxifylline and 3.9 g/mL (0.000016 M) for ribavirin.", [["pentoxifylline", "CHEMICAL", 106, 120], ["ribavirin", "CHEMICAL", 151, 160], ["pentoxifylline", "CHEMICAL", 106, 120], ["ribavirin", "CHEMICAL", 151, 160], ["pentoxifylline", "SIMPLE_CHEMICAL", 106, 120], ["ribavirin", "SIMPLE_CHEMICAL", 151, 160], ["viral plaques", "PROBLEM", 40, 53], ["an IC", "TREATMENT", 68, 73], ["pentoxifylline", "TREATMENT", 106, 120], ["ribavirin", "TREATMENT", 151, 160], ["dependent", "OBSERVATION_MODIFIER", 17, 26], ["reduction", "OBSERVATION_MODIFIER", 27, 36], ["viral plaques", "OBSERVATION", 40, 53]]], ["The TI of ribavirin was 13 and the TI of pentoxifylline was 10, suggesting that both compounds are highly active against JEV.Kinetics of action of pentoxifylline in relation to the replication of JEV in vitroAs a first step to understand the interactions of JEV with the compounds, experiments were designed to determine the kinetics of viral replication in vitro.", [["ribavirin", "CHEMICAL", 10, 19], ["pentoxifylline", "CHEMICAL", 41, 55], ["JEV", "DISEASE", 121, 124], ["pentoxifylline", "CHEMICAL", 147, 161], ["JEV", "DISEASE", 196, 199], ["JEV", "DISEASE", 258, 261], ["ribavirin", "CHEMICAL", 10, 19], ["pentoxifylline", "CHEMICAL", 41, 55], ["pentoxifylline", "CHEMICAL", 147, 161], ["ribavirin", "SIMPLE_CHEMICAL", 10, 19], ["pentoxifylline", "SIMPLE_CHEMICAL", 41, 55], ["JEV", "ORGANISM", 121, 124], ["pentoxifylline", "SIMPLE_CHEMICAL", 147, 161], ["JEV", "ORGANISM", 196, 199], ["JEV", "ORGANISM", 258, 261], ["JEV", "SPECIES", 121, 124], ["JEV", "SPECIES", 196, 199], ["JEV", "SPECIES", 258, 261], ["ribavirin", "TREATMENT", 10, 19], ["pentoxifylline", "TREATMENT", 41, 55], ["pentoxifylline", "TREATMENT", 147, 161], ["JEV in vitro", "TREATMENT", 196, 208], ["viral replication", "TREATMENT", 337, 354], ["ribavirin", "OBSERVATION", 10, 19]]], ["It was noted that the earliest appearance of JEV antigen in infected PS cells was at 10 h post adsorption as detected by IFA (Fig. 2B) .", [["PS cells", "ANATOMY", 69, 77], ["JEV", "ORGANISM", 45, 48], ["PS cells", "CELL", 69, 77], ["JEV antigen", "PROTEIN", 45, 56], ["infected PS cells", "CELL_TYPE", 60, 77], ["JEV", "SPECIES", 45, 48], ["JEV antigen", "PROBLEM", 45, 56], ["infected PS cells", "PROBLEM", 60, 77], ["JEV", "OBSERVATION", 45, 48], ["infected", "OBSERVATION_MODIFIER", 60, 68], ["PS cells", "OBSERVATION", 69, 77]]], ["However, the first infectious progeny of virus was detected in the supernatant medium harvested at 14 h post adsorption (Fig. 2A) .", [["supernatant", "ANATOMY", 67, 78], ["virus", "PROBLEM", 41, 46], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["virus", "OBSERVATION", 41, 46]]], ["The cells stained at earlier time points (2, 4, 6 and 8 h) were not positive for viral antigen, and the supernatant harvested from them did not yield infectious virus.", [["cells", "ANATOMY", 4, 9], ["supernatant", "ANATOMY", 104, 115], ["cells", "CELL", 4, 9], ["viral antigen", "PROTEIN", 81, 94], ["The cells", "TEST", 0, 9], ["viral antigen", "PROBLEM", 81, 94], ["infectious virus", "PROBLEM", 150, 166], ["positive for", "UNCERTAINTY", 68, 80]]], ["Based on these findings, it was concluded that a single replicative cycle of JEV in vitro in the PS cell line requires 14 h for completion.Kinetics of action of pentoxifylline in relation to the replication of JEV in vitroThe antiviral activity of pentoxifylline was subsequently investigated in relation to the kinetics of JEV replication.", [["PS cell line", "ANATOMY", 97, 109], ["JEV", "DISEASE", 77, 80], ["pentoxifylline", "CHEMICAL", 161, 175], ["JEV", "DISEASE", 210, 213], ["pentoxifylline", "CHEMICAL", 248, 262], ["pentoxifylline", "CHEMICAL", 161, 175], ["pentoxifylline", "CHEMICAL", 248, 262], ["JEV", "ORGANISM", 77, 80], ["PS cell line", "CELL", 97, 109], ["pentoxifylline", "SIMPLE_CHEMICAL", 161, 175], ["JEV", "ORGANISM", 210, 213], ["pentoxifylline", "SIMPLE_CHEMICAL", 248, 262], ["JEV", "ORGANISM", 324, 327], ["PS cell line", "CELL_LINE", 97, 109], ["JEV", "SPECIES", 77, 80], ["JEV", "SPECIES", 210, 213], ["JEV", "SPECIES", 324, 327], ["a single replicative cycle of JEV in vitro in the PS cell line", "TREATMENT", 47, 109], ["pentoxifylline", "TREATMENT", 161, 175], ["JEV in vitro", "TREATMENT", 210, 222], ["The antiviral activity of pentoxifylline", "TREATMENT", 222, 262], ["JEV replication", "TREATMENT", 324, 339], ["cell line", "OBSERVATION", 100, 109], ["antiviral activity", "OBSERVATION", 226, 244], ["JEV replication", "OBSERVATION", 324, 339]]], ["A non-toxic concentration of pentoxifylline was added at various time points following entry of JEV into PS cells and the experiments were terminated following 48 h of incubation.", [["PS cells", "ANATOMY", 105, 113], ["pentoxifylline", "CHEMICAL", 29, 43], ["pentoxifylline", "CHEMICAL", 29, 43], ["pentoxifylline", "SIMPLE_CHEMICAL", 29, 43], ["JEV", "ORGANISM", 96, 99], ["PS cells", "CELL", 105, 113], ["PS cells", "CELL_TYPE", 105, 113], ["JEV", "SPECIES", 96, 99], ["A non-toxic concentration of pentoxifylline", "TREATMENT", 0, 43], ["JEV into PS cells", "TREATMENT", 96, 113], ["incubation", "TREATMENT", 168, 178], ["non-toxic", "OBSERVATION_MODIFIER", 2, 11]]], ["Pentoxifylline at a concentration of 0.0017 M was able to inhibit JEV replication completely when added to the infected monolayer up to 14 h post infection, as evidenced by the absence of virus yield and soluble antigen.", [["monolayer", "ANATOMY", 120, 129], ["Pentoxifylline", "CHEMICAL", 0, 14], ["infection", "DISEASE", 146, 155], ["Pentoxifylline", "CHEMICAL", 0, 14], ["Pentoxifylline", "SIMPLE_CHEMICAL", 0, 14], ["JEV", "ORGANISM", 66, 69], ["monolayer", "CELL", 120, 129], ["soluble antigen", "PROTEIN", 204, 219], ["JEV", "SPECIES", 66, 69], ["Pentoxifylline", "TREATMENT", 0, 14], ["JEV replication", "TREATMENT", 66, 81], ["the infected monolayer", "TREATMENT", 107, 129], ["infection", "PROBLEM", 146, 155], ["virus yield and soluble antigen", "PROBLEM", 188, 219], ["infection", "OBSERVATION", 146, 155]]], ["However, beyond 14 h post infection pentoxifylline did not completely inhibit JEV replication (Fig. 3A ).", [["infection", "DISEASE", 26, 35], ["pentoxifylline", "CHEMICAL", 36, 50], ["pentoxifylline", "CHEMICAL", 36, 50], ["pentoxifylline", "SIMPLE_CHEMICAL", 36, 50], ["JEV", "ORGANISM", 78, 81], ["JEV", "SPECIES", 78, 81], ["infection pentoxifylline", "TREATMENT", 26, 50], ["infection", "OBSERVATION", 26, 35]]], ["An intriguing observation was the presence of viral antigen expressed in the pentoxifyllinetreated cells from 0 to 14 h, the time points that inhibited virus yield (Fig. 3B ).Confirmation of the mechanism of action of pentoxifyllineThe presence of viral antigen noted in the pentoxifylline-treated cells from 0 to 14 h (Fig. 3B ) prompted us to confirm whether translation of viral proteins remained unaffected.", [["cells", "ANATOMY", 99, 104], ["cells", "ANATOMY", 298, 303], ["pentoxifylline", "CHEMICAL", 218, 232], ["pentoxifylline", "CHEMICAL", 275, 289], ["pentoxifylline", "CHEMICAL", 218, 232], ["pentoxifylline", "CHEMICAL", 275, 289], ["cells", "CELL", 99, 104], ["pentoxifylline", "SIMPLE_CHEMICAL", 218, 232], ["pentoxifylline", "SIMPLE_CHEMICAL", 275, 289], ["cells", "CELL", 298, 303], ["viral antigen", "PROTEIN", 46, 59], ["pentoxifyllinetreated cells", "CELL_LINE", 77, 104], ["viral antigen", "PROTEIN", 248, 261], ["pentoxifylline-treated cells", "CELL_LINE", 275, 303], ["viral proteins", "PROTEIN", 376, 390], ["An intriguing observation", "TEST", 0, 25], ["viral antigen", "PROBLEM", 46, 59], ["pentoxifylline", "TREATMENT", 218, 232], ["viral antigen", "PROBLEM", 248, 261], ["the pentoxifylline", "TREATMENT", 271, 289], ["viral proteins", "PROBLEM", 376, 390], ["viral", "OBSERVATION", 46, 51], ["viral", "OBSERVATION", 248, 253], ["viral proteins", "OBSERVATION", 376, 390]]], ["Therefore, viral RNA extracted from a series of time-point experiments was subjected to in vitro translation using a commercial kit.", [["viral RNA", "RNA", 11, 20], ["viral RNA", "PROBLEM", 11, 20], ["viral RNA", "OBSERVATION", 11, 20]]], ["The viral RNA obtained from JEV-infected cells treated with pentoxifylline at two time points (4 and 10 h) showed the presence of a 50-kDa protein that reacted with JEV-specific monoclonal antibodies in a Western blot (Fig. 4) .In vivo evaluation of compounds against JEV using a mouse modelIt was observed that i.p. administration of 50, 100 and 200 mg/kg body weight was non-toxic to mice, whilst 300 mg/kg body weight showed signs of toxicity (loss of weight and death) and was therefore found to be unsuitable for use in the study.", [["cells", "ANATOMY", 41, 46], ["body", "ANATOMY", 357, 361], ["body", "ANATOMY", 409, 413], ["pentoxifylline", "CHEMICAL", 60, 74], ["JEV", "DISEASE", 268, 271], ["toxicity", "DISEASE", 437, 445], ["death", "DISEASE", 466, 471], ["pentoxifylline", "CHEMICAL", 60, 74], ["JEV", "ORGANISM", 28, 31], ["cells", "CELL", 41, 46], ["pentoxifylline", "SIMPLE_CHEMICAL", 60, 74], ["JEV", "ORGANISM", 165, 168], ["JEV", "ORGANISM", 268, 271], ["mouse", "ORGANISM", 280, 285], ["body", "ORGANISM_SUBDIVISION", 357, 361], ["mice", "ORGANISM", 386, 390], ["body", "ORGANISM_SUBDIVISION", 409, 413], ["viral RNA", "RNA", 4, 13], ["JEV-infected cells", "CELL_TYPE", 28, 46], ["50-kDa protein", "PROTEIN", 132, 146], ["JEV-specific monoclonal antibodies", "PROTEIN", 165, 199], ["mouse", "SPECIES", 280, 285], ["mice", "SPECIES", 386, 390], ["JEV", "SPECIES", 28, 31], ["JEV", "SPECIES", 165, 168], ["JEV", "SPECIES", 268, 271], ["mouse", "SPECIES", 280, 285], ["mice", "SPECIES", 386, 390], ["The viral RNA", "TEST", 0, 13], ["JEV", "PROBLEM", 28, 31], ["infected cells", "PROBLEM", 32, 46], ["pentoxifylline", "TREATMENT", 60, 74], ["JEV", "PROBLEM", 165, 168], ["specific monoclonal antibodies", "PROBLEM", 169, 199], ["vivo evaluation", "TEST", 231, 246], ["JEV", "PROBLEM", 268, 271], ["a mouse model", "TREATMENT", 278, 291], ["body weight", "TEST", 409, 420], ["signs of toxicity", "PROBLEM", 428, 445], ["loss of weight and death", "PROBLEM", 447, 471], ["the study", "TEST", 525, 534], ["viral RNA", "OBSERVATION", 4, 13], ["infected cells", "OBSERVATION", 32, 46], ["monoclonal antibodies", "OBSERVATION", 178, 199]]], ["The therapeutic potential of pentoxifylline was evaluated in mice using a peripheral challenge model.", [["pentoxifylline", "CHEMICAL", 29, 43], ["pentoxifylline", "CHEMICAL", 29, 43], ["pentoxifylline", "SIMPLE_CHEMICAL", 29, 43], ["mice", "ORGANISM", 61, 65], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["pentoxifylline", "TREATMENT", 29, 43], ["a peripheral challenge model", "TREATMENT", 72, 100], ["therapeutic", "OBSERVATION_MODIFIER", 4, 15]]], ["Three groups (n = 4 per group) of 4-week-old Swiss albino mice infected with 50\u00d7 LD 50 of JEV by the peripheral route were administered 50, 100 and 200 mg/kg body weight of pentoxifylline by the i.p. route twice daily.", [["body", "ANATOMY", 158, 162], ["JEV", "DISEASE", 90, 93], ["pentoxifylline", "CHEMICAL", 173, 187], ["pentoxifylline", "CHEMICAL", 173, 187], ["Swiss", "ORGANISM", 45, 50], ["albino", "ORGANISM", 51, 57], ["mice", "ORGANISM", 58, 62], ["JEV", "ORGANISM", 90, 93], ["body", "ORGANISM_SUBDIVISION", 158, 162], ["pentoxifylline", "SIMPLE_CHEMICAL", 173, 187], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["JEV", "SPECIES", 90, 93], ["JEV", "TREATMENT", 90, 93], ["pentoxifylline", "TREATMENT", 173, 187]]], ["Mice that received 200 and 100 mg/kg body weight of pentoxifylline showed 100% protection, whilst mice that received 50 mg/kg body weight of pentoxifylline showed a 50% reduction in mortality.", [["body", "ANATOMY", 37, 41], ["body", "ANATOMY", 126, 130], ["pentoxifylline", "CHEMICAL", 52, 66], ["pentoxifylline", "CHEMICAL", 141, 155], ["pentoxifylline", "CHEMICAL", 52, 66], ["pentoxifylline", "CHEMICAL", 141, 155], ["Mice", "ORGANISM", 0, 4], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["pentoxifylline", "SIMPLE_CHEMICAL", 52, 66], ["mice", "ORGANISM", 98, 102], ["body", "ORGANISM_SUBDIVISION", 126, 130], ["pentoxifylline", "SIMPLE_CHEMICAL", 141, 155], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["pentoxifylline", "TREATMENT", 52, 66], ["pentoxifylline", "TREATMENT", 141, 155], ["a 50% reduction in mortality", "PROBLEM", 163, 191], ["reduction", "OBSERVATION_MODIFIER", 169, 178]]], ["On the other hand, mice that did not receive the drug succumbed to encephalitis within 7 days.In vivo evaluation of compounds against JEV using a mouse modelMice that survived the challenge post treatment were sacrificed and their brains were harvested and subjected to virus isolation, detection of viral antigen and viral RNA by RT-PCR.", [["brains", "ANATOMY", 231, 237], ["encephalitis", "DISEASE", 67, 79], ["JEV", "DISEASE", 134, 137], ["mice", "ORGANISM", 19, 23], ["JEV", "ORGANISM", 134, 137], ["mouse", "ORGANISM", 146, 151], ["Mice", "ORGANISM", 157, 161], ["brains", "ORGANISM", 231, 237], ["viral antigen", "PROTEIN", 300, 313], ["viral RNA", "RNA", 318, 327], ["mice", "SPECIES", 19, 23], ["mouse", "SPECIES", 146, 151], ["Mice", "SPECIES", 157, 161], ["mice", "SPECIES", 19, 23], ["JEV", "SPECIES", 134, 137], ["mouse", "SPECIES", 146, 151], ["encephalitis", "PROBLEM", 67, 79], ["vivo evaluation", "TEST", 97, 112], ["JEV", "PROBLEM", 134, 137], ["a mouse model", "TREATMENT", 144, 157], ["treatment", "TREATMENT", 195, 204], ["virus isolation", "TREATMENT", 270, 285], ["viral antigen", "PROBLEM", 300, 313], ["viral RNA", "PROBLEM", 318, 327], ["PCR", "TEST", 334, 337], ["viral RNA", "OBSERVATION", 318, 327]]], ["Infectious virus could not be isolated from brain tissues obtained from mice that survived the challenge.", [["brain tissues", "ANATOMY", 44, 57], ["brain tissues", "TISSUE", 44, 57], ["mice", "ORGANISM", 72, 76], ["mice", "SPECIES", 72, 76], ["Infectious virus", "SPECIES", 0, 16], ["mice", "SPECIES", 72, 76], ["Infectious virus", "PROBLEM", 0, 16]]], ["Similarly, viral antigen could not be demonstrated in the brain smears by immunofluorescent staining using monoclonal antibodies to JEV.", [["brain smears", "ANATOMY", 58, 70], ["JEV", "DISEASE", 132, 135], ["brain smears", "ORGANISM_SUBSTANCE", 58, 70], ["JEV", "ORGANISM", 132, 135], ["viral antigen", "PROTEIN", 11, 24], ["monoclonal antibodies", "PROTEIN", 107, 128], ["JEV", "SPECIES", 132, 135], ["viral antigen", "TEST", 11, 24], ["immunofluorescent staining", "TEST", 74, 100], ["monoclonal antibodies", "TEST", 107, 128], ["viral", "OBSERVATION", 11, 16], ["could not be demonstrated", "UNCERTAINTY", 25, 50], ["brain", "ANATOMY", 58, 63]]], ["However, viral nucleic acid was detected in the brain homogenate by RT-PCR, suggesting that viral RNA was present in the brain of animals that survived JEV infection following treatment with pentoxifylline.DiscussionThe use of agents that can interfere with viral replication and concomitantly suppress viral infection by modulating the immune system is one of the strategies that can be used to prevent viral infections.", [["brain homogenate", "ANATOMY", 48, 64], ["brain", "ANATOMY", 121, 126], ["nucleic acid", "CHEMICAL", 15, 27], ["JEV infection", "DISEASE", 152, 165], ["pentoxifylline", "CHEMICAL", 191, 205], ["viral infection", "DISEASE", 303, 318], ["viral infections", "DISEASE", 404, 420], ["pentoxifylline", "CHEMICAL", 191, 205], ["brain homogenate", "ORGANISM_SUBSTANCE", 48, 64], ["brain", "ORGAN", 121, 126], ["JEV", "ORGANISM", 152, 155], ["pentoxifylline", "SIMPLE_CHEMICAL", 191, 205], ["viral RNA", "RNA", 92, 101], ["JEV", "SPECIES", 152, 155], ["viral nucleic acid", "TEST", 9, 27], ["RT-PCR", "TEST", 68, 74], ["viral RNA", "PROBLEM", 92, 101], ["JEV infection", "PROBLEM", 152, 165], ["pentoxifylline", "TREATMENT", 191, 205], ["agents", "TREATMENT", 227, 233], ["viral replication", "TREATMENT", 258, 275], ["viral infection", "PROBLEM", 303, 318], ["the strategies", "TREATMENT", 361, 375], ["viral infections", "PROBLEM", 404, 420], ["nucleic acid", "OBSERVATION", 15, 27], ["brain", "ANATOMY", 48, 53], ["viral RNA", "OBSERVATION", 92, 101], ["brain", "ANATOMY", 121, 126], ["JEV", "OBSERVATION_MODIFIER", 152, 155], ["infection", "OBSERVATION", 156, 165], ["viral", "OBSERVATION_MODIFIER", 404, 409], ["infections", "OBSERVATION", 410, 420]]], ["JEV infection generates a rapid inflammatory response following entry into the host, and elevated levels of tumour necrosis factor-alpha (TNF\u2423) have been correlated with poor outcome in JE patients [14] .", [["JEV infection", "DISEASE", 0, 13], ["necrosis", "DISEASE", 115, 123], ["JE", "DISEASE", 186, 188], ["JEV", "ORGANISM", 0, 3], ["tumour necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 108, 136], ["TNF", "GENE_OR_GENE_PRODUCT", 138, 141], ["patients", "ORGANISM", 189, 197], ["tumour necrosis factor-alpha", "PROTEIN", 108, 136], ["TNF", "PROTEIN", 138, 141], ["patients", "SPECIES", 189, 197], ["JEV", "SPECIES", 0, 3], ["JEV infection", "PROBLEM", 0, 13], ["a rapid inflammatory response", "PROBLEM", 24, 53], ["elevated levels", "PROBLEM", 89, 104], ["tumour necrosis factor", "PROBLEM", 108, 130], ["alpha (TNF\u2423", "TEST", 131, 142], ["infection", "OBSERVATION", 4, 13], ["rapid", "OBSERVATION_MODIFIER", 26, 31], ["inflammatory", "OBSERVATION_MODIFIER", 32, 44], ["elevated", "OBSERVATION_MODIFIER", 89, 97], ["tumour necrosis", "OBSERVATION", 108, 123]]], ["The pathophysiology of central nervous system inflammation in JEV may be attributed to TNF\u2423, which ranges from promoting viral replication to evasion of host defences [15] .", [["central nervous system", "ANATOMY", 23, 45], ["central nervous system inflammation", "DISEASE", 23, 58], ["JEV", "DISEASE", 62, 65], ["central nervous system", "ANATOMICAL_SYSTEM", 23, 45], ["JEV", "ORGANISM", 62, 65], ["TNF\u2423", "GENE_OR_GENE_PRODUCT", 87, 91], ["TNF", "PROTEIN", 87, 90], ["JEV", "SPECIES", 62, 65], ["central nervous system inflammation", "PROBLEM", 23, 58], ["JEV", "PROBLEM", 62, 65], ["TNF", "PROBLEM", 87, 90], ["central", "ANATOMY_MODIFIER", 23, 30], ["nervous system", "ANATOMY", 31, 45], ["inflammation", "OBSERVATION", 46, 58], ["may be attributed to", "UNCERTAINTY", 66, 86], ["viral replication", "OBSERVATION", 121, 138]]], ["These observations raise the possibility that a compound capable of blocking TNF\u2423 could reduce the severity of JEV infection.", [["JEV infection", "DISEASE", 111, 124], ["TNF\u2423", "GENE_OR_GENE_PRODUCT", 77, 81], ["JEV", "ORGANISM", 111, 114], ["TNF", "PROTEIN", 77, 80], ["JEV", "SPECIES", 111, 114], ["blocking TNF", "TREATMENT", 68, 80], ["JEV infection", "PROBLEM", 111, 124], ["raise the possibility", "UNCERTAINTY", 19, 40], ["JEV infection", "OBSERVATION", 111, 124]]], ["Pentoxifylline is a known inhibitor of TNF\u2423 production [16] .", [["Pentoxifylline", "CHEMICAL", 0, 14], ["Pentoxifylline", "CHEMICAL", 0, 14], ["Pentoxifylline", "SIMPLE_CHEMICAL", 0, 14], ["TNF\u2423", "GENE_OR_GENE_PRODUCT", 39, 43], ["TNF", "PROTEIN", 39, 42], ["Pentoxifylline", "TREATMENT", 0, 14]]], ["Furthermore, recent studies have shown that pentoxifylline exhibits antiviral activity against severe acute respiratory syndrome (SARS) virus and HIV [7, 17] .", [["pentoxifylline", "CHEMICAL", 44, 58], ["acute respiratory syndrome (SARS) virus", "DISEASE", 102, 141], ["pentoxifylline", "CHEMICAL", 44, 58], ["pentoxifylline", "SIMPLE_CHEMICAL", 44, 58], ["HIV", "SPECIES", 146, 149], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 95, 141], ["HIV", "SPECIES", 146, 149], ["recent studies", "TEST", 13, 27], ["pentoxifylline", "TREATMENT", 44, 58], ["antiviral activity", "TREATMENT", 68, 86], ["severe acute respiratory syndrome", "PROBLEM", 95, 128], ["SARS) virus", "PROBLEM", 130, 141], ["HIV", "PROBLEM", 146, 149], ["antiviral activity", "OBSERVATION", 68, 86], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["respiratory syndrome", "OBSERVATION", 108, 128]]], ["This study was therefore designed to investigate the antiviral activity of pentoxifylline against JEV in vitro and in vivo.DiscussionIn the present study, it was observed that pentoxifylline inhibited JEV replication post-entry into the cell.", [["cell", "ANATOMY", 237, 241], ["pentoxifylline", "CHEMICAL", 75, 89], ["JEV", "DISEASE", 98, 101], ["pentoxifylline", "CHEMICAL", 176, 190], ["pentoxifylline", "CHEMICAL", 75, 89], ["pentoxifylline", "CHEMICAL", 176, 190], ["pentoxifylline", "SIMPLE_CHEMICAL", 75, 89], ["JEV", "ORGANISM", 98, 101], ["pentoxifylline", "SIMPLE_CHEMICAL", 176, 190], ["JEV", "ORGANISM", 201, 204], ["cell", "CELL", 237, 241], ["JEV", "SPECIES", 98, 101], ["JEV", "SPECIES", 201, 204], ["This study", "TEST", 0, 10], ["pentoxifylline", "TREATMENT", 75, 89], ["JEV in vitro", "TREATMENT", 98, 110], ["the present study", "TEST", 136, 153], ["pentoxifylline", "TREATMENT", 176, 190], ["JEV replication", "TREATMENT", 201, 216], ["cell", "ANATOMY", 237, 241]]], ["Our preliminary experiments indicated that this compound neither interfered with viral adsorption nor possessed any virucidal (inactivating) property (data not presented).", [["this compound", "PROBLEM", 43, 56], ["viral adsorption", "PROBLEM", 81, 97]]], ["The extent of antiviral activity was then confirmed using a plaque reduction assay.", [["plaque", "ANATOMY", 60, 66], ["plaque reduction", "DISEASE", 60, 76], ["plaque", "PATHOLOGICAL_FORMATION", 60, 66], ["antiviral activity", "PROBLEM", 14, 32], ["a plaque reduction assay", "TREATMENT", 58, 82], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["antiviral activity", "OBSERVATION", 14, 32], ["plaque", "OBSERVATION", 60, 66]]], ["The results of the confirmatory plaque reduction assay suggested that pentoxifylline and ribavirin were able to inhibit JEV replication in a dose-dependent manner (Fig. 1 ).", [["plaque", "ANATOMY", 32, 38], ["pentoxifylline", "CHEMICAL", 70, 84], ["ribavirin", "CHEMICAL", 89, 98], ["pentoxifylline", "CHEMICAL", 70, 84], ["ribavirin", "CHEMICAL", 89, 98], ["pentoxifylline", "SIMPLE_CHEMICAL", 70, 84], ["ribavirin", "SIMPLE_CHEMICAL", 89, 98], ["JEV", "ORGANISM", 120, 123], ["JEV", "SPECIES", 120, 123], ["the confirmatory plaque reduction assay", "TEST", 15, 54], ["pentoxifylline", "TREATMENT", 70, 84], ["ribavirin", "TREATMENT", 89, 98], ["JEV replication", "TREATMENT", 120, 135], ["plaque", "OBSERVATION", 32, 38]]], ["There was a significant reduction in JEV plaques by pentoxifylline at a concentration well below the CC 50 , with an IC 50 of 50.3 g/mL (0.00018 M), whilst the IC 50 of ribavirin was 3.9 g/mL (0.000016 M).", [["JEV plaques", "DISEASE", 37, 48], ["pentoxifylline", "CHEMICAL", 52, 66], ["CC", "CHEMICAL", 101, 103], ["ribavirin", "CHEMICAL", 169, 178], ["pentoxifylline", "CHEMICAL", 52, 66], ["ribavirin", "CHEMICAL", 169, 178], ["JEV", "ORGANISM", 37, 40], ["plaques", "PATHOLOGICAL_FORMATION", 41, 48], ["pentoxifylline", "SIMPLE_CHEMICAL", 52, 66], ["ribavirin", "SIMPLE_CHEMICAL", 169, 178], ["JEV", "SPECIES", 37, 40], ["a significant reduction in JEV plaques", "PROBLEM", 10, 48], ["pentoxifylline", "TREATMENT", 52, 66], ["an IC", "TREATMENT", 114, 119], ["ribavirin", "TREATMENT", 169, 178], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["reduction", "OBSERVATION_MODIFIER", 24, 33], ["JEV plaques", "OBSERVATION", 37, 48]]], ["This suggests that both the compounds possess significant inhibitory potential against JEV.", [["JEV", "DISEASE", 87, 90], ["JEV", "ORGANISM", 87, 90], ["JEV", "SPECIES", 87, 90], ["JEV", "PROBLEM", 87, 90]]], ["It was further observed that both the compounds were highly active against JEV, with a TI of 10 and 13 for pentoxifylline and ribavirin, respectively.DiscussionThere are no extensive in vitro studies reported to date on the mechanism of antiviral action of pentoxifylline.", [["JEV", "DISEASE", 75, 78], ["pentoxifylline", "CHEMICAL", 107, 121], ["ribavirin", "CHEMICAL", 126, 135], ["pentoxifylline", "CHEMICAL", 257, 271], ["pentoxifylline", "CHEMICAL", 107, 121], ["ribavirin", "CHEMICAL", 126, 135], ["pentoxifylline", "CHEMICAL", 257, 271], ["JEV", "ORGANISM", 75, 78], ["pentoxifylline", "SIMPLE_CHEMICAL", 107, 121], ["ribavirin", "SIMPLE_CHEMICAL", 126, 135], ["pentoxifylline", "SIMPLE_CHEMICAL", 257, 271], ["JEV", "SPECIES", 75, 78], ["JEV", "PROBLEM", 75, 78], ["a TI", "TREATMENT", 85, 89], ["pentoxifylline", "TREATMENT", 107, 121], ["ribavirin", "TREATMENT", 126, 135], ["vitro studies", "TEST", 186, 199], ["antiviral action", "TREATMENT", 237, 253], ["pentoxifylline", "TREATMENT", 257, 271], ["no", "UNCERTAINTY", 170, 172], ["extensive", "OBSERVATION_MODIFIER", 173, 182]]], ["In the absence of such information, we asked two crucial questions pertaining to the antiviral activity of pentoxifylline. (i) What is the probable stage at which pentoxifylline inhibits virus replication?", [["pentoxifylline", "CHEMICAL", 107, 121], ["pentoxifylline", "CHEMICAL", 163, 177], ["pentoxifylline", "CHEMICAL", 107, 121], ["pentoxifylline", "CHEMICAL", 163, 177], ["pentoxifylline", "SIMPLE_CHEMICAL", 107, 121], ["pentoxifylline", "SIMPLE_CHEMICAL", 163, 177], ["pentoxifylline", "TREATMENT", 107, 121], ["pentoxifylline inhibits virus replication", "TREATMENT", 163, 204], ["probable stage", "OBSERVATION_MODIFIER", 139, 153]]], ["And (ii) how late can addition of pentoxifylline to infected cells be delayed to achieve complete inhibition of virus replication?", [["cells", "ANATOMY", 61, 66], ["pentoxifylline", "CHEMICAL", 34, 48], ["pentoxifylline", "CHEMICAL", 34, 48], ["pentoxifylline", "SIMPLE_CHEMICAL", 34, 48], ["cells", "CELL", 61, 66], ["infected cells", "CELL_TYPE", 52, 66], ["pentoxifylline", "TREATMENT", 34, 48], ["infected cells", "PROBLEM", 52, 66], ["virus replication", "TREATMENT", 112, 129]]], ["To answer these questions, we used an experimental approach similar to that described by Baginiski et al. [18] .", [["an experimental approach", "TREATMENT", 35, 59]]], ["Pentoxifylline was added at 2-h intervals post infection until the completion of one replicative cycle of JEV.", [["Pentoxifylline", "CHEMICAL", 0, 14], ["infection", "DISEASE", 47, 56], ["JEV", "DISEASE", 106, 109], ["Pentoxifylline", "CHEMICAL", 0, 14], ["Pentoxifylline", "SIMPLE_CHEMICAL", 0, 14], ["JEV", "ORGANISM", 106, 109], ["JEV", "SPECIES", 106, 109], ["Pentoxifylline", "TREATMENT", 0, 14], ["infection", "PROBLEM", 47, 56], ["one replicative cycle of JEV", "TREATMENT", 81, 109], ["infection", "OBSERVATION", 47, 56]]], ["It appeared that pentoxifylline was able to inhibit JEV replication very late in the replication cycle.", [["pentoxifylline", "CHEMICAL", 17, 31], ["pentoxifylline", "CHEMICAL", 17, 31], ["pentoxifylline", "SIMPLE_CHEMICAL", 17, 31], ["JEV", "ORGANISM", 52, 55], ["JEV", "SPECIES", 52, 55], ["pentoxifylline", "TREATMENT", 17, 31], ["JEV replication", "TREATMENT", 52, 67]]], ["This assumption is based on several findings obtained in this study: (i) the presence of cell-bound antigen detected by IFA at all time points (Fig. 3A) suggests that protein translation is unaffected by the drug; (ii) the presence of a 50 kDa in vitro translation product (Fig. 4) obtained at both 4 h and 10 h post infection further affirmed that translation of viral proteins was unaffected by the drug; and (iii) neither infectious virus nor soluble viral antigen could be detected (Fig. 3B ) in the supernatant of drug-treated cells until 14-h post infection.", [["cell", "ANATOMY", 89, 93], ["supernatant", "ANATOMY", 504, 515], ["cells", "ANATOMY", 532, 537], ["infection", "DISEASE", 317, 326], ["infection", "DISEASE", 554, 563], ["cell", "CELL", 89, 93], ["cells", "CELL", 532, 537], ["cell-bound antigen", "PROTEIN", 89, 107], ["IFA", "PROTEIN", 120, 123], ["50 kDa in vitro translation product", "PROTEIN", 237, 272], ["Fig. 4", "PROTEIN", 274, 280], ["viral proteins", "PROTEIN", 364, 378], ["soluble viral antigen", "PROTEIN", 446, 467], ["drug-treated cells", "CELL_LINE", 519, 537], ["this study", "TEST", 57, 67], ["cell-bound antigen", "PROBLEM", 89, 107], ["protein translation", "PROBLEM", 167, 186], ["a 50 kDa in vitro translation product", "TREATMENT", 235, 272], ["infection", "PROBLEM", 317, 326], ["viral proteins", "PROBLEM", 364, 378], ["neither infectious virus", "PROBLEM", 417, 441], ["soluble viral antigen", "TEST", 446, 467], ["drug-treated cells", "TREATMENT", 519, 537], ["infection", "PROBLEM", 554, 563], ["protein translation", "OBSERVATION", 167, 186], ["infection", "OBSERVATION", 554, 563]]], ["Taken together, these three observations suggest that pentoxifylline was indeed able to inhibit JEV replication at a stage beyond viral translation, probably interfering with assembly and/or release of the virion.", [["pentoxifylline", "CHEMICAL", 54, 68], ["pentoxifylline", "CHEMICAL", 54, 68], ["pentoxifylline", "SIMPLE_CHEMICAL", 54, 68], ["JEV", "ORGANISM", 96, 99], ["virion", "CELLULAR_COMPONENT", 206, 212], ["JEV", "SPECIES", 96, 99], ["pentoxifylline", "TREATMENT", 54, 68], ["JEV replication", "TREATMENT", 96, 111], ["the virion", "TREATMENT", 202, 212]]], ["Had pentoxifylline interfered with early or late protein translation, detection of JEV antigen by IFA in drug-treated cells would not have been possible (Fig. 3A) .DiscussionHaving established that pentoxifylline was able to inhibit JEV replication in vitro, we investigated its therapeutic potential in an in vivo mouse model.", [["cells", "ANATOMY", 118, 123], ["pentoxifylline", "CHEMICAL", 4, 18], ["pentoxifylline", "CHEMICAL", 198, 212], ["pentoxifylline", "CHEMICAL", 4, 18], ["pentoxifylline", "CHEMICAL", 198, 212], ["pentoxifylline", "SIMPLE_CHEMICAL", 4, 18], ["JEV", "ORGANISM", 83, 86], ["antigen", "GENE_OR_GENE_PRODUCT", 87, 94], ["IFA", "SIMPLE_CHEMICAL", 98, 101], ["cells", "CELL", 118, 123], ["pentoxifylline", "SIMPLE_CHEMICAL", 198, 212], ["JEV", "ORGANISM", 233, 236], ["mouse", "ORGANISM", 315, 320], ["JEV antigen", "PROTEIN", 83, 94], ["drug-treated cells", "CELL_LINE", 105, 123], ["mouse", "SPECIES", 315, 320], ["JEV", "SPECIES", 83, 86], ["JEV", "SPECIES", 233, 236], ["mouse", "SPECIES", 315, 320], ["pentoxifylline", "TREATMENT", 4, 18], ["JEV antigen", "PROBLEM", 83, 94], ["IFA", "TEST", 98, 101], ["drug-treated cells", "TREATMENT", 105, 123], ["pentoxifylline", "TREATMENT", 198, 212], ["JEV replication", "TREATMENT", 233, 248], ["an in vivo mouse model", "TREATMENT", 304, 326]]], ["Indeed, this drug at concentrations of 100 mg/kg and 200 mg/kg body weight was able to protect mice completely against a lethal challenge (50\u00d7 LD 50 ) of JEV.", [["body", "ANATOMY", 63, 67], ["JEV", "DISEASE", 154, 157], ["body", "ORGANISM_SUBDIVISION", 63, 67], ["mice", "ORGANISM", 95, 99], ["JEV", "ORGANISM", 154, 157], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["JEV", "SPECIES", 154, 157], ["a lethal challenge", "TREATMENT", 119, 137]]], ["Although viral RNA was demonstrated in the brains of all drug-treated mice that survived JEV infection, there were no classical signs of illness observed in any of the mice.", [["brains", "ANATOMY", 43, 49], ["JEV infection", "DISEASE", 89, 102], ["illness", "DISEASE", 137, 144], ["brains", "ORGAN", 43, 49], ["mice", "ORGANISM", 70, 74], ["JEV", "ORGANISM", 89, 92], ["mice", "ORGANISM", 168, 172], ["viral RNA", "RNA", 9, 18], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 70, 74], ["JEV", "SPECIES", 89, 92], ["mice", "SPECIES", 168, 172], ["viral RNA", "PROBLEM", 9, 18], ["JEV infection", "PROBLEM", 89, 102], ["classical signs of illness", "PROBLEM", 118, 144], ["viral RNA", "OBSERVATION", 9, 18], ["JEV infection", "OBSERVATION", 89, 102], ["no", "UNCERTAINTY", 115, 117]]], ["This indicates that the virus crossed the BBB following i.p. injection but failed to replicate in the presence of the compounds since there was no viral antigen demonstrable in the brain smears of drug-treated mice.", [["BBB", "ANATOMY", 42, 45], ["brain", "ANATOMY", 181, 186], ["BBB", "MULTI-TISSUE_STRUCTURE", 42, 45], ["i.p.", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 60], ["brain smears", "MULTI-TISSUE_STRUCTURE", 181, 193], ["mice", "ORGANISM", 210, 214], ["viral antigen", "PROTEIN", 147, 160], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 210, 214], ["the virus", "PROBLEM", 20, 29], ["i.p. injection", "TREATMENT", 56, 70], ["viral antigen", "PROBLEM", 147, 160], ["virus", "OBSERVATION", 24, 29], ["no", "UNCERTAINTY", 144, 146], ["viral", "OBSERVATION", 147, 152], ["brain", "ANATOMY", 181, 186]]], ["To ascertain that the viral RNA detected in the brain was not due to persistence of infection, virus isolation was carried out using a C6/36 monolayer.", [["brain", "ANATOMY", 48, 53], ["C6/36 monolayer", "ANATOMY", 135, 150], ["infection", "DISEASE", 84, 93], ["brain", "ORGAN", 48, 53], ["C6/36 monolayer", "CELL", 135, 150], ["viral RNA", "RNA", 22, 31], ["C6/36 monolayer", "CELL_LINE", 135, 150], ["the viral RNA", "PROBLEM", 18, 31], ["infection", "PROBLEM", 84, 93], ["virus isolation", "PROBLEM", 95, 110], ["a C6/36 monolayer", "TREATMENT", 133, 150], ["viral RNA", "OBSERVATION", 22, 31], ["brain", "ANATOMY", 48, 53], ["not due to", "UNCERTAINTY", 58, 68], ["infection", "OBSERVATION", 84, 93]]], ["It was observed that all the mice that survived the infection failed to demonstrate replicating virus.", [["infection", "DISEASE", 52, 61], ["mice", "ORGANISM", 29, 33], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["the infection", "PROBLEM", 48, 61], ["replicating virus", "PROBLEM", 84, 101], ["infection", "OBSERVATION", 52, 61]]], ["This indicates the lack of infectious virus in the brains of mice that survived treatment with pentoxifylline.", [["brains", "ANATOMY", 51, 57], ["pentoxifylline", "CHEMICAL", 95, 109], ["pentoxifylline", "CHEMICAL", 95, 109], ["brains", "ORGAN", 51, 57], ["mice", "ORGANISM", 61, 65], ["pentoxifylline", "SIMPLE_CHEMICAL", 95, 109], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["infectious virus", "PROBLEM", 27, 43], ["pentoxifylline", "TREATMENT", 95, 109], ["infectious", "OBSERVATION_MODIFIER", 27, 37], ["virus", "OBSERVATION", 38, 43]]], ["Notwithstanding these observations, it must be emphasised that pentoxifylline is a potent inhibitor of TNF [16] .", [["pentoxifylline", "CHEMICAL", 63, 77], ["pentoxifylline", "CHEMICAL", 63, 77], ["pentoxifylline", "SIMPLE_CHEMICAL", 63, 77], ["TNF [16]", "GENE_OR_GENE_PRODUCT", 103, 111], ["TNF", "PROTEIN", 103, 106], ["pentoxifylline", "TREATMENT", 63, 77], ["a potent inhibitor of TNF", "TREATMENT", 81, 106]]], ["Recently, it has been reported that JEV induces apoptosis in cell lines via the endoplasmic reticulum stress pathway [19] .", [["cell lines", "ANATOMY", 61, 71], ["endoplasmic reticulum", "ANATOMY", 80, 101], ["JEV", "DISEASE", 36, 39], ["JEV", "ORGANISM", 36, 39], ["cell lines", "CELL", 61, 71], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 80, 101], ["cell lines", "CELL_LINE", 61, 71], ["JEV", "SPECIES", 36, 39], ["JEV induces apoptosis in cell lines", "PROBLEM", 36, 71], ["the endoplasmic reticulum stress pathway", "TEST", 76, 116], ["JEV", "OBSERVATION", 36, 39], ["cell lines", "OBSERVATION", 61, 71]]], ["The underlying mechanism of neuronal apoptosis in JEV has been attributed to the role of the tumour necrosis factor receptor (TNFR) superfamily [20] .", [["neuronal", "ANATOMY", 28, 36], ["JEV", "DISEASE", 50, 53], ["necrosis", "DISEASE", 100, 108], ["neuronal", "CELL", 28, 36], ["JEV", "ORGANISM", 50, 53], ["tumour necrosis factor receptor", "GENE_OR_GENE_PRODUCT", 93, 124], ["TNFR", "GENE_OR_GENE_PRODUCT", 126, 130], ["tumour necrosis factor receptor (TNFR) superfamily", "PROTEIN", 93, 143], ["JEV", "SPECIES", 50, 53], ["neuronal apoptosis in JEV", "PROBLEM", 28, 53], ["the tumour necrosis", "PROBLEM", 89, 108], ["neuronal apoptosis", "OBSERVATION", 28, 46], ["tumour", "OBSERVATION_MODIFIER", 93, 99], ["necrosis", "OBSERVATION", 100, 108]]], ["Therefore, it is also possible that apart from exhibiting anti-JEV activity, pentoxifylline could have also modulated the TNF responses and protected mice against lethal challenge.", [["pentoxifylline", "CHEMICAL", 77, 91], ["pentoxifylline", "CHEMICAL", 77, 91], ["anti-JEV", "CANCER", 58, 66], ["pentoxifylline", "SIMPLE_CHEMICAL", 77, 91], ["TNF", "GENE_OR_GENE_PRODUCT", 122, 125], ["mice", "ORGANISM", 150, 154], ["TNF", "PROTEIN", 122, 125], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 150, 154], ["pentoxifylline", "TREATMENT", 77, 91], ["lethal challenge", "TREATMENT", 163, 179]]], ["However, further studies are warranted to investigate the immunomodulatory role of pentoxifylline in JEV infection.DiscussionIn conclusion, this study has presented unambiguous evidence of anti-JEV activity of pentoxifylline, which necessitates the evaluation of this compound in controlled clinical trials.", [["pentoxifylline", "CHEMICAL", 83, 97], ["JEV infection", "DISEASE", 101, 114], ["pentoxifylline", "CHEMICAL", 210, 224], ["pentoxifylline", "CHEMICAL", 83, 97], ["pentoxifylline", "CHEMICAL", 210, 224], ["pentoxifylline", "SIMPLE_CHEMICAL", 83, 97], ["JEV", "ORGANISM", 101, 104], ["anti-JEV", "CANCER", 189, 197], ["pentoxifylline", "SIMPLE_CHEMICAL", 210, 224], ["JEV", "SPECIES", 101, 104], ["further studies", "TEST", 9, 24], ["pentoxifylline", "TREATMENT", 83, 97], ["JEV infection", "PROBLEM", 101, 114], ["this study", "TEST", 140, 150], ["pentoxifylline", "TREATMENT", 210, 224], ["the evaluation", "TEST", 245, 259], ["this compound", "PROBLEM", 263, 276], ["JEV infection", "OBSERVATION", 101, 114]]]]}